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ABSTRACT 
Crohn’s disease (CD) is a chronic inflammatory bowel disease. Once considered rare in the 
paediatric population, it is recognized with increasing frequency among children of all ages. 
Approximately 20-30% of all patients with CD present when they are younger than 20 years. 
With its increasing recognition, CD has become one of the most important chronic diseases 
that affect children and adolescents. In addition to the common gastrointestinal (GI) 
symptoms (diarrhoea, rectal bleeding, and abdominal pain) children often experience growth 
retardation, pubertal delay, and bone demineralization. In these children, maintenance of 
skeletal health is a complex process that is influenced by a number of different mechanisms 
including steroid therapy, the disease process, nutritional status, endocrine status and the 
response of the body to inflammatory mediators. The recent introduction of biologic therapy 
that targets specific mediators of the proinflammatory process is a promising adjunct in the 
therapeutic management of the child with chronic inflammation. These drugs may also exert 
beneficial effects on the adverse effects of inflammation on growth and skeletal development. 
It is unclear whether these beneficial effects are due to improvement in overall disease or due 
to a direct ‘anti-cytokine’ effect at the level of the target tissue involved in growth and skeletal 
development. 
The hypothesis of this study was that the biologic therapy improves linear growth, puberty, 
bone health, body composition and muscle function in children with CD and this is associated 
with changes in the IGF-1 axis and markers of bone formation and bone resorption.  
 
Chapter 1 is an extensive literature review about the effects of biologic therapy on growth and 
skeletal development in paediatric patients with chronic inflammatory conditions particularly 
inflammatory bowel disease (IBD). The main aim of this review was to summarize and 
evaluate effects of inflammation and biologic therapy on growth and skeletal development in 
children with chronic inflammatory conditions and to explore the areas of interest for further 
research. 
 
Chapter 2 is the study about the growth in children receiving contemporary disease specific 
therapy in children with CD. The aim of this study was to assess the frequency of short 
stature and poor growth and their relationship to disease course and therapy in children with 
CD. Clinical records of all children with a confirmed diagnosis of CD, who were between 2yrs 
and 18yrs at the Royal Hospital for Sick Children, Glasgow were examined retrospectively. 
Data were collected at diagnosis, 1-yr, 2-yr and 3-yr after diagnosis and at maximum follow-
up. The relationship of a number of factors including therapeutic modalities to two commonly 
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used anthropometric markers of growth height velocity standard deviation scores (HVSDS) 
and change in height standard deviation scores (∆HtSDS) was examined. This study 
suggested that ∆HtSDS may be a more valid method of assessing and reporting longitudinal 
growth in children with chronic disease, particularly when there is a high prevalence of 
children of a peri-pubertal age. This study provides clear evidence that despite advances in 
therapy, short stature and slow growth continue to be encountered in a sub-group of children 
with CD. 
 
Chapter 3 is about the effect of Infliximab therapy on growth, puberty and disease activity in 
children with CD. The aim of this study was to assess growth, puberty, markers of disease 
and concomitant therapy over the six months prior to starting Infliximab and for the 6 and 12 
months following treatment. Clinical records of all children with IBD who were started on 
Infliximab therapy between 2003 and 2008 at the Royal Hospital for Sick Children were 
examined retrospectively. This study has shown an average improvement of approximately 
50% in HV in the 6 months after the initiation of Infliximab therapy which was further 
sustained for a further 6 months. Improvement in growth was found to be better in those 
children who were responders as compared to non-responders suggests that growth 
improved as a result of disease control. Improvement in growth was also observed in children 
who remained pre-pubertal and those who had never been on glucocorticoids (GC) compared 
to those who had been on GC. This study suggests that increase in height may not be simply 
due to progress in pubertal status or reduction in glucocorticoid dose. 
 
Chapter 4 is about the effect of Adalimumab therapy on growth in paediatric patients with CD. 
This is the one and only world wide multicentre study that adequately assess the effect of 
Adalimumab on linear growth in children with CD. The aim of this study was to assess the 
effect of Adalimumab therapy on growth, puberty and disease activity over the 6 months prior 
to and 6 months after starting Adalimumab treatment in children with CD. This study provides 
evidence that Adalimumab is associated with improvement in short term linear growth in 
children with CD who enter remission but not in those who do not. It is also more likely to 
happen in children who are on immunosuppression and those in early puberty but seems to 
be relatively independent of steroid use. These findings suggest that growth improves as a 
result of several interrelated factors, including improved disease control. It was also 
interesting to note that the growth response to Adalimumab varied dependent on the reason 
for discontinuing Infliximab; those who had an allergic reaction to Infliximab fared best. 
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Chapter 5 is Longitudinal observational prospective study of changes in physical growth, IGF-
1 axis, bone health, body composition, muscle function and disease activity at baseline (BL), 
2 weeks (2wk), 6 weeks (6wk), 6 and 12 months (6M & 12M) following biologic therapy in 
paediatric patients with CD. The aim of this longitudinal observational prospective study was 
to assess changes in physical growth, puberty, IGF-1 axis, bone health; body composition 
and muscle function following biologic therapy in paediatric patients with CD. Patients either 
newly diagnosed or patients with long-lasting disease in clinical relapse, who started 
treatment with biologic therapy as part of their standard clinical management, were recruited. 
A non significant improvement was observed in both ∆HtSDS and HVcms/yr at 12M as 
compared to BL. Individually, the majority of the children experienced improvement in clinical 
activity and improvement of the systemic inflammatory markers. A significant increase in 
biomarker of bone formation bone specific alkaline phosphatase (BALP) and a non-significant 
increase in a biomarker of bone resorption cross-linked c-terminal telopeptides (CTX-1) was 
observed from BL to 12M. This observation suggests the beneficial effect of biologic therapy 
on bone formation. 
This study showed a significant change in fat mass (FM (kg) in paediatric patients with CD 
following biologic therapy an effect that has not been reported extensively in previously 
published studies. A significant change in both fat free mass (FFM (kg) and fat free mass 
index (FFMI(kg/m²) shows that the treatment with anti-TNF-α therapy also had a significant 
impact on fat mass accrual. This is the first study that charts the effect of biologic therapy on 
changes in lower limb muscle function using jumping mechanography in paediatric patients 
with CD. A non significant change was observed in jump height (m), V-max (m/s), EFI (%), 
efficiency % from BL to 12M following biologic therapy and a significant increase in both F-
max (kN), and P-max (kW) at 12M. Despite the fact that the increase in efficiency % of the 
movement was not significant but however, the change was likely to be through 
improvements in jump height and velocity thereby indicating higher muscular flexibility. These 
data are suggestive of an effect of biologic therapy on lower limb muscle function through 
improvements in the mechanical efficiency of the muscle. Thus, it is possible that the better 
muscle function is mediated through the effect of biologic therapy on muscle mass. 
Peripheral quantitative computed tomography (PQCT) for tibia and radius both indicated 
significant increase in fat and muscle cross sectional area (Fat-CSA (mm²) and Mus-CSA 
(mm²). Moreover, tibia pQCT also indicated significant change in stress strain index (SSI 
(mm³) a surrogate marker of bone strength, at 12M of therapy. No significant changes were 
observed in total body, lumbar spine (L2-L4), proximal femur and femoral neck bone mineral 
density (BMD (g/cm²), insulin like growth factor-1 (IGF-1(ng/ml), insulin like growth factor 
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binding proteins (IGFBP-3 (ng/ml), IGFBP-2 (ng/ml) and acid labile subunits (ALS (ng/ml) 
following biologic therapy. 
In conclusion, these prospective studies of growth, bone health, body composition and 
muscle function have suggested that biologic therapy in children with CD has a beneficial 
effect on muscle mass and muscle function and which can be observed over the first year of 
therapy for conclusive explanation of these changes these data needs to be adjusted for body 
size. These positive changes are also associated with an increase in bone turnover where the 
change in bone formation is much greater than bone resorption. These favourable effects on 
bone health were not accompanied by marked changes in BMD as assessed by DXA but did 
show some beneficial effects on pQCT assessed SSI, a surrogate marker of bone strength. It 
is possible that controlling disease activity with biologic therapy may positively outweigh the 
effects of CD on growth, body composition, muscle function and bone health. The results of 
this preliminary study need to be confirmed in a larger group of children. An improved 
understanding of the effect of biologic therapy may improve future therapy directed at 
promoting growth and skeletal development in a diverse group of children. Further studies are 
required to understand the duration of the window of opportunity during which linear growth, 
bone and muscle mass in children with CD can be optimised. 
 
Chapter 6 focuses on the main findings of this thesis and discusses potential limitations of 
this methodology, and outlines some important and interesting extensions for future research 
in paediatric patients with CD following biologic therapy.  
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Fat-CSA Fat cross-sectional area  
FFM Fat free mass  
FFMI Fat free mass index 
FM Fat mass  
FMI Fat mass index  
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FGFs Fibroblast growth factors  
FSH Follicle-stimulating hormone  
FDA Food and Drug Administration  
INF-γ Gamma interferon  
GLM General linear models  
GC Glucocorticoids  
GnRH Gonadotropin releasing hormone  
GM-CSF Granulocyte macrophage colony stimulating factor 
GRFP Ground Reaction Force Platform  
GH Growth hormone  
GH/IGF-1 Growth hormone/insulin-like growth factor-1 
HBI Harvey-Bradshaw index  
HAHA Human anti-humira antibodies   
HACA Human anti-chimeric antibodies   
Ht Height  
HtSDS Height standard deviation scores  
HV Height velocity  
HVSDS Height velocity standard deviation scores  
HUMIRA Human Monoclonal Antibody in Rheumatoid Arthritis 
IBDU IBD unspecified  
IgG-1 Immunoglobulin-1  
IBD Inflammatory bowel disease  
IFX Infliximab  
IGFBPs Insulin-like growth factor -binding proteins  
IGF-1 Insulin-like growth factor-I  
IGFs Insulin-like growth factors 
IL-1ra Interleukin-1 receptor antagonist 
IL-2 Interleukin-2  
IL-1 Interleukins-1  
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IL-6 Interleukins-6  
IC Intermediate colitis  
JHt Jump height  
JIA Juvenile idiopathic arthritis  
LS Lumbar spine  
LHRH Luteinizing hormone releasing hormone  
MIGF Maximal isometric grip force  
F-max Maximum - force  
MF Maximum follow-up  
P-max Maximum-power  
V-max Maximum-velocity  
Mus-CSA Muscle cross-sectional area  
PINP N- terminal pro-peptides of type I collagen  
ND Non-dominant   
OC Osteocalcin  
ON Osteonectin  
OPG Osteoprotegrin  
PTH Parathyroid hormone  
pQCT Peripheral quantitative computed tomography 
PGA Physicians Global Assessment  
PDGF Platelet-derived growth factors  
CRP Platelets, C-reactive protein  
PEG Polyethylene glycol  
PF Proximal femur  
PYD Pyridinoline  
QUS Quantitative Ultrasound  
RUS Radius ulna short bones  
RANKL Receptor activator of nuclear factor kappa B ligand  
Alb Serum albumin  
S2LJ Single Two-legged Jump  
SH Sitting height  
SDS Standard deviation scores  
SSI Strength strain index  
SLE Systemic lupus erythematosus  
TS Tanner stage  
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TW2 Tanner-Whitehouse  
TRAP5b Tartrate-resistant acid phosphatase  
PCDAI The Paediatric Crohn’s Disease Activity Index  
PUCAI The Paediatric Ulcerative Colitis Activity Index  
TB Total body  
TotBMD Total bone mineral density  
TrbBMD Trabecular bone mineral density  
TGFβ Transforming growth factor-beta  
TNF-α Tumor Necrosis Factor -Alpha  
Th1 Type I helper T-cells  
UC Ulcerative colitis  
vBMD Volumetric bone mineral density  
Wt Weight 
bCL β-Cross Laps  
12M 12 months  
2wk 2 weeks  
5-ASA 5-Aminosalicylates  
6M 6 months  
6wk 6 weeks  
6-MP 6-mercaptopurine  
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1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a group of disorders of the gastrointestinal tract 
characterized by intestinal inflammation and a chronic relapsing course. IBD has traditionally 
been categorized as either ulcerative colitis (UC) or Crohn’s disease (CD) on the basis of 
clinical, radiological, endoscopic and histological criteria. About 10% of colitis cases show 
overlapping features of the two major forms and are called intermediate colitis (IC) or IBD 
unclassified (IBDU).  
Ulcerative Colitis (UC) is a condition in which the inflammatory response and morphologic 
changes remain confined to the colon. The rectum is involved in 95% of patients, with 
variable degrees of proximal extension. Inflammation is limited primarily to the mucosa and 
consists of continuous involvement of variable severity with ulceration, oedema, and 
haemorrhage along the length of the colon. The characteristic histologic findings are acute 
and chronic inflammation of the mucosa by polymorphnuclear leukocytes and mononuclear 
cells, crypt abscesses, distortion of the mucosal glands, and goblet cell depletion (1).  
Crohn’s disease (CD), in contrast to UC, can involve any part of the gastrointestinal tract from 
the oropharynx to the perianal area. Diseased segments frequently are separated by 
intervening normal bowel, leading to the term “skip areas.” Inflammation can be transmural, 
often extending through to the serosa, resulting in sinus tracts or fistula formation. Histologic 
findings include small superficial ulcerations over a Peyer’s patch (aphthoid ulcer) and focal 
chronic inflammation extending to the submucosa, sometimes accompanied by noncaseating 
granuloma formation. The most common location is the ileo-cecal region, followed by the 
terminal ileum alone; diffuse small bowel, or isolated colonic disease in decreasing order of 
frequency (1).  
In around 10% of cases of IBD in which the inflammation is limited to the large bowel it may 
be impossible, at least at presentation, to differentiate between CD and UC. These cases are 
referred to as IBDU (2). 
1.1.1 Phenotypic classification of IBD 
There are a great number of phenotypic classifications of IBD; mostly commonly used 
phenotypic classifications are Vienna, Montreal and the recently developed Paris 
classification (3-5). Vienna classification of CD considered age of onset, disease location and 
disease behaviour as the predominant phenotypic elements (3). Although great efforts were 
made by working group to develop a reproducible classification, but still this classification has 
limitations.  
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This classification is unable to clearly distinguish disease location when it is present in both 
the upper GI tract and the intestinal regions. Moreover, in this classification perianal disease 
is not considered as a separate category (3). A working party of investigators was established 
in 2005 which modified the Vienna phenotypic classification of IBD and named it Montreal 
classification. The Montreal modification of the Vienna classification has not changed the 
three predominant parameters of age at diagnosis, location, and behaviour, but modifications 
within each of these categories have been made. Montreal revision to Vienna classification 
included (1) an additional category to classify children diagnosed at ≤ 16 years of age (2) 
allowing for upper GI tract disease to be classified 
independently of ileocolonic and colonic involvement and (3) addition of perianal disease 
under separate category. For UC, the group proposed that patients be classified according to 
maximal extent of inflammation at any time during follow-up. The Montreal working group has 
recommended that the term ‘‘indeterminate colitis’’ should be reserved only for those cases 
where colectomy has been performed and pathologists are unable to make a definitive 
diagnosis of either CD or UC after full examination (5;6) (Table 1.1.1). Montreal classification 
has several weaknesses with respect to the classification of young patients. It lacks the 
dynamic features of the paediatric disease phenotype i.e change in disease location and 
behaviour over time. Moreover, linear growth is not considered at all in Montreal 
classification. More recently, additional modifications to the existing Montreal classification 
have been made to capture features of the disease that are pertinent to paediatric IBD 
patients by a working party of paediatric IBD experts, in conjunction with the 2nd international 
symposium on paediatric IBD held in Paris France in 2009 (4) (Table 1.1.1) . Paris revision to 
Montreal classification included (1) the subdivision to age so as to ensure that the younger 
patients are appropriately classified (2) an additional behaviour category, combining both 
stricturing and penetrating disease (3) a category denoting the growth status (4). 
1.1.2 Clinical indices in paediatric IBD 
Longitudinal assessment of disease activity is necessary for the estimation of disease activity 
and for studies of therapeutic interventions in children with IBD. The Pediatric Crohn's 
Disease Activity Index (PCDAI) currently the only validated and most widely used tool for 
assessing disease activity in children with CD. It was developed  and validated in April 1990 
by a group of senior paediatric gastroenterologists with extensive experience in the clinical 
management of children with IBD (7). The PCDAI consists of subjective patient reporting of 
symptoms (abdominal pain, number off liquid stools, general well being), physical 
examination (weight, height, abdominal exam, perianal disease and extra-intestinal 
  
41
manifestations) and common laboratory tests (hematocrit, erythrocyte sedimentation rate 
(ESR) and albumin. 
 
Table 1.1.1: The Montreal and Paris classification of IBD (adapted from Levine et al (4) 
Phenotype 
classification 
Montreal Phenotype 
classification 
Paris 
Crohn’s Disease 
Age at Diagnosis 
A1 Below 17 years A1a 0-<10years 
A2 17-40 years A1b 10-<17years 
A3 Above 40 years A2 17-40 years 
  A3 >40 years 
Location 
L1 Terminal Ileal ± limited caecal 
disease 
L1 Distal 1/3 Ileal ± limited caecal 
disease 
L2 Colonic L2 Colonic 
L3 Ileocolonic L3 Ileocolonic 
L4 Isolated upper disease L4a Upper disease proximal to 
ligament of Treitz 
  L4a Upper disease distal to ligament 
of Treitz and proximal to distal 1/3 
Ileal 
Behavior 
B1 Non stricturing, non penetrating B1 Non stricturing, non penetrating 
B2 Stricturing B2 Stricturing 
B3 Penetrating B3 Penetrating 
  B2B3 Both penetrating and stricturing 
disease, either at the same or 
different times 
          p* Perianal disease modifier           p* Perianal disease modifier 
Growth 
n/a  G0 No evidence of growth delay 
  G1 Growth delay 
Ulcerative Colitis 
Extent 
E1 Ulcerative proctitis E1 Ulcerative  
E2 Left-side UC (distal to the 
splenic flexure) 
E2 Left-side UC (distal to the splenic 
flexure) 
E3 Extensive Colitis  (proximal  to 
the splenic flexure) 
E3 Extensive Colitis  (hepatic flexure 
distally) 
  E4 Pancolitis (proximal to hepatic 
flexure 
Severity 
   
S0 Clinical remission 
(Asymptomatic) 
S0 Never Severe 
S1 Mild UC (Passage of four or 
fewer stools/day (with or without 
blood 
S1 Ever Severe 
S2 Moderate UC    
S3 Severe UC   
Inflammatory bowel disease unspecified 
IBDU Reserved only for those cases where colectomy has been performed and pathologists 
are unable to make a definitive diagnosis of either CD or UC after full examination 
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It is a valid and reliable instrument that has been further validated in a multicenter prospective 
study by Hyams et al in 2005 (8) and is commonly used in paediatric CD studies. All of the 
components were obtained at the clinic visit. Disease activity was categorized as: inactive 
(<10 points), mild (11 to 29 points), moderate (30 to 44 points), and severe (≥45 points) (7;8) . 
An increase in score of 15 points was considered clinically significant (7;8). The Paediatric 
Ulcerative Colitis Activity Index (PUCAI) is a non-invasive disease activity index used to 
measure disease activity in children with ulcerative colitis (9). PUCAI was established by item 
selection by a Delphi group of 36 experts in paediatric inflammatory bowel disease. Validation 
was assessed on a separate prospective cohort of 48 children with ulcerative colitis 
undergoing complete colonoscopy. Responsiveness was evaluated at a follow-up visit of 75 
children using effect size statistics and diagnostic utility approaches. The rigorously 
developed PUCAI is a non-invasive, valid, highly reliable, and responsive index with which to 
assess disease activity in paediatric ulcerative colitis. Each of the components was assessed 
at the clinic visit. Disease activity was categorized as: inactive (<10 points), mild (10 to 34 
points), moderate (35 to 64 points), and severe (≥65 points)(9). An increase in score of 20 
points was considered clinically significant (9). 
A clinical suspicion of IBD is raised in children with persistent (≥4 weeks) or recurrent (≥2 
episodes in 6 months) symptoms such as abdominal pain, diarrhoea, rectal bleeding and 
weight loss. For these children height and weight must be recorded at diagnosis and at all 
subsequent visits. Historical data of height and weight are essential to assess deceleration of 
growth velocity. Parental height and weight are required to identify the target height of the 
patient. Pubertal development should be staged according to Tanner (10). The mouth should 
be examined for lip swelling, gingival hyperplasia or aphthous ulcerations. Skin abnormalities 
such as vitiligo or extraintestinal manifestations (erythema nodosum, pyoderma 
gangrenosum) must be recorded. The abdomen should be examined for palpable tenderness 
and abdominal mass (suggestive of ileo-cecal infiltration or abscess). The anal region should 
be inspected for skin tags, fissures, fistulae or abscesses. In case of arthralgia, the joints 
should be inspected for arthritis. Screening blood tests should include full blood count, 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum levels of urea and 
creatinine, serum albumin. Reduced level of haemoglobin, raised markers of inflammation 
(ESR,CRP), elevated platelet count and reduced serum albumin are suggestive of IBD (11). 
Measuring faecal calprotectin can also be highly useful in the diagnosis of patients with IBD 
as it has been approved to be a surrogate marker of intestinal inflammation. Every child 
suspected of IBD should undergo a complete diagnostic program consisting of colonoscopy 
with ileal intubation, upper gastrointestinal endoscopy and radiologic contrast imaging of the 
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small bowel. Multiple biopsies from all segments of the gastrointestinal tract are needed for a 
complete histologic evaluation. 
1.1.3 Epidemiology of IBD 
The incidence of IBD varies around the world, although there is a rising rate of paediatric IBD 
in both developing and developed countries (12). CD and UC are most commonly diagnosed 
in early adulthood but the diagnosis may occur at any age (13) with approximately 15%-25% 
of IBD being diagnosed by 20 years of age (14). Pediatric studies from the United States, 
Scandinavia, and the United Kingdom have shown a definite increase in overall mean annual 
incidence rates and overall disease prevalence over the past 4 decades in both paediatric CD 
and UC. Worldwide, the overall incidence of paediatric IBD currently ranges from 4.0 to 7.0 
cases per 100,000. Kugathasan et al (15) reported 199 new paediatric IBD cases over 24 
months starting from January 2000. The overall incidence of IBD was 7.05 per 100,000, the 
incidence of CD as 4.56 per 100,000, and the incidence of UC was 2.14 per 100,000. A 
Swedish paediatric study looked at incidence and prevalence rates between 1984 and 1998 
and covered more than 56% of the country’s paediatric population, finding a more than 3-fold 
increase in the mean incidence of paediatric UC (16) CD cases, however, remained static. 
Overall, incidence increased from 4.6 to 5.8 per 100,000. European studies have shown 
slightly lower rates of incidence but do reflect trends of steadily increasing numbers of cases 
reported. Studies in the United Kingdom, including Scotland and Wales, have shown an 
increase in overall incidence from 1-2 to approximately 4 cases per 100,000 between the 
1960s and the 1990s (17;18). Scotland presents the highest prevalence for CD and is second 
after Ireland for UC. The highest incidence occurs between 12-16 years (19;20) with almost 
2/3 of the patients diagnosed with CD.  
There is a historical body of evidence with regard to paediatric IBD incidence in Scotland. The 
first report by Barton et al (21) showed the incidence of CD to be 0.7/100,000/yr and UC 
1.9/100,000/yr in 1968, demonstrating the exceptional rise in CD. Armitage et al (17) later 
reported that between 1981-1995 there was an overall incidence of 2.6/100,000/ yr for CD 
and a marginal fall in UC to 1.2/100,000/yr. Another prospective study carried out by the 
British paediatric surveillance unit which recorded all instances of new IBD diagnoses in 
those less than 16 years over a 13-month period during 1998-1999 showed that the overall 
incidence of paediatric IBD UK wide  was 5.2/100,000/yr, with Scotland producing the highest 
rate of 6.5/100,000/yr (20).The recent data by Henderson et al (22) have compared the 
current incidence and other demographic attributes of paediatric IBD in Scottish population to 
previous data.  
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According to Henderson’s study the incidence of CD was 4.75/100,000/year, UC 
2.06/100,1000/year and IBDU 1.01/100,1000/year. This study has shown significant rise in 
the incidence of IBD as compared to 1990-1995. This study also reported a significant 
reduction in median age at IBD diagnosis from 12.7 years to 11.9 years between the periods, 
with a continued male preponderance. Other geographic regions, including Australia and 
Asia, also report an increase in paediatric CD over the past 2 decades, especially in urban 
regions (23;24).  
1.1.4 Pathogenesis of IBD 
Although the exact cause of IBD is still unknown, clinical and laboratory studies indicate that 
these diseases are multi-factorial and involves both the genetic and environmental factors 
(25). Several theories about the pathogenesis of IBD have been revealed, including an 
autoimmune response to a luminal or mucosal antigen, a dysfunction of immune response to 
a commensal bacterium and an infection with a pathogenic organism which remains in the 
intestinal tissue and results in a chronic inflammatory response (1;26). 
1.1.4.1 Genetic factors 
There is strong evidence to suggest a genetic basis for IBD, including familial clustering and 
racial and ethnic differences in risk for IBD. Ten to twenty percent of affected individuals have 
family history of IBD; with the highest risk among first-degree relatives of an affected IBD 
patient (15;27-29). Increased rates of IBD among identical twins compared to fraternal twins, 
and among siblings compared to spouses of affected individuals, suggest that genetic rather 
than environmental factors are primarily responsible for the observed familial aggregation or 
concentration of incidence for the disease (30-33). A large number of candidate genes have 
been held responsible for the pathogenesis of IBD (30). In 1996, French researchers for the 
very first time identified the region on chromosome 16 known as (IBD1) (34). Detailed 
mapping of this chromosome resulted in the identification of the NOD2/CARD15 gene that 
encodes a cytoplasmic protein designated NOD2 or CARD15 which serves as a pattern 
recognition receptor for bacterial lipopolysaccharide, and regulates activation of nuclear 
factor-kβ and secretion of a-defensins by ileal paneth cells (35). People who are homozygous 
for variant NOD2 may have 20-fold or more increased susceptibility to CD (36;37). However, 
fewer than 20% of patients with CD are homozygous for NOD2 variants so it does not fully 
explain the disease pathogenesis. Since these first observations  a number of other 
candidate genes have been identified with the strongest evidence for the HLA region, MDR-1, 
as well as the recently implicated IL23R and ATG16L1 genes (38). Few published studies 
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have investigated association between genetic variants and growth impairment in patients 
with CD. Russell et al (39) reported that patients with an OCTN1/2 now known as SLC224/A5 
haplotype had a lower height at diagnosis. Sawczenko et al (40) reported that patients with 
IL6-174 GG genotype had lower height z-scores as compared to those with GC or CC 
genotypes. Levine et al (41) have reported that patients carrying TNF-α promoter 
polymorphism with loss of function had higher mean height z-score. However, the association 
of these genetic variants has not yet been confirmed. Lee et al (42) investigated genetic 
variants associated with linear growth in paediatric-onset CD and reported significant 
association between growth impairment in CD and a stature related polymorphism in 
dymeclin gene DYM. This study indicated that the genetic influences due to stature-
associated and possibly CD risk alleles may predispose CD patients to alterations in linear 
growth. 
1.1.4.2 Environmental factors 
Environmental factors are essential components of the pathogenesis of IBD and primarily 
responsible for its growing incidence around the world. Epidemiological, clinical and 
experimental evidence support an association between IBD and a large number of seemingly 
unrelated environmental factors, which include smoking, diet, drugs, geographical and social 
status, stress, microbial agents, intestinal permeability and appendectomy (13). 
1.1.4.3 Microbial factors (Intestinal commensal flora) 
Over the past decade, there has been an exponential increase in interest about commensal 
bacteria as aetiological agents of IBD. Based on fairly solid data , a substantial body of 
evidence has accumulated suggesting that the normal enteric flora  plays a key role in the 
development of IBD (43). Additionally, the following clinical observations support this 
hypothesis: 1) that the beneficial effect of antibiotics in the treatment of CD, and to a lesser 
extent UC, has been appreciated for years, 2) diversion of the faecal stream from the 
inflamed bowel loops has been known to induce symptomatic improvement in CD patients, 
while relapse often occurs upon restoration of intestinal continuity and 3) pouchitis, a chronic 
inflammation of a surgically constructed ileo-anal pouch, develops in a considerable 
proportion of UC patients after procto-colectomy and is associated with the dysbiosis caused 
by the  contact of the once near sterile small bowel mucosa with a rich colon-like flora 
repopulating the pouch after surgery (44). Further more recent data demonstrating that 
probiotics (primarily lactic acid bacteria), defined as live microbial feeds, beneficially affect the 
host by modulating gut microbial balance, and improve both human IBD and experimental 
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colitis, adds an important dimension to the role of gut flora in IBD. In addition, it has also been 
observed that much larger numbers and concentrations of bacteria make up the bio film 
covering the intestinal epithelium of IBD patients compared to the epithelium of healthy 
subjects (45). And loss of immune tolerance against the autologous enteric aerobic and 
anaerobic flora has been reported  (46).  Finally, and probably most convincingly, the majority 
of animal models of IBD fail to develop intestinal inflammation when kept in a germ-free 
environment (47).  
1.1.5 Clinical presentation of IBD 
Inflammatory bowel disease manifests during childhood or adolescence in up to 25% of 
cases (48). The presentation of IBD in children and adults depends on the disease location 
and the extent of inflammation (49). The most commonly encountered gastrointestinal 
symptoms are abdominal pain and diarrhoea. Abdominal pain can be located anywhere in the 
abdomen, although in patients with CD it occurs frequently in the right mid quadrant, whereas 
in patients with UC it is located in the lower abdomen. Diarrhoea may be associated with 
blood in the stool, more so in UC. Other gastrointestinal symptoms include loss of appetite, 
weight loss, nausea, vomiting, and perianal disease (50). Approximately 25 to 35% of 
individuals with IBD develop extraintestinal manifestations (51). The most common 
extraintestinal manifestations include erythema nodosum, stomatitis, aphtae, hepatitis, 
uveitis, conjunctivitis, pulmonary vasculitis, fibrosing alveolitis, arthralgia, arthritis, ankylosing 
spondylitis, iron deficiency anaemia, thrombocytosis, autoimmune hemolytic anaemia, vitamin 
B12 deficiency, osteoporosis (50;51). Twenty-five to thirty-five percent of adult patients with 
IBD have at least one extraintestinal manifestation (52). Up to 35% of paediatric IBD patients 
in some series have at least one extraintestinal manifestation as a presenting sign (51;53). 
Patients with colonic involvement are more likely to have extraintestinal manifestations than 
patients with isolated small intestinal lesions (51;52).  
Growth failure, delayed sexual maturation, perianal lesions including fistulae, tags and 
frequent abscesses, abdominal pain, diarrhoea, weight loss and osteoporosis occasionally 
may be the initial presentation of IBD in children especially with CD (Table 1.1.2). The impact 
of IBD on growth and pubertal development of the patients is presented in detail in Section 
1.6 & 1.7. Beyond the health related consequences of IBD, acute active disease may require 
recurrent hospital admission, causing major interruptions in social, family life, professional 
career, and academic attendance in children that consequently lead to low quality of life (54) 
and psychological concerns (55). Psychotherapy is now considered an essential part of the 
IBD management. 
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Table 1.1.2: Clinical presentation of IBD in children and adolescence (adapted from Kim & Ferry 
2004 (56) 
 
Signs and symptoms 
 
Systemic 
Growth Failure (decreased growth velocity; short stature delayed 
bone age), weight loss 
Anorexia 
Malaise 
Fever of unknown aetiology 
 
 
 
Gastrointestinal  
Abdominal pain 
Diarrhoea (with or without blood and mucus) 
Gastrointestinal bleeding 
Nausea/vomiting 
Early satiety/bloating 
Oral ulcerations 
Jaundice 
 
Endocrine 
Delayed sexual maturation (late-onset of puberty) 
Osteopenia/osteoporosis 
 
1.1.6 Management of IBD 
Currently, the main therapeutic objectives in IBD are to induce symptomatic remission and to 
decrease mucosal inflammation. Though IBD has long been considered a disease 
characterized by exacerbations and remissions, evidence now reveals that endoscopic and 
histologic lesions may persist despite resolution of symptoms and biochemical abnormalities 
(57;58). Therefore, control of intestinal inflammation is included as an important therapeutic 
goal. Goals for the therapy in paediatric IBD are the induction and maintenance of remission, 
prevention of cancer of the affected bowel in adult life, facilitation of normal growth and 
development and improvement of the quality of life (59). The choice of treatment depends on 
disease subtype, localization and associating presenting features such as weight loss and 
short stature (60). In moderate to severe IBD, the current therapeutic strategy may involve 5-
aminosalicylate (5-ASA) preparations, Glucocorticoids, immunomodulators (e.g. 6-
mercaptopurine, Azathioprine, Methotrexate and Cyclosporine), nutritional interventions, 
biologic therapy (Infliximab, Adalimumab) and surgery (61). The common treatment options 
and their impact on growth and skeletal development along with their indications of use in 
paediatric IBD are presented in (Table 1.1.3). 
1.1.6.1 5-Aminosalicylates (5-ASA)  
5-ASA preparations sulfasalazine and mesalazine are a widely used to induce and maintain 
remission in mild to moderate UC. Mainly due to transmural inflammation efficiency of 5-ASA 
in CD remained controversial, especially for preventing relapse (62). Sulphasalazine consists 
of a sulphapyridine linked to a 5-aminosalicylate, which is the active moiety, released as a 
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result of bacterial cleavage in the colon (63) . The precise mechanism of action of these drugs 
is as yet unclear; however, one of the most important mechanistic effects is most likely the 
inhibition of cyclo-oxygenase and 5-lipoxygenase which blocks the production and pro-
inflammatory activity of prostaglandin E2 and leukotrienes (64). High level evidence supports 
the use of 5-ASAs for induction of remission in UC (65) and for a moderate benefit in 
maintenance of remission in UC (65). Modest benefits have been demonstrated with 5-ASAs 
in inducing remission in patients with mild to moderate colonic CD, but, the evidence does not 
support their use in maintaining remission in CD (66). 5-ASAs also have a well documented 
adverse effect profile, including rash, headache and pruritus and, more rarely, toxic hepatitis, 
leucopoenia, pancreatitis and neurotoxicity (66). Because of the limitations of both steroids 
and 5-ASA in maintaining remission in many IBD patients often require additional therapy 
with immunomodulating agents is required. There are very few trials on 5-ASA use in children 
with IBD and no data could be found regarding their growth. 
1.1.6.2 Nutritional management 
Medical therapy usually alleviates the symptoms associated with intestinal inflammation 
(abdominal pain, diarrhoea, and bleeding), but chronic issues of malnutrition and mineral 
deficiencies often persist. Enteral therapy, defined as a specific liquid formula diet 
administered either orally or by nasogastric tube as the primary or sole means of nutrition, 
has been used both for nutritional support and as a method of treatment in place of 
corticosteroids. Elemental enteral therapy has included elemental formulas (consisting of free 
amino acids) or either oligomeric (protein hydrolysates) or polymeric (whole proteins) 
formulas. Enteral nutrition is usually administered exclusively for and initial 6-8 weeks course, 
followed by progressive reintroduction of normal feeding over several weeks. Studies have 
demonstrated additional beneficial impact of EEN which include mucosal healing, 
improvement in anthropometric measurements and bone turnover (67-72). The exact 
mechanism for catch-up growth with EEN is still unclear. However, it has been shown that 
besides restoring multiple nutritional deficits and providing required caloric intakes, EEN 
induces a significant mucosal healing and reduces the production of mucosal inflammatory 
cytokines (73;74). It has also been reported that EEN causes bowel rest and modification of 
intestinal flora (75). 
Studies have examined serum markers of nutrition such as IGF-1, as well as anthropometric 
markers as outcome measures indicating the nutritional impact of this form of therapy. EEN 
can lead to prompt improvement in weight (76) along with rapid increases in IGF-1(67;68). 
Combination of EEN and Infliximab might be an attractive approach to ensure optimal growth 
in children. Indeed prolonged EN, even administered intermittently, has clear positive effects 
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on anthropometric parameters, with significant increase in weight and height velocity 
(69;70;77). An early study in children showed that elemental formula was as effective as 
steroids in controlling disease and was associated with better linear growth compared to 
steroid treated patients (78).  
Furthermore, children treated with EEN have better growth velocity than those treated with 
GC (79). In fact, after EEN initiation, a rapid increase in growth factors IGF-1 and IGFBP-3 
level is observed (67;68;70), which is probably due to the reduction in inflammation rather 
than an improvement in nutritional status. Whitten, at al (72) demonstrated changes in 
markers of bone turnover in children managed with EEN. In this prospective cohort, EEN led 
to a reduction of a marker of bone breakdown and increased levels of a marker of bone 
formation. Together these changes suggest that EEN may have beneficial effects on bone 
metabolism as well, which is likely consequent to altered levels of pro-inflammatory cytokines. 
Interesting, these changes do not always correspond directly with changes in serum or 
mucosal inflammatory markers, suggesting that EEN may act via multiple coincident 
mechanisms. 
1.1.6.3 Corticosteroids 
Corticosteroids have a strong anti-inflammatory effect and remain widely used to induce 
remission in moderate and severe acute flares in IBD patients (80). A Cochrane systematic 
review has demonstrated that they are effective in achieving clinical remission in CD in 
comparison to placebo (81). Corticosteroids are also effective in inducing remission in 
patients with active UC (82). Corticosteroids show their effects by binding to a specific 
intracellular receptors to effect the transcription of steroid responsive genes (83). It is also 
recognised that activated steroids receptors interact with NF-κβ in regulating the inflammatory 
response (83). Pro-inflammatory proteins suppressed by corticosteroids include IL-1, IL-2, IL-
8, IL-6, γ-interferon, and TNF-α. These in turn result in impaired inflammatory signalling in 
terms of antigen presentation, and inflammatory cells activation (84). 
However the adverse effects of oral corticosteroids are high with cushingoid appearance, 
hypertension and increased infections being commonly encountered in the short-term and 
osteoporosis, adrenal suppression and growth retardation as long-term concerns (84). The 
mechanism by which Corticosteroids suppress growth and bone metabolism are multiple and 
complex. It has been shown that Corticosteroids show their impact on growth and bone 
metabolism by (i) by decreasing calcium absorption from gut and increase calcium urinary 
excretion, with subsequent secondary hyperparathyroidism, further promoting bone 
resorption (ii) by decreasing the expression of hepatic GH receptors leading to decreased 
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IGF-1 production (iii) impair GH receptor expression, reduce  IGF-1 production and activity 
and inhibit proliferation of chondrocytes at the level of growth plate (85;86;86-88). 
1.1.6.4 Immunomodulators 
The 6-mercaptopurine (6-MP) and its precursor, Azathioprine, have been used in clinical 
practice for the treatment of IBD for over four decades. The majority of clinical experience, in 
the UK, is with Azathioprine, which was developed in 1957 as a slower release formulation of 
6-mercaptopurine (89). Azathioprine is rapidly metabolised to 6-MP in the body which exerts 
its effect by inhibiting purine synthesis in DNA and RNA and thus reducing cell proliferation 
and thereby causing immunosuppression (89). Azathioprine has been shown to be effective 
in both inducing remission and for maintenance therapy for CD, with significant steroid-
sparing effects (90). Azathioprine may reduce the requirements for steroids in inducing 
remission in UC (91) and appears to reduce maintenance relapse rates long term (92). 
Azathioprine/6-MP is being used in paediatric IBD since 1970s (93). Immunosuppression 
induced by Azathioprine/6-MP allows maintenance of clinical and biological remission and 
leads to the disappearance of mucosal ulceration in 50% of patients with CD (94). Therefore 
these drugs should enable normal growth and puberty in paediatric IBD patients. Due to the 
steroid sparing effect of Azathioprine (95) it could improve growth. Only two studies have 
reported the impact of Azathioprine of growth (96;97). 
Methotrexate also causes immunosuppression by inhibiting purine synthesis in DNA and 
reducing T-cell proliferation. Methotrexate at higher dose (25mg weekly) appears to induce 
remission in CD (98). Methotrexate has also been shown to be superior to placebo for the 
maintenance of remission in CD and is now commonly used as an adjunct to therapy in 
patients who relapse on or are intolerant to thiopurines (99). Although the experience of 
Methotrexate on paediatric setting is limited however; Methotrexate appears to be well-
tolerated and good therapeutic alternative for children unresponsive or intolerant to 
Azathioprine/6-MP (100;101). The impact of low dose Methotrexate on growth have been 
observed by Turner D et al (100) in 60 children with CD unresponsive or intolerant to 
Azathioprine/6-MP and have been reported to improve height velocity z-scores. 
Adverse events with immunosuppressants are significant with nausea and vomiting both 
common. Over-immunosuppression leading to leucopoenia is a potential risk with both 
Azathioprine and Methotrexate, which requires frequent white cell level monitoring (91). In 
addition Methotrexate is also associated with the development of hepatitis and 
hypersensitivity pneumonitis (99).  
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Fatal sepsis and malignancy risk are low (102). A significant proportion of patients are 
intolerant of, or do not achieve long-term remission of symptoms, with immunosuppressive 
agents. 
1.1.6.5 Biological therapies  
Biologic therapies have been developed to target more specific aspects of the inflammatory 
cascade because of the limited success of immunosuppressive agents to treat moderate and 
severe IBD, and because of their adverse effect profile. Biological therapy refers to the use of 
medication that is tailored to specifically target an immune or genetic mediator of disease 
(103). The biological agents that have been evaluated for the treatment of CD include: the 
anti-tumor necrosis factor alpha (TNF-α) Infliximab, Adalimumab, certolizumab pegol and 
anti-adhesion molecule (Natalizumab) drugs. Biologic therapies are discussed in detail in 
Section 1.8. 
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Table 1.1.3: Therapeutic interventions in paediatric IBD and their impact on growth and skeletal development (compiled from (104-106) 
Drug Examples    Mechanism of action Indication of use in IBD Effect on growth Effect on bone 
Aminosalicylates 
(5ASA) 
Mesalazine 
Sulfasalazine 
Balsalazide 
Olsalazine 
Inhibition of the cyclo-
oxygenase that impedes the 
production of pro-
inflammatory prostaglandins 
and leukotrienes 
Induction and maintenance of 
remission for mild/moderate UC 
& CD 
No No 
Corticosteroids Prednisolone 
Prednisone 
Hydrocortisone 
Budesonide 
 
Inhibit many inflammation-
associated molecules such 
as cytokines, chemokines, 
arachidonic acid metabolites, 
and adhesion molecules 
Maintenance of remission for 
mild/moderate UC & CD 
Inhibitory Yes (suppression of 
osteblastogenesis, 
inhibition of chondrocyte 
proliferation and collagen 
synthesis)  
Immunomodulators Azathioprine 
6-mercaptopurine 
 
Inhibiting purine synthesis in 
DNA and RNA and thus 
reducing cell proliferation and 
thereby causing 
immunosuppression 
Maintenance of remission for 
moderate/severe UC & CD, 
steroid refractory/dependency, 
fistulae, concomitant therapy 
with Infliximab 
Stimulatory No known 
Antibiotics Metronidazole 
Ciprofloxacin 
Changes in bacterial flora Induction of remission No No 
Immunosuppressants Methotrexate Methotrexate competitively 
inhibits dihydrofolate 
reductase an enzyme that 
participates in the 
tetrahydrofolate synthesis 
Maintenance of remission for 
moderate/severe UC & CD, 
steroid refractory/dependency, 
fistulae, concomitant therapy 
with Infliximab 
Stimulatory Not known 
 
Biologic agents Infliximab 
Adalimumab 
Inhibit the activity of the pro-
inflammatory cytokine TNF-α 
Maintenance of remission for 
moderate/severe UC & CD 
Unresponsive to conventional 
therapy and for severe fistulizing 
disease 
Stimulatory Indirectly by removing 
suppression of 
chondrocytes proliferation 
and differentiation induced 
by proinflammatory 
cytokines 
Exclusive  
enteral nutrition  
Polymeric feeds 
Elemental feeds 
Reduction in inflammatory 
markers 
Direct mucosal healing, 
bowel rest with a decreased 
intestinal metabolic activity, 
secretions and altered 
motility 
Induction of remission 
Mild/Moderate CD 
Stimulatory Enhancing bone 
metabolism 
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1.2 Bone biology 
Bone is a specialized, dynamic, highly vascular and mineralized connective tissue that makes 
up together with cartilage the skeletal system. Bone performs several functions in the body: 
(1) mechanical, as support and site of muscle attachment for locomotion; (2) protective, for 
vital organs and bone marrow; and (3) metabolic, for the maintenance of serum homeostasis, 
which is essential to the life. Furthermore, it is capable of maintaining an optimal shape and 
structure throughout life.  
Two types of bones can be distinguished in the skeleton: flat bone (skull ones, scapula, 
mandible and ileum) and long bones (tibia, femur, humerus, etc). External-examination of 
long bone shows two wider extremities (Figure 1.2.1) the epiphysis, diaphysis and a 
metaphysis. The external part of the bone is formed by a thick and dense layer of calcified 
tissue, the cortex (compact bone), which in the diaphysis, encloses the medullary cavity 
where the hematopoietic bone marrow is housed. Toward the metaphysis and the epiphysis, 
the cortex becomes progressively thinner, and the internal space is filled with a network of 
thin, calcified trabeculae; this is the cancellous bone also named as spongy or trabecular 
bone. The spaces enclosed by these thin trabeculae are also filled with hematopoietic bone 
marrow and are in continuity with the medullary cavity of the diaphysis. The bone surface at 
the epiphysis take part in the joint, covered with a layer of articular cartilage that does not 
calcify. There are consequently two bone surface at which the bone is in contact with soft 
tissue, external surface (the periosteum surface) and an internal surface (the endosteal 
surface).  
1.2.1 Bone tissue 
Bone is classified in to two different types of tissues, one of which is relatively dense, known 
as cortical bone (compact bone), while the other consists of a network of struts or trabeculae 
surrounding interconnected spaces known as trabecular bone (cancellous bone). The 
microscopic difference between compact and cancellous bone is that the compact bone 
consists of haversian sites and osteons, while cancellous bones do not. Also, bone surrounds 
blood in compact bone, while blood surrounds bone in the cancellous bone. 
1.2.1.1 Cortical bone 
The hard outer layer of the bone is composed is composed of a thick and a dense layer of 
calcified tissue (compact bone tissue), so-called due to its minimal gaps and spaces. Its 
porosity is 5-30%.  
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Figure 1.2.1: Structure and components of long bone.  Long bones are longer than they are 
wide, consisting of a long shaft (the diaphysis) and two articular (joint) surfaces, called 
epiphysis. They are comprised mostly of compact bone, but are generally thick enough to 
contain considerable spongy bone and marrow in the hollow centre. 
 
 
 
Articular Cartilage
Endosteum
Periosteum
Compact Bone
Proximal 
Epiphysis
Diaphysis
Distal 
Epiphysis
Metaphysis
Spongy Bone
Fused Growth Plate
  
55
This tissue gives bones their smooth, white, and solid appearance, accounts for 80% of the 
total bone mass of an adult skeleton (107). It provides protection and support by helping the 
long bones resist the stress of weight placed upon them (95). Blood vessels, lymphatic 
vessels, and nerves from the periosteum penetrate the cortical bone through perforating 
(Volkmann’s) canals. The blood vessels and nerves of these canals connect with those of the 
medullary cavity, periosteum, and central (Haversian) canals of the osteons. The central 
canals run longitudinally through the bone, and around the canals are concentric lamellae- 
rings of hard, calcified matrix. Between the lamellae are small spaces, or lacunae, which 
contain osteocytes. Radiating in all directions from the lacunae are minute canals known as 
canaliculi, which are filled with extracellular fluid. Inside these canaliculi are slender finger-like 
processes of osteocytes. The canaliculi connect lacunae with one another and, eventually, 
with the central canals. Thus, there is an intricate branching network of canals which provide 
a route for nutrients and oxygen to reach the osteocytes and for wastes to diffuse away. 
Osteocytes from neighbouring lacunae form gap junctions with one another, facilitating easy 
movement of materials from cell to cell. Each central canal, with its surrounding lamellae, 
lacunae, osteocytes and canaliculi, forms an osteon (Haversian system).  
1.2.1.2 Trabecular bone 
In contrast to cortical bone, trabecular (cancellous) bone does not contain true osteons, but 
instead consists of lamellae arranged in an irregular latticework of thin columns of bone called 
trabeculae. The macroscopic spaces between the trabeculae of some bones are filled with 
red bone marrow, which produces blood cells. Within the trabeculae are osteocytes that lie in 
lacunae, and radiating from the lacunae are canaliculi. Blood vessels from the periosteum 
penetrate through to the trabecular bone, and osteocytes in the trabeculae receive 
nourishment directly from the blood circulating through the marrow cavities. Osteons are not 
necessary in spongy bone as osteocytes are not deeply buried as they are in cortical bone, 
and so have access to nutrients directly from the blood. Trabecular bone constitutes the 
majority of bone tissue of short, flat and irregularly shaped bones and most of the epiphyses 
of long bones. Trabecular bone tissue in the ribs, sternum, vertebrae and in the ends of some 
long bones is the only site of red bone marrow storage, and hence haemopoiesis in adults. 
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1.2.2 Bone cells 
1.2.2.1 Osteoblasts 
Osteoblasts arise from multipotent precursor cells of mesenchymal origin (Figure 1.2.2). 
Osteoblasts are responsible for bone formation and secrete collagen and other bone matrix 
proteins. The organic bone matrix is called the osteoid. Osteoblasts also contribute to 
mineralization of the osteoid by secreting several proteins, such as alkaline phosphatase, 
osteocalcin, and osteopontin (bone sialoprotein) that are essential in the mineralization 
process. Osteoblast activity is regulated by numerous hormones and cytokines. Osteoblast 
lineage cells regulate osteoclasts by secreting osteoprotegrin (OPG), which is an important 
inhibitor of osteoclastogenesis. Osteoblast lineage cells have receptors for e.g. 1,25-
dihydroxyvitamin D [1,25-(OH)
2
D] and parathyroid hormone (PTH) (108).  
1.2.2.2 Osteoclast 
Osteoclasts originate from the hematopoietic lineage (Figure 1.2.2) and are responsible for 
bone resorption. Osteoclasts function on the surface of calcified bone. The key regulators of 
osteoclastogenesis are receptor activator of nuclear factor kappa B ligand (RANKL) and 
OPG. RANKL and OPG are produced by osteoblasts. Mature osteoclasts secrete acid and 
proteolytic enzymes causing bone resorption. Degradation products, including collagen 
fragments, phosphate, and calcium, are released into the circulation. In an optimal/normal 
situation, bone formation and resorption are coupled (109). 
1.2.2.3 Osteocytes 
Osteocytes originate from osteoblasts (Figure 1.2.2). Osteocytes comprise the largest 
proportion of cells in mineralized bone and give support to bone structure by forming 
numerous cytoplasmic connections with adjacent cells. Remodeling is thought to be mediated 
by osteocytes. Further, osteocytes respond to mechanical strain on bones and mediate 
signals for bone formation and resorption. Osteocytes may undergo apoptosis, which is 
important for skeletal development, but also contributes to bone loss in osteoporosis (110). 
1.2.3 Bone modeling and remodeling 
During growth the bones maintain their normal shape by bone modeling. The process of bone 
maintenance, in which old bone is removed and then replaced by new bone, is called 
remodeling (Figure 1.2.3). Modeling and remodeling mechanisms are influenced by a vast 
variety of systemic and local factors, and they respond rapidly to the body’s metabolic 
homeostasis. Bone formation is mediated by osteoblasts and bone resorption by osteoclasts 
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(108). Bone is continuously turned over in the remodeling process, which consists of bone 
resorption and formation in a lifelong process with successive (111). In this process, 
osteoclasts resorb old bone tissue. This part is soon replaced by new bone made by 
osteoblasts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.2: Origin of osteoblasts, osteocytes, and osteoclasts. 
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Remodeling maintains the normal shape of bones and renews bone tissue. Further, through 
remodeling, damaged bone tissue can be removed and replaced by new bone.  Normally, the 
activities of osteoblasts and osteoclasts are balanced in adults, and remodeling has no effect 
on the amount of bone. Bone loss occurs, as in menopausal osteoporosis, when the amount 
of bone resorption is higher than the amount of bone formation. Trabecular bone is more 
active in remodeling than cortical bone (111). In the modeling process, osteoblasts form new 
bone without prior bone resorption, and consequently, an increase in the amount of bone 
tissue is possible (111). Further, osteoblasts form more bone than osteoclasts remove, and 
this leads to net increase in bone tissue. During childhood there is more modeling than 
remodeling. Modeling maintains the normal shape of bones during growth and is responsible 
for the increase in bone circumference during growth (111). Both bone modeling and 
remodeling are influenced by parathyroid hormone (PTH), sex, growth, and thyroid 
hormones; glucocorticoids; growth factors, cytokines, and prostaglandins; hereditary and 
nutritional factors; and physical activity (112;113). Longitudinal bone growth is called 
endochondral bone formation and occurs mainly in growth plate cartilage (114). Growth 
plates are present in the ends of long bones. In the growth plates, mesenchymal cells 
condense and turn into chondrocytes. Chondrocytes synthesize collagens and other matrix 
molecules. This spongiosa is subsequently remodeled into mature trabecular bone.  
1.2.4 Bone development and growth  
1.2.4.1 Ossification 
There are two types of processes involved in the bone ossification (development); 
intramembranous ossification (flat bones) and endochondral ossification (long bones). The 
main difference between them is the presence of the cartilaginous phase in the latter. 
1.2.4.1.1 Intramembranous ossification 
In intramembranous ossification, a group of mesenchymal cells, under the influence of the 
local growth factors, forms a condensation within the highly vascularised area of the  
embryonic connective tissue by proliferating and differentiating directly into pre-osteoblasts 
and then on osteoblasts. Osteoblasts cluster together to form an ossification centre and 
secrete osteoid element. The subsequent mineralisation of the osteoid matrix begins working 
outward from the ossification centre. The early trabeculae forms and the periosteum develop 
resulting in the formation of woven bone. 
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Figure 1.2.3:Bone Remodeling Cycle: Resortptive phase: activated multinucleated osteoclasts 
derived from bone marrow monocytes resorb a discrete area of mineralized bone matrix. 
Reversal phase: subsequently osteoprogenitor cells (osteoblast precursor) cells, which can 
locally proliferate and differentiate into osteoblasts migrates into the lacuna and disclose the 
former osteoclastic activity. Formative phase: the osteoblast deposits new bone matrix which 
is initially unmineralized and called osteoid, and in this way fill the resorption lacuna. Resting 
phase: once embedded in the osteoid, the osteoblasts mature into terminally differentiated 
osteocytes. The osteoblasts lying on the surface of the newly formed bone packet are 
quiescent lining cells until activated. 
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1.2.4.1.2 Endochondral ossification 
In endochondral ossification the hyaline cartilage model grows and develops. In this process 
the mesenchymal cells proliferate and differentiate in to pre-chondroblasts and then into 
chondroblasts instead of osteoblasts.  
Chondroblasts begin to secrete collagen and other proteins forming the cartilage matrix. 
Some of the chondroblasts that become caught in the matrix are subsequently known as 
chondrocytes. A membrane (perichondrium) surrounds the cartilage model. Formation of 
blood vessels takes place in and around the cartilage matrix to bring nutrients and allow the 
removal of waste. A bone collar and the periosteum form around the diaphysis of the cartilage 
precursor when the perichondrium develops osteogenic cells. Enlargement of the 
hypertrophic chondrocytes located at the edges of the primary ossification centres occur. The 
cells eventually degenerate, the matrix becomes compressed and subsequently mineralises. 
This area is known as the proliferative zone. A representation of the growth plate and 
adjacent metaphysis during growth is illustrated in (Figure 1.2.4). The original cartilage model 
is then gradually replaced by woven bone in a complex system of bone apposition, resorption 
and elongation. This process occurs in the zone of cartilage transformation and the resulting 
trabeculae form the primary ossification centre. Osteoclasts then begin to resorb the woven 
bone and cartilage remnants, osteoblasts begin to deposit bone matrix and the crystals 
produced inside the matrix vesicles become organised into the matrix, producing lamellar 
bone. This process occurs in the zone of ossification and the resulting mature trabeculae. 
More blood vessels form during growth because of the constant need to bring nutrients to the 
newly developing bone. 
Appearance of the secondary ossification centres at the epiphyses of long bones allows 
formation of more blood vessels, to bring nutrients to these areas. The development of a 
medullary cavity occurs through osteoclastic resorption and the endosteum begins to form. 
Then bone marrow begins to develop in the newly created cavity. The epiphyses do not have 
separate medullary cavities. The smaller bones do not develop medullary cavities but all 
bones have some degree of marrow within their trabecular structure. The articular cartilage 
forms and remains to form the joint margins. When the epiphysis and diaphysis of a growing 
long bone become adjacent to one another, the diaphysis will gradually fuse with the 
epiphysis via the creation of mineralised bridges until the hyaline-cartilaginous growth plate 
has been completely replaced by bone and bone marrow (115) making a complete bone. The 
articular cartilage remains at joint surfaces to form the joints and prevent attrition. Long bones 
must also have a mechanism for increasing their diaphyseal circumference and their length.  
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Figure 1.2.4: Bone Development. The schematic diagram shows the initial stages of 
endochondral ossification 
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They do this by sub periosteal addition of bone combined with endosteal resorption. This 
mechanism ensures that the cortical bone layer does not become too thick, which would 
therefore make the bone much heavier and mechanically disadvantaged. The size, shape 
and density of the cortical and trabecular bone will generally develop to a stage at which they 
are sufficiently strong and light to accommodate loading and activity to which the skeleton is 
normally exposed  
 
1.2.5 Growth plate 
1.2.5.1 Structural organization of growth plate 
The process of bone growth relies upon chondrocytes produced at the epiphyseal growth 
plate, which are progressively synthesized and replaced by bone with accompanying 
longitudinal (endochondral) bone growth. Growth plate (epiphyseal plate) is a layer of hyaline 
cartilage in growing bone located in the metaphysis between the epiphysis and diaphysis. It is 
left over cartilage from the endochondral ossification. The epiphyseal plate consists of four 
zones (Figure 1.2.5). 
1.2.5.1.1 The zone of resting cartilage 
The zone of resting cartilage is near the epiphyses and consists of a small, scattered 
chondrocytes. These cells do not function in bone growth therefore; these are termed as 
“resting”. They attach the epiphyseal growth plate to the bone of the epiphysis. 
1.2.5.1.2 The zone of proliferative cartilage 
The zone of proliferating cartilage consists of slightly larger chondrocytes arranged like stack 
of coins. Chondrocytes divide to replace those that die at the diaphyseal surface of the 
epiphyseal plate. 
1.2.5.1.3 The zone of hypertrophic cartilage 
The zone of hypertrophic cartilage is also called as maturing cartilage. It consists of even 
larger chondrocytes that are also arranged in columns. The lengthwise expansion of the 
epiphyseal plate is the result of cell division in the zone of proliferating cartilage and 
maturation of the cells in the zone of hypertrophic cartilage. 
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Figure 1.2.5: Structure of growth plate 
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1.2.5.1.4 The zone of calcified cartilage 
The zone of calcified cartilage is only a few cells thick and consists mostly of dead cells 
because the matrix around them has calcified. The calcified matrix is taken up by the 
osteoclasts, and the area is invaded by osteoblasts and capillaries from the bones in the 
diaphysis. 
These cells lay down bone on the calcified cartilage that persists. As a result, the diaphyseal 
border of the epiphyseal plate is firmly cemented to the bone of diaphysis. The activity of the 
epiphyseal plate is the only mechanism by which the diaphysis can increase in length. 
The epiphyseal growth plate allows the diaphysis of the bone to increase in length until early 
adulthood. It also shapes the articular surfaces. As the child grows cartilage cells are 
produced on the growth plate. They are then destroyed and the cartilage is replaced by the 
bone on the diaphyseal side of the plate. In this way the thickness of the growth plate remains 
almost constant, but the bone on the diaphyseal side increases in length. Eventually, the 
epiphyseal cartilage cells stop dividing, and the bone replaces the cartilage. The newly 
formed bony structure is called epiphyseal line, a trace of the once active growth plate. With 
the appearance of the epiphyseal line, bone stops growing in length. In general, lengthwise 
growth in bones is in females is completed before that in males 
1.2.6 Bone matrix and minerals 
Bone extracellular matrix has two main components: the organic collagen fibers and the 
inorganic bone mineral crystals. Together they make up approximately 95% of the dry weight 
of bone, the remainder being composed of other organic molecules, collectively known as 
non-collagenous proteins. Collagen accounts for 70-90% of non-mineralized components of 
bone matrix; it consists of carefully arranged arrays of tropocollagen molecules, which are 
long rigid molecules, composed of three left handed helices of peptide, known as α-chains, 
which are bound together in a right-handed triple helix. The organic part of matrix is mainly 
composed of type-I collagen which is composed of tropocollagen molecules containing two 
identical and one dissimilar α-chains (α1 (I)
 2 α 2). 
The inorganic composition of bone (bone mineral is formed from hydroxyl apatite, a hydrated 
calcium phosphate ceramic, with a similar crystallographic structure to normal bone mineral, 
which has a chemical formula of ca (PO4)6(OH) 2; however bone-apatite is characterized by 
calcium, phosphate and hydroxyl bone-apatite is characterized by calcium, phosphate and 
hydroxyl deficiency, internal crystal disorder, and ionic substitutions, thus resulting in the 
presence of significant levels of additional trace elements within bone mineral: it is not a 
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direct analogue of hydroxyl apatite, but more closely a carbonate-substituted apatite. All 
these factors contribute to an apatite that is insoluble enough for stability, yet sufficiently 
reactive to allow the in vivo crystallites to be constantly resorbed and reformed as required by 
the body. 
The most important non-collagenous organic constituents of bone matrix are four proteins: 
osteocalcin (OC), bone sialoprotein (BSP), osteopontin (OP) and osteonectin (ON). They are 
produced by bone cells and their relative composition within the bone matrix appears to be 
self-regulating through a feedback effect on their expression by osteoblasts. They all appear 
to be multi-functional, and are all involved in regulating bone mineralization and remodeling. 
Bone matrix also contains a great number of growth factors, including fibroblast growth 
factors (FGFs), insuline-like growth factors (IGFs), platelet-derived growth factors (PDGF), 
transforming growth factor-beta (TGFβ) superfamily, and bone morphogenic proteins (BMPs): 
they play several critical roles in regulating cell proliferation and differentiation, inducing the 
complete sequence of endochondral bone formation, when cartilage forms first and is 
subsequently replaced by bone. 
1.2.7 Markers of bone metabolism 
Biochemical markers of bone turnover are bone tissue proteins or their fragments, or 
enzymes released from bone cells during bone turnover. Proteins can be by-products of 
collagen formation or products of collagen degradation, or non-collagenous proteins such as 
osteocalcin and bone sialoprotein. Enzymes such as bone-specific alkaline phosphatase and 
tartrate-resistant acid phosphatase 5b can also be used as markers of bone turnover. Bone 
turnover markers can be detected in serum or urine. Ideally, they should reflect only the 
activity of osteoblasts or osteoclasts.  
The bone turnover markers that are mainly released during bone formation or resorption are 
known as bone formation or resorption markers, respectively (Table 1.2.1). Formation and 
resorption are usually tightly coupled in time and space; thus, any such marker reflects the 
overall rate of bone turnover. Certain bone turnover markers may reflect different stages of 
formation and resorption, but they cannot reflect disease-specific processes and cannot 
distinguish between the activities at cortical or trabecular bone.  
Assessment of bone turnover using bone turnover markers has the advantages of relatively 
low cost and non-invasive sample collection compared to the evaluation of bone turnover rate 
by histomorphometry in bone biopsies from the iliac crest. Although bone biopsy may give 
direct evidence concerning the aetiology, pathogenesis and progress of metabolic bone 
diseases, it has the disadvantage of being invasive and of giving information on bone 
turnover only concerning that specific skeletal region. 
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1.2.7.1 Bone formation markers 
1.2.7.1.1 Bone specific alkaline phosphatase 
Alkaline phosphatase (ALP) is an enzyme located on the cell surface. Three different tissue-
specific genes encode the intestinal, placental and germ-line enzymes, and the tissue-
unspecific gene is expressed in numerous tissues, including bone and the liver. 
 
Table 1.2.1: Markers of bone turnover (adapted from (116) 
Markers of bone 
formation 
Tissue of origin Markers of bone 
resorption 
Tissue of origin 
Alkaline 
phosphatase 
Liver, bone, 
placenta, intestine, 
germ cells 
Tartrate-resistant acid 
phosphatase 5b 
bone (osteoblasts) 
Bone-specific 
alkaline phosphatse 
bone (osteoblasts), 
platelets 
C-terminal cross-linking 
telopeptide of type I 
collagen 
bone, soft tissue, skin 
Osteocalcin (intact, 
total, carboxylated) 
bone (osteoblasts) N-terminal cross-linking 
telopeptide of type I 
collagen 
bone, soft tissue, skin 
Procollagen I C-
terminal extension 
peptide 
bone, soft tissue, 
skin 
C-terminal cross-linking 
telopeptide of type I 
collagen, generated by 
metaproteinases 
bone, skin 
Procollagen I N-
terminal extension 
peptide 
bone, soft tissue, 
skin 
Deoxypyridinoline Bone, dentine 
  Pyridinoline Bone cartilage, tendon, 
blood vessels 
  Osteocalcin bone 
 
Tissue-unspecific ALPs are produced by the same gene but there are tissue-specific 
differences in their post-translational modification of the carbohydrate chains (117). The most 
common sources of elevated serum ALP levels are liver and bone. In bone, ALP is present 
on the cell surface of the osteoblasts, and it is probably cleaved off from the membrane and 
released into circulation. In healthy individuals, about half of the serum alkaline phosphatase 
(S-ALP) is derived from bone. Thus, measurement of S-ALP can be used as a marker of 
bone turnover, but it lacks sensitivity and specificity, especially under conditions in which 
there is only a small increase in bone turnover. Measurement of the bone-specific isoform S-
bone ALP has better sensitivity for detecting changes in bone turnover. However, the S-bone 
ALP assays that are currently available still have cross-reactivity with the liver isoenzyme of 
15–20% (118). 
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1.2.7.1.2 Osteocalcin 
Osteocalcin (or bone Gla protein) is the most abundant non-collagenous matrix protein in 
bone. It forms about 1% of the organic component of bone. It is a low-molecular-weight 
protein consisting of 49 amino acids and is expressed by osteoblasts, osteocytes, 
odontoblasts and hypertrophic chondrocytes. Osteocalcin has a high affinity for Ca
2+ 
in bone 
hydroxyapatite, due to the three γ-carboxy glutamic acid residues at positions 17, 21 and 24 
(119). Part of the newly synthesized osteocalcin is incorporated into new bone matrix and 
part of it enters the circulation, where it can be detected. Serum osteocalcin (S-OC) is 
considered to be a specific marker of osteoblast activity, and its serum levels thus reflect the 
rate of bone formation. Circulating osteocalcin consists of different immune-reactive forms. 
Approximately one third of serum osteocalcin is intact, one third consists of the mid-molecule 
fragment 1-43 and one third is smaller fragments (120). It is not clear whether these 
fragments are by-products during the biosynthesis of OC, from proteolysis of osteocalcin in 
the circulation or whether they are released directly from bone during bone resorption. 
Different osteocalcin assays can detect different fragments of osteocalcin in serum. The 
presence of multiple isoforms of OC in serum and the differences between assays in 
detection of these isoforms limit the clinical usefulness of S-OC (121). Osteocalcin may also 
be released from the bone matrix during bone resorption (122). Osteocalcin that enters the 
circulation is rapidly degraded (123). Breakdown fragments are cleared via the liver and the 
kidneys, and immune-reactive osteocalcin fragments can also be detected in the urine (124). 
Urinary osteocalcin (U-OC) appears to be more related to bone resorption than bone 
formation (125;126). 
1.2.7.1.3 Procollagen type-1propetide 
During the extracellular processing of newly-synthesized type I collagen, the amino-terminal 
and carboxy-terminal extension peptides are cleaved before fibril formation (127). These 
extension peptides guide the helical folding of the collagen molecule and the released N- and 
C-terminal pro-peptides of type I collagen (PINP and PICP, respectively) can be detected in 
the circulation. PICP and PINP are considered to be quantitative measures of the newly 
formed type I collagen. Type I collagen is also a component of several soft tissues; thus, 
there is a possible contribution from sources other than bone. However, the rate of collagen 
turnover in bone is faster than in other tissues, and therefore the changes in S-PINP and S-
PICP are assumed to primarily reflect changes in collagen synthesis in bone (127). 
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1.2.7.2 Bone resorption markers 
1.2.7.2.1 Tartrate-resistant acid phosphatase (TRAP5b) 
Acid phosphatases are catalytic enzymes that act on phosphoesters in an acidic 
environment. Six isoenzymes of acid phosphatase have been identified in humans. Type 5 is 
expressed by osteoclasts and by alveolar and monocyte-derived macrophages, and is 
resistant to tartrate inhibition. Two isoforms of TRAP5 can be found in the human circulation. 
TRAP5a is sialylated and originates from macrophages and dendritic cells, whereas TRAP5b 
lacks sialic acid and is derived from osteoclasts. 
The two isoforms also have different pH optima. The biological function of S-TRAP 5b in 
osteoclasts remains elusive. It is believed to destroy the endocytosed bone matrix 
degradation products during trans-cytosis through the osteoclast. TRAP-containing vesicles 
are added to the trans-cytotic vesicles transporting matrix degradation products, and TRAP is 
believed to assist matrix degradation in vesicles by producing reactive oxygen species (ROS) 
(128). TRAP has been reported to reflect the bone resorption rate, but more recent data have 
shown that it more accurately reflects the number of osteoclasts rather than their activity 
(129). Circulating TRAP5b levels are not affected by the renal function, and the effect of food 
intake is negligible (130). Furthermore, the level of TRAP5b is relatively stable in serum 
samples (131). 
1.2.7.2.2 Collagen cross-links and cross-linked telopeptides 
Collagen structure is stabilised by intra- and intermolecular cross-links. In bone, the 
predominant cross-links are pyridinoline (PYD) and deoxypyridinoline (DPD). Pyridinoline and 
deoxypyridinoline cross-links are released during bone resorption when type I collagen is 
degraded. PYD is more predominant in collagen while DPD is the minor component, but 
since DPD is most abundant in bone and dentin, it is considered to be a more bone-specific 
cross-link (132). Cross-links are cleared by the kidney, and they can be measured in serum 
or urine either as free cross-links or when bound to short collagen peptides.  
Cross-linked telopeptides of type I collagen include the cross-linked N-terminal telopeptides 
(NTX) and cross-linked C-terminal telopeptides (CTX and ICTP). Fragments are generated by 
different collagenolytic pathways. NTX and CTX are released by cathepsin K cleavage and 
ICTP is a larger fragment produced by matrix metalloproteinases (133). CTX exists in an 
isomerised beta-CTX form and a non-isomerised alpha-CTX form. Isomerisation is 
associated with the aging of bone, and the assay for beta-CTX is therefore considered to 
measure the degradation of relatively old bone (134). Currently, beta-CTX-I is perhaps the 
most commonly used cross-link assay.  
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1.2.7.3 Use of bone turnover markers  
Bone turnover markers assessed in serum or urine can be used in three main clinical areas, 
although individual patient management guidelines are still to come. The clinical areas are: (i) 
prediction of bone loss and the risk of developing osteoporosis, (ii) identification of individuals 
with a high risk of fracture, and (iii) monitoring of anabolic or anti-resorptive therapy. 
1.2.8 Bone health assessment 
Bone can be quantitatively assessed in vivo using imaging techniques. Clinically, the 
techniques available for measuring bone mineral in children are the same as those used in 
adults, but due to the reduced availability of normal values for children, selecting an imaging 
technique and interpreting the results (135) becomes more difficult. This is because growth is 
non-linear and children of the same age can have different levels of skeletal maturity. Also, 
children of different ages, heights, weights and ethnicities cannot necessarily be compared to 
one another easily. Techniques which are commonly used for assessment of bone health are 
peripheral quantitative computed tomography (pQCT), dual energy X-ray absorptiometry 
(DXA), Quantitative Ultrasound (QUS). 
1.2.8.1 Dual energy X-ray absorptiometry (DXA) 
Dual energy X-ray absorptiometry (DXA) has been made available since the late 1980s. It is 
widely used in adult medicine as the current gold standard. Its use in paediatric is rising 
rapidly as bone health in children is becoming an area of growing concern. 
The fundamental principle of DXA is to measure the transmission of X-rays through the body 
at high and low energies. The use of two energies is to allow discrimination between soft 
tissue and bone. X-ray attenuation values are converted to pixel-by-pixel measurement of 
‘areal’ bone mineral density (aBMD in g/cm²). Software algorithms detect the bone edges and 
bone area (BA in cm²) is calculated by summing the pixels within the bone edges. The 
reported value of the aBMD is the mean bone density overall the pixels within the bone area 
and the bone mineral content (BMC in g) are calculated by multiplying the mean aBMD by 
BA. The most commonly measured sites are spine, then hip and total body; peripheral 
measurements can also be made, for example the distal forearm. Radiation dose at all the 
sites is appreciably less than that which we are exposed to from the natural environment 
(background radiation). Since the ionizing radiation dose that is used is relatively low, at only 
a tenth of that of a chest radiograph, and since the scan time is less than five minutes, this 
technique is suitable for examining children. DXA may be applied to the whole body or 
skeletal regions of interest, for example the spine, proximal femur and radius. In pre-pubertal 
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children the lumbar spine is the most useful site to scan in clinical practice. In older children 
the spine and the hip are generally scanned. 
The most significant limitation of DXA is the size dependence of the measurement. DXA 
provides a bone mineral density (BMD) based on two-dimensional projection of a three 
dimensional structure. By doing this, it does not account for the depth of the bone measured. 
The net result of this is that the BMD is of small bone is underestimated and the large bones 
BMD is overestimated. This may result in underestimation of BMD in paediatric subjects with 
growth retardation, such as some of our IBD patients. It is possible to compensate for these 
inaccuracies by correcting BMD values for bone age. Several methods have been proposed 
to adjust for the size dependence of the measurement (136-142). 
In addition to the size dependence of DXA measurements, longitudinal studies may also be 
influenced by changes in body composition, i.e. the amount of fat/lean mass overlying the 
scanned region of interest. DXA corrects for the tissue around the bone by assuming a 
homogenous distribution; in a growing child the soft tissue will be undoubtedly change and 
may cause some inaccuracies in measurement. Another limitation of DXA is that it cannot 
make distinctions between cortical and trabecular bone. 
1.2.8.2 Peripheral quantitative computed tomography (pQCT) 
Peripheral Quantitative computed tomography (pQCT) first became available in early 1990s 
(143-145). This method uses a traditional rotate-translate CT technology, and only single 
slice can be obtained (1 to 2mm thick). Peripheral QCT offers the same advantages as axial 
QCT (volumetric VMD [vBMD, mg/cm³] so size dependent; separate measures of trabecular 
and cortical bone). The technique is only applicable to the peripheral skeleton (the radius, 
tibia and femur) so is obtained at a lower cost and radiation exposure than axial QCT. 
Furthermore, pQCT distinguishes between cortical and trabecular bone. This procedure has 
so far only been put to limited use for paediatric patients (146;147). 
1.2.8.3 Quantitative ultrasound (QUS) 
Quantitative ultrasound (QUS) was first introduced in 1984 (148), when calcaneal ultrasound 
scanner was developed for assessment of bone status in adults. Measurements obtained 
from QUS are based upon the attenuation of the ultrasound beam when it passes through the 
investigated region of interest. QUS can only be applied to the peripheral skeleton and sites 
for the measurements are the phalanges, radius, calcaneus, patella, and tibia. Axial sites 
cannot be measured by QUS due to the large amount of the soft tissue and muscle that 
overlie these sites and attenuate the ultrasonic beam. Since QUS does not use ionizing 
radiation, it is especially appropriate for examining children. Paediatric studies of both healthy 
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and diseased children have been carried out to assess the method. A study of paediatric 
patients with CD showed that by comparison with the DXA method, the investigation of the 
radius and tibia with QUS was not sufficiently sensitive to detect lower BMD (149). QUS 
should therefore only be used to complement clinical practice. 
 
1.3 Cytokines in paediatric IBD 
Cytokines are the key signals in the intestinal immune system, and are known to participate in 
the distribution of the so-called normal state of controlled inflammation (physiological 
inflammation of the gut) (150). Cytokines are small peptide proteins produced mainly by 
immune cells  that facilitate communication between cells and mediate the local and systemic 
inflammation in an autocrine, paracrine and endocrine pathways (151). In IBD the innate 
immune response plays a critical role. Active dendritic cells and macrophages secrete 
cytokines that actively regulate the inflammatory response in CD and UC. Once secreted by 
these antigens presenting cells cytokine trigger and differentiate many T-cell activating the 
adaptive immune response. IBD also has a T-cell dysregulation where clearance of 
overeactive and autoreactive cells is distributed. The lack of appropriate regulation from T-
cells, participate in the exacerbation of IBD (152). CD is associated with Type I helper T-cells 
(Th1) mediated response and their cytokines: interleukin-2 (IL-2) and gamma interferon (INF-
γ). Theses Th-1 products promote a self-sustaining cycle of activation with macrophages that 
includes interleukin-12 (IL-12), which further increased Th-1 activity, and interleukins-1 and 6 
(IL-1,IL-6) and tumor necrosis factor alpha (TNF-α), which create a broader inflammatory 
response. Although macrophage derived IL-6 and TNF-α are also important for the 
pathophysiology of UC demonstrate an atypical type 2 helper-T-cell (Th2) phenotype, with 
interleukine-5 (IL-5) as a distinctive cytokine mediator (153). The anti-inflammatory cytokine, 
interleukin-1 receptor antagonist (IL-1ra), is decreased (154). 
1.3.1 Role of proinflammatory cytokines in IBD 
Pro-inflammatory cytokines are produced by various cell types and have actions as diverse 
as T-cell activation, induction of an acute phase proteins and inflammatory chemical 
pathways, stimulation of cell growth and differentiation and control of apoptosis. Evidence of 
an imbalance of proinflammatory cytokines in patient with IBD includes the positive 
correlation of serum cytokines concentrations with IBD disease activity and the effectiveness 
of IBD therapies that involve cytokine modulation (155;156). The major proinflammatory 
cytokine influential in IBD include Interleukine-1β (IL-1β), TNF-α, and IL-6 (157;158).  Data 
also suggest that the normal IL-1 receptor antagonist IL-1ra/IL-1β ratio in which IL-1ra 
predominates is decreased systemically and in the mucosa of the patients with IBD especially 
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those with CD. The imbalance of IL-1ra and IL-1β ratio appears to be associated with 
increasing mucosal inflammation but it is still unclear about the direct effect of this imbalance 
on growth and puberty in children with IBD (159;160). 
1.3.1.1 Tumor necrosis factor alpha (TNF-α) 
Tumor necrosis factor alpha is the most recognised cytokine due to the increasing use of 
TNF-α blockers for the treatment of CD and UC. TNF-α is secreted by the macrophages, 
monocytes, neutrophils, T-cells, natural killer cells (NK), following their stimulation by 
bacterial lipopolysaccharides. CD+4 T lymphocyte secrete TNF-α while, CD+8 T-cells do not. 
The synthesis of TNF-α is mainly induced by different stimuli including interferons, IL-2 and 
granulocyte macrophage colony stimulating factor (GM-CSF). The production of TNF-α is 
inhibited by IL-6 and transforming growth factor β (TGFβ). It is a potent proinflammatory 
cytokine that exerts its stimulatory effects on cells which produce INF-γ. In resting, 
macrophages, TNF-α induces the synthesis of IL-1 and prostaglandin E2 which can act in 
concert to potentiate the inflammatory cascade. TNF-α can also enhance the proliferation of 
T-cells induced by various stimuli in the absence of IL-2. Beyond its effect on immune 
response, TNF-α activates osteoclasts and thus induce bone resorption. The cytokine 
possesses both growth stimulating properties and growth inhibiting properties, and appears to 
have self regulatory properties as well. The signalling of TNF-α starts with serum soluble TNF 
receptor I and II (sTNF-RI, II) levels correlate with disease activity in IBD patients. More, 
specifically sTNF-RI is up regulated in the serum from active CD patients as compared to IBD 
patients compared to healthy controls and could be used as a marker of disease activity 
(161). sTNF-RII levels are significantly more elevated in serum from active CD patients as 
compared to UC and can be used additional parameter to differentiate both diseases (162). 
1.3.1.2 Interleukin-1 (IL-1) 
In addition to TNF-α, IL-1 seems to be important in the pathogenesis of IBD because of its 
immunological up-regulated and proinflammatory activities. The IL-1 system consists of IL-1α 
and IL-1β. IL-1 system can be also highly regulated by IL-1 receptor antagonist (IL-1Ra), as 
supported by the findings of high plasma and tissue levels of IL-1Ra in patients with IBD, 
indicating that IL-1Ra may be a part of the host mechanism for down regulation of 
inflammation (163). The IL-1Ra/IL-1 ratio decreases with increasing IBD activity, while 
remaining constant in uninvolved CD and inflammatory control specimens that may contribute 
to the pathogenesis of chronic gut inflammation (164). Increase levels of IL-1 in IBD may be 
the result of stimulation of colonic macrophages that can activate IL-1 converting enzyme and 
hence release mature IL-1β into the colonic mucosa (165). 
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1.3.1.3 Interleukin-6 (IL-6) 
In contrast to the other cytokines, IL-6 is a pleiotropic cytokine that exerts its proinflammatory 
effects largely by means of its soluble IL-6 receptor (sIL-6R). The combination of sIL-6R and 
IL-6 stimulates cells that only express glycoprotein 13 (gp130) and IL-6R, a process known 
as trans-signalling. IL-6 signalling through signal transducers and activator of transcription 3 
(STAT3) plays a central role in several immunologic reactions during the development of IBD 
and circulating levels of IL-6 and sIL-6R correlates with many clinical features of CD and UC 
(166;167). Blockade of IL-6 trans-signalling causes T-cell apoptosis, indicating that IL-6- sIL-
6R system mediates the resistance of T-cell to apoptosis in CD (168). 
1.3.2 Proinflammatory cytokines and IGF-binding proteins interactions 
Studies have reported potential interactions between proinflammatory cytokines and insulin 
like growth factor binding proteins (IGFBPs) (169-174). These studies have shown that the 
interactions were cell specific, and studies in adult rats have shown that the effects of 
cytokines on IGFBPs could also be organ specific (175). Modifications in mucosal IGFBPs 
could account for the intestinal mucosal damage that occurs in patients with IBD (174). 
Endogenous production of  IL-1 mediates the changes in IGF-I and IGFBPs induced by 
chronic abdominal sepsis in rats (176). The in vivo IL-1β administration in rats decreases 
IGF-I, increases IGFBP-1 and IGFBP-2 levels in plasma, liver and skeletal muscle and 
suppresses GH induced acid-labile subunit (ALS) mRNA levels and secretion in primary 
hepatocytes (177). There is also evidence suggesting that IL-6 is associated with reduced 
levels of IGFBP-3 which then leads to an increased clearance of circulating free IGF-1 (178). 
Moreover, the addition of IL-1β and IL-6 to cell cultures of the intestinal line Caco-2 
decreased IGFBP-2 and IGFBP-4 secretion in both undifferentiated and differentiated cells 
(174). In vivo study, in rats, has shown that the infusion of TNF-α may decrease total and free 
IGF-1 and IGFBP-3 concentration (179). 
 
1.4 Insulin-like growth factor system (IGFs) 
The IGFs were initially discovered as factors in human serum that mediate the growth 
promoting actions of growth hormone (GH) on the skeleton (180).The IGFs are proteins with 
high sequence similarity to insulin. IGFs are a part of complex system which cells use to 
communicate with their physiologic environment. This complex system often referred to as 
the IGF "axis" consists of two cell-surface receptors (IGF1R and IGF2R), two ligands (IGF-1 
and IGF-2), a family of six high-affinity IGF-binding proteins(IGFBP 1-6), as well as 
associated IGFBP degrading enzymes , referred to collectively as proteases. 
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1.4.1 Insulin like growth factor-1 (IGF-1) 
IGF-1 is a single polypeptide chain produced mainly from liver under stimulation of GH. IGF-1 
is the predominant post-natal IGF that mediates many of the growth promoting actions of the 
GH between birth and puberty (180). IGF-1 promotes longitudinal bone growth by increasing 
both size of the hypertrophic zone and the chondrocyte proliferation rate during the early 
stage of bone growth (181). The effect of IGF-1 at the proliferative phase is induced by 
shortening the time cycle rather than by clonal expansion (182).  Not only is IGF-1 abundant 
in the bone, but it appears to affect bone health through a myriad of pathways (183). In vitro 
studies have shown that IGF-1 stimulated proliferation of bone cells and collagen synthesis 
and contributed to up to 50% of the proliferation in bone cell cultures (184). IGF-1 also 
stimulated bone growth in vivo studies, and increased osteoclast differentiation (184). IGF-1 
increases both longitudinal bone growth (185) and circumferential bone growth (186). An in 
vitro study shows that the IGF-1 signalling pathway plays a vital role in regulating 
endochondral bone growth independently through the p44/42 mitogen activated protein 
kinase (Erk1/2) and phosphor-inositide 3-kinase (PI3K) pathways (87). The cellular actions of 
IGF-1 are activated by a receptor tyrosine kinase (IGF-1R) and this receptor is expressed in 
the chondrocytes of growth plate. Binding IGF-1 to its receptors in the chondrocytes initiates 
a number of autophosphorylation reactions. The IGF-1 signaling pathway can be interrupted 
by different expressions such as TNF-α and IL-1 (187). IGF-1R null mice die shortly after birth 
and show disorganisation in chondrocyte pattern and abnormalities in vascularisation and 
mineralization (188). Furthermore, the GHR/IGF-1R knocked out mice show a greater 
reduction in bone growth compared with individual gene mutation only in the IGF-1R and 
missing the GHR. In fact, the functional correlation between the GH and IGF-1 is still unclear. 
Nevertheless, IGF-1 can stimulate bone growth in the lack of GH. IGF-1 influences on 
chondrocyte functions is regulated, in part, by IGF-binding proteins (IGFBP) (189). 
1.4.2 IGF binding proteins (IGFBPs) 
There are six IGFBP that bind IGFs with high affinity and specificity. The major functions of 
these binding proteins are to 1) prolong the half-life of IGFs in circulation 2) prevent IGF 
induced hypo-glycemia 3) regulate the passage of IGFs from the vasculature to the extra 
vascular space 4) limit the bioavailability of the IGFs to interact with cell surface receptors 5) 
enhance IGF actions and 6) affect cellular proliferation and death via IGFBP receptors (190). 
The most abundant IGFBP in serum is IGFBP-3 (190-192). IGFBP-3 predominates in the 
circulation (90-95%)(193). In serum, most of the IGF-I and IGF-II are found in a complex 
formed by IGFs, IGFBP-3 and a non-IGF binding glycoprotein known as the acid labile 
subunit (ALS) (190-192). The molecular weight of IGFBP-3 in its non-glycosolated form is 29 
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kDa. However, IGFBP-3 is found in circulation in its glycosylated form with a molecular weight 
between 40 and 44 kDa (191). Its primary function in the circulation is thought to be the 
prolongment of the half-life of IGF-I. Mukherjee and Rotwein (194) demonstrated that IGFBP-
4 and IGFBP-5 predominate in bone. IGFBP-4 has ability to block the action of IGFs and 
inhibits bone formation. On the other hand, the exact function of IGFBP-5 remains 
controversial. IGFBP-5 is a polypeptide chain and the amino terminal is attached with IGF1. 
This protein is released during endochondral formation and it deposits in adult bone. Global 
knockout of IGFBP-5 in mice causes low changes in bone minerals or whole animal 
physiology. However, its over expression has a significant detrimental effect on 
mineralisation. In contrast, other studies show that IGFBP-5 in combination with IGF-1 has 
both stimulatory and inhibitory effects on bone. However, it has been found that the bone 
morphogenetic proteins -2 induced osteoblasts differentiation can be blocked by IGFBP-5 
and also suppress longitudinal growth and bone mineralisation in mice. Therefore, this study 
supports the inhibitory effect of IGFBP-5 (194). 
 
1.5 Bone health in paediatric IBD 
IBD in children leads to a profound disturbance in skeletal development. Poor bone health 
and reduced bone mineral density has been increasingly reported in children and adults with 
IBD (195;196). 
1.5.1 Mechanism of bone impairment in paediatric IBD 
The pathophysiology of bone impairment in paediatric IBD is complex and is associated with 
multiple risk factors, including growth retardation, pubertal delay, malnutrition, malabsorption, 
micronutrient deficiencies, alteration in growth hormone/IGF axis, decreased muscle mass 
and  weight-bearing activity, corticosteroid therapy and increased circulatory cytokines 
(Figure 1.5.1). Inflammation from CD may compromise bone accrual directly through bone 
active cytokines and indirectly through delayed growth and maturation, decreased physical 
activity, malnutrition and anti-inflammatory medication.  
Malnutrition, mainly due to reduced intake of calories and protein is common in children with 
IBD and can result in suboptimal bone development (197). Inflammatory cytokines promote 
osteoclastogenesis and accelerated bone resorption. TNF- α induces the expression of 
receptor activator of nuclear factor-kB ligand (RANKL). RANKL stimulates osteoclast 
differentiation and activation and inhibits osteoclast apoptosis (198;199) thereby dramatically 
prolonging osteoclast survival and increasing bone resorption.  
 
  
76
Additionally, TNF-α decreases expression of osteoprotegrin (OPG), a decoy receptor that 
blocks RANKL (200;201). Inflammatory mediators, including interleukin (IL)-1 and IL-6, also 
increase RANKL secretion and contribute to bone loss (202). TNF-α has direct effects on 
bone formation by inhibiting osteoblast differentiation and osteoblast collagen secretion, 
causing increased resorption by inducing osteoblasts secretion of IL-6, and inducing 
osteoblast apoptosis (203;204). These effects on bone formation are strikingly similar to the 
effects of glucocorticoids (205). Control of inflammation improves inflammatory cytokine 
profiles, nutrition status, muscle mass, and BMD. Use of Infliximab in adults has been shown 
to improve not only bone formation as indicated by bone biomarkers, but also BMD (206). In 
children with CD, Infliximab therapy is associated with improved bone formation biomarker 
(207) .The effect of Infliximab on bone is discussed in detail in Section (1.10). 
Hormonal disturbances associated with IBD can affect bone development and maintenance. 
Delayed puberty is often a feature of IBD (208) and is associated with a relative oestrogen 
deficiency, which may affect bone mass accrual. Hypo-gonadism can be seen in adults and 
may similarly impair bone remodeling (209). Serum insulin like growth factor-1 (IGF-1), a 
potent growth factor for bone, is commonly reduced in children with active inflammation. This 
is due to a combination of malnutrition and growth hormone signalling blockade in the liver 
and peripheral tissues (210). Low IGF-1 may impair longitudinal growth by chondrocytes, 
expansion of the outer cortical layer by periosteal osteoblasts, and recruitment of 
undifferentiated stroma cells into the osteoblast linage (211). Normal bone development is 
stimulated by weight-bearing exercise. Patients with IBD may have limited endurance and 
energy and prefer more sedentary activities. Potentially this can decrease mechanical stress 
on bone that is important to maintain its strength. Crohn's disease is associated with 
persistent deficits in lean body mass and musculature (212;213), which result in reduced 
mechanical strain and decreased bone formation (214).  
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Figure 1.5.1: Mechanism of bone impairment in paediatric IBD 
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1.6 Growth in children with chronic inflammation 
1.6.1 Normal growth in children 
Normal children grow at very different rates. A child’s growth is the result of both genes and 
environment; it appears principally mediated by hormones and nutrition (215). Linear growth 
can be represented by stature (attained height) or by the rate of growth (height velocity). A 
child’s attained height represents the culmination of growth in all preceding years; height 
velocity reflects growth status over a particular period in time. Growth can be conceptualized 
as the product of three overlapping biological phases: infancy, childhood, and puberty. Final 
height represents the sum of each of the individual components. The growth hormone/insulin-
like growth factor-1 (GH/IGF-1) axis plays a pivotal role in normal postnatal growth. IGF-1 
stimulates mitosis of epiphyseal chondrocytes resulting in linear bone growth (216). 
Thyroxine, cortisol and sex steroids are also implicated in the maintenance of normal linear 
growth. Linear growth velocity decreases from birth onwards, punctuated by a short period of 
growth acceleration (the “adolescent growth spurt”) just prior to completion of growth. As the 
rapid growth of infancy tails off, the steady growth of childhood predominates. Healthy 
children grow at a consistent rate in the range of 4 to 6 centimetres annually from six years of 
age until the onset of puberty (217). The age at which children enter puberty and the speed 
with which they progress through puberty is variable and may be influenced by a number of 
factors including genetics and the environment. 
1.6.2 Growth in children with chronic inflammatory conditions 
Chronic inflammatory disease such as juvenile idiopathic arthritis (JIA), inflammatory bowel 
disease (IBD), cystic fibrosis (CF) and systemic lupus erythematosus (SLE) may impair 
growth and lead to significant deficits in bone mass and alterations in bone microarchitecture. 
Impaired linear growth and bone mass are commonly encountered in children suffering from 
chronic inflammatory diseases both at disease presentation and following treatment. In these 
children, maintenance of skeletal health is a complex process that is influenced by a number 
of different mechanisms, including not only the steroid therapy, but also other factors such as 
the disease process, nutritional status, endocrine status and the response of the body to 
inflammatory mediators. Inflammation has a profound effect on a number of key mediators of 
skeletal development and it is likely that improvement in disease and reduction of 
inflammation will lead to improvement. The recent introduction of biologic therapy that targets 
specific mediators of the proinflammatory process is proving to be a useful adjunct in the 
therapeutic management of the child with chronic inflammation.  
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These drugs may also exert beneficial effects on the adverse effects of inflammation on 
growth and skeletal development. It is currently unclear whether these beneficial effects may 
be simply due to improvement in overall disease or due to a direct effect of the ‘anti-cytokine’ 
at the level of the target tissue involved in growth and skeletal development. 
1.6.2.1 Mechanism of growth impairment in chronic inflammation 
Chronic inflammation in children can disturb skeletal development and impair growth. This 
can be caused by a combination of factors relating both to the disease itself and to its 
secondary effects, and also to the maintenance therapy, mainly glucocorticoids, employed to 
control disease (Figure 1.6.1). Growth retardation can be variably defined as “height below 
third percentile”, “height velocity or weight gain below the third percentile”, “bone age retarded 
by two years” (69)  or “height velocity below third percentile for age and bone age greater 
than two standard deviation below chronological age” (70) and “no signs of puberty”, and out 
with the target range (218;219). In JIA, linear growth impairment is reported in 11% to 41% of 
patients with systemic forms of JIA (220;221). In CD final height may be substantially reduced 
in 15-30% of patients (219). Growth failure is frequently seen in cystic fibrosis (CF), and has 
been attributed to both malnutrition and to chronic inflammation (222). One study in 70 
patients with childhood systemic lupus ertythematosus found that the average height was 
less than age- and sex-matched healthy controls (223). Nutrition is another important factor 
that determines bone mass and growth. Protein intake is important for muscle development, 
calcium intake for skeletal development and, in JIA; these factors have been shown to be 
associated with bone mineral density (224). The association between body weight and bone 
mass (225), may be attributed to the effect of leptin, the GH/IGF-1 axis (226) as well as the 
mechanical effect of muscle on bone (227).  
The effect of under nutrition on skeletal development has been studied primarily in children 
affected by IBD who may have low lean mass and low bone mineral density (228). Besides 
low IGF-1 levels, impaired nutrition state may also be associated to reduced levels of thyroid 
hormone (229). In CD prospective studies show that growth failure correlates strongly with 
disease activity (230). In children with systemic JIA, childhood CD and perinatal HIV 
infections, an inverse correlation has been found between circulating IL-6 and both IGF-1 and 
IGFBP-3 levels. Furthermore, a direct link between IL-6 and adverse bone health has been 
found in CF, where raised IL-6 levels were associated to reduced bone mineral content gain 
and raised markers of bone resorption (231;232).  
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Figure 1.6.1: Mechanism of growth failure in children with chronic inflammatory conditions 
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In CD, serum IL-6 has been reported as an important inhibitory mediator and has been shown 
to inhibit bone mineralization in vitro (233). Increased IL-6 may therefore represent a general 
mechanism by which chronic inflammation affects the developing skeleton. Most studies that 
have studied final adult height in those with childhood-onset CD show a variable degree of 
persistent short stature on completion of growth (221;234). Some studies have suggested 
that up to 25% of patient may not be able to achieve full growth potential (235;236). 
 
1.7 Puberty development in children with IBD 
1.7.1 The pubertal processes in healthy children and adolescents 
Puberty is defined as the sequential biologic process that ultimately leads to reproductive 
capacity (237). Serum levels of dehydroepiandrosterone (DHEA) and its sulphate (DHEAS) 
begin to rise at approximately 6-8 years of age before the physical changes of puberty. This 
is called adrenarche and typically antedates the onset of gonadal puberty, i.e. gonadarche, by 
a couple of years. In adrenarche a slight increase in linear growth rate (mid-childhood growth 
spurt) and possibly the appearance of some pubic and/or axillary hair, predominantly in girls, 
can take place (238). 
The onset of gonadarche is initiated following the synthesis and secretion of luteinizing 
hormone releasing hormone (LHRH, also called as gonadotropin releasing hormone GnRH), 
in the hypothalamus and its transport to ganadotrophs inside the pituitary. Once stimulated by 
LHRH, the ganadotrophs secretes the gonadotropin luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) which regulate ovarian and testicular function. Pituitary sensitivity 
to LHRH varies throughout life but increases prior to the onset of puberty. During this time the 
LH begins to be secreted in a pulsatile manner during sleep but subsequently changes to 
pulsatile pattern throughout the day as puberty progresses (239). This pulsatile secretion of 
gonadotropin is responsible for the enlargement of the testicles and the ovaries and the 
secretion of sex steroids, testosterone and estradiol. The sex steroids then cause the 
development of the secondary sex characteristics. These can be classified in 5 stages 
according to Tanner (10) evaluating breast development and pubic hair in girls, and genital 
organ development and pubic hair in boys. Serum levels of testosterone and estradiol, as well 
as DHEAS, continue to increase throughout puberty. 
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1.7.1.1 Pubertal assessment 
The Tanner Pubertal Stages are commonly used to assess the progression through 
adolescence and puberty for both males and females (240). The system rates, over five 
stages, the development of genitalia and pubic hair in males and pubic hair and breast 
development in females (10). Adolescents are often asked to rate themselves, or self-report, 
using the Tanner stages for their sex. Black and white drawings of the stages of genital, 
breast and pubic hair development for females, or genital and pubic hair development 
combined with an orchidometer (a string of 12 wooden beads approximating the size, shape 
and volume of the testes) for males are used. It is important to note that there will always be a 
certain amount of error in every self-reporting system, however self-assessment may 
sometimes be preferable to being examined by a study investigator (241). Puberty and 
skeletal maturity are closely related. In fact, puberty is much more related to skeletal 
maturation than it is to chronological age (10). In normal circumstances, children who reach 
maturity faster and begin puberty earlier are often shorter in stature than those who mature at 
a slower rate (10). This is because sex-steroids or hormones, which play an essential role in 
puberty, also play an essential role in determining the timing of the cessation of bone growth, 
e.g. epiphyseal fusion (242). 
1.7.2 Pubertal delay in children with IBD 
The complex interactions between severity of disease, fluctuations in inflammatory cytokines 
and their effect on nutritional status and hormonal profile make it difficult to determine how 
individual factors influence the onset and progression of puberty in paediatric patients with 
IBD. Under nutrition in the absence of disease may cause delay in menarche and sexual 
maturation. Reduction in calorie intake has been documented in many studies of paediatric-
onset IBD, especially CD (79;243;244). Thus, under-nutrition is likely to be one of the 
contributing factors leading to delay in the onset and progression of puberty. In vitro studies 
have elucidated ways in which pro-inflammatory cytokines, known to be elevated in patients 
with IBD such as TNF-α, IL-6 and IL-1β affect endocrine function. Several, of these findings 
may be applicable to explaining pubertal delay in patients with chronic IBD (219).  
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1.8 Biologic therapy in paediatric IBD 
In paediatric patients with IBD, therapeutic interventions should be aimed to resume weight 
gain and promoting growth and development as these are the major complications of 
paediatric IBD, particularly in CD. Therefore, these aims should be achieved within a 
relatively short period of opportunity, before growth impairment and development deficiencies 
become permanent. Conventional treatment of CD consists of enteral nutrition, 
corticosteroids, anti inflammatory agents and immunomodulators. However, these treatments 
have been largely unsuccessful in altering the natural course of the disease (245). The 
1990’s have been characterized by the introduction of biological therapies. Biological therapy 
refers to the use of medication that is tailored to specifically target an immune or genetic 
mediator of disease (103). Biologics are proteins which selectively block or neutralize the 
effects of cytokines, such as TNF-α and include fusion proteins and monoclonal antibodies 
(246;247). Biologic therapy has found a niche in the management of cancer (248;249), 
autoimmune disease (250) and diseases of unknown cause that result in symptoms due to 
immune related mechanisms (251;252). The biological agents that have been evaluated for 
the treatment of CD include: the anti-TNF-α inhibitors Infliximab, Adalimumab, Certolizumab 
pegol and anti-adhesion molecule (Natalizumab) (Table 1.8.1). 
1.8.1 Infliximab 
Infliximab (Remicade) is a chimeric IgG-1 monoclonal antibody with a high specificity for TNF-
α. It was the first biologic therapy that was approved for IBD by the U.S. Food and Drug 
Administration (FDA) in 1998. According to the National Institute for Health and Clinical 
Excellence (NICE), Infliximab was licensed in 2008 for use in paediatric CD and 2012 for UC.    
Infliximab, within its licensed indication, is recommended for the treatment of paediatric 
patients aged 6-17 years with severe active CD whose disease has not responded to 
conventional therapy (including corticosteroids, immunomodulators and primary nutrition 
therapy), or who are intolerant of or have contraindications to conventional therapy.  This drug 
is 25% murine-derived and 75% human (Figure 1.8.1). It is administered as an IV infusion, 
and has a half-life of 9.5 days. The binding epitope for TNF-α is of murine origin while the IgG 
fragment is of human origin. Infliximab neutralizes the biological activity of TNF-α by binding 
with high affinity to the soluble (free floating in the blood) and transmembrane (located on the 
outer membranes of T-Cells and similar immune cells) forms of TNF-α and inhibits or 
prevents the effective binding of TNF-α with its receptors.  
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Besides neutralization of TNF-α, Infliximab also blocks leucocytes migration and induces 
apoptosis of T-lymphocytes and monocytes (253-257). The latter is believed to be one of the 
key mechanisms of action of the drug. A third mechanism involves complement fixation and 
complement-dependent cytotoxicity and antibody-dependent cytotoxicity (258).  
1.8.2 Adalimumab 
Adalimumab (HUMIRA (Human Monoclonal Antibody in Rheumatoid Arthritis) produced by 
the phage-display technology. It was the first humanised monoclonal antibody drug approved 
by the FDA in 2002. Adalimumab is indicated for the treatment of severe, active CD in 
patients whose disease has not responded despite full and adequate treatment with an 
immunosuppressant and/or corticosteroid, or who are intolerant to or have contraindications 
to such therapies. Adalimumab is not currently licensed for use in paediatric IBD patients in 
UK. Adalimumab is a fully human IgG1 monoclonal antibody to TNF-α (Figure 1.8.1). It fixes 
complement, mediates antibody-dependent cytotoxicity, and induces T-cell apoptosis 
(259;260). It is administered subcutaneously, and has a half-life of 12–14 days. Controlled 
trials have shown that Adalimumab is effective for the treatment of rheumatoid arthritis 
(261;262), psoriatic arthritis (263) and ankylosing spondylitis (264). In addition, 4 placebo 
controlled trials have demonstrated that Adalimumab is effective for the induction and 
maintenance of remission in adult patients with CD and based on these studies it recently 
received regulatory approval in the U.S for this indication (265-268). 
1.8.3 Certolizumab pegol 
Certolizumab is a humanized TNF-α Fab monoclonal antibody fragment linked to 
polyethylene glycol (PEG) (Figure 1.8.1) that is administered subcutaneously. Its half-life is 
2weeks. In vitro, certolizumab pegol has a high affinity for TNF-α, it is devoid of the Fc portion 
of the antibody and does not induce complement activation or antibody-dependent cellular 
cytotoxicity, and it does not induce apoptosis in T-cells or macrophages. 
1.8.4 Natalizumab 
Natalizumab is a humanized IgG4 monoclonal antibody against the adhesion molecule α4 
integrin, which is involved in migration of leukocytes across the endothelium, and is up-
regulated in sites of inflamed endothelium. It is administered intravenously every 4 weeks. Its 
half-life is 11 ± 4 days. Natalizumab is used in the treatment of multiple sclerosis (269) and 
CD (270). It was approved in 2004 by the U.S FDA. It was the first drug developed in the 
class of selective adhesion molecule inhibitors. 
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1.8.5 Safety profile and side effects of biologic therapy in IBD 
Crohn’s disease refractory to conventional therapy, fistulising CD and chronic active UC 
generally respond well to anti-TNF therapy. However, the use of biologics is associated with 
significant, but rarely, fatal complications, leading to serious concerns about safety and long-
term consequences. Potential side effects of anti-TNF therapy include opportunistic 
infections, which show a higher incidence when concomitant immunosuppressive therapy, 
such as steroids or thiopurine is used (271). Serious infections during anti-TNF therapy 
include the reaction of the latent tuberculosis. Therefore, tuberculosis screening prior to 
starting anti-TNF therapy is recommended.  
The monoclonal antibodies used for anti-TNF therapy frequently induce the formation of 
antibodies (ATIs), human anti-chimeric antibodies (HACA) and human anti-humira antibodies 
(HAHA).  ATIs are associated neutralising and interfere with the efficacy and safety of the 
drug. ATIs are associated with acute infusion reactions and loss of response and with 
delayed hypersensitivity phenomena. Acute infusion reactions are manifested by shortness of 
breath, chest pain, palpitation, flushing, headache, urticaria and hypotension. The prevalence 
of acute infusion reactions varies greatly between studies depending on the sample size, 
dosing, regimen (episodic or maintenance) and concomitant therapies, but ranges in most 
studies between 15-25% (252;272;273). 
1.8.6 Infliximab in paediatric CD 
Studies evaluating the safety and efficacy of Infliximab in children were first reported in 
several non-randomized studies (156;274-277). These initial studies showed that the 
response and remission rates (both partial and complete) were far superior compared to 
conventional therapy. Interestingly, its efficacy in children appeared to be higher than in 
adults (156;275). In a multicentre, open-label, dose-blinded trial (n = 21), Baldassano and co-
workers demonstrated the efficacy and safety of a single infusion of Infliximab in the 
treatment of paediatric CD. During the 12-week duration of the study, 100% achieved a 
clinical response and 48% achieved clinical remission, with significant improvements in the 
paediatric CD activity index (PCDAI), modified CDAI, erythrocyte sedimentation rate, and 
other outcome variables of interest. There were no infusion reactions in any of the patients 
and it was suggested that Infliximab may be safe and effective as short term therapy of 
medically refractory moderate to severe CD (278). A prospective study published by Cezard 
and coworkers also explored the efficacy and toxicity of Infliximab in children with severe CD. 
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Twenty-one children (median age 15, range 13 to 17) were treated with Infliximab with an 
induction sequence of 5 mg/kg at 0, 15, and 45 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8.1:  Structure of biological therapies to treat Crohn’s disease 
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Table 1.8.1:Biological therapies in IBD and their mechanism of action  
 
Drug 
 
Action 
 
Route of 
administration 
 
Dose 
 
Indications 
 
Infliximab 
(Remicade) 
 
Chimeric human/mouse monoclonal antibody that binds to the 
soluble TNF- α and its membrane bound precursor neutralizing its 
action 
 
IV infusion 
 
5mg/kg 0, 2 and 6 
weeks 
 
Rheumatoid arthritis 
Psoriatic arthritis 
Ankylosing spondylitis 
Plaque psoriasis 
Crohn’s disease  
Ulcerative colitis  
 
Adalimumab 
(Humira) 
 
A humanized immunoglobulin G1 monoclonal antibody which 
binds to  TNF- α 
 
Sub/cut injection  
 
24mg/m2  
Maximum 40mg 
every other week 
 
Rheumatoid arthritis 
Psoriatic arthritis 
Ankylosing spondylitis 
Plaque psoriasis 
Crohn’s disease  
 
 
Natalizumab 
(Tysabri) 
 
 
Humanized IgG4 monoclonal antibody  against the adhesion 
molecule
 
α4 integrin 
 
 
IV infusion 
 
 
3mg/kg 0, 2 and 6 
weeks 
 
 
Multiple Sclerosis 
Crohn’s Disease 
 
Certolizumab pegol 
(Cimzia) 
 
Humanized TNF- α Fab monoclonal antibody fragment linked to 
polyethylene glycol(PEG) 
 
Sub/cut injection  
 
400 mg 0,2 and 4 
weeks, then every 
4weeks 
 
Crohn’s Disease in Adults 
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Nineteen children were in complete remission (defined as Harvey-Bradshaw index (HBI) <4) 
on day 45. 14/21 patients had stopped taking steroids at 3 months, and all had stopped 
parenteral nutrition. All perianal fistulas (n = 12) were also closed by day 90 and the drug 
appeared to be well tolerated (279). Much evidence at present comes from retrospective 
analysis of children treated with Infliximab, often as a rescue medication. In a retrospective 
study in children and adolescents with either corticosteroid dependent or resistant CD, 
patients were randomized to receive 1 to 3 infusions of Infliximab (5 mg/kg/dose) over a 12-
week period. The mean daily prednisone dosages decreased significantly in all the patients 
(P<0.01) studied. A significant initial improvement (as assessed by a significant decline in 
PCDAI value) was noted in all subjects (P<0.0001). Interestingly, over the subsequent 8-
week period, 8 of 19 treated subjects had worsening of symptoms (280). Lamireau and 
coworkers (272) described yet another retrospective study in 88 children and adolescents 
(median age: 14, range: 3.3 to 17.9) treated with Infliximab for active disease (66%) and/or 
fistulas (42%) that were refractory to corticosteroids (70%), and/or other immunosuppressive 
(82%) agents, and/or parenteral nutrition (20%). Patients received a median of 4 (1 to 17) 
infusions of 5 mg/kg of Infliximab during a median time period of 4 months (1 to 17 months). 
From day 0 to day 90, the Harvey-Bradshaw score decreased from 7.5 to 2.8 (P<0.001), with 
a significant decrease in both C-reactive protein and ESR (P< 0.001). At day 90 after the first 
infusion of Infliximab, 49% of patients had symptom improvement, 29% were in remission; 
53% of patients could be weaned off of corticosteroids and 92% off of parenteral nutrition 
(272). The authors in both these studies concluded that treatment with Infliximab was well 
tolerated and effective in most children and adolescents with CD refractory to conventional 
immunosuppressive therapy. No serious events were noted in any of these studies. 
The FDA approval for the use of Infliximab therapy in paediatric CD was based on the results 
of the much publicized REACH clinical study, a randomized, multicenter, open-label study to 
evaluate the safety and efficacy of Infliximab in paediatric subjects with moderate to severe 
CD. A total of 112 paediatric patients (ages 6 to 17 years) with moderate to severe CD who 
took part in this study received Infliximab at 5 mg/kg at week 0, 2 and 6. Patients, who had 
symptom improvement or showed response, were then randomized to 2 groups and received 
Infliximab every 8 or 12 weeks for almost 1 year. A concurrent immunomodulator was also 
required. At week 10, 88% patients showed response (defined as decrease from baseline in 
the PCDAI score ≥15 points; total score ≤30) and 58% patients achieved clinical remission 
(defined as PCDAI score ≤10 points).  
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At week 54, 63% and 56% patients receiving Infliximab every 8 weeks were in clinical 
response and clinical remission, respectively, compared with 33% and 23% patients receiving 
treatment every 12 weeks (P=0.002 and P<0.001, respectively). The data from this important 
prospective trial thus suggested that Infliximab is not only highly effective in inducing clinical 
response and remission but also in maintenance of remission, more so with an 8-week 
dosing compared with every 12-week dosing (273).The same research consortium also found 
Infliximab to be an effective therapy in children with perianal disease, including patients with 
perianal fistula (281) and in prolonging the withdrawal of corticosteroids over a 3-year follow-
up period (282). Similar observations have also been made in a European study in children 
with CD. In that study, children on an on-demand treatment schedule were more-likely to 
experience a relapse (92%) when compared to patients on 2-month infusion schedule (23%) 
(283). 
1.8.7 Adalimumab in paediatric CD 
Adalimumab is used primarily in clinical practice for patients who are primary anti-TNF 
responders, but become intolerant or non responsive to Infliximab (284-286). Adalimumab is 
not currently licensed for use in paediatric IBD patients. The published experience to date of 
Adalimumab in children is limited mostly to case reports (287-290) and small clinical case 
series (291-294) with the exception of one large retrospective RESEAT study by Rosh et al 
(295) and recently published prospective IMAgINE 1 study by Hyams et al (296)(Table 1.8.2). 
RESEAT study reposted Adalimumab to be well-tolerated and effective rescue therapy for 
moderate-to-severe paediatric CD patients previously treated with Infliximab. Moreover it was 
also reported that Adalimumab response was steroid sparing as it was not enhanced by the 
use of concomitant immunomodulators and >70 % of patients achieved rapid response that 
was sustained through 12 months (295). 
IMAgINE 1, is a randomized, multicenter, open-label study which evaluated the safety and 
efficacy of 2 Adalimumab double blind maintenance dosing regimens in paediatric patients 
with moderate to severe CD. A total of 192 paediatric patients (ages 6 to 17 years) with 
moderate to severe CD who took part in this study received open label induction therapy with 
Adalimumab at week 0 and week 2. Patients who weighed ≥40 kg at baseline received 
subcutaneous adalimumab 160 mg at week 0 and 80 mg at week 2, and patients who 
weighed ≤40 kg at baseline received subcutaneous adalimumab 80 mg at week 0 and 40 mg 
at week 2. At week 4, patients were randomly assigned (1:1) to high-dose or low-dose 
adalimumab double-blind maintenance therapy for 48 weeks, stratified according to their 
week 4 responder status and prior exposure to Infliximab.  
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Clinical response was defined as decrease in the PCDAI score ≥15 points from baseline. 
Starting at the week 12 study visit, patients who experienced disease flare or nonresponse to 
treatment were switched from blinded every other week dosing to blinded weekly dosing, 
continuing with the same dose. Disease flare was defined as an increase in the PCDAI of ≥15 
points when compared with week 4 and an absolute PCDAI >30. Nonresponse was defined 
as 2 consecutive visits at least 2 weeks apart in which a decrease in PCDAI ≥15 points from 
baseline was not achieved. Patients were assessed at baseline and weeks 2, 4, 8, 12, 16, 20, 
26, 32, 40, 48, and 52. A total of 152 patients (80.9%) completed all 26 weeks of the study. At 
week 26, 63 patients (33.5%) were in clinical remission, with no significant difference 
between high-dose (38.7%) and low-dose groups (28.4%) (p=0.075). This study did not raise 
any safety concerns (296). It is now increasingly clear that Adalimumab is used widely in 
paediatric clinical practice. 
1.8.8 Infliximab in paediatric UC 
The experience with Infliximab in the treatment of paediatric patients with ulcerative colitis is 
quite limited, except one all published studies are retrospective, non-controlled, and include a 
small number of patients (Table 1.8.3) (297-301). Moreover, there is no homogeneity either in 
the inclusion criteria for treatment (although most patients had a steroid-refractory or steroid- 
dependent moderate-to-severe disease), or the definition of short- and long-term response. 
There is also a lack of consensus regarding the induction and maintenance dose as well as in 
the concomitant use of immunomodulators. Hyams et al (301) prospectively evaluated the 
efficacy and safety of Infliximab for inducing and maintaining benefit in paediatric patients 
with moderately to severely active UC. In this study paediatric patients (ages 6 to 17 years) 
who had active UC and had not responded to or tolerated conventional treatment were given 
5 mg/kg Infliximab at weeks 0, 2, and 6. The primary end point was the response at 8 weeks. 
Patients, who responded, were then randomized to 2 groups and received Infliximab every 8 
or 12 weeks and followed through 54 weeks. At week 8, Infliximab induced a response in 
73.3% of patients. Among responders, twice as many were in remission at week 54 after 
8weeks (8 of 21, 38.1%) than 12 weeks (4 of 22, 18.2%; p=0.146) therapy. The overall 
remission rate at week 54 for all enrolled patients was 28.6% (301). Eidelwein et al (297), 
reported the outcome of 12 paediatric patients with UC who received Infliximab for the 
treatment of fulminant colitis, acute exacerbation of colitis, steroid-dependent colitis and 
steroid refractory colitis. Nine patients had a complete short-term response, and 3 had partial 
improvement. With a median follow-up time of 10.4 months in this study, three patients 
underwent colectomy (297).  
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Another study by Mamula et al (298) have reviewed charts of 17 children with UC that were 
unsuccessfully treated with a traditional pharmacologic approach and underwent Infliximab 
therapy clinical improvement, i.e. avoidance of restorative proctocolectomy or lack of need for 
rescue medications, was observed in 75% of the patients. A response to the initial dose of 
Infliximab seen in 14 of 17 (82%), while 10 of 16 (63%) had a sustained response. 
Concomitant corticosteroid could be discontinued in six patients; two patients underwent 
colectomy after two years follow-up (298;302). Russell and Katz (299), described 14 children 
with UC treated with Infliximab: a clinical response occurred in 9 (299). Serrano et al (300) 
reported Infliximab to be associated with remarkable clinical improvement. McGinnis et al 
(303) conducted a largest paediatric study to date evaluating the effectiveness of Infliximab in 
UC and reported 75% response rate. Although the few published reports about the use of 
Infliximab in paediatric UC patients are encouraging, but still larger studies with more 
extensive follow-up are needed to adequately position this drug in paediatric UC also. 
Adalimumab has not been proven to be effective for paediatric ulcerative colitis. 
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Table 1.8.2: Published paediatric Adalimumab studies to date (adapted from Russell et al (304)) 
 
Study 
 
N 
 
Prior Infliximab 
 
Initial dosing used in mg (no of 
patients) 
 
Clinical 
Response 
 
Comments 
US 
2012 (296) 
192 46.3% 160/80(93),80/40(95) 63% No safety signals 
detected,  
Included >18years 
 
UK and ROI 
2011(304) 
 
72 
 
94% 
 
160/80(3), 80/40(41), 24 mg/m² (16) 
other (10) 
 
71% 
 
2 deaths 
 
USA 
2008(294) 
 
10 
 
100% 
 
80/40(4), 40(5), 80(1) 
 
80% 
 
Mean PCDAI 12 at start 
 
USA 
2008(292) 
 
15 
 
100% 
 
80/40(11), 40(1), 80(1), 40/20(1), 
160/80(51) 
 
64% 
 
Included >18years 
 
USA(RESEAT) 
2009 (295) 
 
115 
 
95% 
 
160/80(22), 80/40(51), 40/40 (17) 
other/unknown (9) 
 
65% 
 
Short follow-up period 
 
Israel 
2010(293) 
 
14 
 
71% 
 
Dosing schedule not available 
 
85% 
 
Included >18years 
 
Italy  
2009(291) 
 
23 
 
61% 
 
160/80(13), 120/80(2) 
 
91% 
 
Prospective;80mg 
maintenance in most 
In addition to the case series listed there have been at least four published paediatric case reports (287-290)  
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Table 1.8.3: Studies evaluating the efficacy of Infliximab in paediatric patients with UC (adapted from (305;306) 
 
Study 
 
N 
 
Severity 
(mild/mod/severe) 
 
Pre- Imm 
(N) 
 
Repeated 
infusion 
 
Short-term outcome 
 
Duration 
(weeks) 
 
Long-term outcome 
 
Duration 
(months) 
Hyams et al, 
2012 (301) 
60 0/0/60 - Yes Response: 44/60 (73.3%) 8 Response 8 weekly group (38.1%) 
Response 12 weekly group (18.2%) 
Overall remission : 28.6% 
54 
 
Eidelwein at al,  
2005(297) 
 
12 
 
0/6/6 
 
8 
 
 
Yes 
 
 
Response: 12/12 (100%) 
Remission: 9/12 (75%) 
 
2 
 
Response: 8/12 (67%) 
Remission: 9/12 (75%) 
 
10.4 
 
Mamula et al, 
2002,2004(298;302) 
 
 
17 
 
1/10/6 
 
12 
 
Yes 
 
Response: 14/17 (82%) 
Remission: 6/9 (66%) 
 
0.3 
 
Response: 1016(63%) 
 
 
9.5 
Russell and Katz 
2004(299) 
14 
 
0/5/9 7 
 
Yes 
 
Response: 8/14 (57%) 
 
2.6 
 
Remission: 8/14 (57%) 
 
12 
 
 
McGinnis et al, 
2004(307) 
 
29 
 
0/0/29 
 
- 
 
- 
 
Response: 18/29 (70%) 
 
4 
 
Response: 5/29 (17%) 
 
 
12 
 
Serrano et al, 
2001(300) 
 
3 
 
- 
 
3 
 
- 
 
Response: 3/3(100%) 
 
 
- 
 
Response: 1/3 (33%) 
 
 
1.5 
 
Olivia-Hemker et al, 
2002(308) 
 
5 
 
- 
 
3 
 
Yes 
 
Response: 5/5 (100%) 
Remission: 2/5 (40%) 
 
2 
-  
- 
Except one all studies are retrospective and non-controlled series 
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1.9 Effect of biologic therapy on growth  
1.9.1 Effect of biologic therapy on growth in paediatric CD 
Studies that report the effect of biologics on growth in children with CD are summarized in 
(Table 1.9.1). Although two studies have shown no improvement in growth after Infliximab 
therapy (247;309) a number of studies have reported beneficial effects of Infliximab on growth 
in children with CD, as early as 6 months after start of therapy (156;207;279;310;311). 
Cezard et al prospectively followed 21 children with severe CD and reported an improvement 
in a subset of 10 children who had growth measurements (279). Borrelli et al reported an 
improvement in SDS for height 6 months after initiating a maintenance course of Infliximab in 
eight patient ages 6-18 years. Another important finding in this study was that the weight and 
height gain were significantly higher in patients on maintenance therapy than in those treated 
with only three infusions of Infliximab (156). Walters et al not only reported an improvement in 
height velocity but also suggested that growth was more likely to improve in those who were 
in the earlier stages of puberty and those who showed clinical response (311).  
The multicentre REACH study evaluated the role of Infliximab as a maintenance medication 
in 103 children responsive to Infliximab over 54 weeks. In this study, HtSDS improved 
significantly from baseline -0.76±1.24 to 54-week -0.49 ± -0.50 (207). In a recent review of 
growth and its relationship to treatment modalities in 176 children with CD, improvement in 
height was least likely in those receiving GC therapy, reported improvement in median height 
z-scores from baseline -0.5(-1.2-0.6) to -0.5(-2.2-0.1) and -0.8(-2.8-1.4) at 6 and 12 months 
follow-up(312). Crombé et al, demonstrated that the height z-scores of children responding to 
Infliximab improved from -0.57 ± 1.18 to -0.25 ± 0.99 over the period of follow-up. In contrast, 
non-responders to Infliximab had no catch-up growth (313). The recently published 
multicentre IMAgINE 1, randomized, open-label study of Adalimumab for paediatric patients 
with moderate to severe CD also reported significant improvement in HV z-score from BL to 
26weeks and 52weeks (296).  
1.9.2 Effect of biologics on growth in paediatric JIA 
Biological agents, particularly Etanercept and Infliximab, have also been found to be effective 
in restoring normal growth in children with JIA (Table 1.9.2). Schmeling et al reported an 
increase in growth velocity from 3.7 ± 1.2 cm before the beginning of Etanercept therapy to 
7.6 ± 1.2 cm in the first year of treatment. The average Ht SDS increased from -2.4 to -1.9 
after one year and to -1.1 ± 0.9 after two years indicating catch-up growth. However, 7 out of 
18 patients with refractory JIA treated with Etanercept demonstrated growth retardation 
leading to short stature (314). Tynjala et al observed a significant increase in growth velocity 
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over a two-year follow up period before and after the initiation of anti-TNF treatment. This 
mainly reflected the increase in the growth velocity of the 53 patients with previously delayed 
growth. Mean HtSDS increased by +0.45 during the two years on anti-TNF treatment. There 
were no differences between the patients receiving Etanercept or Infliximab treatment in the 
change of growth velocity, height adjusted relative weight, or BMI (315). Vojvodich et al 
studied the longitudinal growth in response to Etanercept treatment in pre-pubertal and 
pubertal patients with JIA. This is the only study which reported the effect of TNF-α blocker 
therapy on longitudinal growth in relation to puberty and separately analyzed the growth 
response to Etanercept treatment in pre-pubertal and pubertal children (316).  
Two other studies have shown that the beneficial effect of biologic therapy on growth may be 
more likely when the patient is receiving background immunnosuppression therapy using 
methotraxate (317;318). Giannini et al (318) conducted a 3-year, open label nonrandomised 
study to evaluate the effects of longterm anti-TNF-α Etanercept treatment with or without 
methrotrexate on growth in children with selected categories of JIA. This study reported 
statistically significant increase in mean height percentiles from baseline for Etanercept 
monotherapy at year 3 only and for etanercept in combination with the methrotrexate group at 
1,2 and 3 years (318). In a similar study Billiau et al (317) also reported a significant 
improvement in growth velocity allowing catch-up growth in in a comibined etanercept and 
Methotrexate group only (317).  
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Table 1.9.1: Biologics in chronic inflammatory conditions: growth outcome studies in Crohn’s disease 
 
Study 
 
N 
 
Study 
 (months) duration 
 
Study Design 
 
Results 
Hyams et al 
2012 (296) 
192 12 Prospective-randomized  to 
2 doses 
 
Mean HV z-score increased from -0.98 at baseline to 1.66 at 26 weeks 
(p=<.001) and 1.80 at 52weeks (p=<.001) in low dose Adalimumab group  
Mean HV z-score increased from -0.37 at baseline to 1.38 at 26 weeks 
(p=0.008) and 2.07 at 52weeks (p=0.001) in high dose Adalimumab group  
Crombé et al 
2011(313) 
 
102 32 Retrospective Mean Ht z-scores increased from (-0.57± 1.18) to (-0.25 ± 0.99) p=0.04 in IFX 
responders  
Mean Ht z-scores decreased from (-0.54± 1.44) to (-0.52 ± 1.27) p=0.52 in IFX 
non-responders  
 
Sinitsky et al  
2010(312) 
 
16 12 Retrospective Median Ht-z-score baseline -0.5(-1.2-0.6) 
Median Ht-z-score 6 months follow-up -0.5(-2.2-0.1) 
Median Ht-z-score  1 year follow-up -0.8(-2.8-1.4) 
Pfefferkorn et al 
2009(310) 
176 12-24 Prospective Mean HtSDS at diagnosis: 0.49±1.2 (-0.66 to -0.31) 
Mean HtSDS 1 year follow-up: 0.50±1.2 (-0.67 to -0.32) 
Mean HtSDS 2 year follow-up: 0.46± 1.1 (0.96 to -0.23) 
Diamanti et al 
2009(247) 
28 10 Retrospective matched 
control 
Case group (14) 
Mean HtSDS baseline (146.1±0.2) to final  (147.8±0.3) 
Control group (14) 
Mean HtSDS baseline (147.4±0.2) to final (148.5±0.1) 
Thayu et al 
2008(207) 
103 12 Prospective-randomized  to 
2 doses 
 
Mean HtSDS from baseline (-0.76± 1.24) to 54-week (-0.49 ± -0.50) 
 
Walters et al  
2007(311) 
24 12 Retrospective 
 
Mean HtSDS at baseline (-1.15 ±1.2)  
Tanner I-III: Mean ∆HVSDS  +3.94 , mean ∆HtSDS +0.50, P < 0.001  
Tanner IV-V: Mean ∆ HV SDS +0.22, mean ∆HtSDS 0.02, P = NS 
Wever et al 
2006(309) 
24 3 Retrospective 
 
Mean HV cm/month before 0.32 & after 0.42 P =0.36 
 
Borrelli et al 
2004(156) 
 
18 
 
6 
 
Prospective non-
randomized 
 
 
Overall group 
HtSDS baseline ( -0.99 ± 0.62) to 6 months after (-0.74 ± 0.71) p<0.01 
Non-retreated group  
HtSDS baseline (-0.86 ± 0.42) to 6 months after (0.83 ± 0.40) p=NS 
Retreated group  
HtSDS baseline (-1.15 ± 0.81) ) to 6 months after (-0.62 ± 0.99) p<0.01  
Cezard et al 
2003(279) 
10 12 Prospective non-
randomized 
 
Mean HtSDS before -0.5 (-1-1.3) & after +0.5 (0 -1.3) p=0.004 
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Table 1.9.2: Biologics in chronic inflammatory conditions: growth outcome studies in juvenile idiopathic arthritis 
 
Study 
 
N 
 
Study duration 
 
 Study Design 
 
Results 
 
 
Giannini et al  
2010 (318) 
 
 
594 
 
 
3 years 
 
 
Open-label nonrandomized 
Mean height percentiles increased from baseline in Etanercept treated patients at year 
3 (4.8 percentile points) 
Mean height percentiles increased from baseline in Etanercept + Methotrexate  
treated patients at 1,2, and 3 years (2.4, 3.3, and 5.6percentile points) 
 
 
Billiau et al 
2010(317) 
 
 
24 
 
 
18 months 
 
 
Prospective open-label 
 
Median growth velocity increased in Etanercept + Methotrexate 
Treated group at 12 months compared with baseline and this increased persisted till 
18 months  
 
 
Schmelling et al 
2007(314) 
 
 
 
7 
 
 
12 months 
 
 
Prospective 
 
HV cm/year before (3.7 ± 1.2) to (7.6 +/- 1.2) in the first year of treatment (p= 0.001). 
Average SDS increased from (-2.4 ± 1.0) to (-1.9 ± 0.9) after I & 2 years (-1.1 ± 0.9) p 
= 0.05 
 
 
Tynjala et al 
2006(315) 
 
 
71 
 
 
24 months 
 
 
Retrospective 
 
Patients with delayed growth 
Mean ∆HSDS +0.45 (0.33 to 0.56) p=0.001 
Patients with normal growth 
Mean ∆HSDS +0.05 (0.07 to  0.16) p = 0.39 
 
Vojvodich et al 
2003(316) 
 
52 
 
12 months 
 
Retrospective 
 
Mean ∆HSDS in pre-pubertal group (+0.2± 0.1) p= 0.001 
Mean ∆HSDS in pubertal group (+0.2± 0.1) p= 0.071  
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1.10 Effect of biologic therapy on bone health 
1.10.1 Effect of biologic therapy on bone in children with IBD 
To date, only one study has evaluated the impact of Infliximab therapy on bone biomarkers in 
children with CD (Table 1.10.1). Thayu et al (207), in REACH study of 103 children with CD 
observed the changes in the bone biomarkers, which had Infliximab induction therapy of 
5mg/kg at 0, 2 and 6 weeks. Changes in the bone biomarkers were observed at week 10 
after Infliximab induction therapy. This study also examined the association of these changes 
in the bone biomarkers with subsequent changes in disease activity and linear growth during 
the 54-week interval after initiation of Infliximab therapy. This study reported the improvement 
in markers of bone formation, bone specific alkaline phosphatase (BSAP) and pro-collagen 
type 1 N propeptide (P1NP) during the 10-week interval; the median increases were 87% and 
103% respectively (both p<.001). Moreover, increase in BSAP at week-10 was significantly 
associated with the reductions in PCDAI at week 10 but no association was observed at 
between changes in PINP and PCDAI. The bone resorption markers CTX-1 and DPD also 
increased significantly during the induction period (both p<.001); however, the magnitude of 
the changes (18% and 23%) was markedly less pronounced than the changes in markers of 
bone formation (207). 
1.10.2 Effect of biologic therapy on bone in adult IBD 
Data regarding the effect of anti-TNF-α on bone mineral density (BMD) and bone metabolism 
are limited. Studies that report the effect of biologics on bones in patients with IBD are 
summarized in (Table 1.10.1). In adults, an increase in BALP by 15-18% has been observed 
after a single Infliximab infusion (206;319-321). Other bone formation markers, such as BALP 
and osteocalcin, have also been reported to increase after induction therapy. Franchimont et 
al (319) studied 71 patients treated with Infliximab (5 mg/kg) for refractory CD who were 
naïve to Infliximab and compared their results with 68 matched healthy controls. The study 
included 21 fistulizing refractory CD patients and 50 luminal refractory CD patients. Patients 
were treated with a single infusion of 5mg/kg Infliximab at baseline for luminal refractory 
disease and with three infusions of 5mg/kg Infliximab at baseline, week 2 and week 6 for the 
fistulizing refractory disease. Serum bone formation markers such as BALP, OC and pro- 
P1NP, and the serum caboxyterminal telopeptide (sCTX); a marker of bone resorption were 
measured at baseline and 8 weeks after completion of Infliximab treatment (8 week for 
luminal refractory CD and 14 week for fistulizing refractory CD. In this study Crohn’s disease 
activity index score (CDAI) was considered as a confounding factor. In this study, the serum 
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concentration of the markers of bone formation (BSAP, OC and P1NP) were found to be 
lower in CD patients before Infliximab therapy as compared to the controls, and were back to 
normal levels at 8 weeks after Infliximab therapy. Relative improvement in bone formation 
(defined as increase of at least 30% in the bone formation marker (BALP, OC, P1NP) was 
found after Infliximab therapy in 30%, 61% and 47% of patients, respectively. Serum 
concentration of CTX was significantly increased in CD patients at baseline, but was no 
longer different from controls at 8 weeks after Infliximab therapy. Relative improvement in 
marker of bone resorption (decrease of at least 30% in sCTX serum levels) was observed in 
38% patients after Infliximab therapy Franchimont et al (319). Ryan et al (321), in a 
prospective trial of 24 patients with active CD who were treated with Infliximab (5mg/kg) for 
the first time, reported a significant increase in serum BALP and OC in patients with active 
CD. No significant improvement in marker of bone resorption (serum N-telopeptide cross-
linked type I) was found. In this study five time points were assayed, i.e. baseline, 1-2, 4-6, 8-
10 and 12-18 weeks after Infliximab infusion. This study, reported a significant increase in 
markers of bone formation BALP and OC. Levels of both bone formation markers remained 
significantly increased even at 4 months after Infliximab therapy. No significant change was 
observed in the serum N-telopeptide cross linked type I levels at 4 months and was found to 
be lower than at baseline. This study also demonstrated that the effect of Infliximab on bone 
metabolism was independent of the clinical response in terms of effect on disease activity. 
Moreover, the trend of increase in bone formation markers and decrease in bone resorption 
markers was greater in those who were responders as compared to non-responders (321). 
Abreu et al (206) reported a significant increase in BALP at 4 week compared to the base line 
after a single Infliximab infusion in a prospective study of 38 patients who had refractory CD. 
Findings in this study were not compared to age-matched control group and only two 
confounding factors, i.e. the effect of glucocorticoid use and the clinical response based on 
CDAI on changes were analyzed in detail. In this study sera were also analyzed for the 
proinflammatory cytokines (IL-1α, IL-6, and TNF-α), calcium and immunoreactive parathyroid 
hormone (iPTH) at baseline and at 4weeks after Infliximab therapy. At 4 weeks PTH levels 
were reduced and serum calcium levels were increased significantly. Serum cytokine levels 
remained unchanged from baseline to week 4. This study suggested that the effect of 
Infliximab on bone formation was independent of glucocorticoid use and Infliximab response, 
as improvement in bone formation markers were observed in both the responders and non-
responders as well as in those patients who were receiving glucocorticoid therapy and those 
who were not on glucocorticoids (206). Miheller et al (322), also studied the effect of 
Infliximab on bone formation and resorption markers in 27 patients with fistulizing CD and 
compared the results with 54 patients with inactive CD (controls). Clinical response to the 
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therapy based on defined as the decrease in the number of draining fistulas by half 
(responders) and no improvement in the number of draining fistulas by half (non-responders). 
A significant difference in β-Cross Laps (bCL) a marker for bone resorption on days 0 and 14, 
and days 0 and 42. OC, levels were found to be increased between day 0 and 42. This study 
reported the beneficial effect of Infliximab only in those who were Infliximab responders (320). 
There are currently no published studies looking at the effect of Adalimumab on bone 
metabolism in IBD patients. However, only one open label prospective study reported the 
effects of Adalimumab on bone mineral density (BMD) in 50 patients who had active 
rheumatoid arthritis. In this study the BMD of both the lumbar spine (L1 and L4) and left 
femoral neck was measured before treatment and one year after by DXA. In this study, BMD 
of lumbar spine and femoral neck remained unchanged after 1 year of Adalimumab therapy 
and both disease activity at baseline and disease duration were found to be inversely 
correlated with lumbar spine and femoral neck BMD. This study concluded that Adalimumab 
therapy can stop the progression for bone loss (323). 
1.10.3 Effect of biologics in bone mineral density in paediatric IBD 
To, date only one study has looked at the effects of Infliximab on bone mineral density in 
children with CD and suggested that bone density improves following treatment with 
Infliximab (324). This study reported significantly lower BMAD in those patients who had 
never received Infliximab than those undergoing biological therapy with Infliximab (324) 
(Table 1.10.1).  
1.10.4 Effect of biologics in bone mineral density in adult IBD 
To, date few published studies have looked at the effects of biologics on actual bone loss in 
CD patients by measuring BMD (Table 1.10.1). Pazianas et al (325), conducted a 
retrospective study on 61 CD patients who had low BMD. In this study a number of 
confounding factors which could affect study outcome were analyzed including sex, number 
of postmenopausal women, and number of women on hormone replacement therapy, 
glucocorticoid use and Infliximab infusions. In this study 23 patients were on Infliximab 
therapy and 36 patients were on bisphosphonates. After controlling for corticosteroid use, 
patients with concurrent Infliximab and bisphosphonate treatment had a greater increase in 
BMD as compared to those who had bisphosphonate alone; corticosteroids inhibited this 
effect. However, Infliximab alone had no effect on BMD (325;326). Mauro et al (326), 
conducted a retrospective study of 15 CD patients who had Infliximab therapy for the first 
time and who underwent DXA before and during Infliximab therapy. These patients were then 
compared with 30 CD patients who were naïve to Infliximab therapy and who had DXA done 
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at least one year apart. Age, gender, age at diagnosis, disease duration, final weight, change 
in weight, disease activity and the use of bisphosphonate and corticosteroids were used as 
confounding factors in this study. Patients in this study had Infliximab therapy (5mg/kg) at 
intervals of 4-8 weeks for a mean period of 18 months. Those patients who had Infliximab 
therapy had a significant increase in lumbar bone area, bone mineral content (BMC) and 
BMD as compared to the control group. The increase in BMC in patients who had Infliximab 
therapy was significant when compared with controls who had received glucocorticoid 
therapy or who had evidence of disease activity (326). Bernstein et al (327), also found that 
the maintenance treatment with Infliximab (5mg/kg) at 6-8 weeks interval for 1 year in 46 CD 
patients resulted in the improvement in BMD after 1 year in lumbar spin, at the femoral 
trochanter and at the femoral neck and this effect was independent of the glucocorticoids, 
calcium supplementation or changes in C-reactive protein (CRP) (327). 
1.10.5 Effect of biologics on GH/IGF-1 axis 
The effect of Infliximab on the GH/IGF-I axis has been assessed in a series of 14 adult IBD 
patients with low levels of IGF-I and IGFBP-3 treated with three induction doses (weeks 0, 2 
and 6) plus two additional infusions every eight weeks (328). Peripheral resistance to GH was 
apparently reversed after the second infusion of Infliximab, as judged by the significant 
increase in the serum levels of IGF-I andIGFBP-3 as compared to baseline. However, this 
effect was not sustained since they return to baseline values between the first and second 
maintenance dose (328). TNF blockade by Infliximab could account for the initial 
improvement of GH sensitivity as increased TNF activity suppressed the GH/IGF-I axis in the 
liver. The late impairment of GH sensitivity during maintenance therapy was harder to 
explain, but one could speculate that during this period some degree of subclinical mucosal 
inflammation might persist. Another study conducted by Eivindson et al (329) assessed 
changes in the IGF system in patients with active CD before and during Infliximab treatment 
and studied 13 patients with therapy refractory CD, treated with Infliximab (5 mg/kg body-
weight) at baseline and after 2 weeks. The IGF system and markers of inflammation were 
examined at baseline, on days 2-5 and after 1, 4, and 8 weeks. Ten healthy age- and gender-
matched persons served as controls. This study has shown treatment with Infliximab 
normalized circulating levels of total IGF-I and IGFBP-3, and partially normalized IGFBP-2, 
whereas free IGF-I remained suppressed and suggest that the changes in the IGF system 
may be part of the catabolic state in active CD and may have an association with metabolic 
bone disease and muscle wasting (329). 
  
102 
Table 1.10.1:Effect of biologics on bone metabolism and BMD in Crohn’s disease   
 
Study 
 
N 
 
Study duration 
 
Study Design 
 
Results 
  
ADULT STUDIES 
 
 
Pazianas et al 
2006(325) 
 
 
61 CD 
 
12 months 
 
Retrospective 
Patients with concurrent Infliximab and bisphosphonate 
treatment exhibited a greater increase in BMD 
compared to those on bisphosphonates alone 
(+6.7%/year vs. +4.46%/year, P = 0.045). Infliximab 
alone had no effects on BMD 
 
 
Mauro et al 
2007(326) 
 
 
15 CD, 30 controls 
 
 
12 months 
 
 
Retrospective 
Infliximab group had a significant increase in the lumbar 
bone are (4.15%±6.6%), BMC (12.8%±13.6), and BMD 
(8.13%±7.7%) (p<0.01), than the control group 
 
Miheller et al 
2007(320) 
 
29 CD 
 
6 weeks 
 
Retrospective 
OC concentrations increased from 28.93 ± 14.95 ng/mL 
to 36.33 ± 20.05 ng/mL (p<0.005) at days 1 and 42 
sRANKL concentrations increased from 0.0112 ± 0.028 
ng/mL to 0.0411 ± 0.123 ng/mL (NS) at days 1 and 42 
bCL concentrations decreased from 0.636 ± 0.594 
ng/mL to 0.519 ± 0.235 ng/mL (NS) at days 1 and 42 
OPG concentrations decreased from 3.739 ± 1.485 
ng/mL to 3.419 ± 1.618 ng/mL (p<0.05) at days 1 and 
42 
 
 
Miheller et al 
2006(322) 
 
 
27 CD, 54 controls 
 
 
6 weeks 
 
Prospective 
Significant differences in bCL concentrations on days 0 
and 14 p<0.01 and days 0 and 42 p<0.05. OC levels 
increased significantly between day 0 and 42 p<0.05 
 
Abreu et al 
2005 (206) 
 
 
38 CD 
 
4 weeks 
 
Prospective 
 
Median BAP increased from 6.6(2.5,27.0) to 7.2 
(2.1,26.0) p=0.010 and Median NTX remained 
unchanged from 15.5(7.9,36.0) to 15.5(11.0,36.0) p= 
0.801 at 4 weeks following Infliximab therapy 
 
    
 
 
 Ryan et al  
2004(321) 
 
 
24 CD 
 
18 weeks 
 
Prospective 
Increase in bALP p=0.022 and OC p=0.008 and 
remained significantly higher at 4 months post Infliximab 
therapy. No significant change in sNTx  p=0.5 at 4 
months post Infliximab therapy 
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Franchimont et al 
2004(319) 
 
 
71CD, 68 controls 
 
 
8 weeks 
 
 
Open-label nonrandomized 
 
Median BALP increased from 7.3(5.8, 9.1) to 15(6.2, 12) 
p=0.0008, OCS 15(8.7, 18.6) to 17.2(12.8, 28.3) 
p=0.001, P1NP 30.3(20.2, 40.6) p= 0.003, at 8 week 
following Infliximab therapy. Median CTx decreased 
from 256.6(157,427.2) to 224.3(103.1, 374.1) p=0.04 at 
8 week following Infliximab  
 
 
 
Bernstein et al 
2005(327) 
 
 
 
  
 46 CD 
 
 
 
12 months 
 
 
 
 
Prospective 
 
 
Mean BMD increased at Lumbar spine from 1.117 ± 
0.022 to 1.145 ± 0.023 (p<0.001), femoral neck 0.76 ± 
0.018 to 0.915 ± 0.017 (p=0.002), femoral trochanter 
0.021 ± 0.022 to 0.767 ± 0.020 (p=0.02) from baseline 
to 1 year  
   PAEDIATRIC STUDIES  
 
 
Thayu et al  
2008(207) 
 
 
103CD 
 
 
12 months 
 
   
Randomised open-label 
 
 
 
 
 
 
 
 
 
Median BSAP increased from 44.2(14.1-161.7) to 
86.2(12.2, 285.6) p<.001 from baseline to week 10 
 
Median P1NP increased from 253.8(29.2,1026.5) to 
615.1(25.3,1706.2) p<.001 from baseline to week 10 
 
Median CTX-1 increased from 768.0(229.0.2203.9) to 
925.2(134.9,345.6) p<.001 from baseline to week 10 
 
Median DPD increased from 12.8(1.8,38.2) to 13.7(2) 
p<.001 from baseline to week 10 
Paganelli et al  
2007(324) 
35 CD, 25 controls 6 month 
 prospective Infliximab treated group had increase in mean BMAD z- 
score (-1±0.8), than those never treated with Infliximab 
(-1.8 ±0.8) P<0.05 
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1.11 Overall conclusions and proposed areas of research 
The extensive literature review presented above has reviewed the effects of biologic therapy 
on growth and skeletal development in chronic inflammatory conditions particularly IBD. The 
main aim of this review is to summarize and evaluate effects of inflammation and biologic 
therapy on growth and skeletal development in children with chronic inflammatory conditions 
and to explore the areas of interest for further research. The role of conventional therapies on 
growth is not clear; the existing evidence from paediatric IBD studies is limited. It is unclear 
whether recent therapeutic advances have had a beneficial impact on the growth of children 
with CD. Despite advances in therapy, short stature and slow growth continue to be 
encountered in children with CD. There is a need for simple definitions of growth that can 
identify poor growth in children with chronic disease and this is explored in Chapter 2. 
As was described in Section 1.9, infliximab therapy has a positive impact on growth in 
paediatric CD. However, factors that may improve growth e.g. changes in dose of 
corticosteroid, background immuno-suppressants, and surgery have not been accounted for.  
Not all studies have reported change in growth rates in relation to changes in puberty. This is 
investigated in Chapter 3. 
The published clinical studies to date of Adalimumab use in children are relatively limited with 
no studies yet conducted to examine the effects of Adalimumab on growth in children with 
CD. This is explored in Chapter 4. 
As was described in Section 1.10, biologic therapy has a positive impact on bone health in 
paediatric CD. To date, few published studies have examined the effect of anti-TNF-α therapy 
on bone density and bone metabolism and most of the data originate from studies performed 
in adult patients with CD. To date only one study has reported the effect of biologic therapy 
on bone formation, body composition and muscle mass in children with CD. The effect of 
biologic therapy on insulin-like growth factor (IGF) system in IBD has rarely been 
investigated. There are no published data regarding effect of biologic therapy on IGF-1 
system in paediatric patients with CD. The impact of biologic therapy on volumetric bone 
mineral density (vBMD), bone structure, and muscle mass measured by using pQCT is not 
reported so far. This is investigated in chapter 5. 
 
The hypothesis of this study was that the biologic therapy improves linear growth, puberty, 
bone health, body composition and muscle function in children with CD and this is associated 
with changes in the IGF-1 axis and markers of bone metabolism. 
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CHAPTER 2 
 
Growth in children receiving contemporary disease specific 
therapy in children with Crohn’s disease 
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2.1 Summary 
Introduction: It is unclear whether recent therapeutic advances have had a beneficial impact 
on the growth of children with Crohn’s Disease (CD). 
Aim: To assess the frequency of short stature and poor growth and their relationship to 
disease course and therapy in children with CD. 
Subjects & methods: The anthropometric and treatment details of 116 children (68 male) 
with a mean (range) age at diagnosis of 10.8yrs(4.9, 15.5) and a mean age at maximum 
follow-up(MF) of 15.4yr(9.4,19.3) were studied retrospectively at diagnosis(T0), 1-yr(T1), 2-
yr(T2) and 3-yr(T3) after diagnosis and at MF. 
Results: At T0, mean height standard deviation score (HtSDS) was -0.5(-3.3, 2.6) compared 
to a mid-parental HtSDS of 0.2 (-2.0, 01.4) (p=0.002). At T1, T2, T3 and MF, mean Ht SDS 
was -0.6(-4.8,7.8), -0.6(-2.9,2.2), -0.7(-3.6, 2.5) and -0.5(-3.5, 2.9) respectively. Mean Ht 
Velocity (HV) SDS at T1, T2, T3 and MF was -1.4(-7.4, 7.4),-0.6(-7.5, 6.1),-0.1(-6.6, 7.6), and 
0.6(-4.8,7.8) respectively,(p<0.05). In final models, HtSDS was associated negatively with the 
use of prednisolone (p=0.0001), Azathioprine (p=0.0001), Methotrexate (p=0.0001) and 
WtSDS (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS 
(p=0.01). ∆HtSDS was associated negatively with the use of prednisolone (p<0.02). 
Conclusion: Although contemporary therapy of CD is associated with an improvement in 
rate of growth over the first few years of therapy, a substantial proportion of children continue 
to remain short. This study highlights the need for consistency in describing growth in children 
with chronic diseases. 
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2.2 Introduction 
Poor growth and short stature are common complications of CD and may not only be present 
at diagnosis but also during treatment (330). Short stature has also been described in those 
with CD who have reached final height (234;331). The prevalence of short stature and poor 
growth at diagnosis may be related to the duration and severity of symptoms before diagnosis 
as well as whether the child has pubertal delay  and was reported to be as high as 88% in the 
1980’s (332). Studies that have reported growth problems during therapy are those where the 
use of glucocorticoids (GC) has generally been more prevalent (235;333;334). Although the 
use of GC therapy has reduced and more attention has been paid to the nutrition of affected 
children,  there is a persisting concern that poor growth may still exist (310;335). Whilst GC 
therapy plays a direct role in affecting longitudinal growth and skeletal development, there is 
ample accumulating evidence that proinflammatory cytokines by themselves exert an 
important detrimental effect on growth. This effect may be mediated directly at the level of the 
growth plate or through the systemic GH/IGF-1 axis (219) and in vivo and in vitro studies 
suggest that these effects may be abrogated by administration of GH or IGF-1 (336;337) . 
Promoting growth through manipulation of this axis may be a therapeutic option which 
requires further exploration. However, designing such studies requires a clear assessment of 
the prevalence of growth problems in children receiving contemporary therapy. The aim of the 
present study was to assess the frequency of short stature and poor growth and their 
relationship to disease course and therapy in children with CD. 
 
2.3 Methods & subjects 
Clinical records of all children with a confirmed diagnosis of CD, who were between 2yrs and 
18yrs at the Royal Hospital for Sick Children, Glasgow were examined retrospectively. Data 
were collected at diagnosis (T0), 1-yr (T1), 2-yr (T2) and 3-yr (T3) after diagnosis and at 
(maximum follow-up) MF. Of the 165 children with CD, case notes were available in 142 and 
of these children, 26 were excluded as 5 had growth data missing at diagnosis, 2 were less 
than 2yrs old at diagnosis and 19 were recently diagnosed and had less than one year growth 
data (Figure 2.3.1). Mean (range) age at diagnosis in the 116 children who were studied was 
10.8yrs (4.9,15.5) and mean age at maximum follow-up (MF) was 15.4yr (9.4,19.3). Crohn’s 
disease location and behaviour at diagnosis were classified according to the Montreal 
classification (5). Data on pubertal status at all time points were available in 33 children. On 
the basis of pubertal stage, the children were categorized as, pre-pubertal (n=14) and 
pubertal (n=19).  
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Figure 2.3.1: Flow diagram of study recruitment 
 
 
 
I year Follow-up 
n,116
Case notes reviewed
n,142
CD Patients 
n,165
Case notes missing
n,23
Excluded
n,26
No 1 year data
n,19
Pts<2yrs of age
n,2
No diagnosis data
n,5
II year Follow-up
n,98
III year Follow-up 
n,78
Max Follow-up 
n,78
∆HtSDS
n,116
HVSD
n,113
ALB n,99
ESR n,96
CRP n,98
PLT n,99
ALKP n,99
∆HtSDS
n,97
HVSDS
n,90
ALB n,76
ESR n,74
CRP n,74
PLT n,76
ALKP n,76
∆HtSDS
n,75
HVSD
n,63
ALB n,58
ESR n,57
CRP n,58
PLT n,58
ALKP n,58
∆HtSDS
n,64
HVSD
n,35
ALB n,57
ESR n,57
CRP n,57
PLT n,57
ALKP n,57
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Cumulative data on erythrocyte sedimentation rate (ESR), platelets, C-reactive protein (CRP), 
serum albumin (Alb), and total Alkaline Phosphatase (ALP), were collected in the year prior to 
each time point. Details of therapeutic interventions including enteral therapy, medications 
and resectional surgery were collated from the case records within prior each year of 
treatment. Those who had growth-promoting endocrine therapy (T2-4, T3-5, MF-5) were 
excluded from further study in the year after starting this therapy. Growth was assessed in 
relation to systemic markers and therapeutic interventions. Height was measured with a 
Harpenden stadiometer and used to calculate annual height velocity (HV) and body mass 
index (BMI). Tanner stage was estimated by either clinical examination or self-estimation 
(338;339). Height (Ht), Weight (Wt) and body mass index (BMI) were converted into SDS for 
chronological age using 1990 UK standards (340;341). Height velocity (HV cms/yr) was 
calculated using a two-point technique from the difference between the two height 
measurements divided by the decimalized time interval.  For boys under 16.6 yrs and girls 
under 15 years, HV was converted to height velocity standard deviation scores (HVSDS) 
using the 1966 standards (342;343).  
 
2.4 Statistical analysis 
All data were analysed using Minitab software version 16.1 and are described as mean, and 
range. Univariable analysis was performed using general linear models (GLM) to account for 
repeated measures for HtSDS, WtSDS, BMISDS and HVSDS. Random effects were used to 
incorporate the repeated measures structure of the data into GLMs. Factors significant at the 
p<0.2 level in the univariable analysis were included in the initial multivariable models. 
Multivariable linear regression models were tested to evaluate the influence of factors on 
growth. Final multivariable models were derived using stepwise forward elimination 
procedure. At each step of the forward stepwise regression analysis, the eligible independent 
variable with the highest statistical value (p<0.05) were included in the model. 
Clinical/therapeutic/laboratory data for the groups with the worst and best growth outcomes 
were compared using Fishers’ exact test. 
 
2.5 Results 
2.5.1 General characteristics 
Clinical and therapeutic details at all time-points are outlined in (Table 2.3.1). Disease 
location was most commonly panenteric (Ileo-colonic and upper GI tract, L3 + L4) in 49(42%) 
and behaviour type B1 98(85%) with 23 (20%) having perianal disease and 4(3%) having 
genital involvement. The use of GC remained constant and was used in 28(24%) of cases at 
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T0 and then in 31(27%), 20(21%), 13(17%) and 22(21%) of children at T1, T2, T3 and MF 
respectively. Exclusive enteral nutrition at T0 was recorded in 54(63%) of cases; in 
subsequent years of study it ranged between 11% to 16% in any one year. Throughout the 
study period, a total of 23 children had resectional surgery. 
 
2.5.2 Growth 
Mean HtSDS at diagnosis -0.5(-3.3, 2.6) was lower than the mean mid-parental height SDS 
of 0.2(-2.0, 1.4) (p=0.002). After a small but significant fall in Ht SDS between T0 and T1  
there was no change in Ht SDS subsequently (Figure 2.3.2a).The percentage of children with 
height SDS (HtSDS) <-2 was 9.4%, 10.3%, 12.2% and 11.5% at T0, T1, T2 and T3, 
respectively, and was 8.9% at MF. The mean ∆HtSDS did not change from -0.0(-0.9,2.0) to -
0.0(-0.8,1.0), (p=0.45) between T1 and  T2, -0.0(-0.8,1.0) to 0.0(-0.9,0.7), (p=0.07) between 
T2 and T3 and from 0.0(-0.9,0.7) to 0.0(-0.5,0.7), (p=0.72) between T3 and MF (Figure 
2.3.2b). However, the mean HVSDS increased from -1.4(-7.4,7.4) to -0.6(-7.5,6.1), (p=0.005) 
between T1 and T2, and from -0.6(-7.5,6.1) to -0.1(-6.6,7.6), (p=0.01) between T2 and T3 
and from -0.1(-6.6,7.6), to 0.6(-4.8, 7.8), (p=0.03) between T3 and MF (Figure 2.3.2c).The 
percentage of children with HVSDS between -1 and -2 changed from 49% at T1 to 9%, 22%, 
and 20% at T2, T3 and MF. Children with a HVSDS <-2 changed from 17% at T1 to 39%, 
24% and 20% at T2,T3 and MF, respectively. Weight and BMI SDS showed an improvement 
over the first year of therapy and then remained within the normal range (Table 2.3.1).  
 
2.5.3 Puberty and growth 
In 33 children, data on pubertal status were available from diagnosis to 3-year follow-up and 
of these children, 14 remained pre-pubertal and 19 were pubertal. Mean age of children in the 
pre-pubertal group and pubertal group at T1 was 8.6yrs (5.9, 11.4) and 12.2yrs (9.4, 14.7) 
respectively. Those who remained pre-pubertal had a mean HVSDS of -1.1(-6.8,1.8), -1.6(-
4.4,2.7) and -1.8(-6.5,5.0) at T1, T2 and T3, respectively, and did not improve between T1 
and T3 (p=0.61).  Mean ∆HtSDS of this group was 0.2 (-0.2,0.7), -0.1(-0.7,0.5) and -0.0(-
0.8,0.3) at T1, T2 and T3 respectively. Mean ∆HtSDS of this group reduced between T1 and 
T2 (p=0.04). In the pubertal group, mean HVSDS was -1.8(-4.0, 3.3), -1.0(-6.5,5.0) and 1.2(-
6.7,6.9) at T1, T2 and T3, respectively. In this group HVSDS increased between T1 and T3 
(p=0.007). Mean ∆HtSDS of this group was -0.2(-0.6,0.5), -0.1(-0.6,0.6) and 0.2(-0.3,0.7) at 
T1, T2 and T3 respectively. Mean ∆HtSDS increased between T1 and T3 (p=0.001) and T1 
and T2 (p=0.01) (Figure 2.3.3 a,b,c,d). 
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Table 2.3.1: Demographic and clinical details of children with CD at1-yr (T1), 2-yr (T2) and 3-yr (T3) after diagnosis 
 
 
T0 
 
T1 
 
T2 
 
T3 
 
MF 
 
Gender (M/F) 
 
68/48 
    
 
Age (mean) years 
 
10.8(4.9,15.5) 
 
11.9(5.9,16.5) 
 
12.9(6.8,17.7) 
 
13.5(7.9,18.7) 
 
16.1(9.4,19.3) 
Follow-up duration (mean) 
years 
 
                4.6(1.4,8.6) 
HtSDS -0.5(-3.3,2.6.) -0.6(-4.8,7.8) -0.6(-2.9,2.2) -0.7(-3.6,2.5) -0.5(-3.5,2.9) 
BMISDS -0.6(-3.8,3.7) -0.1(-2.2,2.7) 0.1(-2.8,2.6) -0.0(-2.1,4.5) 0.0(-2.5,2.6) 
WtSDS -0.7(-3.4,2.6) -0.4(-3.6,2.5) -0.3(-2.2,2.5) -0.5(-3.1,3.3) -0.3(-2.5,3.2) 
∆HtSDS  -0.0(-0.9,2.0) 0.0(-0.8,1.0) 0.0(-0.9,0.7) 0.0(-0.5,0.7) 
HVSDS  -1.4(-7.4,7.4) -0.6(-7.5,6.1) 0.1(-6.6,7.6) 0.6(-4.8,7.8) 
Concomitant Medication (n)%      
-Aminosalicylic acid 33(28) 52(45) 46(47) 42(54) 33(42) 
-Exclusive enteral nutrition 63(54) 15(13) 16(16) 11(14) 9(12) 
-Azathioprine 14(12) 50(43) 36(37) 30(28) 23(29) 
-Prednisolone 28(24) 31(27) 20(21) 13(17) 22(21) 
-Methotrexate 2(2) 22(19) 39(40) 32(41) 43(55) 
-Biologic 1(1) 16(14) 11(11) 16(21) 16(21) 
-Resection surgery 4(3) 3(2) 4(5.1) 3(4) 9(10) 
Biomarkers mean(range)      
Serum albumin (g/l)  36.1(18-55) 37.8(26-45) 36.9(20-49) 35.3(12-44) 
≤30 (g/l) %  33.3 27.6 32.7 31.5 
ESR (mm/hr)  23.5(1.0,68) 20.1(3.0,56) 24.8(2.0,59) 18.5(1.0,52) 
>20  mm/hr %  48.9 40.5 54.3 38.5 
CRP (mg/l)  15.8(7,93) 15.2(7,82) 18.1(7,154) 13.9(7-84) 
>7 (mg/l)  46.9 37.8 50.0 42.1 
Platelets (109/L)  411.8(207,877) 384.5(193,717) 383(180,797) 325.4(310.657) 
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Figure 2.3.2: Growth in children with CD at diagnosis (T0), year 1(T1), year 2(T2), year 3(T3) and at Maximum follow-up (MF), expressed as mean 
(range) 
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Figure 2.3.3: Growth in children with CD at year 1(T1), year 2(T2), and year 3(T3) after diagnosis expressed as mean (range) 
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2.5.4 Surgery and growth 
Throughout the study period, 23(M,9) children had resectional surgery. The most common 
surgical procedure was hemicolectomy in 17(73.9%); 3 children had colectomy, 3 children 
had stricturoplasty and 1 child had ileocolonic resection. The impact of surgery on growth was 
assessed in children with CD 12 months(T-12) prior to surgery, at the time of surgery(T+0) 
and 12 months(T+12) post surgery (Table 2.3.2). Of 23, 14(M,6) had sufficient growth data 
available at all time points. The mean age at diagnosis and at the time of surgery was 10.6yrs 
(5.0,13) and 14.6yrs(12.0,17.6) respectively. The mean change in height SDS (∆HtSDS) in 
the whole group increased from -0.1 (-0.6,0.8) at T0 to 0.2(-0.4,0.7) at T+12, (p=0.01) (Figure 
2.3.4 a & b). 
2.5.5 Association of growth to therapy and disease  
Clinical/therapeutic/laboratory data for the groups with the worst and best growth outcomes 
were compared in terms of ∆HtSDS at T1 and T3 (Table 2.3.3). At T1 the use of Methotrexate 
was significantly associated with better growth, (p=0.01), and at T3 the use of prednisolone, 
(p=0.01) and raised ESR, (p=0.02) were significantly associated with worse growth.  
Multivariable regression models were used to determine the association of disease and 
therapy on growth (HtSDS, WtSDS, BMISDS, HVSDS and ∆HtSDS) at T1, T2, T3 and MF by 
fitting linear mixed effect models. In final models, HtSDS was associated negatively with the 
use of prednisolone (p=0.0001), Azathioprine (p=0.0001), Methotrexate (p=0.0001) and 
WtSDS (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS 
(p=0.01). ∆HtSDS was associated negatively with the use of prednisolone (p<0.02). BMISDS 
was associated positively with prednisolone (p=0.0007), and serum albumin (p=0.0001) 
(Table 2.3.4). 
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Table 2.3.2: Demographic details of children with CD who had surgery 
 
 
 
  
T-12 
N,14 
 
T+0 
N,14 
 
T+12 
N,14 
 
        
 T-12 VS T+0 
 
        p-value 
 
   T+0 VS T+12 
 
 
 
    T-12 VS T+12 
 
 
Age mean(range) 
 
12.5 
(9.9-15.7) 
 
13.5 
(11.1-16.7) 
 
14.6 
(12.1-17.6) 
   
 
Concomitant Medication 
      
-Enteral nutrition  9 4    
-Aminosalicylic acid  8 5    
-Azathioprine  4 6    
-Methotrexate  7 5    
-Prednisolone  3 3    
-Biologics  2 -    
Growth failure and Pubertal delay  5     
       
Anthropometry Mean(range)       
Height SDS -0.8 
(-3.4, 1.4) 
-0.9 
(-2.8,-0.5) 
-0.6 
(-2.6,0.1) 
0.43 0.004          0.37 
BMI SDS -0.1 
(-1.8, 1.9) 
0.1 
(-2.4,2.2) 
0.4 
(-1.7,2.3) 
   
Height Velocity (cm/yr)  4.2 
(0.4,9.1) 
5.8 
(0.4,11.7) 
 0.13  
∆HtSDS  -0.1 0.2  0.01  
  (-0.6,0.8) (-0.5,0.7)    
Pubertal status (n,11)       
-I 8 5 2    
-II 1 4 5    
-III - - 2    
-IV - - -    
-V 1 1 1    
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Figure 2.3.4: Growth in children with CD during the 12 months prior to surgery (T0) and in the 12 months following surgery (T+12) 
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Table 2.3.3: Clinical/therapeutic/laboratory data for the groups with ∆HtSDS  ≥0.50 (good growth) and ≤-0.50 (worst growth) at T1(Year-1), T3(year-3) 
                                 T1                            T3   
Growth ∆HtSDS ≥0.50 ∆HtSDS ≤-0.50 p-value ∆HtSDS ≥0.50 ∆HtSDS ≤-0.50                             p-value 
N, 8 12  6 5  
Sex M/F 4/4 7/5  5/1 2/3  
Age (median) 11.7 13.9  14.7 13.5  
∆HtSDS (median(range) 0.6(0.5,2.0) -0.6(-0.8,-0.4)  0.7(0.5,0.7) -0.6(-0.8,-0.5)  
-Aminosalicylic acid       
Yes 6 6 0.20 2 2 0.45 
No 2 6  4 3  
-Exclusive EN       
Yes 1 4 0.25 2 1 0.45 
No 7 8  4 4  
-Azathioprine       
Yes 0 5 0.05 3 3 0.43 
No 8 7  3 2  
-Prednisolone       
Yes 0 4 0.10 0 4 0.01 
No 8 8  6 1  
-Methotrexate       
Yes 6 2 0.01 2 2 0.45 
No 2 10  4 3  
-Biologic       
Yes 1 1 0.50 1 2 0.36 
No 7 11  5 3  
Serum albumin (g/l)       
≥35 (g/l) 6 7 0.28 6 2 0.06 
≤35 (g/l) 2 5  0 3  
ESR (mm/hr)       
<20  mm/hr 4 6 0.35 6 1 0.02 
>20  mm/hr 4 6  0 4  
CRP (mg/l)       
<7 (mg/l) 3 6 0.30 5 1 0.06 
>7 (mg/l) 5 6  1 4  
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Table 2.3.4:Multivariable analysis (General Linear Model), SDS (standard deviation scores), HV (height velocity), ∆Ht (change in height) 
 
Parameter 
 
 
t 
 
HtSDS 
p-value 
 
 
t 
 
WtSDS 
p-value 
 
 
t 
 
BMISDS 
p-value 
 
 
t 
 
HVSDS 
p-value 
 
 
t 
 
∆HtSDS 
p-value 
Age - - - - - - 6.25 0.0001 - - 
WtSDS 7.8 0.0001 - 
- 
- - 2.39 0.01 - - 
Azathioprine 
 
-3.62 0.0001 - 
- 
- - - - - - 
Methotrexate 
 
-3.66 0.0001 - 
- 
- - - - - - 
Prednisolone 
 
-3.78 0.0001 - 
- 
2.69 0.0007 - - -2.34 0.02 
Serum albumin (g/l) - - 4.8 0.0001 3.79 0.0001 - - - - 
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2.6 Discussion 
Although the majority of children with CD were not particularly short and there was an 
improvement in growth over the first year after diagnosis, this study provides clear evidence 
that despite advances in therapy, short stature and slow growth continue to be encountered 
in a sub-group of children with CD. The mean HtSDS of our population as well as the 
percentage of children with a HtSDS of less than -2 were similar to that reported in other 
contemporary studies (310;335). Our observation that HtSDS did not show an improvement 
despite a significant improvement in HVSDS is also similar to the study by Pfefferkorn et al 
(310) and may suggest that the reduction in growth deceleration, as reflected by an improving  
HV is not sufficient to improve overall height but simply prevents any further deterioration in 
height. We observed significant improvement in HVSDS of children who were pubertal as 
compared to those who were pre-pubertal, suggesting that the improvement in growth may in 
part be due to progression through puberty (310). However, the reliability of calculating 
HVSDS for chronological age in older children with delayed puberty is somewhat 
questionable as they may have a higher calculated HVSDS based on age-matched normal 
data.  
Several inter-related factors may influence growth in children with CD, including poor 
nutrition, long-term use of GC and uncontrolled disease. In our cohort, early use of enteral 
nutrition was greater and the use of GC in our population was lower than that reported 
recently by the North American group (310). However, despite these differences, the 
prevalence of growth problems was similar. As described previously, we observed an 
improvement in ∆HtSDS in the children who had surgery during the study period (344). 
Treatment of CD continues to change over time and it is possible that the children at T3 and 
maximum follow-up represent those who had greater exposure to drugs such as 
glucocorticoids. This may introduce a degree of selection bias in the study. Pubertal status 
was assessed in a small subgroup of patients and given that it was not performed routinely in 
the clinic, it is possible that it may have been performed in those where there was a concern 
about growth and puberty, thus introducing further selection bias. A routine surveillance 
programme of growth and puberty in IBD clinics would eliminate such selection bias. 
In our study, HVSDS was particularly poor in the first year after diagnosis when children were 
more likely to be exposed to GC therapy. We examined the relationship of a number of 
factors including therapeutic modalities to two commonly used anthropometric markers of 
growth - HVSDS and ∆HtSDS. We did not find a consistent association between individual 
markers of disease activity and growth and given that an association between individual 
markers of disease and disease activity may not exist (345), our finding is not unexpected. By 
examining temporal associations, we could also compare the association of growth with 
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markers of disease activity and therapeutic modalities that would play a dominant role in 
induction of remission of disease and those which play a role in maintenance of remission. 
The negative association between the use of prednisolone and markers of growth was only 
evident on multivariable analysis with the ∆HtSDS and not HVSDS. The negative association 
between other steroid sparing drugs and growth may be explained by the fact that these 
children would have been the ones who had more severe disease. However, interestingly, 
during the first year of therapy, the use of Methotrexate was associated with better growth. 
Our temporal observations suggest that the relationship between these factors and growth 
needs to be carefully interpreted. It also suggests that there may be specific windows which 
could be targeted for growth promoting endocrine-therapy but this need to be explored 
through prospective studies.  
 
There are a number of methods of defining change in growth and in the context of growth 
promoting therapy, there is little consensus. However, change in HtSDS (346;347) and 
HVSDS (348) remain the most commonly used parameters. These parameters of growth 
have been studied most widely for assessing response to growth hormone therapy in children 
with GH deficiency where an adequate first year response in gain in Ht SDS in pre-pubertal 
children may range between 0.4 to 0.9 SDS (349).The marked age dependency of HVSDS 
particularly around the peripubertal years makes HVSDS a less reliable marker of growth 
especially when assessing growth in children with pubertal delay. Furthermore, the normative 
data for calculating HVSDS are based on older reference data than HtSDS data. We would, 
therefore, recommend that change in HtSDS may be a more valid method of assessing and 
reporting longitudinal growth in children with chronic disease, particularly when there is a high 
prevalence of children of a peripubertal age. This will also allow comparison with studies that 
report results of endocrine growth promoting therapy. 
 
In summary, in our population of children with CD, contemporary therapy was associated with 
a reduction in growth deceleration but this was not associated with sufficient catch up growth 
for an improvement in overall height SDS. A substantial proportion of children continues to 
show poor growth irrespective of the therapeutic regimen for the disease and may benefit 
from novel therapeutic strategies aimed at improving growth. 
 
 
  
121
 
 
 
 
CHAPTER 3 
 
Improvement in growth of children with Crohn’s disease 
following anti-TNF-α therapy with Infliximab 
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3.1 Summary 
Introduction: Treatment with anti-TNF-α antagonists therapy such as Infliximab may improve 
growth in children with Crohn’s disease (CD) but the extent of improvement in growth and its 
relationship to pubertal progress and glucocorticoid therapy are unclear. 
Aim: A retrospective study of growth, puberty and disease activity over the 6 months prior (T-
6) to starting Infliximab, at baseline (T0) and for the following 6 months (T+6) and 12 months 
(T+12) in children with CD.  
Subjects & methods: The growth and treatment details of 28 children (M: 17) who were 
started on Infliximab at a median (10th, 90th) age of 13.1yr (10.0, 15.7) were reviewed. Data 
on disease markers (CRP, ESR, and Albumin), total alkaline phosphatase (ALP) and a 
physician global assessment were also collected. Results are expressed as median (10th, 
90th). 
Results: Out of 28 cases, 21 (75%) demonstrated a clinical response to Infliximab treatment. 
Overall, height velocity (HV) increased from 3.6cm/yr (0.4, 7.8) at T0 to 5.5cm/yr (2.1, 9.2) at 
T+6 (p=0.003). In Infliximab responders, HV increased from 2cm/yr (0.3, 7.1) to 6.4cm/yr (2.3, 
9.1) (p=0.004) and in the non-responders, HV remained static at 4.3cm/yr (2.5, 8.6) at T0 and 
3.0cm/yr (2.0, 11.3) (p=0.701) at T+6. HV also increased in the subgroup of 13 children who 
had remained pre-pubertal from 4.5cm/yr (0.4, 8) to 5.5cm/yr (3.3, 8.4) (p=0.05). In the 
subgroup of 11 children who had a reduction (n,2) or cessation in GC (n,9), HV increased 
from 1.8cm/yr (0.3,8.3) at T0 to 5.6cm/yr (2.2,9.2) at T+6 (p=0.14), whereas those children 
who did not receive GC over the 12 months had an increase from 3.7cm/yr (0.6,6.5) to 
6.4cm/yr (2.9,9.0) (p<0.05).HV at T0 and T+6 showed a significant association with the 
average ALP over the prior 6 months(r,0.39, p<0.05). HV did not show any association with 
individual markers of disease activity. 
Conclusion: Clinical response to Infliximab therapy is associated with an improvement in 
linear growth over the short term in children with CD. This increase in height may not be 
simply due to progress in pubertal status or reduction in glucocorticoid dose. 
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3.2 Introduction 
Abnormalities of growth, puberty and skeletal health are commonly encountered in children 
with IBD, especially, CD (330). Poor growth may persist in a substantial proportion of children 
despite optimal management of disease by contemporary regimens. Poor nutrition, 
abnormalities of sex steroid and the growth hormone (GH)/insulin like growth factor-1 (IGF-1) 
axis, and chronic use of glucocorticoid (GC) are important contributory factors; 
interdependent with these factors are the modulatory role of disease severity mediated via 
pro-inflammatory cytokines such as tumour necrosis factor (TNF α), interleukin (IL) 1β and 
IL6 (219). Whilst GC therapy plays a direct role in affecting longitudinal growth and skeletal 
development, there is ample accumulating evidence that proinflammatory cytokines by 
themselves exert an important effect on growth. This effect may be mediated directly at the 
level of the growth plate or through the systemic GH/IGF-1 axis (219) . Studies by our group, 
as well as others, have shown that pro-inflammatory cytokines play a vital role in inhibiting 
growth plate chondrogenesis and promoting bone resorption (187;233). 
Biological therapy such as Infliximab, a chimeric monoclonal antibody against TNF-α has 
been shown to be effective in childhood onset CD for both induction and maintenance of 
disease remission (273;279). Although preliminary studies suggest that children starting 
Infliximab show an improvement in growth (156;311) over a third may continue to 
demonstrate poor growth (247;309;350) and the factors that are associated with this growth 
response are unclear. It is also unclear whether any demonstrable improvement is related to 
a reduction in GC dose or due to a progression through puberty. In children, pubertal 
progress and growth are intricately linked and abnormalities of growth in childhood CD may 
be manifested as poor growth before puberty, during puberty and, sometimes as a reduction 
in final adult height (234;330). Current reports of Infliximab therapy suggest that growth is 
most likely to improve in those who are in early stages of puberty and this observation may 
be a function of pubertal progress akin to similar results from studies of resectional surgery 
(351). A study of children who remain pre-pubertal throughout the treatment period or who did 
not have GC therapy would improve our understanding of the effects of Infliximab on growth. 
 
The aim of this study was to assess growth, puberty, markers of disease and concomitant 
therapy over the six months prior to starting Infliximab and for the six months and 12 months 
following treatment. By paying particular consideration to puberty and GC usage, we 
attempted to tease out the respective importance of these factors, as well as determine the 
extent of the growth promoting effect of Infliximab that was independent of these factors. 
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3.2.1 Subjects and methods 
Clinical records of all children with IBD who were started on Infliximab therapy between 2003 
and 2008 at the Royal Hospital for Sick Children were examined retrospectively. Out of a total 
of 42 children, there were 38 children (male, 24) who were diagnosed with CD as defined by 
standard criteria (352;353). Sufficient data on growth were available for the 6 months before 
starting Infliximab (T-6), at starting Infliximab (T0) and 6 months after starting Infliximab (T+6) 
in 34 children. Out of these 34 children, 6 had completed their growth and reached final 
height during the period of study so these children were excluded from further analysis 
(Figure 3.1.1). The median age of the remaining 28 (M, 17) children at diagnosis and start of 
Infliximab was 10.8yr (6.6, 13.4) and 13.1yr (9.9, 15.7) respectively. Disease location was 
small and large bowel in 13 cases, large bowel only in 11 cases, small bowel only in 3 cases 
and perianal only in 1 case. In 20 of the 28 children, data on pubertal status were available at 
pre and post 6 months. Pubertal status was measured by a validated self-assessment form. 
Thirteen children remained pre-pubertal throughout the study period, whereas those who 
progressed in puberty were considered as pubertal. In 25 children growth data were available 
over the 12 month period following Infliximab therapy. Data on erythrocyte sedimentation rate 
(ESR), platelets, C-reactive protein (CRP), serum albumin (Alb), total alkaline phosphatase 
(ALP), alanine transaminase (ALT) were assessed as systemic markers of disease and 
growth. 
Height was measured with a Harpenden stadiometer and used to calculate height velocity 
(HV) and body mass index (BMI). Tanner pubertal stage was estimated by either clinical 
examination or self-estimation (338;339). Height (Ht) and body mass index (BMI) were 
converted into SDS using 1990 British childhood standards (340;341). T-6,T0,T+6 and T+12 
HV(cm/yr) were calculated for the prior 6 months of these time points with T0 representing 
the point of starting Infliximab therapy. To account for delayed puberty, HV at T-6,T0,T+6 and 
T+12 was converted into SDS adjusted for breast stage for girls >11 yrs and genital stage for 
boys >12 years by using age-related references for attainment of pubertal stages (354). A 
Physician’s Global assessment was used to classify patient’s response to therapy based on 
remission or improvement in symptoms as well as general patient well-being. Using this 
assessment, children were categorized as a “Responder” or a “Non-responder” to Infliximab; 
the former category included those who reached clinical remission. Details of concomitant 
medications were obtained from the case notes and are presented in (Table 3.3.1). Only 3 
children at T0 and 1 child at T+6 were on supplemental feeds. None of the children were on 
any form of direct growth or puberty promoting drugs. Eight children received scheduled 
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maintenance with Infliximab for 12 months after starting Infliximab therapy; none of these had 
resectional surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.1: Flow diagram of study recruitment 
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3.2.2 Statistical analysis 
All data are described as medians and 10th and 90th centiles and were analysed with 1-
sample Wilcoxon non-parametric test by using Minitab software version 15. Univariate linear 
regression analysis was used for univariate analysis of association. Statistical significance 
was set at p < 0.05. Assessment of a relationship of HV at T0 and T+6 with systemic 
biochemical and haematological markers was performed by comparing the HV at T0 to the 
average value of the marker at T-6 and T0 and by comparing HV at T+6 to the average value 
of the marker at T0 and T+6. Logistic regression analysis was used to assess independent 
factors associated with change in absolute HV at T+6. The dependent reference group 
included those with a greater than two-fold rise in absolute HV at T+6. Independent factors 
assessed were prednisolone use at T0 and T+6, and Methotrexate use at T0 and T+6. 
 
3.3 Results  
3.3.1 General Characteristics 
Over six months from T0 to T+6, each patient received a median of 4 Infliximab infusions (2, 
6). 27 children started an induction regime of 5mg/kg at 0, 2wk and 6wk, but one of 27 
children did not complete induction and in one child the corresponding dose was 7mg/kg.12 
children progressed to maintenance therapy. Table 3.3.1 shows the clinical details of these 
children 6 months prior (T-6) to starting Infliximab, at baseline (T0) and for the following 6 
months (T+6). Out of the 28 children, 21(75%) demonstrated a clinical response to Infliximab 
therapy out of whom 10(36%) achieved clinical remission. 4 of 28 cases, had an immediate 
adverse reaction which could be attributed to the Infliximab. These included headache, 
urticaria, anaphylactic reaction, nausea and vomiting. The patient with anaphylactic reaction 
completed the induction regime. During the 12 month period of study none of these children 
had resectional surgery. 
3.3.2 Linear growth & disease status 
The median HV in the overall group increased from 3.6cm/yr(0.4,7.9) at T0 to 
5.5cm/y(2.1,9.2) at T+6, (p=0.003).The median change in height SDS (∆HtSDS) of this group 
also increased from -0.1 (-0.31, 0.16) at T0 to 0.05 (-0.14, 0.45) at T+6, (p=0.006) (Figure 
3.3.1 a & b). This was reflected in the HtSDS which increased from a median of -1.01 (-2.35,-
0,03) at T0 to -0.93(-2.13,-0-04) at T+6,(p=0.005) (Table 3.3.1).  
Out of the 28 children, 17 had a reduction in HtSDS between T-6 and T0 and 11 out of these 
17 (65%) children showed an increase in HtSDS between T0 and T+6, 2(12%) showed no 
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change in HtSDS and the remaining 4(23%) continued to show a deterioration in HtSDS after 
starting Infliximab therapy. In the 10 children who had an increase in HtSDS before Infliximab 
therapy, 7(70%) showed a continuing improvement in HtSDS after starting therapy and 
3(30%) showed a deterioration after starting therapy (Figure 3.3.2). HV at T0 and T+6 in the 7 
non-responders was 4.3cm/yr (2.5,8.6) and 3.0cm/yr (2.0, 11.3), respectively (p=0.71) (Figure 
3.3.3a). The median ∆HtSDS of this group also remained unchanged from -0.0 (-0.1, 0.4) at 
T0 to -0.1 (-0.2, 0.6) at T+6, (p=0.60) (Figure 3.3.3b), whereas, in those who showed a 
clinical response, HV increased from 2cm/yr (0.3, 7.0) to 6.4cm/yr (2.3, 9.1) (p=0.004) (Figure 
3.3.3c). The median ∆HtSDS of this group also increased from -0.1 (0.00, 0.10) at T0 to 0.05 
(0.00, 0.4) at T+6, (p=0.001) (Figure 3.3.3d). 
HV at T0 and T+6 showed a positive association to the average serum ALP, a recognized 
marker of growth and skeletal development, during the 6 months prior to starting Infliximab 
(r,0.39, p=0.046) and the 6 months after starting Infliximab (r,0.53, p=0.003), respectively 
(Figure 3.3.4). HV T+0 and T+6 did not show an association with any of the systemic disease 
markers that were studied.  
In 25 children growth data were available over the 12 month period following Infliximab 
therapy. The median HV in the overall group changed from 3.6cm/yr(0.4,7.9) at T0 to 5.2cm/y 
(0.4,9.0) at T+12, (p=0.4). The ∆HtSDS of this group also increased from -0.1 (-0.31, 0.2) at 
T0 to 0.12 (-0.4, 0.61) at T+12, (p=0.050) (Figure 3.3.5 a & b). 
3.3.3 Pubertal status & growth 
Of the 20 children with complete pubertal data, 13, with a median age of 10.3 years (8.09-
12.91) at T-6, remained pre-pubertal 6 months prior (T-6) to starting Infliximab, at baseline 
(T0) and for the following 6 months (T+6). In the 20 children who had puberty assessed and 
in whom HV could be adjusted for pubertal age, HV SDS was -2.2 (-8.3, 5.3) and 1.0 (-2.9, 
4.0) at T0 and T+6, respectively (p=0.03). Analysis in the sub-group of pre-pubertal children 
demonstrated an increase in HV from 4.5cm/yr (0.4, 8) at T0 to 5.5cm/yr(3.3, 8.4) at T+6 
(p=0.05) (Figure 3.3.6). 
  
128 
Table 3.3.1: Clinical details of children at 6 months before starting Infliximab (T-6), at starting Infliximab (T0), at 6 months (T+6) and 12 months (T+12) 
after starting Infliximab 
  
 
T-6 
N,28 
 
 
T+0 
N,28 
 
 
T+6 
N,28 
 
 
T+12 
N,25 
 
 
T-6 VS 
T+0 
 
 
T+0 VS 
T+6 
p-Value 
 
T-6 VS 
T+6 
 
 
T+6 VS 
T+12 
 
 
T+0 VS  
T+12 
 
 
T-6 VS  
T+12 
Age 12.6 
(9.2-15.4) 
13.1 
(10.0-15.7) 
13.6 
(10.4-16.4) 
14.3 
(10.8-17) 
      
Concomitant 
Medication 
          
-Aminosalicylic acid  17 16 14       
-Azathioprine  13 9 7       
-Methotrexate  13 21 19       
-Prednisolone  12 6 5       
           
Anthropometry           
Height SDS -0.83 
(-2.62,0.16) 
-1.01 
(-2.35,-0.03) 
-0.93 
(-2.13,-0.04) 
0.12 
(-0.43,0.61) 
 
0.006 
 0.9 0.050 0.0049 
BMI SDS -0.29 
(-1.94,0.93) 
-0.56 
(-2.00,1.47) 
-0.38 
(-1.52,1.31) 
-0.3 
(-1.5,1.24) 
      
Height Velocity (cm/yr) 2.5 
(0.4,6.9) 
3.64 
(0.4,7.8) 
5.55 
(2.1,9.2) 
5.2 
(0.4,9.0) 
 
0.003 
 0.22 0.4 0.05 
           
Pubertal status (n,20)           
-I 17 15 13 6       
-II 2 3 5 6       
-III 1 2 1 7       
-IV - - 1 -       
Biomarkers    1       
Serum albumin (g/l) 35 
(27,42) 
35 
(24,39) 
38 
(33,43) 
37 
(28,42) 
0.86 0.007 0.006 0.31 0.01 0.5 
ALP(U/l) 119 
(83,186) 
92 
(60,146) 
157 
(108,208) 
166 
(86,234) 
0.013 <0.0001 0.01 0.8 0.0001 0.15 
ALT(U/l) 13 
(8,26) 
8 
(7,20) 
16 
(11,26) 
16 
(10,34) 
0.12 0.0007 0.04 1.0 0.007 0.08 
ESR (mm/hr) 28 
(10,46) 
40 
(13,56) 
16 
(11,26) 
22 
(6,42) 
0.23 0.002 0.002 0.5 0.02 0.13 
CRP (mg/l) 7 
(7,31) 
7 
(7,36) 
7 
(7,11) 
7 
(7,30) 
0.19 0.04 0.4 0.8 0.2 0.8 
Platelets (109/L) 435 
(262,563) 
403 
(289,670) 
342 
(213,516) 
321 
(250,298) 
0.97 0.04 0.03 0.4 0.01 0.02 
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Figure 3.3.1: Growth in children with CD during the 6 months before Infliximab therapy (T0) and in the 6 months following the start of therapy (T+6). 
Box and whisker plots representing median 10th, 25th, 75th, and 90th centiles 
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  Figure 3.3.2: The relationship between change in height standard deviation scores (∆HtSDS) 
during the 6 months before (∆HtSDS+0, x-axis) and the 6 months after (∆HtSDS+6, y-axis) 
starting Infliximab therapy in children with CD. The children in quadrant (A) had slow growth 
before starting Infliximab therapy but had improved growth after treatment. The children in 
quadrant (B) had normal growth both before and after Infliximab therapy. The children in 
quadrant (C) had normal growth before but had slow growth after starting Infliximab therapy. 
The children in quadrant (D) had slow growth before and after starting Infliximab therapy 
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Figure 3.3.3: Growth in children with CD during the 6 months prior to Infliximab therapy (T0) and in the 6 months following start of therapy (T+6); 
Box and whisker plots representing median, 10th, 25th, 75th, 90th centiles 
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Figure 3.3.4: The association between HV (cm/y) and ALP (U/L)  
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Figure 3.3.5: Growth in children with CD during the 6 months before Infliximab therapy (T0) and in the 6 months (T + 6) and 12 months (T + 12) 
following start of therapy. Box and whisker plots representing median 10th, 25th, 75th, and 90th centiles 
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Figure 3.3.6: Height velocity (HV, cm/yr) in pre-pubertal children with CD during the 6 months prior to Infliximab therapy (T0) and in the 6 months 
following start of therapy (T+6). Box and whisker plots representing median 10th, 25th, 75th, and 90th centiles 
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3.3.4 Glucocorticoid status & growth 
The cohort of children could be divided into three groups based on whether they received 
prednisolone in the 6 months prior to starting Infliximab or in the 6 months after starting 
Infliximab. Out of the 28 children, 13 (45%) did not receive prednisolone either before or after 
starting Infliximab; 9(32%) had a complete cessation of prednisolone therapy and 2(7%) had 
a reduction; and the third group consisting of 4 children had an increase (n,1) or initiation 
(n,3) of prednisolone therapy in the 6 months after starting Infliximab. In the first group of 
children, HV increased from 3.7cm/yr(0.6,6.5) at T0 to 6.4cm/yr(2.2,9.3) at T+6, (p=0.04); in 
the second group, HV also increased from 1.8cm/yr(0.3,8.3) at T0 to 5.6cm/yr(2.9,9.0) at T+6 
but the difference did not reach statistical significance (p=0.11). In the third group HV at T0 
and T+6 was similar at 3.9cm/yr and 4.1cm/yr, respectively (p=0.14) (Figure 3.3.7 a, b & c). 
3.3.5 Methotrexate therapy 
In 12 cases, children were on Methotrexate therapy before and after starting Infliximab. 
Median HV before and after starting Infliximab in this group of children was 2.7(0.0, 8.2) and 
7.1(1.4, 14.1), respectively (p= 0.001). In these 12 children, median cumulative prednisolone 
dose for the prior 6 month period at T0 and T+6 was 0.02mg/kg/day (0.00,0.04) and 
0mg/kg/day (0.00,0.03) (NS). In 9 cases, children were not on Methotrexate before starting 
Infliximab but were commenced on Methotrexate in the 6 months after starting Infliximab. 
Median HV at T0 and T+6 was 5.2cm/yr (2.2,9.2) and 5.7cm/yr(0.4,11.5), respectively (0.26). 
For these 9 children, median cumulative prednisolone dose for the prior 6 month period at T0 
and T+6 was 0mg/kg/day (0.00, 0.05) and 0mg/kg/day (0.00, 0.03), respectively (NS). In 7 
cases, Methotrexate therapy was not administered before or after starting Infliximab and their 
HV at T0 and T+6 was 3.3cm/yr (1.6, 7.7) and 3.7cm/yr (0.4, 7.2), respectively (0.37). Median 
cumulative prednisolone dose at these two time points was 0mg/kg/day (0.00, 0.06) and 
0mg/kg/day (0.00, 0.05) (NS), respectively (Figure 3.3.8 a, b & c). 
3.3.5.1 Multivariate analysis 
Multivariate analysis using logistic regression with change in actual HV at T+6 (greater than 2 
fold increase in HV as reference category) and prednisolone category and Methotrexate 
category as independent variables (Nagerlkerke R square 0.40) revealed no significant 
independent factor. 
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Figure 3.3.7: Height Velocity (HV cm/yr) according to prednisolone therapy status in the 6 months before (T0) and the 6 months (T+6) after starting 
Infliximab therapy 
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Figure 3.3.8: Height Velocity HV (cm/yr) according to Methotrexate therapy status in the 6 months before (T0) and the 6 months (T+6) after starting 
Infliximab therapy 
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3.3.6 Discussion 
Infliximab therapy in children with CD has been reported to be associated with an 
improvement in linear growth and our study supports these findings (233;273;311). Overall, 
there was an average improvement of approximately 50% in height velocity in the 6 months 
after the initiation of therapy and improvement was further sustained for a further 6 months. 
Whilst this improvement in growth is noteworthy, the median age of this group at the time of 
starting therapy was 13yrs and a height velocity of 5.5cm/yr at this age is still relatively low. In 
general, boys are close to approaching their peak height velocity at this age and their 
expected median height velocity would be approximately 10cm/yr (355); in girls, median 
height velocity is approximately 5cm/yr at this age (355). However, these data assume a 
normal timing of puberty; accordingly, over 50% of healthy girls over the age of 13 years 
would be expected to reach menarche. The cohort in our study excluded all girls that had 
reached menarche and in the 20 cases where puberty data were available, none were more 
advanced than Tanner Stage 3 at the start of therapy. The relatively low height velocity for 
age is reflected in the height SDS and how it changed following Infliximab therapy. In those 
children whose height SDS was falling before start of Infliximab therapy, an improvement in 
height SDS was seen in approximately 60% and these findings are similar to previous reports 
(247;309;350). 
In other groups of children, such as those with juvenile idiopathic arthritis, treatment with 
TNF-α antagonist receptor therapy has also been associated with an improvement in growth 
but this improvement has been partly attributed to a reduction in the use of GC therapy (315). 
In CD, a recent review of growth and its relationship to treatment modalities in 176 children 
suggested that poor growth was more likely in those who were receiving GC therapy and the 
authors called for eliminating the use of GC (310). Our observation that initiation of Infliximab 
was associated with an improvement in growth in those children who had not been exposed 
to exogenous GC at all, is noteworthy, and suggests that the growth-promoting effects of 
Infliximab are not solely due to its ‘GC-sparing effect’. The finding that growth was more likely 
to improve in those children who were judged to be ‘responders’, also suggests that growth 
improves as a result of improved disease control. Our observation that the increase in height 
velocity was more marked in the children who had never been on GC compared to those who 
had been on GC, suggests a possible adverse priming effect of GC on growth. It is equally 
plausible GC administration may also be a proxy marker of disease severity. Given that GC 
and proinflammatory cytokines may exert adverse effects on the growth plate through 
common as well as distinct mechanisms, the possibility that prior therapy with GC hinders the 
growth-promoting effect of Infliximab does require further study. 
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Proinflammatory cytokines and chronic inflammation maybe associated with altered gonadal 
function and reduced sex steroid synthesis and affected children and adults may exhibit a 
combined picture of central and peripheral hypo-gonadism (356). In adolescents, this may 
present as delayed onset of puberty, slow progression through puberty and/or associated 
growth retardation. Improvement of the disease status would be expected to be associated to 
pubertal progression and improved growth. Previous report of growth following Infliximab 
therapy have suggested that improvement is more likely in those, which are in early puberty 
(310;311), and this may be due to the possibility of pubertal progress following initiating 
Infliximab therapy. Our observation that growth improved in children who remained pre-
pubertal for the 6 months before and after starting Infliximab suggests that the improvement 
in growth may not simply be due to pubertal onset or progression through puberty. Previously 
published studies have suggested that growth is more likely to improve in those who were in 
early puberty at introduction of Infliximab therapy (310;311). Whilst this implies that growth 
improvement may be secondary to progression in puberty, our study shows that growth 
improvement is not simply due to pubertal progress. 
While our review of this cohort clearly shows the relationship between growth and clinical 
response to Infliximab therapy, there was no clear relationship between individual markers of 
disease activity and growth. A lack of an association between individual markers of disease 
and disease activity has been reported previously (345). Our data also suggest that the 
beneficial effect of Infliximab on growth may be more likely when a child is receiving a 
background of Methotrexate. A beneficial synergistic effect of Methotrexate and Infliximab on 
disease activity has been previously reported in children with rheumatoid arthritis (357). In 
vivo studies in children and in vitro studies at the level of bone and growth plate, suggest that 
Methotrexate promotes bone resorption and suppresses chondrogenesis (358;359). 
However, it is possible that this adverse effect of Methotrexate on the skeleton may only be 
observed at higher doses and the synergistic effect may only occur at tissue exposure at a 
lower level (357). This may further depend on the dose and route of administration of 
Methotrexate and these issues will require further studies in a larger cohort of cases. 
Nevertheless, our observations would support the early use of Methotrexate in children 
before Infliximab is used as the subsequent component of step-up therapy (100).The 
association between ALP and height velocity that was observed in our study suggests that an 
improvement in growth is associated with an improvement in bone formation. Although, the 
total ALP assay reflects intestinal, placental, liver, bone and kidney isoforms of ALP, in 
children without liver disease, the correlation between bone and total ALP is greater than 0.9 
(360). In addition to being present in mature osteoblast and the matrix vesicles that are 
associated with bone mineralization; the bone isoform of ALP is also present in the 
  
140
hypertrophic chondrocytes of the epiphyseal growth plate, and in the matrix vesicles 
associated with bone mineralization; it is also the predominant isoform in the plasma of 
growing children (185). In cross-sectional studies, both total and bone ALP parallel the 
childhood height velocity curve (361) and longitudinal studies of short-term and medium-term 
growth in healthy children have reported a high level of correlation between growth and total 
or bone ALP (359;362;363). Proinflammatory cytokines and GC can affect osteoblast activity 
independently, as well as through common mechanisms such as the 11β-hydroxysteroid 
dehydrogenase shuttle which regulates tissue glucocorticoid exposure in response to 
cytokines (364). Our preliminary data suggest that, in addition to improving growth, it is 
possible Infliximab use is associated with an improvement in bone health and this observation 
was recently confirmed in a report of an improvement in biomarkers of bone formation in 
another similar cohort of children (207). Our study suggests that this improvement may be 
independent of a reduction in GC and changes in pubertal stage. A recent report suggests 
that Infliximab therapy may also be associated with improvements in lean mass corrected for 
height (365). There is, therefore, a need to further understand the wider benefits of anti-TNF 
therapy.  
 
In summary, linear growth in children with CD improves following Infliximab therapy in those 
who show a clinical response. This increase is clearly multifactorial but of note also seen in 
pre-pubertal and GC naïve children and cannot solely be attributed to a change in these 
factors alone. 
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CHAPTER 4 
 
The effects of anti-TNF-α treatment with Adalimumab on 
growth in children with Crohn’s disease 
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4.1 Summary 
Introduction: Adalimumab is used to treat children with Crohn’s disease (CD), but the effects 
of Adalimumab on growth in CD have not been studied. 
Aim: To study growth and disease activity over 12 months (6 months prior to (T-6), baseline 
(T0) and for 6 months following (T+6) Adalimumab.  
Subjects & methods: The growth and treatment details of 36 children (M: 22) who started 
Adalimumab at a median (10th, 90th) age of 14.7years (11.3, 16.8) were reviewed. 
Results: Of 36 cases, 28 (78%) went into remission. Overall 42% of children showed catch 
up growth, which was more likely in: (i) those who achieved remission (median change in 
height SDS (∆HtSDS) increased from -0.2 (-0.9, 1.0) at T0 to 0.2 (-0.6, 1.6) at T+6, 
(p=0.007), (ii) in those who were on immunosuppression ∆HtSDS increased from -0.2(-0.9, 
1.0) at T0 to 0.1 (-0.8, 1.3) at T+6, (p=0.03) and (iii) in those whose indication for using 
Adalimumab therapy was an allergic reaction to Infliximab median ∆HtSDS increased 
significantly from -0.3(-0.9, 1.0) at T0 to 0.3(-0.5, 1.6) at T+6, (p=0.02). Median change in 
height SDS (∆HtSDS) also increased from -0.4 (-0.8, 0.7) at T0 to 0.0(-0.6, 1.6) at T+6, 
(p=0.04) in 15 children who were on prednisolone therapy when starting Adalimumab. 
Conclusion: Clinical response to Adalimumab therapy is associated with an improvement in 
linear growth in a proportion of children with CD. Improved growth is more likely in patients 
entering remission and on immunosuppression but is not solely due to a steroid sparing 
effect. 
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4.2 Introduction 
Crohn’s disease in children often results in malnutrition, growth retardation, pubertal delay 
and poor bone health (330). Several interrelated factors contribute to linear growth retardation 
in children with CD, including poor nutrition, chronic use of GC and lack of IGF-1 
interdependent with these factors are the modulatory role of disease activity mediated via 
pro-inflammatory cytokines such as TNF α, IL 1β and IL6 (219). Conventional treatment of 
CD consists of enteral nutrition, corticosteroids, anti inflammatory agents and 
immunomodulators. However, these treatments have been largely unsuccessful in altering 
the natural course of the disease (245). Growth is a vital outcome in intervention studies in 
paediatric IBD, yet is rarely reported as a secondary outcome let alone as the primary 
outcome (366). Although the initial therapeutic strategy for CD has not been changed for a 
long time, the emergence of biological therapy, with its record of rapid efficacy and use as 
maintenance therapy has changed the management of severe paediatric CD dramatically 
(273). Adalimumab (Humira®, Abbott UK) is a humanized anti-TNF therapy that has been 
shown to be efficacious for induction and maintenance of remission for adults with CD 
(265;267). Adalimumab is generally used in those patients who have an attenuated response 
or an adverse reaction to Infliximab (284-286). Infliximab treatment has been shown to allow 
catch up growth and reduce steroid use in paediatric patients with CD in several studies 
(156;207;247;279;309-312;367). Adalimumab, however, is not currently licensed for use in 
paediatric IBD patients in the UK at least. The published clinical studies to date of 
Adalimumab use in children are relatively limited (276;288;289;291-295) with no studies yet 
conducted to examine the effects of Adalimumab on growth in children with CD. The aim of 
the present study was to assess the effect of Adalimumab therapy on growth, puberty and 
disease activity over the 6 months prior to and 6 months after starting Adalimumab treatment 
in children with CD. 
 
4.3 Subjects and methods 
All members of the British Society of Paediatric Gastroenterology Hepatology and Nutrition 
(BSPGHAN) were approached by e-mail and invited to take part in the study.  The full study 
methodology has been published previously (304). Data collected included; patient 
demographics, anthropometry, drug treatments (including previous Infliximab use) and details 
of any prior surgery (304). No growth data were included in the initial publication. Data for this 
study were collected and provided by Dr David Wilson and Michelle Wilson, School of clinical 
sciences, the University of Edinburgh. Of the 70 cases in the original study cohort with CD, 
those included in this study were children who had sufficient growth data available at all 3 
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time points. Sufficient data on growth were available for the 6 months before starting 
Adalimumab (T-6), at starting Adalimumab (T0) and 6 months after starting Adalimumab 
(T+6) in 36 children who were then studied further. Thirty-four of 36 had previously received 
Infliximab (Figure 4.5.1). The median (10th, 90th) ages at diagnosis and start of Adalimumab 
were 10.3 years (6.5, 13.1) and 14.7 years (11.3, 16.8) respectively. CD was diagnosed using 
standard criteria (6;353). In 28 of the 36 children, data on pubertal status was available at 
start of Adalimumab therapy (T0). Additionally, in 11 children growth data were also collected 
at 12 months following Adalimumab therapy.  
Height was measured with a Harpenden stadiometer and Tanner pubertal stage was 
assigned using either clinical examination or self-estimation (338;339). Height (Ht) data were 
converted into SDS (standard deviation scores) using 1990 British childhood standards 
(340;341). T-6,T0,T+6 and T+12 HV(cm/year) were calculated from the prior 6 months of 
growth before  time points with T0 representing the point of starting Adalimumab therapy. 
Disease phenotype was assigned using the Montreal classification (5). Adalimumab effect 
was assessed using the Paediatric Crohn’s Disease Activity Index (PCDAI), where available, 
or Physicians Global Assessment (PGA) when PCDAI was not available (7;368). Using this 
assessment, children were then categorized as either “Remission” or “No-remission”. 
Standard definitions were used for PCDAI disease status and remission (remission, PCDAI 
≤10)(7). Details of concomitant medications were recorded and are presented in (Table 
4.5.1). None of the children were on growth or puberty promoting treatments during the 
period of study. 
 
4.4 Statistical analysis 
All data are described as medians and 10th and 90th centiles and were analyzed with 1-
sample Wilcoxon non-parametric test by using Minitab software version 16. Statistical 
significance was set at p < 0.05. To evaluate how growth was affected by Adalimumab, 
change in height SDS (∆HtSDS) was calculated as well as height velocity. 
 
4.5 Results  
4.5.1 General characteristics 
Thirty-four (94%) had prior Infliximab usage of whom 7 were primary non-responders, 16 had 
loss of clinical response and 11 had had an allergic reaction necessitating discontinuation. 
The induction dose of Adalimumab most commonly used was 80mg followed by 40mg 2 
weeks later  in 18 patients (50%), 24mg/m2 in 9 patients (25%), 160mg then 80mg 2 weeks 
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later in 2 patients (6%) and the 7 patients remaining received a combination of other dosing 
regimens(19%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.1: Flow diagram of study recruitment 
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Table 4.5.1: Demographic details of children at starting Adalimumab (T0) & at 6 months (T+6) after starting Adalimumab. Continuous variables are 
presented as medians and 10th and 90th centile 
 
 
                                           T+0 
N,36 
 
T+6 
N,36 
 
T+0 VS T+6 
p-value 
Age (yrs) 14.7(11.3,16.8 15.2(11.9,17.3) 
 
 
Concomitant Medication    
Background immunosuppression 
(Azathorprine or Methotrexate 
23   
-Prednisolone 15   
-Infliximab 36   
Anthropometry    
∆HtSDS -0.2 (-0.7, 0.2) 0.0(-0.5, 0.8) 0.005 
BMI SDS -0.8(-2.2,1.3) -0.4(-1.3,1.2)  
Height Velocity (cm/yr) 2.0  (0.0, 5.8) 4.0 (0.0, 11.2) 0.02 
Pubertal status (n,29)    
-I 6   
-II 7   
-III 4   
-IV 3   
-V 9   
PCDAI (n,19) 25(7.5,65) 10(0,55) 0.0001 
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All 36 patients commenced maintenance Adalimumab therapy at 40mg (n=33, 92%) or 
24mg/m2 (n=3, 8%). One patient suffered an adverse reaction leading to withdrawal after 
Adalimumab therapy. Of 36 cases, 4 had resectional surgery during the study period. Other 
previous medications included, 30(83%) who had enteral nutrition, 32(89%) who had 
glucocorticoids, 34(94%) had prior Azathioprine/6-mercaptopurine and 20(56%) had previous 
Methotrexate. 
 
4.5.2 Disease characteristics  
Disease location was most commonly panenteric (Ileo-colonic and upper GI tract, L3 + L4) in 
15(42%); 15 (42%) children had perianal disease. Of the 36 children, 28(78%) achieved 
remission on Adalimumab therapy in this cohort. A PCDAI score was available in 19 children 
at baseline (T0) and at 6 months (T+6) after Adalimumab therapy. Median PCDAI score 
decreased significantly from 25(7.5, 65) at T0 to 10 (0, 55) at T+6, (p=0.0001). Of 19 patients 
with PCDAI data, 14 achieved clinical remission as assessed by the PCDAI. Twelve of the 19 
children had a PCDAI score available at 6 months and 12 months after starting Adalimumab 
therapy. In this group median PCDAI Score also was reduced significantly from 27.5(7.5, 65) 
at T0 to 6.25(0, 55) at T+6, (p=0.001) and 5(0, 37.5) at T+12, (p=0.0005) (Figure 4.5.2a & b). 
 
4.5.3 Linear growth in the whole cohort 
The median change in height SDS (∆HtSDS) in the whole group increased from -0.2 (-0.7, 
0.2) at T0 to 0.0(-0.5, 0.8) at T+6, (p=0.005) (Figure 4.5.3 a). Categorizing the subjects by 
gender showed improvement of linear growth in both genders (data not presented). The 
median HV of the whole group also increased significantly from 2.0cm/year(0.0,5.8) at T0 to 
4.0cm/year(0.0,11.2) at T+6, (p=0.02) (Figure 4.5.3 b). Of the 36 children, 15 (42%) 
demonstrated catch-up growth with median ∆HtSDS of this group increasing from -0.3 at T0 
to 0.3 at T+6, in 6 (14%) children median ∆HtSDS was 0 (4 both before and after the initiation 
of Adalimumab therapy), 1 (2.7%) had a reduction in ∆HtSDS from 0, 1 to 0.0 and 14 (39%) 
had ongoing growth deterioration with median ∆HtSDS of this group decreasing from  -0.4 to 
-0.3 after starting Adalimumab therapy (Figure 4.5.4).  
In 11 children growth data were available over the 12 month period following Adalimumab 
therapy. The median ∆HtSDS in the overall group changed from -0.2 (-0.9, 0.7) at T0 to 0.0 (-
0.6, 0.7) at T+12, (p=0.10).The median HV of this group changed from 2.6cm/year (0.0, 8.9) 
at T0 to 4.2cm/year (0.0, 10.3) at T+12, (p=0.30). Median ∆HtSDS increased from -0.2 (-0.7, 
0.2) at T0 to 0.03 (-0.5, 0.8) at T+6, (p=0.007) in children who achieved remission. 
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Figure 4.5.2: PCDAI values in children with CD at baseline (T0) and in the 6 months (T+6) and 12 months (T+12) following start of 
Adalimumab therapy 
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Figure 4.5.3: Growth in children with CD during the 6 months prior to Adalimumab therapy (T0) and in the 6 months following start of therapy (T+6) 
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 Figure 4.5.4: The relationship between change in height standard deviation scores over the 6 
months before (∆HtSDS0, x-axis) and the 6 months after (∆HtSDS+6, y-axis) starting 
Adalimumab therapy in children with CD. The children in quadrant (a) had slow growth before 
starting Adalimumab therapy but had improved growth after treatment. The children in 
quadrant (b) had normal growth both before and after Adalimumab therapy. The children in 
quadrant (c) had normal growth before but had slow growth after starting Adalimumab therapy. 
The children in quadrant (d) had slow growth before and after starting Adalimumab therapy 
Growth in those achieving remission. 
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Median HV of this group increased significantly from 2.0cm/year (0.0, 9.9) to 5.1cm/year (0.0, 
14.1) at T+6, (p=0.03) (Figure 4.5.5 a & b). In those who had no remission, median ∆HtSDS 
did not show any significant change; -0.1 (-0.7, 0.1) at T0 and -0.3 (-0.8, 0.2) at T+6, (p=0.87) 
and likewise median HV also did not show any improvement being 2.6cm/year (0.3, 6.1) at T0 
and 1.5cm/year (0.0, 4.5) at T+6, (p=0.36) (Figure 4.5.5 c & d).  
Growth response was also examined based upon the indication for using Adalimumab 
therapy as (i) allergic reaction to Infliximab (ii), loss-of-response to Infliximab and (iii) primary 
non responder to Infliximab (Figure 4.5.6 a, b & c). Of thirty four patients 11 had an allergic 
reaction, 16 had a loss of response and 7 were primary non responders. Median ∆HtSDS 
increased from -0.3(-0.9, 1.0) at T0 to 0.3(-0.5, 1.6) at T+6, (p=0.02) in children who had an 
allergic reaction; median HV changed from 0.2 cm/year (0.0, 8.6) to 5.3cm/year (0.0, 14.1) at 
T+6, (p=0.058). Median ∆HtSDS did not show any significant change from -0.1(-0.7,1.0) at T0 
to -0.1(-0.8,0.7) at T+6, (p=0.73) in children who had loss of response nor in children who 
were primary non-responders -0.1(-0.5, 0.1) at T0 to 0.0(-0.8, 0.2) at T+6, (p=0.93).  
 
4.5.4 Pubertal status & growth  
In 28 of the 36 children, data on pubertal status were available at start of Adalimumab 
therapy (T0). On the basis of pubertal stage patients were categorized into two groups 
according to the method previously published by Walters et al (311) i.e. Tanner stages I-III 
and Tanner stages IV-V patient groups. Of 28 patients 17 were at Tanner stages I-III with a 
median age 13.5years (6.8, 6.5) and 11 were at Tanner IV-V with a median age 16.6years 
(14.2, 17.3). In Tanner stages I-III patient group, median ∆HtSDS increased significantly from 
-0.4 (-0.8, 0.6) at T0 to 0.2 (-0.8, 1.3) at T+6, (p=0.02). Median HV of this group was also 
increased from 2.0cm/year (0.2, 8.8) at T0 and 5.3cm/year (0.1, 14.1) at T+6, (p=0.03). In 
Tanner stages IV-V patient group, median ∆HtSDS did not change significantly from -0.0 (-
0.8, 0.2) at T0 to -0.0 (-0.2, 1.5) at T+6, (p=0.10). Median HV of this group also showed an 
increase from 0.0 cm/year (0.0,8.6) at T0 to 2.0cm/year (0.0,13.6) at T+6, (p=0.34) but the 
difference was not significant (Figure 4.5.7 a, b c & d). 
 
4.5.5 Glucocorticoids  
The cohort of children was divided into two groups based on whether they were on 
glucocorticoids (prednisolone) or not when Adalimumab was commenced. Of the 36 children, 
15 (42%) were receiving prednisolone therapy when starting Adalimumab and 21 (58%) were 
not.
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Figure 4.5.5: Growth in children with CD during the 6 months prior to Adalimumab therapy (T0) and in the 6 months following start of therapy (T+6); 
Box and whisker plots representing median, 10th, 25th, 75th, 90th centiles. 
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Figure 4.5.6: Growth response based upon the indication for using Adalimumab therapy 
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Figure 4.5.7: Growth in relation to pubertal status in children with CD during the 6 months prior to Adalimumab therapy (T0) and in the  
6 months following start of therapy, Box and whisker plots representing median, 10th, 25th, 75th, 90th centiles 
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In the prednisolone group, median ∆HtSDS increased from -0.4 (-0.8, 0.7) at T0 to -0.0(-0.6, 
1.6) at T+6, (p=0.04). Median HV of this group also changed, but not significantly, from 
1.4cm/year (0.0, 9.9) at T0 to 4.0cm/year (0.0, 14.1) at T+6, (p=0.22); in the prednisolone-
free group, median ∆HtSDS increased from -0.1(-0.9, 1.0) at T0 to 0.1 (-0.8, 1.0) at T+6, 
(p=0.02). Median HV of this group also increased from 2.7cm/year(0.0,8.6) at T0 to 
4.0cm/year(0.0,12.0) at T+6 but the difference did not reach statistical significance (p=0.28) 
(Figure 4.5.8 a, b, c & d). 
 
4.5.6 Immunosuppression  
The cohort of children was divided into two groups based on whether or not they were on 
immunosuppression therapy (either thiopurine or Methotrexate) at commencement of 
Adalimumab. In the 23/36 (64%) children who were on immunosuppression therapy, median 
∆HtSDS increased from -0.2(-0.9, 1.0) at T0 to 0.1 (-0.8, 1.3) at T+6, (p=0.03). Median HV of 
this group changed from 2.0cm/year (0.0,9.9) at T0 to 5.1cm/year(0.0,12.1) at T+6 (p=0.23); 
in the other 13 children median ∆HtSDS did not change significantly at -0.1 (-0.8,0.1) at T0 to 
-0.0 (-0.6,1.6) at T+6, (p=0.12). Median HV of this group also remained similar at 2.0cm/year 
(0.0, 5.6) at T0 to 3.0cm/year (0.0, 14.1) at T+6, (p=0.32) (Figure 4.5.9 a, b, c & d).  
 
4.5.7 Discussion 
At present there are no published studies that adequately assess the effect of Adalimumab 
on linear growth in children with CD. This study provides evidence that Adalimumab is 
associated with improvement in short term linear growth in children with CD who enter 
remission but not in those who do not. It is also more likely to happen in children who are on 
immunosuppression and those in early puberty but seems to be relatively independent of 
steroid use. These findings suggest that growth improves as a result of several interrelated 
factors, including improved disease control.  
Use of co-immunosuppression therapy with biologics remains controversial (369). Our study 
has shown significant improvement in growth in children who were on immunosuppression 
therapy (either thiopurine or Methotrexate) at Adalimumab commencement compared to 
those children who were not. This complements the findings in the larger cohort of children 
treated with Adalimumab where higher response rates were seen in those who were on 
immunosuppression therapy at starting Adalimumab (304). There are no other published data 
on growth in children with CD receiving Adalimumab, but there are in other groups of 
  
156 
Figure 4.5.8: Growth in children with CD who were on prednisolone therapy at starting Adalimumab-Box and whisker plots representing median, 
10th, 25th, 75th, 90th centiles 
              
T+6T0
1.5
1.0
0.5
0.0
-0.5
-1.0
Δ
Δ Δ
Δ
H
t
S
D
S
(a) Pred 
p= 0.04
-----------------------------------------------------------------------------------------------
_________________________
       
T+6T0
16
14
12
10
8
6
4
2
0
H
V
 
c
m
s
/
y
r
(b) Pred
p=0.22
_________________________
 
                                   
T+6T0
1.0
0.5
0.0
-0.5
-1.0
 
Δ
Δ Δ
Δ
H
t
S
D
S
(c) No Pred
p= 0.02
-----------------------------------------------------------------------------------------------
_________________________
       
T+6T0
16
14
12
10
8
6
4
2
0
H
V
 
c
m
s
/
y
r
(d) No Pred
p=0.28
_________________________
                           
  
157 
Figure 4.5.9: Growth in children with CD who were on immunosuppression therapy at starting Adalimumab. Box and whisker plots representing 
median, 10th, 25th, 75th, 90th centiles 
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children, such as those with juvenile idiopathic arthritis, which have shown that the beneficial 
effect of biologic therapy on growth may be more likely when the patient is receiving 
background immunosuppression therapy using Methotrexate (317;318). Giannini et al (318) 
conducted a 3-year, open label nonrandomised study to evaluate the effects of longterm anti -
TNF-α etanercept treatment with or without Methotrexate on growth in children with selected 
categories of juvenile idiopathic arthritis. This study reported statistically significant increase 
in mean height percentiles from baseline for Etanercept monotherapy at year 3 only and for 
Etanercept in combination with the Methotrexate group at 1,2 and 3 years (318). In a similar 
study Billiau et al (317) also reported a significant improvement in growth velocity allowing 
catch-up growth in a comibined Etanercept and Methotrexate group only (317). 
In our cohort there was a significant improvement in the ∆HtSDS of both children who 
received steroids and those who did not. There was no difference in both groups. Our data 
suggests that the growth-promoting effects of Adalimumab therefore is not solely due to it’s 
‘‘GC-sparing effect’’. This complements Infliximab data where the improvement in growth was 
similarly not only due to its steroid sparing effect (367).  
Improvement of the disease status would be expected to be associated with pubertal 
progression and improved growth. We observed significant improvement in ∆HtSDS of 
children who were at Tanner stages I-III as compared to those who were at Tanner stages IV-
V at time of starting Adalimumab. Suggesting that the improvement in growth may in part be 
due to progression through puberty replicating similar observations made in children treated 
with Infliximab (311). Pfefferkorn et al have suggested that growth is more likely to improve in 
those who were in early puberty at the introduction of Infliximab therapy (310), whilst this 
study (albeit smaller) implies that growth improvement may be secondary to progression in 
puberty. 
Therapeutic interventions that have been reported to improve growth in children with CD 
include Infliximab, enteral nutrition and growth targeting growth hormone therapy. Short-term 
improvement in growth has been observed by the use of Infliximab in children with CD 
(156;207;279;310-312;367). Substantial evidence suggests that nutritional therapy, both 
elemental and polymeric formulation, has growth-promoting effects (370). Nutritional therapy 
has also been shown to improve height velocity (68;371) and accelerated linear development 
in growth in children with growth retardation (69;372). Studies have also been conducted to 
examine the effects of recombinant growth hormone on linear growth in children with CD and 
short stature (373;374). Most of these studies however, that have been conducted so far 
have reported changes in growth over the short term only. A recent North American study 
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observed changes in height z-scores at diagnosis, as well as 1 year and 2 years post 
diagnosis in children with CD and have reported that the distribution of height z-scores 
remained similar during the 2-year observation period despite improved disease activity plus 
the frequent use of immunomodulators and biologics (310). A recent study has also shown 
that at maximum follow-up no treatment was significantly associated with height improvement 
(335). Groups that have reported growth data in whole IBD patient cohorts including UK data 
from a Scottish cohort in the west of Scotland (375) have shown that current therapies do not 
improve final height outcome; although current treatments improve short term height most 
children do not improve their final height (310;335). Therefore although we are reporting short 
term improvement in growth, future studies need to look at final height as an outcome rather 
than the short term changes in height presented in most studies to date. 
Improvement in linear growth after Adalimumab was observed in children who enter 
remission but not in those who do not. This effect of Adalimumab is similar to that of 
Infliximab where responders improved growth and non responders did not (311;367) . Our 
data also suggest that the beneficial effect of Adalimumab on growth is more likely when a 
child is receiving background immunosuppression therapy (either thiopurine or Methotrexate) 
at Adalimumab commencement. This effect of Adalimumab with concurrent 
immunosuppression is also similar to the findings in the cohort of children treated with 
Infliximab (367). In a similar manner the growth promoting effect of Adalimumab does also 
not seem solely due to the simple explanation of a steroid sparing effect (367). It is also 
interesting to note that the growth response to Adalimumab varied dependent on the reason 
for discontinuing Infliximab; those who had an allergic reaction to Infliximab fared best 
paralleling preliminary Adalimumab clinical trial data suggesting clinical response and 
remission are higher in patient who are anti-TNF naïve rather than those who have had 
no/lost response to Infliximab previously (376). 
 
In summary, we have demonstrated that clinical response to Adalimumab therapy is 
associated with an improvement in linear growth over the short term in children with CD most 
of whom have been treated with previous Infliximab. Adalimumab continues to be mainly 
used at present as the second line biological agent in clinical paediatric IBD practice in the 
UK and elsewhere. Further prospective studies are required to clarify the effect of 
Adalimumab on growth, including long term follow-up to final adult height. 
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CHAPTER 5 
 
Effect of biologic therapy on growth, puberty and bone 
health in children with Crohn’s disease 
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5.1 Summary 
Background: Paediatric Crohn’s disease (CD) is associated with abnormalities in bone 
health, body composition and bone metabolism. Biologic therapy (Infliximab/Adalimumab) 
may improve bone health, body composition and muscle function in children with CD but the 
extent of improvement and its relationship to disease activity are unclear. 
Aim: Longitudinal observational prospective study of changes in physical growth, IGF-1 axis, 
bone health, body composition, muscle function and disease activity at baseline (BL), 2 
weeks (2wk), 6 weeks (6wk), 6 and 12 months (6M & 12M) following  biologic therapy in 
paediatric patients with CD.  
Patients & methods: Eleven patients (M:9) commencing treatment with biologic therapy as a 
part of their standard medical management (<18 years), who failed to reach remission 
disease despite conventional therapy (corticosteroids, and/or background 
immunosuppression therapy with Azathioprine or Methotrexate) at a median (range) age of 
14.7 years (11.2, 17.2) were recruited in the study. Data on growth, puberty, paediatric 
Crohn’s disease activity index (PCDAI), disease markers (CRP, ESR, and Albumin), body 
composition using bio-electrical impedance analysis (BIA), muscle function using Leonardo 
mechanograph and grip strength, markers of growth hormone secretion; Insulin like growth 
factor-I (IGF-1 (ng/ml), Insulin like growth factor binding protein 2 (IGFBP-2 (ng/ml) and 
Insulin like growth factor binding protein 3 (IGFBP-3 (ng/ml), and markers of bone turnover 
bone-specific alkaline phosphatase (serum BALP(µg/L) and C-telopeptide of collagen cross-
links (serum CTX-1 (ng/ml) were measured at BL, 2wk, 6wk, 6M and 12M. Bone and muscle 
parameters were measured at BL, 6M and 12M. Lumbar spine (LS), proximal femur (PF), 
femoral neck (FN) and total body bone mineral density (BMD (mg/cm²) and body composition 
were assessed by Dual Energy X-ray Absorptiometry (DXA). DXA bone mineral content 
(BMC (g) data were corrected for bone area and presented as BMC z-score (SD). Bone and 
muscle parameters were also measured by using peripheral quantitative computed 
tomography (pQCT) at the non-dominant distal radius and tibia.  
Results: At 12 months from baseline all patients who were receiving biologic therapy 
demonstrated a continued clinical response. Overall, height velocity (HV cms/yr) was  
3.9cm/yr (0.2,7.4) at BL and 4.7cm/yr (0.0,9.2) at 12M (p=0.30). Median (range) BALP (µg/l) 
changed from 21.3 (9.2,70.5) at BL to  28.1 µg/l (5.5,117.5) at 6M(p=0.01) and 38.3 
(10.9,110.5) at 12M(p=0.03). Median CTX-1(ng/ml) was 0.73(0.22,2.41) at BL and 1.21 
(0.73,2.35) at 6M(p=0.04) and 1.08(0.29,2.01) at 12M(p=0.50). A positive association was 
observed between BALP and HV (cms/yr) at 6M (r,0.55;p=0.01) and 12M (r,0.35;p=0.049). A 
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significant inverse association was observed between BALP and PCDAI at BL 
(r,0.46;p=0.02). DXA and TANITA both indicated significant change in FFM and FFMI from 
BL to 12M. pQCT for tibia and radius both indicated significant change in Fat-CSA and Mus-
CSA. Tibia median Fat-CSA changed 1809(892,2763) at BL to 1971(986,3505) at 6M(p=0.04) 
and 1899(1026,3475) at 12M(p=0.08). Tibia Mus-CSA increased significantly from 
4665(3018,6184) at BL to 5356(3210,6959) at 6M (p=0.02) and 5392(3373,7055) at 
12M(p=0.04). Radius median Fat-CSA was 695(684,1231) at BL and 871(600,1817) at 
6M(p=0.26) and 758(366,2204) at 12M(p=0.68). Radius median Mus-CSA increased from 
1827(1216,2848) at BL to 2219(1369,3094) at 6M (p=0.01) and 2539(1203,4238) at 
12M(p=0.08). Leonardo mechanography showed a change in JHt(m), V-max(m/s), EFI (%), 
F-max(kN), P-max (kW), efficiency (%) of the movement at 1 year of biologic therapy. An 
inverse association was observed between JHt(m), V-max(m/s) and  EFI% and PCDAI score 
at BL(r,0.51;p=0.01), (r,0.60;p=0.008),(r,0.63;p=0.006) and with efficiency(%) of the 
movement at BL (r,0.51;p=0.02) and 6wk(r,0.52;p=0.03) indicating the impact of disease 
activity on muscle function in patients with CD. However, no significant change was observed 
in total body, lumbar spine and proximal femur, femoral neck BMD. There were no significant 
changes in IGF-1, IGFBP-3, IGFBP-2 and ALS following biologic therapy.  
Conclusion: In conclusion, these prospective studies of growth, body composition and 
muscle function suggests that biologic therapy in children with CD has a beneficial effect on 
muscle mass and muscle function and these can be observed over the first year of therapy 
but for comprehensive conclusion this data needs to be adjusted for body size. These 
positive changes are also associated with an increase in bone turnover where the change in 
bone formation is much greater than bone resorption. These favourable effects on bone 
health were not accompanied by marked changes in BMD as assessed by DXA but did show 
some beneficial effects on pQCT assessed SSI, a surrogate marker of bone strength. The 
results of this preliminary study need to be confirmed in a larger group of children. 
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5.2 Introduction 
Children with CD have numerous risk factors for decreased bone mass, including poor 
growth, delayed puberty, malnutrition, changes in the growth hormone/ insulin-like growth 
factor axis (GH/IGF-1 axis), decreased physical activity, glucocorticoid therapy (GC) and 
increased inflammatory cytokines. Children with IBD, especially CD, frequently have short 
stature at diagnosis and height deficits which may become permanent (310). At diagnosis, 
growth retardation may be associated with reduced bone turnover. The pathogenesis of bone 
loss and growth retardation in IBD is a complex process. Both bone formation and bone 
resorption are decreased as reflected by the fact that biomarkers of bone formation and 
resorption are 30% to 50% of normal (377). Although anti-inflammatory treatment and 
improved nutrition are associated with normalization of bone biomarkers, bone mineral 
content (BMC) lags behind (377), and mechanical properties of bone may in fact worsen over 
time (378). In addition, height z-scores may not improve with conventional IBD therapy (310), 
and muscle mass deficits may also persist (213;365), which can affect the accrual of bone 
mass. Active inflammation may be the central mechanism responsible for alterations of 
normal bone metabolism. The effect of inflammation on the bone health of children with IBD 
has been examined in many cross-sectional (228;324) and a few longitudinal studies 
(377;378). Intestinal inflammation can affect bone cell function in multiple ways. Serum of 
children with active CD contains factors that inhibit bone formation in vitro (379). Activated T 
cells may shuttle inflammatory signals from gut to bone (380), and intestinal inflammation 
may induce an inflammatory response in the bone microenvironment (381). Sarcopenia, a 
specific lean mass deficit, has been found to be prevalent among both adults and children 
with IBD and may also adversely influence bone health (212;228;378;382). 
Although the initial therapeutic strategy for CD has not been changed for a long time, the 
emergence of biological therapy, with its record of rapid efficacy and use as maintenance 
therapy has changed the management of severe paediatric CD dramatically (273;273). 
Studies have reported that biologic therapy restores bone formation and linear growth in 
children with IBD (207;311;367;383). Recent evidence suggests that Infliximab is also 
associated with increased muscle mass in children with CD, which should further stimulate 
bone mass accrual (207). Collectively, these data suggest that adequate control of 
inflammation is both anti-catabolic and anabolic to bone. In vitro studies have demonstrated 
that TNF-α inhibits bone formation by osteoblasts and promotes bone resorption by 
osteoclasts (199;384;385). Consistent with the hypothesis that TNF-α contributes to bone 
deficits in CD, recent studies in adults have demonstrated significant increases in bone 
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formation markers and reductions in bone resorption markers following anti-TNF-α therapy 
with Infliximab (319-322). To date, few published studies have examined the effect of anti-
TNF-α therapy on bone density and bone metabolism and most of the data originate from 
studies performed in adult patients with CD (206;319;321;322;325-327). Data regarding the 
effect of biologic therapy on bone metabolism, body composition and BMD in children with 
CD is scarce and to date only one study has evaluated the impact of Infliximab therapy on 
bone biomarkers in children with CD (207;324). Thayu et al (207), in the REACH study of 103 
children with CD observed the changes in the bone biomarkers at week 10 after Infliximab 
induction therapy. This study also examined the association of these changes in the bone 
biomarkers with subsequent changes in disease activity and linear growth during the 54-week 
interval after initiation of Infliximab therapy. Low BMD is relatively common complication in 
IBD. Osteopenia and osteoporosis are reported to affect up to 70% of both adult (386) and 
paediatric (382;387) patients with IBD. The mechanism by which inflammatory process 
affects BMD in IBD is unclear.  Few studies of adults with IBD have described the beneficial 
impact of both short and long lasting administration of Infliximab using dual energy x-ray 
absorptiometry (DXA) (325-327) and only one study has reported effect of Infliximab on BMD 
in children with IBD (324). The impact of biologic therapy on volumetric bone mineral density 
(vBMD), bone structure, and muscle mass measured by using peripheral quantitative 
computed tomography (pQCT) is not reported so far. 
To date longitudinal changes in the insulin-like growth factor (IGF) system in IBD has rarely 
been investigated. The majority of these studies have mainly investigated the alterations of 
the IGF system in growth-retarded IBD children (371;374;388). It has been generally thought 
that the serum IGF system which includes IGF-1, IGF-2 and their binding proteins (IGFBPs), 
IGFBP-3 being the most important, is down-regulated during active IBD through several 
systemic mechanisms (389). Moreover, only three studies (328;329;390) in adult patients 
have documented the impact of biologic therapy on the IGF-1 system. There are no published 
data regarding effect of biologic therapy on IGF-1 system in paediatric patients with CD. The 
administration of Infliximab leads to highly variable concentrations among patients. 
Therapeutic drug monitoring of Infliximab may be useful because there is an inter-individual 
variability of Infliximab pharmacokinetics associated with an increase in clinical response with 
Infliximab trough concentrations as shown in CD patients (391;392). Maser et al (392) 
observed a relationship between Infliximab concentrations and clinical outcomes when 
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studying a population of CD patients as a whole. Data regarding pharmacokinetics of 
Infliximab in the paediatric population is scarce at the moment there are no published studies 
which reported relationship between Infliximab pharmacokinetic levels and disease activity in 
paediatric patients with CD. 
5.2.1 Aims 
The aim of this longitudinal observational prospective study was to assess changes in 
physical growth, puberty, IGF-1 axis, bone health; body composition and muscle function 
following biologic therapy in paediatric patients with CD. 
5.2.2 Objectives 
The objective of the study was to collect clinical data and biochemical data at baseline (BL), 2 
weeks (2wk), 6 weeks(6wk), 6 and 12 months (6M & 12M) following biologic therapy in 
paediatric patients with CD in line with the current clinical practice in management of children 
with CD at the Royal Hospital for Sick Children Yorkhill, Glasgow.  
5.2.3 Hypothesis  
Biologic therapy improves linear growth, bone health and body composition in children with 
CD and this is associated with changes in the IGF-1 axis and markers of bone formation and 
bone resorption.  
5.2.4 Outcome measures 
The primary outcome measures were (i) changes in height standard deviation scores 
(HtSDS) and Height velocity (HV), from baseline to 6 and 12 months after starting biologic 
therapy. Secondary, outcome measures were (i) change in pubertal status (ii) changes in 
systemic markers of growth hormone secretion i.e. insulin-like growth factor-1(IGF-1), insulin-
like growth factor binding protein-2 (IGFBP-2), insulin-like growth factor binding protein-3 
(IGFBP-3) and  acid labile subunits (ALS) (iii) changes in markers of bone formation (BALP) 
and bone resorption (CTX-1) (iv) changes in skeletal health, body composition and muscle 
function measured by pQCT, DXA and bioelectrical impedance analysis (BIA), grip strength 
and mechanograph (v) changes  in disease activity including and blood inflammatory markers 
erythrocyte sedimentation rate (ESR), platelets, C-reactive protein (CRP), serum albumin 
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(Alb), Alanine transaminase (ALT), platelets and paediatric Crohn’s disease activity index 
(PCDAI) (V) changes in Infliximab pharmacokinetic levels. 
5.2.5 Subjects and methods 
In the period between June 2009 and March 2011, all children with CD who have not 
completed growth (Tanner stage 1-4) attending Royal Hospital for Sick Children Yorkhill, 
Glasgow commencing treatment with biologic therapy as part of their standard medical 
management (<18 years), who failed to achieve disease remission despite conventional 
therapy (EEN and/or corticosteroids, and/or background immunosuppression therapy with 
Azathioprine or Methotrexate) were eligible to participate in the study. These patients were 
either newly diagnosed or patients with long-lasting disease in clinical relapse. Patients on 
the same biologic over the prior six months were excluded from the study. All patients were 
approached prior to starting biologic therapy and were provided with information sheets. 
Information sheets can be seen in (Appendix B to D). Written informed consent was obtained 
from all parents/guardians and assent was obtained from children to enter the study protocol. 
Consent and assent forms can be found in (Appendix F to H).  
Between June, 2009 and March, 2011 a total of thirteen patients started biologic therapy 
(Infliximab/Adalimumab). Eleven of 13 patients were recruited (10 Infliximab and 1 
Adalimumab); two patients refused to participate (1 Infliximab and 1 Adalimumab) (Figure 
5.2.1). All patients were diagnosed with CD using standard criteria (6;353). None of the 
patient was on growth or puberty promoting treatments during the period of study. The 
median (range) ages at diagnosis and start of biologic therapy were 11.5 years (6.3, 15.5) 
and 14.7 years (11.2, 17.2) respectively. 
5.2.5.1 Ethical Approval 
The study protocol was approved by the local research ethics committee (LREC) Reference 
Number: 09/S0703/58 and the research and development office. Informed consent was 
obtained from patients and the parents or guardians. 
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Figure 5.2.1:  Flow chart of the Study Recruitment process 
 
 
 
Ethics Approval June 2009
June 2009 –Sep2011
Patients 
N,13
Not recruited N,2
1 IFX
1 ADA 
Visits 0,2,6wks 
N,11
6 Mon FU
N,11
12 Mon FU
N,11
Recruited N,11
10 IFX
1 ADA 
Stopped IFX & 
started ADA
N,2
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5.2.5.2 Anthropometric measurements 
Height was measured with a Harpenden stadiometer. Height (Ht) and BMI (body mass index) 
data were converted into SDS (standard deviation scores) using 1990 British childhood 
standards (340;341), -6M, BL, 6M and 12M height velocity (HV cms/year) and change in 
height standard deviation scores (∆HtSDS) were calculated from the prior 6 months of growth 
before time points with BL representing the point of starting biologic therapy. 
5.2.5.3 Disease activity  
Disease phenotype was assigned using the Montreal classification (6). Disease activity was 
assessed at all time points using the Paediatric Crohn’s Disease Activity Index (PCDAI) 
based on symptoms (30%), physical examination (30%, laboratory parameters (20%, and 
growth data (20%, with scores ranging from 0-100) (7). An overall score was calculated 
taking into consideration a week history recall of symptoms, laboratory markers of disease 
and clinical examination. Standard definitions were used for PCDAI disease activity and 
remission (remission, PCDAI ≤10) (7).  
5.2.5.4 Pubertal and skeletal maturation 
Pubertal status was determined at BL, 6M and 12M follow-up. Puberty was self-assessed by 
all children, indicating their stage of development using pictures of the Tanner stages of 
pubertal development (338). The categories include: pre-pubertal (stage I), peri-
pubertal/pubertal (stages II-III), and late pubertal/post-pubertal (stages IV-V). Bone age (BA) 
was assessed at BL) and 12M after the initiation of anti-TNF treatment and was assessed 
using the Tanner-Whitehouse (TW2) RUS method clinically by one single observer (393). 
 
5.2.5.5 Body composition 
5.2.5.5.1    Dual energy X-ray absorptiometry (DXA) 
The DXA technique is based on the attenuation properties of bone, lean and fat tissues at two 
different x-rays energies and it measures directly the bone mineral content, lean and fat mass 
(FM) (394;395). Densitometric evaluation included bone area, bone mineral content (BMC), 
and BMD (BMD=BMC/projected area of the region scanned [g/cm²]) for the lumbar spine 
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(LS), total body (TB), femoral neck (FN) and proximal femur (PF). Bone mineral apparent 
density (BMAD) is another frequent method for bone size adjustment used in paediatric DXA. 
BMAD was developed to minimize the size-related effects of DXA aBMD measurements. 
BMAD at lumbar spine can be calculated by estimating the vertebral depth as the square root 
of the area measured by DXA (Bone area). Then, the vertebral volume is calculated by simply 
multiplying the height x width(BA) x depth(136). Recently, Zemel et al (396). have shown that 
DXA BMC/BMD z-scores adjusted for height for age z-score (HAZ) provided the least biased 
approach for estimating the effect of short (or tall) stature on measures of BMD. Adjustments 
using HAZ were the least biased compared with age z-score, height age z-score, height z-
score and BMAD. Therefore, this approach can be applied to assess the effect of short or tall 
stature on BMC/BMD z-score. 
BMAD was calculated for LS and FN and was converted to z-scores (397). DXA scans were 
obtained at the baseline, 6M and 12M visit and were performed with a narrow fan beam lunar 
prodigy densitometer (GE Medical Systems, Waukesha, Wisconsin, U.S.A) and phantoms 
analyzed using the Encore software (Version 8.80.001). The measurements were obtained 
with standard positioning techniques and were analyzed to generate estimates of WB-BMC 
(g) and whole body lean mass (WB-LM, kg). Each scan took approximately 10-15 min to 
complete. All DXA scans were carried out by Dr Sheila Khanna at Yorkhill hospital for sick 
children, Glasgow. 
5.2.5.5.2 Foot to foot impedance measurements 
Bioelectrical impedance analysis (BIA) was performed u the foot to foot technique using a 
TANITA body fat analyzer (TBF-300, Tokyo, Japan) which provides a print out of the 
measured weight, impedance, and two compartment body composition analysis. Gender, age 
and height to the nearest centimeter were entered manually into the keypad interface. 
Subjects stood on the two metal sole-pad electrodes embedded on the platform scales. The 
electrode for each foot was subdivided into anterior and posterior electrodes. A current was 
applied through the anterior portion of the footpad electrodes and the voltage drop was 
measured in the posterior portion. The impedance measurement used a 50 kHz, 500 µA 
insensible current. Subjects were asked to void their bladder before the measurements. All 
the measurements were performed after a period of at least 10 min standing upright to 
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minimize potential errors from acute shifts in fluid distribution. Every measurement was 
performed in triplicate and averaged (398).  
5.2.5.6 Bone health assessment 
5.2.5.6.1 Peripheral quantitative computed tomography (pQCT) 
Peripheral quantitative computed tomography is used to analyze trabecular and cortical bone 
characteristics, volumetric bone mineral density (vBMD; mg/cm3), bone strength and to 
assess bone and muscle (CSAs) (212;399). As the radiation dose is extremely low with 0.6 
µSv, pQCT is highly suitable for a longitudinal investigation of bone strength and muscle 
mass in children and adolescents. The most common peripheral skeletal sites selected for 
measurement are the radius and tibia. In this study pQCT analysis were performed using 
(XCT-2000; Stratech, Pforzheim, Germany). All pQCT scans were carried out by Dr Sheila 
Khanna at Yorkhill hospital for sick children, Glasgow. The scanner was equipped with a low-
energy (38 keV) X-ray tube. The effective radiation was about 45kV at 150 µA. Calibration of 
the machine was performed once every three days (single slice) or once per month (multiple, 
slice cone phantom), respectively using phantoms provided by the manufacturer. The 
measuring time for a measurement run was about 4-5 minutes depending upon the cross-
sectional size of the leg and the forearm. A voxel size of 0.4mm was used for both sides 
scan. The speed of the translational scan movement was set at 15 mm/sec. In this study 
pQCT measurements were performed for both radius and tibia, because the impact of 
impaired biomechanical stimulation and bone modeling may be more pronounced at a 
weight-bearing site, and cortical thickness is greater in the tibia than in the radius and is 
therefore less subject to partial volume effects (147). Cross-sectional slices (2mm) of the non-
dominant distal radius and tibia were measured by pQCT at relative distance of 4% and 
66%.The distal metaphysis (4% distal cross section) of the radius and tibia was used to 
determine total BMD (TotBMD) and trabecular vBMD. The diaphysis (66% distal cross 
section) was used to determine total, cortical cross-sectional area (CSA, mm2); cortical 
vBMD. The muscle cross sectional area (CSA (mm2), FatCSA (mm2) and polar strength strain 
index (pSSI mm3) were derived from the diaphyseal measurements and used as surrogates 
for muscle bone and strength. Analysis was performed with manufacturer supplied software 
(v.5.50; stratec). Dominance was determined by the subject report of left or right handedness. 
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As growth impairment is common in CD children and adolescents, all radius bone size- 
dependent parameters were corrected for height.  
 
5.2.5.6.2 Distal radius 
Cross-sectional slices of the non-dominant distal radius were measured by pQCT. The length 
of the forearm to be scanned (arm length) was measured from the ulnar styloid process to the 
olecranon. The subject’s arm was then extended into the instrument gantry where their hand 
rested on a hand-grip. This allowed the subject to keep his/her arm still, thus avoiding 
movement artefact. The scanner was positioned on the distal forearm and a scout view was 
carried out. The scout view was used to position the scanner at the measurement site, and 
then the 4% distal cross section was identified and measured by scanner. The subject’s 
forearm was repositioned to align the gantry positioning laser and the 66% cross section was 
measured (400). 
5.2.5.6.3 Tibia 
Tibia length was measured manually from the medial malleolus to the superior margin of the 
medial chondyle. The average of two measurements was used to determined tibia length. 
The 66% measurement site was calculated (tibia length [cm] × 0.66), measured distally from 
the medial malleolus and marked on the subject’s calf with nonpermanent ink. The subject’s 
leg was then extended into the instrument gantry. A scout scan was performed to visualize 
the distal growth plate and reference line placed at the most proximal line of the growth plate 
or at the end plate in case of the fussed growth plate. After establishing the distal line, the 4% 
distal cross section was identified and measured by scanner. The subject’s leg was 
repositioned to align the gantry positioning laser with the reference mark on the subject’s calf 
and the 66% cross section was measured (146).  
5.2.5.7 Muscle function 
5.2.5.7.1  Maximal isometric grip force  
Maximal isometric grip force (MIGF) was determined for both the dominant and non-dominant 
hand with a standard adjustable-handled Jammer dynamometer (Preston, Jackson, MI, 
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U.S.A.). The test was performed sitting down with the shoulder adducted and elbow flexed at 
90◦. The starting position was sitting with the fore-arm held freely across the stomach. The 
patients were told to put maximal force on the dynamometer and to squeeze the handle as 
forcefully as possible for a few seconds and then released. Both hands were alternately 
measured in triplicate, with 60-ses rest between each test. The highest of the three measures 
was used for analysis. The MIGF was measured at all study time points and the result for 
each patient was transformed to an age- or height-dependent SDS (401).  
5.2.5.7.2 Jumping mechanography  
The Leonardo Mechanograph® Ground Reaction Force Platform (GRFP) Novotec Medical 
GmbH, Pforzheim, Germany), is a device used to assess the dynamic (kinetic) parameters 
deriving from motor performance (402). It is a force platform with a length of 66 cm, a width of 
66 cm and a height of 7 cm. The platform is composed of two symmetrical force plates that 
separate the platform into a left and a right half. The resonance frequency of each plate is at 
150 Hz. Each plate contains four strain gauge force sensors (the whole platform thus has 
eight force sensors). The force sensors measure the vertical ground reaction force exerted on 
the platform. The sensors are connected to a laptop computer via a USB 2.0 connection. The 
signal from the force sensors is sampled at a frequency of 800 Hz and is analyzed using the 
Leonardo mechanography GRFP software (402).  
The Leonardo mechanograph software version 4.2 was used to measure lower limb muscle 
force, power, velocity, and jumping height (403;404). Other measurements include the 
Esslinger Fitness Index, which compares the maximum power relative to body weight to an 
age- and gender-matched reference population (405;406) and efficacy which is the maximum 
power relative to the peak force, i.e. maximum output for the lowest amount of force 
expenditure. To measure power (W/kg), velocity (m/sec), height (m), the Esslinger Fitness 
Index (%), and each patient performed a counter movement jump with arms moving freely, 
each jump was Single Two-legged Jump (S2LJ), and patients were instructed to jump as high 
as possible, standing upright before and after the jump. Prior to each test, patients were 
provided a description of the procedure and physical demonstration of the test. The force 
platform was adjusted to indicate a task of mass zero kg before the patient stepped onto it. 
Following a single-tone pitch, the patient performed the test. The termination of the test was 
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indicated by a double-tone pitch. Test was performed three times with a 60-sec rest between 
each test. The S2LJ of greatest height was selected for the analysis (402).  
5.2.5.8 Biochemical markers of bone metabolism 
In all children blood samples (10mls) were collected at BL, 2wk, 6wk, 6 & 12 months when 
possible prior to Infliximab infusion and Adalimumab injection. Samples were immediately 
centrifuged for 5min at 2500 rpm and then stored at -70◦C until the assays were performed. 
Insulin like growth factor binding protein-2(IGFBP-2) and Insulin like growth factor binding 
protein-3(IGFBP-3) were measured by enzyme immunoassay (ELISA; Mediagnost) with intra-
assay and interassay coefficients of 3.92% and 5.65 % for IGFBP-2 and 8.7% and 15.3% 
IGFBP-3 and no cross-reaction with other IGFBPs. Insulin-like growth factor-I was measured 
by an IGFBP-blocked specific EIA (IGF-R20; Mediagnost, Tuebingen, Germany) with a cross-
reactivity to IGF-II of less than 0.05% and intra- and interassay coefficients of variation of 
6.0% and 4.9%. Biomarkers of bone formation bone-specific alkaline phosphatase (serum 
BALP) and bone resorption C-telopeptide of collagen cross-links (serum CTX-1) were 
measured by a commercial immunoenzymetric assay kit (Immunodiagnostic Systems (IDS) 
Ltd), with intra-assay and interassay coefficients of variation of 7.7% and 8.8% for BALP and  
3.4% and 2.7% for CTX-1. ALS was measured by enzyme immunoassay (ELISA; 
Mediagnost) with intra-assay and interassay coefficients of variation of 8.6% and 14.5%. IGF-
1 and IGFBP-3 were converted to standard deviation scores (SDS) using computer software 
SDS Easy; Mediagnost GmbH, Reutlingen, Germany). In vitro determination of 
pharmacokinetic concentrations of Infliximab was performed by ELISA using (Immundiagnostik 
assay kit). The ELISAs for IGF-1, IGFBP-2, IGFBP-3, BALP, CTX-1, ALS and Infliximab 
pharmacokinetic concentrations) were performed by Martin McMillan in the department of child 
health, Yorkhill, Glasgow. 
 
5.3 Statistical analysis 
All data were analysed using by using Minitab software version 16.1 and are described as 
median and range and were analyzed with 1-sample Wilcoxon non-parametric test. Statistical 
significance was set at p < 0.05. Change in markers of bone metabolism, change in markers 
of growth hormone secretion and bone parameters measured by DXA and pQCT were 
expressed as percentage change between the baseline and 6 and 12 months visits. The 
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Pearson correlation and Spearman rank test was used to determine correlation coefficients 
for different variables. 
 
5.4 Results 
5.4.1 General characteristics 
Infliximab induction therapy of 5 mg/kg was administered at 0, 2 and 6 weeks in all patients 
followed by 8 weekly infusions in those who had maintenance therapy. In one patient who 
had therapy with Adalimumab, induction dose of 80mg followed by 40mg 2 weeks later was 
used and the maintenance regimen was 2 weekly initially. One patient suffered a 
hypersensitivity reaction leading to withdrawal after Infliximab induction therapy and was 
switched to Adalimumab therapy and had an induction dose of 40mg followed by 20mg 2 
weeks later was used and the maintenance regimen was 2 weekly initially. One patient lost 
response to Infliximab therapy after 8-months and switched to Adalimumab and had  an 
induction dose of 80mg followed by 40mg 2 weeks later was used and the maintenance 
regimen was 2 weekly initially. At  baseline,  6  patients  were  taking corticosteroids  
(prednisone  [median  0. 07  mg/kg/day]),  9  patients  had  Methotrexate,  2 patients  had  
Azathioprine,  and  6  patients  had  enteral  nutrition  (n,5  exclusive  and  n,1 supplemental) 
(Table 5.4.1) 
Table 5.4.1: Crohn’s disease therapies at BL, 6M & 12M following biologic therapy 
Treatment BL 6M 12M 
5-Aminosalicylates 6 5 4 
Systemic 
Glucocorticoids 
6 2 3 
Methotrexate 9 9 9 
Azathioprine 2 2 2 
Enteral Nutrition 
Exclusive 
Supplemental 
 
5 
1 
 
2 
1 
 
2 
- 
5.4.2 Biologic therapy response 
Of 11 patients, 9 demonstrated a clinical response to induction therapy, one was intolerant 
and developed Infliximab related peripheral neuropathy and one was primary non-responder. 
Two patients had an episodic therapy with Infliximab; none of these had resectional surgery. 
At 12 months from baseline all patients who were still receiving biologic therapy 
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demonstrated a continued clinical response (Table 5.4.2). Based on histopathology two 
patients had complete mucosal healing, seven patients had clinical remission, one was non-
responder and one had no follow-up endoscopic reports available (Table 5.4.3). 
5.4.3 Disease characteristics 
Distribution of CD was as follows: colonic (n,6), Ileo-colonic (n,3), upper GI tract (n,1), upper 
and Ileo-colonic (n,1), perianal involvement(n,6). Individually, the majority of the children 
experienced improvement in clinical activity and improvement of the systemic inflammatory 
markers. All participants had active disease at BL as indicated by the PCDAI and the 
systemic inflammatory markers (Table 5.4.4). The median (range) value of the PCDAI 
decreased significantly from 35(0,55) at BL to 15(0,37.5) after 2wk, 5(0,37.5) after 6wks, 
5(0,25) after 6M and 5(0,22.5) after 12M respectively, (p<0.01) at all time points compared 
with baseline (Table 5.4.5;Figure 5.4.1). PCDAI remained the same (PCDAI=0) for one 
patient from BL to 6M but found to be increased at 12M. 
5.4.4 Change in markers of disease activity 
The median(range) serum albumin (g/l) remained unchanged from 33(22,38)at BL to 
35(17,39) after 2wk(p=0.62), 34(26,38) after 6wks(p=0.09), 36(26,41) after 6M(p=0.16) and 
35(26,40) after 12M(p=0.09). The median ALT(U/l) remained unchanged from 13(6,64) at BL 
to 14(10,38) after 2wk (p=0.32), 10(6,42) after 6wks(p=0.26), 12(9,14) after 6M(p=0.31) and 
13(7,36) after 12M(p=0.72).The median ESR(mm/hr) decreased significantly from 24(5,70) at 
BL to 12(4,98) after 2wk(p=0.01), 12(3,51) after 6wks(p=0.12), 13(4,56) after 6M(p=0.23) and 
12(2,48) after 12M, (p=0.15).The median CRP(mg/l) remained unchanged from 10(3,95) at 
BL to 7(3,86) after 2wk(p=0.44), 7(3,56) after 6wks(p=0.28), 7(3,39) after 6M(p=0.14) and 
6(3,23) after 12M(p=0.15). The median platelet count (109/L)(g/l) changed from 345(193,447) 
at BL to 329(148,489) after 2wk(p=0.87), 295(148,624) after 6wks(p=0.91), 319(174,565) 
after 6M(p=0.62) and 281(115,480) after 12M(p=0.06)(Table 5.4.5). 
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Table 5.4.2: Biologic therapy response in paediatric patients with CD 
Pt.No Drug 3M Tot INF/INJ 6M Tot INF/INJ 12M Tot 
INF/INJ 
Episodic Maintenance ADR 
1 IFX Responder 3 Responder 6 Responder 9 N Y N 
2 IFX Intolerant 3 Stopped IFX 
Started ADA 
3 Responder 38 N Y Hypersensitivity 
reaction 
3 IFX Responder 3 Responder 5 Responder 9 N Y N 
4 ADA Responder 3 Responder 13 Responder 38 N Y N 
5 IFX Responder 3 Responder 6 Responder 9 N Y N 
6 IFX Responder 3 Responder 5 Responder 9 N Y N 
7 IFX Responder 3 Responder 5 Responder 9 N Y N 
8 IFX Responder 3 Responder 5 Responder 9 N Y N 
9 IFX Responder 3 Stopped IFX 
Bridging to AZA 
3 Responder 6 Y N N 
10 IFX Primary 
non-
responder 
3 Stopped IFX 
Secondary loss 
of response 
4 Started ADA 
Responder 
6 N Y N 
11 IFX Responder
/Intolerant 
3 Stopped IFX 4 Responder 9 Y N Peripheral 
neuropathy 
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Table 5.4.3: Biologic therapy response in paediatric patients with CD based on histopathology 
Pt.No Drug Baseline to follow-up 
1 Infliximab Complete mucosal healing 
2 Infliximab/Adalimumab Intolerant to Infliximab but perianal disease responded for Adalimumab 
3 Infliximab Clinical responder 
4 Adalimumab Clinical remission but no endoscopic remission 
5 Infliximab Responder to Infliximab but not in remission 
6 Infliximab Clinical responder but still have microscopic disease 
7 Infliximab Complete mucosal healing 
8 Infliximab No follow-up endoscopic reports 
9 Infliximab Clinical remission 
10 Infliximab/Adalimumab  Non-responder to Infliximab 
11 Infliximab Clinical remission 
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5.4.5 Change in linear growth 
Height standard deviation scores (HtSDS) remained below zero and did not change 
significantly during the study interval overall although some patients demonstrated 
improvement in HtSDS from BL to 12M. Median (range) HtSDS at diagnosis -1.6(-2.1, 1.5) 
was lower than the mean mid-parental height SDS of 0.0(-0.9,1.1) (p=0.62). The median 
HtSDS was -0.7(-2.6,1.6) at BL, -0.7(-2.9,1.7) after 6M and -0.4(-3.1,1.7) after 12M 
respectively. Median SHtSDS was -0.8(-1.7,1.5) at BL, -1.1(-2.3,1.5) at 6M(p=0.35) and -0.2(-
2.2,0.9) at 12M (p=0.19). The median BMISDS at diagnosis was -1.6(-2.1,-0.0), and remained 
below zero during the study interval overall, although some patients demonstrated 
improvement in BMISDS from BL to 12M. Median BMISDS was -0.3(-2.6,0.9) at BL, -0.6(- 
2.2,0.1) after 6M(p=0.03) and -0.5(-1.8,1.1) after 12M(p=0.16) respectively (Table 
5.4.6;Figure 5.4.2). Median ∆HtSDS did not show any significant change from -0.1(-0.5,0.3) 
at BL to -0.1(- 0.1,-0.5) at 6M (p=0.61) to 0.1(-0.3,0.4) at 12M (p=0.22) (Figure 5.6.3). Median 
HV of overall group was 3.9cm/year (0.2,7.4) at T0, 2.1cm/year (0.7,9.8) at 6M(p=0.78) and 
4.7(0.0,9.2) at 12M (p=0.30) (Table 5.4.6;Figure 5.4.3). 
5.4.6 Change in skeletal maturation and bone age 
Median bone age changed from 14.2(9.3,16.9) at BL to 15.3(9.7,18.2) (p=0.009) and did not 
differ significantly when compared to chronological at BL and 12M. At BL, 7 patients were in 
tanner stage (TS) I-III and three were in TS-IV none of the patients were in TSV. At 6M seven 
patients were in TS (II-III), two were in TS-IV and two progressed to TS-IV. At 12M four 
patients were in TS-III, three in TS-IV and four in TS-V (Table 5.4.6). 
 
5.4.7 Change in muscle function 
5.4.7.1 Maximum isometric grip force 
Individual patient measurements for MIGF for both dominant and non-dominant hand are 
show in (Table 5.4.7). The median measurement of the MIGF(kg) dominant hand was 
19(10,25) at BL and 22(8,35) at 2wk (p=0.68), 21(8,39) at 6wk(p=0.44), 27(11,36)(p=0.02) 
and 22(11,36) at 12M(p=0.01) (Table 5.4.8).The median measurement of the MIGF(kg) non-
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dominant hand was 18(8,27) at BL, 19(8,30) at 2wk (p=0.18), 18(6,37) at 6wk(p=0.90), 
22(9,33)(p=0.01) and 20(10,34) at 12M (p=0.01) (Table 5.4.8). 
5.4.7.1.1 Height adjusted MIGFSDS 
The median measurement of the dominant hand height adjusted MIGFSDS changed from -
1.0(-2.3,1.4) at BL to -1.1(-2.0,1.6) at 2wk(p=1.0), -0.5(-2.3,1.8) at 6wk(p=0.67), 
0.3(1.9,1.7)(p=0.05) at 6M and -0.5(-1.7,1.2) at 12M(p=0.04). The median measurement of 
the non-dominant hand height adjusted MIGFSDS changed from -1.5(-2.7,0.5) at BL to -1.3(-
2.2,1.0) at 2wk(p=0.26), -1.3(-2.9,1.9) at 6wk(p=0.81), -0.7(-2.2,1.1)(p=0.06) and -0.9(-
2.1,0.5) at 12M(p=0.04)(Table 5.4.8; Figure 5.4.4) 
  
5.4.7.1.2 Age adjusted MIGFSDS 
The median measurement of the dominant hand age adjusted MIGFSDS changed from -1.9(-
3.5,-0.1) at BL to -1.3(-3.8,0.6) at 2wk (p=1.0), -0.7(-4.3,0.7) at 6wk(p=1.0), -0.8(-
3.2,0.9)(p=0.04) and -1.3(-3.6,0.4) at 12M (p=0.08). The median measurement of the non 
dominant hand age adjusted MIGFSDS changed from -2.1(-3.3,-0.5) at BL to -1.6(-4.2,0.0) at 
2wk (p=0.26), -1.8(-5.5,0.8) at 6wk(p=1.0), -1.3(-4.0,0.1)(p=0.10) and -1.2(-4.0,0.3) at 12M 
(p=0.15) respectively (Table 5.4.8; Figure 5.4.4) 
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Figure 5.4.1: Individual changes in paediatric Crohn’s disease activity index (PCDAI) at BL, 2wks, 6wks, 6M & 12M following biologic therapy in 
paediatric patients with CD 
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Table 5.4.4: Individual changes in PCDAI and systemic markers of disease activity at BL, 2wks, 6wks, 6M & 12M following biologic therapy in 
paediatric patients with CD  
 
Pt.No 1 2 3 4 5 6 7 8 9 10 11 
PCDAI  
BL 
2wk 
6wk 
6M 
                12M 
 
52.5 
37.5 
10 
0 
0 
 
27.5 
25 
37.5 
25 
5 
 
25 
15 
20 
5 
15 
 
35 
37.5 
20 
17.5 
0 
 
37.5 
15 
5 
17.5 
22.5 
 
55 
15 
10 
0 
0 
 
35 
12.5 
5 
5 
5 
 
0 
0 
0 
0 
7.5 
 
35 
0 
5 
5 
5 
 
5 
0 
5 
0 
5 
 
27.5 
15 
2.5 
15 
7.5 
Serum albumin (g/l)  
BL 
2wk 
6wk 
6M 
      12M 
 
26 
30 
34 
36 
36 
 
30 
26 
26 
26 
34 
 
33 
35 
31 
32 
29 
 
25 
17 
28 
27 
36 
 
28 
30 
32 
28 
26 
 
22 
25 
29 
* 
32 
 
33 
35 
37 
40 
37 
 
36 
35 
37 
37 
35 
 
38 
39 
38 
41 
39 
 
38 
36 
38 
* 
40 
 
34 
36 
37 
37 
35 
ALT(U/l) 
                 BL 
2wk 
6wk 
6M 
      12M 
 
28 
21 
25 
9 
11 
 
13 
10 
8 
14 
36 
 
11 
10 
10 
12 
13 
 
7 
11 
12 
14 
18 
 
54 
38 
10 
12 
19 
 
13 
14 
6 
* 
11 
 
6 
17 
19 
14 
7 
 
18 
16 
23 
12 
8 
 
16 
10 
10 
9 
21 
 
6 
10 
6 
* 
11 
 
64 
35 
42 
14 
18 
ESR (mm/hr) 
                BL 
2wk 
6wk 
6M 
      12M  
 
33 
26 
15 
8 
18 
 
45 
50 
40 
49 
10 
 
15 
6 
6 
6 
4 
 
70 
98 
51 
56 
12 
 
13 
5 
8 
25 
48 
 
66 
19 
4 
* 
6 
 
* 
11 
17 
4 
5 
 
5 
4 
6 
11 
25 
 
22 
12 
12 
13 
2 
 
13 
12 
3 
* 
12 
 
25 
9 
25 
16 
22 
CRP (mg/l)             
                BL 
2wk 
6wk 
6M 
      12M 
 
29 
7 
7 
7 
7 
 
11 
29 
28 
9 
7 
 
10 
7 
7 
7 
3.7 
 
70 
86 
56 
27 
7 
 
9 
7 
7 
39 
18 
 
95 
7 
7 
* 
3 
 
15 
7 
7 
7 
3 
 
7 
7 
7 
3 
23 
 
7 
7 
3 
3 
3 
 
3 
3 
13 
* 
3 
 
3 
3 
6 
3 
6 
Platelets (109/L) 
                BL 
2wk 
6wk 
                  6M 
                12M 
 
342 
329 
241 
237 
239 
 
447 
471 
624 
565 
282 
 
323 
263 
258 
303 
293 
 
420 
489 
487 
450 
361 
 
362 
323 
311 
316 
269 
 
329 
445 
409 
* 
480 
 
* 
381 
234 
319 
271 
 
347 
320 
295 
350 
115 
 
193 
148 
148 
174 
165 
 
258 
318 
264 
* 
281 
 
357 
347 
337 
351 
312 
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Table 5.4.5: Changes in PCDAI and systemic markers of disease activity at BL, 2wks, 6wks, 6M & 12M following biologic therapy in paediatric 
patients with CD Median(range) 
 
 
BL 
N,11 
 
2wk 
N,11 
 
6wk 
N,11 
 
6M 
N,11 
 
12M 
N,11 
p-Value 
 
BL -2wk        BL- 6wk       BL -6M       BL-12M 
PCDAI 35 
(0,55) 
15 
(0,37.5) 
5 
(0,37.5) 
5 
(0,25) 
5 
(0,22.5) 
0.009 0.01 0.006 0.008 
Serum albumin (g/l) 33 
(22,38) 
35 
(17,39) 
34 
(26,38) 
36 
(26,41) 
35 
(26,40) 
0.62 0.09 0.16 0.09 
ALT(U/l) 13 
(6,64) 
14 
(10,38) 
10 
(6,42) 
12 
(9,14) 
13 
(7,36) 
0.32 0.26 0.31 0.72 
ESR (mm/hr) 24 
(5,70) 
12 
(4,98) 
12 
(3,51) 
13 
(4,56) 
12 
(2,48) 
0.12 0.01 0.23 0.15 
CRP (mg/l) 10 
(3,95) 
7 
(3,86) 
7 
(3,56) 
7 
(3,39) 
6 
(3,23) 
0.44 0.28 0.14 0.15 
Platelets (109/L) 345 
(193,447) 
329 
(148,489) 
295 
(148,624) 
319 
(174,565) 
281 
(115,480) 
0.87 0.91 0.62 0.06 
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Table 5.4.6: Anthropometric details of children (n,11) at starting biologics (BL) at 6 & 12 months (6M &12M ) following biologic therapy 
in paediatric patients with CD. Results are presented as median (range) 
  
BL 
N,11 
 
T+6 
N,11 
 
T+12 
            N,11 
p-Value 
 
BL - T+6                      BL- T+12 
Age (yrs) 14.7 
(11.2,17.2) 
15.3 
(11.8,17.7) 
15.9 
(12.4,18.2) 
  
Bone age (yrs)  14.2 
(9.3,16.9) 
 15.3 
(9.7,18.2) 
 
0.009 
Anthropometry      
Height SDS -0.7 
(-2.7,1.7) 
-0.5 
(-2.9,1.7) 
-0.4 
(-3.1,1.7) 
0.82 0.89 
∆Height SDS -0.1 
(-0.5,0.3) 
-0.1 
(-0.1,-0.5) 
0.1 
(-0.3,0.4) 
0.61 0.22 
BMI SDS -0.3 
(-2.7,0.1) 
-0.6 
(-2.3,0.6) 
-0.6 
(-1.8,1.1) 
0.03 0.16 
Height Velocity (cm/yr) 3.9 
(0.2,7.4) 
2.1  
(0.7,9.8) 
4.7 
(0.0,9.2) 
0.78 0.30 
SHt SDS -0.8 
(-1.7,1.5) 
-1.1 
(-2.3,1.5) 
-0.2 
(-2.2,0.9) 
0.35 0.19 
Pubertal status (n ;%)       
-I 2 (18.1) - -   
-II 2(18.1) 2(18.1) -   
-III 3(27.2) 5(45.4) 4(36.3)   
-IV 4(36.3) 2(18.1) 3(27.2)   
-V - 2(18.1) 4(36.3)   
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Figure 5.4.2: Individual changes in height SDS (HtSDS) and body mass index SDS (BMISDS) and sitting height SDS (SHtSDS) following treatment 
with biologic therapy in paediatric patients with CD 
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Figure 5.4.3: Individual changes in height velocity (HV) and change in height SDS (∆HtSDS) at BL, 6M & 12M following treatment with biologic 
therapy in paediatric patients with CD 
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Table 5.4.7: Individual changes in maximum isometric grip force (MIGF) at BL, 2wks, 6wks, 6M & 12M following treatment with biologic therapy in 
paediatric CD patients 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
Dominant hand MIGF (kg) 
BL 
2wk 
6wk 
6M 
12M 
 
18 
12 
16 
18 
22 
 
10 
9 
8 
11 
* 
 
* 
35 
39 
32 
30 
 
20 
24 
20 
29 
29 
 
10 
8 
10 
13 
15 
 
16 
15 
14 
34 
19 
 
13 
18 
21 
20 
21 
 
25 
26 
26 
36 
35 
 
24 
22 
27 
20 
21 
 
20 
35 
36 
36 
36 
 
22 
24 
23 
27 
26 
Dominant Ht-matched MIGF SDS 
BL 
2wk 
6wk 
6M 
12M 
 
1.4 
-0.5 
0.9 
0.7 
1.1 
 
-0.6 
-1.1 
-1.6 
-0.3 
-0.7 
 
* 
0.6 
1.1 
0.1 
-0.2 
 
-2.3 
-1.5 
-2.3 
-0.7 
-0.9 
 
-0.8 
-1.8 
-0.8 
-0.3 
0.0 
 
-1.7 
-2.0 
-2.3 
1.7 
-0.9 
 
-1.8 
-0.3 
0.4 
-0.7 
-0.5 
 
-0.6 
-0.4 
-0.4 
0.6 
0.0 
 
-1.1 
-1.5 
-0.5 
-1.9 
-1.7 
 
-0.8 
1.6 
1.8 
1.4 
1.2 
 
-2.2 
-1.9 
-2.1 
-1.4 
-1.6 
Dominant Age-matched MIGF SDS 
BL 
2wk 
6wk 
6M 
12M 
 
-0.1 
-2.0 
-0.7 
-0.5 
0.2 
 
-3.3 
-3.7 
-4.3 
-3.2 
-3.6 
 
* 
-0.9 
-0.5 
-1.4 
-2.1 
 
-2.0 
-1.3 
-2.2 
-0.8 
-1.1 
 
-2.4 
-3.3 
-2.5 
-1.8 
-1.3 
 
-3.5 
-3.8 
-4.1 
-0.8 
-3.4 
 
-1.8 
-0.6 
0.0 
-0.4 
-0.6 
 
-0.3 
-0.1 
-0.2 
0.9 
-1.3 
 
-0.6 
-0.9 
-0.1 
-1.4 
-1.3 
 
-1.7 
0.6 
0.7 
0.4 
0.1 
 
-1.9 
-1.5 
-1.8 
-1.3 
-1.8 
Non-dominant hand MIGF (kg) 
BL 
2wk 
6wk 
6M 
12M 
 
11 
13 
14 
19 
18 
 
10 
8 
6 
9 
* 
 
* 
23 
32 
28 
22 
 
26 
25 
25 
27 
34 
 
8 
9 
9 
12 
10 
 
17 
16 
13 
30 
19 
 
13 
15 
13 
20 
20 
 
20 
22 
23 
22 
34 
 
20 
19 
18 
19 
19 
 
27 
30 
37 
33 
31 
 
20 
24 
21 
24 
30 
Non-dominant Ht-matched MIGF SDS 
BL 
2wk 
6wk 
6M 
12M 
 
-0.9 
-0.1 
0.2 
0.9 
0.2 
 
-0.6 
-1.6 
-2.9 
-1.2 
-1.1 
 
* 
-1.3 
0.2 
-0.4 
-1.6 
 
-1.1 
-1.3 
-1.3 
-1.0 
-0.2 
 
-1.8 
-1.3 
-1.3 
-0.6 
-1.8 
 
-1.4 
-1.7 
-2.6 
1.1 
-0.9 
 
-1.8 
-1.1 
-1.8 
-0.7 
-0.7 
 
-1.5 
-1.1 
-0.9 
-1.6 
-0.1 
 
-1.9 
-2.2 
-2.4 
-2.2 
-2.1 
 
0.5 
1.0 
1.9 
1.1 
0.5 
 
-2.7 
-1.9 
-2.5 
-2.0 
-1.0 
Non-dominant Age-matched MIGF SDS 
BL 
2wk 
6wk 
6M 
      12M 
 
-2.3 
-1.6 
-1.3 
-0.3 
-0.7 
 
-3.3 
-4.2 
-5.5 
-4.0 
-4.0 
 
* 
-2.6 
-1.3 
-2.0 
-3.3 
 
-1.0 
-1.2 
-1.2 
-1.1 
-0.5 
 
-3.3 
-2.8 
-2.9 
-2.1 
-3.0 
 
-3.2 
-3.5 
-4.4 
-1.3 
-3.4 
 
-1.8 
-1.3 
-1.9 
-0.4 
-0.8 
 
-1.2 
-0.8 
-0.7 
-1.1 
0.3 
 
-1.3 
-1.6 
-1.8 
-1.6 
-1.7 
 
-0.5 
0.0 
0.8 
0.1 
-0.5 
 
-2.3 
-1.5 
-2.1 
-1.8 
-1.2 
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Table 5.4.8: Changes in maximum isometric grip force (MIGF) at BL, 2wks, 6wks, 6M & 12M following treatment with biologic therapy in paediatric  
CD patients (median-range) 
 
 
 
Value 
 
 
BL 
N,11 
 
 
2wk 
N,11 
 
 
6wk 
N,11 
 
 
6M 
N,11 
 
 
12M 
N,11 
p-Value 
 
  BL -2wk       BL- 6wk      BL -6M         BL-12M 
 
D- hand MIGF(kg) 
 
 
19 
(10,25) 
 
22 
(8,35) 
 
21 
(8,39) 
 
27 
(11,36) 
 
22 
(11,36) 
 
      0.68 
 
0.44 
 
0.02 
 
0.01 
 
D- hand Ht-matched MIGF SDS 
 
 
-1.0 
(-2.3,1.4) 
 
-1.1 
(-2.0,1.6) 
 
-0.5 
(-2.3,1.8) 
 
-0.3 
(-1.9,1.7) 
 
-0.5 
(-1.7,1.2) 
 
1.0 
 
0.67 
 
0.05 
 
0.04 
D- hand Age-matched MIGF SDS 
 
-1.9 
(-3.5,-0.1) 
-1.3 
(-3.8,0.6) 
-0.7 
(-4.3,0.7) 
-0.8 
(-3.2,0.9) 
-1.3 
(-3.6,0.4) 
 
1.0 
 
1.0 
 
0.04 
 
0.08 
 
ND-hand MIGF(kg) 
 
 
18 
(8,27) 
 
19 
(8,30) 
 
18 
(6,37) 
 
22 
(9,33) 
 
20 
(10,34) 
 
0.18 
 
0.90 
 
0.01 
 
0.01 
 
ND  hand  Ht-matched MIGF SDS 
 
-1.5 
(-2.7,0.5) 
 
-1.3 
(-2.2,1.0) 
 
-1.3 
(-2.9,1.9) 
 
-0.7 
(-2.2,1.1) 
 
-0.9 
(-2.1,0.5) 
 
0.26 
 
 
0.81 
 
0.06 
 
0.04 
 
ND  hand Age-matched MIGF SDS 
 
 
-2.1 
(-3.3,-0.5) 
 
-1.6 
(-4.2,0.0) 
 
-1.8 
(-5.5,0.8) 
 
-1.3 
(-4.0,0.1) 
 
-1.2 
(-4.0,0.3) 
 
0.26 
 
1.0 
 
0.10 
 
0.15 
D-(dominant), ND- (non-dominant) 
 
 
 
 
 
 
 
  
188
 
Figure 5.4.4: Changes in maximum MIGF age-adjusted and height-adjusted z-score (SD) for dominant and non-dominant hand at BL, 2wks, 6wks, 6M & 
12M during treatment with biologic therapy in paediatric CD patients 
12M6M6wk2wkBL
2
1
0
-1
-2
 
D
-
M
 
I
G
F
 
S
D
S
 
h
t
-
m
a
t
c
h
e
d
10
11
1
2
3
4
5
6
7
8
9
Pt.No
___________
________________________
____________________________________
_______________________________________________
p=1.0
p=0.67
p=0.053
p=0.04
-----------------------------------------------------------------------------------
_
_
_
_
_
     
12M6M6wk2wkBL
2
1
0
-1
-2
-3
 
N
D
-
M
 
I
G
F
 
S
D
S
 
h
t
-
m
a
t
c
h
e
d
___________
________________________
_______________________________________________
____________________________________
p=0.26
p=0.81
p=0.06
p=0.04
------------------------------------------------------------------------------------
_
_
_
_
_
 
                                  
12M6M6wk2wkBL
1
0
-1
-2
-3
-4
-5
 
D
-
M
 
I
G
F
 
S
D
S
 
a
g
e
-
m
a
t
c
h
e
d
___________
____________________________________
________________________
_______________________________________________
p=1.0 p=1.0 p=0.04 p=0.08
_
_
_
_
_
--------------------------------------------------------------------------------------
   
12M6M6wk2wkBL
1
0
-1
-2
-3
-4
-5
-6
N
D
 
M
 
I
G
F
 
S
D
S
 
a
g
e
-
m
a
t
c
h
e
d
___________
________________________
____________________________________
_______________________________________________
p=2.62
p=1.0 p=0.10 p=0.15
_
_
_
_
_
--------------------------------------------------------------------------------------------
 
189 
 
5.4.8 Mechanograph 
The Leonardo mechanograph was used to measure lower limb muscle force, power, velocity, 
jumping height and efficiency of the movement. Individual patient measurements for jump 
height (m), maximum-velocity (V-max (m/s), Esslinger fitness index (EFI (%), maximum - 
force (F-max (kN), maximum-power (P-max (kW), efficiency (%) of the movement are shown 
in (Table 5.4.10;Figure 5.4.5). Median (range) jump height (m) changed from 0.29(0.20,0.43) 
at BL to 0.34(0.24,0.50) at 2wk(p=0.54), 0.35(0.20,0.75) at 6wk(p=20), 0.35(0.32,0.53) 6M 
(p=10) and 0.36(0.27,0.52) at 12M (p=0.12). Median maximum-velocity (Vmax (m/s) changed 
from 1.96(1.42,2.46) at BL to 2.05(1.61,2.73) at 2wk (p=0.72), 2.19(1.57,2.70) at 6wk 
(p=0.52), 0.22(2.03,2.79) 6M (p=0.09) and 2.30(1.91,2.87) at 12M (p=0.05). Median Esslinger 
fitness index (EFI%) changed from 73(50,108) at BL to 80(55,116) at 2wk (p=0.91), 
92(63,105) at 6wk(p=0.72), 94(81,108) 6M (p=0.14) and 96(65,109) at 12M (p=0.05). Median 
maximum-force (F-max (kN) changed from 1.01(0.60,1.41) at BL to 1.09(0.56,1.64) at 2wk 
(p=0.91), 1.15(0.24,1.48) at 6wk(p=1.0), 1.27(0.69,1.41) 6M (p=0.10) and 1.28(0.68,1.79) at 
12M(p=0.03). Median maximum-power (P-max (kW) changed from 1.35(0.74,2.70) at BL to 
1.95(0.66,3.48) at 2wk (p=0.61),2.16(0.66,3.17) at 6wk(p=0.29), 2.31(1.19,3.11) 6M (p=0.08) 
and at 2.26(0.99,3.68) 12M (p=0.03). Median efficiency % also changed from 87(46,105) at 
BL to 91(53,107) at 2wk (p=0.51), 92(64,102) at 6wk (p=1.0), 95(85,104) 6M (p=0.14) and 
96(65,109) at 12M (p=0.10) (Table 5.4.10). Despite the fact that the improvement in 
efficiency% of the movement was not significant, but the change was likely to be through 
improvements in jump height and velocity thereby indicating higher muscular flexibility. 
 
5.4.8.1 Association of mechanograph and disease activity 
A significant negative association was observed between jump height (m), V-max (m/s and  
EFI% and PCDAI score at BL (r,0.51;p=0.01), (r,0.60;p=0.008),(r,0.63;p=0.006) and with 
efficiency (%) of the movement at BL (r,0.51;p=0.02) and 6wk(r,0.52;p=0.03) respectively 
(Figure 5.4.6). 
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Table 5.4.9: Individual changes in maximum isometric grip force (MIGF) at BL, 2wks, 6wks, 6M & 12M following treatment with biologic therapy in 
paediatric CD patients 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
Jump Ht(m) 
BL 
2wk 
6wk 
6M 
     12M 
 
0.22 
0.35 
0.32 
0.40 
0.36 
 
0.22 
0.20 
0.20 
0.55 
0.27 
 
* 
0.50 
0.53 
0.51 
0.52 
 
0.42 
0.36 
0.35 
0.35 
0.47 
 
0.36 
0.30 
0.75 
0.33 
0.29 
 
0.20 
0.24 
* 
0.41 
* 
 
0.28 
0.24 
0.29 
0.35 
* 
 
0.38 
0.42 
0.41 
0.32 
0.36 
 
0.30 
0.34 
0.33 
0.34 
0.29 
 
0.43 
0.45 
0.45 
* 
0.44 
 
0.37 
0.35 
* 
* 
* 
V-max(m/s) 
BL 
2wk 
6wk 
6M 
12M 
 
1.61 
1.72 
2.19 
2.23 
2.30 
 
1.72 
1.61 
1.57 
2.79 
1.91 
 
* 
2.73 
2.70 
2.74 
2.87 
 
2.45 
2.35 
2.28 
2.29 
2.67 
 
1.95 
2.04 
1.79 
2.10 
2.05 
 
1.42 
1.67 
* 
2.07 
* 
 
1.82 
1.91 
2.07 
2.09 
* 
 
2.37 
2.23 
2.30 
2.12 
2.31 
 
1.97 
2.15 
2.24 
2.22 
1.93 
 
2.46 
2.54 
2.56 
* 
2.51 
 
2.13 
2.09 
* 
* 
* 
EFI% 
BL 
2wk 
6wk 
6M 
12M 
 
63 
67 
92 
102 
106 
 
70 
62 
63 
108 
72 
 
* 
116 
105 
107 
108 
 
99 
90 
80 
84 
109 
 
88 
95 
84 
99 
91 
 
50 
55 
* 
82 
* 
 
68 
80 
92 
94 
* 
 
108 
91 
96 
81 
91 
 
64 
71 
77 
82 
65 
 
101 
104 
103 
* 
101 
 
76 
74 
* 
* 
* 
F-max(tot)kN 
BL 
2wk 
6wk 
6M 
12M 
 
0.8 
0.7 
1.0 
1.2 
1.2 
 
0.6 
0.5 
0.5 
1.3 
0.7 
 
* 
1.6 
1.4 
1.3 
1.2 
 
1.4 
1.2 
1.1 
1.3 
1.7 
 
0.6 
0.7 
0.2 
0.7 
0.7 
 
1.0 
1.1 
* 
0.8 
* 
 
0.6 
0.7 
0.8 
0.9 
* 
 
1.4 
1.3 
1.4 
1.4 
1.8 
 
1.0 
1.1 
1.1 
1.3 
1.4 
 
1.0 
1.1 
1.2 
* 
1.1 
 
1.2 
1.2 
* 
* 
* 
P-max(tot)kW 
BL 
2wk 
6wk 
6M 
12M 
 
0.8 
0.9 
1.4 
1.8 
2.1 
 
0.7 
0.6 
0.6 
3.1 
0.1 
 
* 
3.4 
3.1 
3.1 
3.0 
 
2.7 
2.4 
2.2 
2.3 
3.6 
 
1.0 
1.1 
1.1 
1.1 
1.1 
 
0.1 
1.2 
* 
1.3 
* 
 
0.9 
1.1 
1.4 
1.5 
* 
 
2.5 
2.2 
2.4 
2.4 
2.7 
 
1.7 
1.9 
2.2 
2.4 
2.1 
 
2.1 
2.2 
2.3 
* 
2.3 
 
2.0 
2.0 
* 
* 
* 
Efficiency % 
BL 
2wk 
6wk 
6M 
12M 
 
63 
75 
85 
86 
106 
 
     70 
66 
64 
103 
72 
 
* 
97 
97 
104 
108 
 
95 
92 
92 
85 
109 
 
99 
101 
87 
103 
91 
 
46 
53 
* 
95 
* 
 
86 
88 
92 
95 
* 
 
97 
91 
94 
89 
75 
 
89 
93 
100 
98 
65 
 
105 
107 
102 
* 
101 
 
85 
85 
* 
* 
* 
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Table 5.4.10: Changes in mechanography jump height (m), maximum-velocity (V-max (m/s), Esslinger fitness index (EFI (%), maximum -force 
(Fmax(kN), maximum-power (P-max (kW), efficiency (%) at BL, 2wks, 6wks, 6M & 12M following treatment with biologic therapy in paediatric CD 
patients (median-range) 
 
 
Value 
 
 
BL 
N,11 
 
 
2wk 
N,11 
 
 
6wk 
N,11 
 
 
6M 
N,11 
 
 
12M 
N,11 
p-Value 
 
  BL -2wk       BL- 6wk      BL -6M         BL-12M 
 
Jump height (m) 
 
0.29 
(0.20,0.43) 
 
0.34 
(0.24,0.50) 
 
0.35 
(0.20,0.75) 
 
0.35 
(0.32,0.53) 
 
0.36 
(0.27,0.52) 
 
0.54 
 
0.20 
 
0.10 
 
0.12 
 
V-max(m/s) 
 
 
1.96 
(1.42,2.46) 
 
2.05 
(1.61,2.73) 
 
2.29 
(1.57,2.70) 
 
2.22 
(2.03,2.79) 
 
2.30 
(1.91,2.87) 
 
0.72 
 
 
0.52 
 
0.09 
 
0.05 
 
EFI% 
 
 
73 
(50,108) 
 
80 
(55,116) 
 
92 
(63,105) 
 
94 
(81,108) 
 
96 
(65,109) 
 
0.91 
 
0.72 
 
0.14 
 
0.05 
 
F-max(tot)kN 
 
 
1.0 
(0.6,1.4) 
 
1.1 
(0.5,1.6) 
 
1.1 
(0.2,1.5) 
 
1.2 
(0.6,1.4) 
 
1.2 
(0.6,1.7) 
 
0.91 
 
1.0 
 
0.10 
 
0.03 
 
P-max(tot)kW 
 
 
1.3 
(0.7,2.7) 
 
1.9 
(0.6,3.4) 
 
2.1 
(0.6,3.1) 
 
2.3 
(1.1,3.1) 
 
2.2 
(0.9,3.6) 
 
0.61 
 
0.29 
 
0.08 
 
0.03 
 
Efficiency % 
 
87 
(46,105) 
 
91 
(53,107) 
 
92 
(64,102) 
 
95 
(85,104) 
 
96 
(65,109) 
 
0.51 
 
1.0 
 
0.14 
 
0.10 
 
 
 
 
 
 
 
  
192 
 
Figure 5.4.5: Changes in Mechanography, jump height (m), maximum-velocity (V-max (m/s), Esslinger fitness index (EFI ( %), maximum force 
(Fmax(kN), maximum-power (P-max (kW), efficiency (%) at BL, 2wks, 6wks, 6M & 12M following treatment with biologic therapy in paediatric CD 
patients (median-range)  
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Figure 5.4.6: Association of mechanographic parameters jump height (JHt m), maximum-velocity (V-max (m/s), Esslinger fitness index (EFI (%), 
efficiency (%) of the movement and paediatric Crohn’s disease activity index (PCDAI) 
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5.4.9 Change in body composition 
Measurements of body composition compartments were carried out by two different methods 
i.e. through foot to foot technique using a TANITA body fat analyzer (TBF-300, Tokyo, Japan) 
and DXA technique. 
5.4.9.1 Changes in body composition measured by DXA 
Individual changes in body composition compartments fat mass (FM (kg), fat mass index 
(FMI (kg/m²), fat free mass (FFM kg), fat free mass index (FMI kg/m²) and percent (%) body 
fat) measured by DXA are presented in (Table 5.4.11;Figure 5.4.7). Median (range) FM (kg) 
was 10.7(3.6,16.2) at BL and 10.3(3.7,24.7) at 6M (p=0.23) and 8.5(3.9,31.8) at 12M(p=0.14). 
Median FMI (kg/m²) was 3.9(2.0,5.4) at BL, and 4.3(2.1,8.2) at 6M(p=0.16) and 3.4(2.1,10.5) 
at 12M(p=0.50), respectively. Median FFM (kg/m²) changed from 36.7(20.6,47.5) at BL, to 
39.1(22.8,49.1) at 6M(p=0.004) and 38.9(23.7,54.8) at 12M(p=0.004). Median FFMI (kg/m²) 
was also increased from 13.1(11.3,17.1) at BL, to 14.0(11.9,16.8) at 6M(p=0.02) and 
14.7(11.9,17.5) at 12M(p=0.009). Total body fat (%) however, remained unchanged from 
23.1(14.7,32.2) at BL, to 22.6(14.6,40.4) at 6M(p=0.26) and 20.8(14.3,46.7) at 12M(p=0.96) 
respectively(Table 5.4.12). 
5.4.9.2 Changes in body composition measured by TANITA 
Individual changes in body composition compartments measured by TANITA are presented in 
(Table 5.4.13;Figure 5.4.8). Median (range) FM (kg) changed from 4.9(1.4,17.5) at BL to 
5.3(2.0,18.1) at 2wk (p=0.12), 6.4(3.1,18.3) at 6wk(p=0.02), 6.1(2.1,17.5) at 6M(p=0.02) and 
5.5(1.7,26.7) at 12M(p=0.04). Median FMI(kg/m²) also changed from 1.9(0.8,5.8) at BL to 
2.3(1.2,5.8) at 2wk(p=0.10), 2.1(0.9,8.8) at 6wk(p=0.02), 1.8(1.1,6.0) at 6M(p=0.09) and 
2.5(1.4,6.1) at 12M(p=0.12). FFM (kg) changed from 37.7(23.6,53.4) at BL to 40.5(23.2,52.0) 
at 2wk (p=0.41), 40.8(23.0,53.4) at 6wk(p=0.07), 46.3(24.5,53.7) at 6M(p=0.02) and 
46.5(25.8,61.0) at 12M(p=0.01). FFMI (kg/m²) changed from 14.1(12.6,17.7) at BL to 
15.4(12.8,17.7) at 2wk(p=0.50), 15.8(13.2,18.2) at 6wk(p=0.07), 16.4(13.2,17.9) at 
6M(p=0.03) and 17.2(12.9,22.9) at 12M(p=0.009). Total body (%)fat  however, remained 
unchanged from 10.7(5.5,30.3) a BL, to 10.1(7.9,30.4) at 2wk(p=0.24) and 9.8(2.4,29.2) at 
6wk(p=0.47), 11.4(7.7,27.0) at 6M(p=0.95) and 12.1(5.6,37.2) at 12M(p=0.31) respectively 
(Table 5.4.14). Improvement in FFM seems to be a specific effect of anti-TNF-α therapy. 
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Table 5.4.11: Individual changes in body composition compartments (fat mass (FM kg), fat mass index (FMI (kg/m²), fat free mass (FFM kg), fat  free 
mass index (FFMI (kg/m²) and percent (%) body fat) measured by DXA at BL,6M & 12M following treatment with biologic therapy in paediatric CD 
patients 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
Fat Mass (kg) 
BL 
6M 
12M 
 
7.8 
9.2 
11.2 
 
3.6 
3.7 
3.9 
 
14.4 
10.1 
8.1 
 
11.9 
16.2 
12.9 
 
5.0 
6.5 
6.0 
 
11.1 
7.0 
8.2 
 
5.7 
11.1 
8.5 
 
8.5 
10.3 
12.8 
 
16.2 
24.7 
31.8 
 
10.7 
11.9 
8.1 
 
13.0 
15.0 
19.6 
Fat Mass Index (kg/m2) 
BL 
6M 
12M 
 
3.9 
4.2 
4.9 
 
2.0 
2.1 
2.0 
 
4.9 
3.4 
2.7 
 
3.9 
5.2 
4.1 
 
2.8 
3.3 
3.0 
 
4.4 
2.7 
3.2 
 
2.5 
4.6 
3.3 
 
3.1 
3.5 
4.1 
 
5.4 
8.2 
10.5 
 
4.2 
4.4 
2.9 
 
4.1 
4.6 
6.0 
Fat-free Mass (kg) 
BL 
6M 
       12M 
 
26.5 
32.9 
35.6 
 
21.5 
22.8 
24.1 
 
42.1 
44.1 
43.1 
 
42.5 
48.9 
54.8 
 
20.5 
23.4 
23.6 
 
32.6 
33.1 
34.5 
 
25.8 
28.2 
31.6 
 
47.5 
49.1 
48.7 
 
36.6 
39.0 
38.9 
 
37.4 
39.3 
42.1 
 
41.5 
44.8 
49.2 
Fat-free Mass Index (kg/m2) 
BL 
6M 
12M 
 
13.3 
15.2 
15.6 
 
12.3 
12.8 
13.0 
 
14.5 
15.1 
14.7 
 
14.0 
16.0 
17.5 
 
11.5 
12.1 
11.8 
 
12.9 
13.1 
13.6 
 
11.3 
11.8 
12.5 
 
17.1 
16.7 
15.6 
 
12.1 
12.9 
12.8 
 
14.6 
14.7 
15.2 
 
13.1 
13.9 
15.2 
Percent (%) Body Fat 
BL 
6M 
12M 
 
23.4 
22.6 
24.8 
 
14.7 
14.6 
14.3 
 
26.4 
19.3 
16.5 
 
22.8 
25.8 
19.8 
 
20.3 
22.3 
20.8 
 
26.3 
18.2 
19.9 
 
18.9 
29.1 
22.0 
 
15.7 
18.1 
21.7 
 
32.2 
40.4 
46.7 
 
23.1 
24.1 
16.9 
 
24.8 
26.2 
29.5 
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Figure 5.4.7: Individual changes in body composition (DXA) at BL, 6M & 12M following treatment with biologic therapy in paediatric CD patients 
12M6MBL
35
30
25
20
15
10
5
0
F
a
t
m
a
s
s
 
(
K
g
)
10
11
1
2
3
4
5
6
7
8
9
Pt.No
_________________
_________________________________________
p=0.12
p=0.23
_
_
_
 
12M6MBL
11
10
9
8
7
6
5
4
3
2
F
a
t
m
a
s
s
 
I
n
d
e
x
 
(
k
g
/
m
2
)
_________________
_________________________________________
p=0.16
p=0.50
_
_
_
 
12M6MBL
50
40
30
20
10
%
 
B
o
d
y
 
f
a
t
_
_
_
_________________
_____________________________________________
p=0.26
p=0.95
 
12M6MBL
55
50
45
40
35
30
25
20
F
r
e
e
 
F
a
t
 
M
a
s
s
 
(
K
g
)
_
_
_
_____________________________________________
_________________
p=0.004
p=0.004
12M6MBL
18
17
16
15
14
13
12
11
F
r
e
e
 
F
a
t
 
M
a
s
s
 
I
n
d
e
x
(
k
g
/
m
2
)
_
_
_
______________________________________________
_________________p=0.02
p=0.009
 
  
197
Table 5.4.12: Changes body composition compartments (fat mass (FM kg), fat mass index (FMI (kg/m²), fat free mass (FFM (kg), fat free mass 
index (FFMI (kg/m²) and percent (%) body fat) measured by DXA at BL, 6M & 12M following treatment with biologic therapy in paediatric CD 
patients (median-range) 
 
Value 
 
 
BL 
N,11 
 
6M 
N,11 
 
12M 
N,11 
                                p-Value 
 
             BL-6M                                BL-12M 
FM (kg) 10.7 
(3.6,16.2) 
10.3 
(3.7,24.7) 
8.5 
(3.9,31.8) 
0.23 0.14 
FMI (kg/m2) 3.9 
(2.0,5.4) 
4.3 
(2.1,8.2) 
3.4 
(2.1,10.5) 
0.16 0.50 
FFM (kg) 36.7 
(20.6,47.5) 
39.1 
(22.8,49.1) 
38.9 
(23.7,54.8) 
0.004 0.004 
FFMI (kg/m2) 13.1 
(11.3,17.1) 
14.0 
(11.9,16.8) 
14.7 
(11.9,17.5) 
0.02 0.009 
% Body Fat 23.1 
(14.7,32.2) 
22.6 
(14.6,40.4) 
20.8 
(14.3,46.7) 
0.26 0.95 
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Table 5.4.13: Individual changes in body composition compartments (fat mass (FM (kg), fat mass index (FMI (kg/m²), fat free mass (FFM (kg), fat free 
mass index (FFMI (kg/m²) and percent (%) body fat) measured by TANITA at BL, 2wks, 6wks, 6M & 12M following treatment with biologic therapy in 
paediatric CD patients 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
FM (kg) 
BL 
2wk 
6wk 
6M 
12M 
 
5.8 
5.3 
6.4 
5.9 
10.3 
 
1.4 
2.0 
9.3 
2.1 
1.7 
 
* 
5.6 
5.0 
9.6 
2.9 
 
6.1 
5.5 
7.5 
13.9 
6.6 
 
4.0 
6.1 
7.6 
4.7 
4.0 
 
2.6 
3.7 
4.3 
* 
* 
 
2.7 
3.2 
3.1 
4.6 
4.3 
 
3.0 
4.4 
5.5 
6.6 
8.0 
 
17.5 
18.0 
18.3 
17.5 
26.7 
 
6.6 
7.5 
7.2 
6.5 
2.9 
 
5.8 
5.1 
4.6 
6.2 
10.8 
FMI (kg/m2) 
BL 
2wk 
6wk 
6M 
12M 
 
2.9 
2.7 
3.2 
2.7 
4.5 
 
0.8 
1.1 
5.3 
1.2 
0.9 
 
* 
1.9 
1.7 
1.6 
1.0 
 
2.0 
1.8 
2.5 
4.5 
2.1 
 
2.2 
3.4 
4.3 
2.4 
2.0 
 
1.0 
1.5 
1.7 
* 
* 
 
1.2 
1.4 
1.4 
1.9 
1.7 
 
1.1 
1.6 
2.0 
2.3 
2.6 
 
5.8 
6.0 
6.1 
5.8 
8.8 
 
2.6 
2.9 
2.8 
2.4 
1.1 
 
1.8 
1.6 
1.5 
1.9 
3.4 
FFM (kg) 
BL 
2wk 
6wk 
6M 
12M 
 
27.8 
31.0 
33.3 
38.1 
36.4 
 
23.6 
23.2 
23.0 
24.5 
27.8 
 
* 
51.5 
52.4 
49.6 
48.9 
 
50.5 
49.2 
48.3 
49.4 
61.0 
 
24.5 
24.0 
24.6 
25.3 
25.8 
 
36.1 
38.9 
40.2 
* 
* 
 
29.0 
29.2 
32.0 
33.8 
35.8 
 
49.4 
49.3 
50.5 
52.6 
51.1 
 
40.4 
42.2 
44.2 
47.4 
45.3 
 
39.2 
40.5 
40.8 
45.2 
47.6 
 
53.4 
52.0 
53.4 
53.7 
58.0 
FFMI (kg/m2) 
BL 
2wk 
6wk 
6M 
12M 
 
13.9 
15.5 
16.7 
17.6 
15.9 
 
13.5 
13.3 
13.2 
13.9 
15.0 
 
* 
* 
* 
17.0 
16.7 
 
16.6 
16.2 
15.9 
16.2 
19.5 
 
13.7 
13.4 
13.8 
13.2 
12.9 
 
14.3 
15.4 
15.9 
* 
* 
 
12.7 
12.8 
14.0 
13.4 
14.1 
 
17.8 
17.7 
18.2 
17.9 
16.4 
 
13.4 
14.0 
14.6 
15.7 
15.0 
 
15.3 
15.8 
15.9 
17.0 
17.3 
 
16.8 
16.4 
16.8 
16.7 
18.0 
% Body Fat 
BL 
2wk 
6wk 
6M 
12M 
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Figure 5.4.8: Individual changes in body composition (TANITA) at BL, 2wks, 6wks, 6M & 12M following treatment with biologic therapy in paediatric CD patients 
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Table 5.4.14: changes in body composition compartments (fat mass (FM (kg), fat mass index (FMI (kg/m²), fat free mass (FFM (kg), fat free mass 
index (FFMI (kg/m²) and percent (%) body fat) measured by TANITA at BL, 2wks, 6wks, 6M & 12M following treatment with biologic therapy in 
paediatric CD patients (median-range) 
 
 
Value 
 
 
BL 
N,11 
 
 
2wk 
N,11 
 
 
6wk 
N,11 
 
 
6M 
N,11 
 
 
12M 
N,11 
                              p-Value 
 
       BL -2wk               BL- 6wk            BL -6M             BL-12M 
FM (kg) 4.9 
(1.4,17.5) 
5.3 
(2.0,18.1) 
6.4 
(3.1,18.3) 
6.1 
(2.1,17.5) 
5.5 
(1.7,26.7) 
0.12 0.02 0.02 0.04 
FMI (kg/m2) 1.9 
(0.8,5.8) 
2.3 
(1.2,5.8) 
2.1 
(0.9,8.8) 
1.8 
(1.1,6) 
2.5 
(1.4,6.1) 
0.10 0.02 0.09 0.12 
FFM (Kg) 37.7 
(23.6,53.4) 
40.5 
(23.2,52) 
40.8 
(23,53.4) 
46.3 
(24.5,53.7) 
46.5 
(25.8,61) 
0.41 0.07 0.02 0.01 
FFMI(kg/m2) 14.1 
(12.6,17.7) 
15.4 
(12.8,17.7) 
15.8 
(13.2,18.2) 
16.4 
(13.2,17.9) 
17.2 
(12.9,22.9) 
0.50 0.07 0.03 0.009 
% Body Fat 10.7 
(5.5,30.3) 
10 
(7.9,30.4) 
9.8 
(2.4,29.2) 
11.4 
(7.7,27) 
12.1 
(5.6,37.2) 
0.24 0.47 0.95 0.31 
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5.4.9.3 Comparison between DXA and TANITA 
All body composition compartments (FM(kg), FFM(kg), %body fat) measured by BIA were 
found to be positively and highly correlated with those by DXA at BL, 6M and 12M (Table 
5.4.15). FM, FFM and % body fat calculated by DXA were linearly regressed against those 
predicted by TANITA. There were no significant correlations between FM, FMI, %fat, FFM or 
FFMI and disease duration and markers of inflammation. 
 
Table 5.4.15: Spearman rank correlation (R-coefficient and p-values) for body composition 
variables between DXA and TANITA at BL, 6M & 12M following biologic therapy 
Parameters R coefficient p-value 
FM (kg) 
BL 
6M 
12M 
 
0.45 
0.60 
0.84 
 
0.03 
0.008 
0.0001 
FFM (kg) 
BL 
6M 
12M 
 
0.85 
0.87 
0.99 
 
0.0001 
0.0001 
0.0001 
(%) Body Fat 
BL 
6M 
12M 
 
0.58 
0.63 
0.90 
 
0.01 
0.006 
0.0001 
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5.4.10 Densitometric changes 
5.4.10.1 Total body 
Individual changes in total body bone mineral content (TB-BMC (g), total body bone area (TB 
BA (cm²), total body bone mineral content z-score (TB-BMC z-score (SD), total body bone 
mineral density (TB-BMD (g/cm²) are presented in (Table 5.4.16; Figure 5.5.9). Median 
(range) BMC (g) increased from 1833(815,2548) at BL to 1954(876,2629) at 6M (p=0.045) 
and 2025(901,2650) at 12M(p=0.009). The median BMC z-scores (SD) remained unchanged 
from -0.1(-0.7,0.4) at BL to -0.1(-0.8,0.2)(p=0.44) at 6M and -0.2(-0.8,0.1) at 12M(p=0.07) and 
remained below zero from BL to 6M & 12M. Median TB-BMD (g/cm²) remained unchanged 
from 0.99(0.78,1.16) at BL to 1.01(0.79,1.13) at 6M (p=0.26), and 1.04(0.79,1.13) at 12M 
(p=0.16)(Table 5.4.17). The median percentage change of TB-BMC (g) from BL to 6M was 
3.2%(-2.9,20.1) (p=0.03) and BL to 12M was 10.5%(-2.6,40.3) (p=0.009). The median 
percentage change of TB-BMD (g/cm²) from BL to 6M was 0.9%(-2.1,3.9) (p=0.26) and BL to 
12M was 0.8%(-2.8,10.0) (p=0.19) (Table 5.4.17; Figure 5.4.10). 
5.4.10.2 Lumbar spine 
Individual changes in lumbar spine bone mineral content (LS-BMC (g), lumbar spine bone 
mineral content z-score (LS-BMC z-score (SD), lumbar spine bone mineral density (LS-BMD 
(cm²) lumbar spine bone area (LS-BA (cm²), Lumbar spine volumetric bone mineral apparent 
density (BMAD (g/cm³), lumbar spine volumetric bone mineral apparent density z-score (LS-
BMAD z-scores (SD) are presented in (Table 5.4.18; Figure 5.4.11-11). Median (range) LS-
BMC (g) remained unchanged from 32(11,41) at BL to 29(12,53) at 6M (p=0.10) and 
30(15,52) at 12M(p=0.06). The median LS-BMC z-scores (SD) was -0.6(-1.3,0.2) at BL and -
0.4(- 1.6,0.3)(p=0.51) at 6M and -0.4(-1.3,0.2) at 12M(p=0.88) and remained below zero from 
BL to 6M & 12M. Median LS-BMD (g/cm²) remained unchanged from 0.8(0.7,1.3) at BL to 
0.8(0.7,1.2) at 6M (p=0.62), and 0.9(0.7,1.2) at 12M (p=0.10)(Table 5.4.19). 
The median percentage change of LS-BMC (g) from BL to 6M was 8.9%(13.1,29.4) (p=0.54) 
and BL to 12M was 13.5%(-28.2,80.9)(p=0.06). The median percentage change of LS-BMD 
(g/ cm²) from BL to 6M was 0.9%(-9.2,16.9) (p=0.62) and BL to 12M was 5.4%(-6.7,29.4) 
(p=0.05). Median LS-BMAD (g/cm³) did not change from 0.13(0.11,0.19) at BL to 
0.13(0.18,0.16) at 6M (p=0.82), and 0.14(0.11,0.16) at 12M (p=0.12). Median LS-BMAD z-
scores (SD) also remained unchanged from -1.6(-2.7,1.7) at BL to -1.8(-3.1,0.2) at 6M 
(p=0.35), and -1.5(-2.4,-0.2) at 12M (p=0.68) and remained below zero throughout the study 
interval. The median percentage change of LS-BMAD (g/cm³) from BL to 6M was 0.9%(-
9.2,16.9) (p=0.62) and BL to 12M was 5.4%(-6.7,29.4) (p=0.05) (Table 5.4.19;Figure 5.4.13). 
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Table 5.4.16: Individual changes in densitometric evaluations of total body (bone mineral content (BMC (g), bone mineral content z-score (BMC 
z-score (SD), bone mineral density (BMD (g/cm²) and bone area (BA (cm²) at BL, 6M & 12M following treatment with biologic therapy in 
paediatric CD patients 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
BA(cm²) 
BL 
6M 
12M 
 
1333 
1541 
1700 
 
1075 
1079 
1182 
 
2040 
1963 
1971 
 
2143 
2220 
2308 
 
1041 
1108 
1141 
 
1722 
1694 
1714 
 
1418 
1415 
1617 
 
2004 
2138 
2217 
 
2200 
2318 
2357 
 
1803 
1890 
1925 
 
2162 
2213 
2401 
BMC(g) 
BL 
6M 
12M 
 
1090.4 
1309.6 
1530.0 
 
867.7 
876.7 
958.9 
 
2073.8 
2012.7 
2045.2 
 
2340.6 
2379.0 
2488.1 
 
815.4 
876.1 
901.2 
 
1555.7 
1514.3 
1515.5 
 
1317.9 
1325.4 
1501.3 
 
1970.0 
2178.9 
2329.9 
 
2547.8 
2628.9 
2650.6 
 
1833.4 
1954.1 
2024.8 
 
2225.8 
2356.5 
2598.7 
BMD(g/cm²) 
BL 
6M 
12M 
 
0.818 
0.580 
0.900 
 
0.807 
0.813 
0.812 
 
1.017 
1.026 
1.040 
 
1.092 
1.071 
1.080 
 
0.783 
0.791 
0.790 
 
0.904 
0.894 
0.884 
 
0.930 
0.937 
0.928 
 
   0.983 
1.019 
1.051 
 
1.158 
1.134 
1.125 
 
1.017 
1.034 
1.052 
 
1.029 
1.065 
1.082 
BMC for BA SDS 
BL 
6M 
12M 
 
-0.7 
-0.8 
-0.8 
 
0.2 
0.2 
-0.2 
 
-0.3 
-0.2 
-0.1 
 
0.0 
-0.1 
-0.2 
 
0.1 
-0.1 
-0.2 
 
-0.7 
-0.7 
-0.8 
 
0.0 
0.0 
-0.4 
 
-0.5 
-0.4 
-0.2 
 
0.4 
0.2 
0.1 
 
-0.1 
-0.1 
0.0 
 
-0.3 
-0.2 
-0.2 
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Figure 5.4.9: Individual changes in densitometric evaluations of total body (bone mineral content (BMC (g), bone mineral content z-score (BMC 
z-score (SD), bone mineral density (BMD (g/cm²) and bone area (BA (cm²) at BL, 6M & 12M following treatment with biologic therapy in 
paediatric CD patients 
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Table 5.4.17: Individual changes in densitometric evaluations of total body (bone mineral content (BMC (g), bone mineral content z-score (BMC 
z-score (SD), bone mineral density (BMD (g/cm²) and bone area (BA (cm²) at BL, 6M & 12M following treatment with biologic therapy in 
paediatric CD patients (median-range) 
 
Value 
 
 
BL 
N,11 
 
6M 
N,11 
 
12M 
N,11 
p-Value 
 
BL-6M               BL-12M 
%change 
 
BL-6M             BL-12M         
     p-Value 
 
  BL-6M        BL-12M 
Bone area(cm²)             1803 
(1041,2200) 
1890 
(1079,2318) 
1925 
(1141,2401) 
0.05 0.009 3.6 
(-3.8,15.6) 
9.6 
(-3.4,24.5) 
0.045 0.009 
BMC(g) 1833 
(815,2548) 
1954 
(876,2629) 
2025 
(901,2650) 
0.045 0.009 3.2 
(-2.9,20.1) 
10.5 
(-2.6,40.3) 
0.03 0.009 
BMD(g/cm²) 0.99 
(0.78,1.16) 
1.01 
(0.79,1.13) 
1.04 
(0.79,1.13) 
0.26 0.16 0.9 
(-2.1,3.9) 
0.8 
(-2.8,10.0) 
0.26 0.19 
BMC for Bone Area SDS -0.1 
(-0.7,0.4) 
-0.1 
(-0.8,0.2) 
-0.2 
(-0.8,0.1) 
0.44 0.07     
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Figure 5.4.10: Percentage (%) change total body (bone mineral content (BMC (g), bone mineral density (BMD (g/cm²) and bone area (BA (cm²) 
at BL, 6M & 12M following treatment with biologic therapy in paediatric CD 
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Table 5.4.18: Individual changes in densitometric evaluations of lumbar spine bone mineral content (LS-BMC (g), lumbar spine bone mineral 
content z-score (LS-BMC z-score(SD), lumbar spine bone mineral density (LS-BMD (g/cm²) lumbar spine bone area (LS-BA (cm²), lumbar spine 
volumetric bone mineral apparent density (BMAD(g/cm³), lumbar spine volumetric bone mineral apparent density z-score (LS-BMAD z-scores 
(SD) at BL, 6M &12M following treatment with biologic therapy in paediatric patients with CD 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
Bone area(cm²) 
BL 
6M 
12M 
 
26.6 
29.3 
31.5 
 
25.2 
25.0 
19.3 
 
37.1 
37.2 
38.8 
 
42.0 
40.2 
30.7 
 
16.5 
18.0 
28.1 
 
37.0 
37.5 
37.7 
 
26.7 
27.9 
30.15 
 
39.5 
41.1 
41.5 
 
32.3 
44.6 
44.1 
 
27.8 
30.4 
31.4 
 
40.2 
41.6 
43.4 
BMC(g) 
BL 
6M 
12M 
 
19.8 
25.5 
30.4 
 
17.5 
17.5 
14.8 
 
32.7 
34.4 
37.1 
 
33.3 
28.9 
23.9 
 
10.8 
12.4 
19.5 
 
31.6 
31.1 
31.8 
 
21.0 
20.4 
23.7 
 
32.3 
35.9 
35.2 
 
40.8 
52.8 
52.0 
 
23.1 
25.2 
27.5 
 
37.8 
42.6 
49.1 
BMD(g/cm²) 
BL 
6M 
12M 
 
0.74 
0.87 
0.96 
 
0.69 
0.70 
0.76 
 
0.88 
0.92 
0.95 
 
0.79 
0.71 
0.77 
 
0.65 
0.68 
0.69 
 
0.85 
0.82 
0.84 
 
0.78 
0.73 
0.78 
 
0.81 
0.87 
0.85 
 
1.26 
1.18 
1.17 
 
0.83 
0.82 
0.87 
 
0.94 
1.02 
1.13 
BMC for Bone Area SDS 
BL 
6M 
12M 
 
-0.6 
-0.3 
-0.1 
 
-0.4 
-0.3 
-0.3 
 
-0.6 
-0.4 
-0.3 
 
-1.3 
-1.6 
-1.3 
 
-0.5 
-0.7 
-0.8 
 
-0.7 
-0.7 
-0.8 
 
-0.1 
0.3 
-0.5 
 
-1.0 
-0.9 
-1.0 
 
0.2 
0.2 
0.0 
 
0.0 
-0.3 
-0.2 
 
-0.5 
-0.2 
0.2 
BMAD(g/cm³) 
BL 
6M 
12M 
 
0.12 
0.14 
0.15 
 
0.12 
0.12 
0.15 
 
0.12 
0.13 
0.13 
 
0.10 
0.09 
0.12 
 
0.13 
0.13 
0.13 
 
0.12 
0.11 
0.12 
 
0.13 
0.12 
0.12 
 
0.11 
0.12 
0.11 
 
0.19 
0.15 
0.15 
 
0.14 
0.13 
0.14 
 
0.13 
0.14 
0.15 
BMAD SDS 
BL 
6M 
12M 
 
-1.79 
-0.99 
-0.49 
 
-1.20 
-1.99 
-0.49 
 
-1.74 
-1.38 
-1.28 
 
-2.74 
-3.13 
-1.94 
 
-1.13 
-1.08 
-2.39 
 
-1.89 
-2.14 
-2.04 
 
-1.43 
-2.04 
-1.79 
 
-2.39 
-2.09 
-2.28 
 
1.66 
-0.19 
-0.19 
 
-1.13 
-1.53 
-1.18 
 
-1.15 
-1.03 
-0.44 
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Figure 5.4.11: Individual changes in densitometric evaluations of lumbar spine bone mineral content (LS-BMC (g), lumbar spine bone mineral 
content z-score (LS-BMC z-score (SD), lumbar spine bone mineral density (LS-BMD (g/cm²), lumbar spine bone area (LS-BA (cm²) at BL, 6M 
&12M following treatment with biologic therapy in paediatric patients with CD 
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Figure 5.4.12: Individual changes in lumbar spine volumetric bone mineral apparent density (BMAD (g/cm³), lumbar spine volumetric bone 
mineral apparent density z-score (LS-BMAD z-scores (SD) at BL, 6M &12M following treatment with biologic therapy in paediatric patients with 
CD 
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Table 5.4.19: Changes in densitometric evaluations of lumbar spine bone mineral content (LS-BMC (g), lumbar spine bone mineral content z-
score (LS-BMC z-score(SD), lumbar spine bone mineral density (LS-BMD (g/cm²) lumbar spine bone area (LS-BA (cm²), lumbar spine 
volumetric bone mineral apparent density (BMAD(g/cm³), lumbar spine volumetric bone mineral apparent density z-score (LS-BMAD z-scores 
(SD) at BL, 6M &12M following treatment with biologic therapy in paediatric patients with CD (median-range) 
 
Value 
 
 
BL 
N,11 
 
6M 
N,11 
 
12M 
N,11 
p-Value 
 
BL-6M               BL-12M 
%change 
 
BL-6M             BL-12M 
p-Value 
 
 BL-6M            BL-12M 
Bone area(cm²) 32.3 
(17,42) 
37 
(18,45) 
32 
(19,44) 
0.04 0.16 4.1 
(-4.3,38.2) 
8.1 
(-26.8,69.6) 
0.03 0.16 
BMC(g) 32 
(11,41) 
29 
(12,53) 
30 
(15,52) 
0.10 0.06 8.9 
(-13.1,29.4) 
13.5 
(-28.2,80.9) 
0.54 0.06 
BMD(g/cm²) 0.8 
(0.7,1.3) 
0.8 
(0.7,1.2) 
0.9 
(0.7,1.2) 
0.62 0.10 0.9 
(-9.2,16.9) 
5.4 
(-6.7,29.4) 
0.62 0.05 
BMC for Bone Area SDS -0.6 
(-1.3,0.2) 
-0.4 
(-1.6,0.3) 
-0.4 
(-1.3,0.2) 
0.51 0.88     
BMAD(g/cm³) 0.13 
(0.11,0.19) 
0.13 
(0.18,0.16) 
0.14 
(0.11,0.16) 
0.82 0.12 -0.7 
(-1.9,12.8) 
-1.7 
(-19.0,25.8) 
0.82 0.60 
BMAD SDS -1.6 
(-2.7,1.7) 
-1.8 
(-3.1,0.2) 
-1.5 
(-2.4,-0.2) 
0.35 0.68     
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Figure 5.4.13: Percentage (%) change Lumbar spine (bone mineral content (LS-BMC (g), bone mineral density (LS-BMD (g/cm²) and bone area 
(LS-BA(cm²) and lumbar spine volumetric bone mineral apparent density (LS-BMAD (g/cm³) at BL, 6M & 12M following treatment with biologic 
therapy in paediatric CD 
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5.4.10.3 Proximal femur 
Individual changes in proximal femur bone mineral content (PF-BMC (g), proximal femur one 
mineral density (PF-BMD (g/cm²) and proximal femur bone area (PF-BA (cm²) are presented 
in (Table 5.4.20; Figure 5.4.14). Median (range) PF-BMC (g) was 23(12,33) at BL and 
24(12,37) at 6M (p=0.75) and 27(13,36) at 12M(p=0.06). Median PF-BMD (g/cm²) was 
0.77(0.65,1.06) at BL and 0.81(0.63,1.11) at 6M (p=0.68), and 0.88(0.66,1.07) at 
12M(p=0.11) (Table 5.4.21). The median percentage change of PF-BMC (g) from BL to 6M 
was -0.3%(-7.5,18.5)(p=0.75) and BL to 12M was 5.2%(-7.1,40.1)(p=0.08). The median 
percentage change of PF-BMD (g/cm²) from BL to 6M was 1.3%(-8.3,8.9)(p=0.62) and BL to 
12M was 4.4%(-8.3,23.7) (p=0.12) (Table 5.4.21;Figure 5.4.15). 
5.4.10.4 Femoral neck 
Individual changes in femoral neck bone mineral content (FN-BMC (g), femoral neck bone 
area (FN-BA), femoral neck bone mineral density (FN-BMD (g/ cm²), femoral neck volumetric 
bone mineral apparent density (FN-BMAD (g/cm³), lumbar spine volumetric bone mineral 
apparent density z-score (FN-BMAD z-score (SD) are presented in (Table 5.4.22; Figure 
5.4.16-16). Median (range) FN-BMC (g) was 3.9(2.2,5.2) at BL, 3.8(2.2,5.5) at  6M (p=0.68) 
and 4.1(2.2,5.4) at 12M(p=0.14). Median FN-BMD (g/cm²) was 0.76(0.61,1.05) at BL, 
0.78(0.61,1.09) at 6M (p=0.45), and 0.86(0.66,1.06) at 12M (p=0.06) (Table 5.4.23). 
The median percentage change of FN-BMC (g) from BL to 6M was 1.3%(- 7.6,16.3)(p=0.75) 
and BL to 12M was 4.4%(-7.9,31.9) (p=0.23). The median percentage change of FN-BMD (g/ 
cm²) from BL to 6M was 3.1%(-8.5,12.6) (p=0.45) and BL to 12M was 4.3%(-7.8,24.6) 
(p=0.05). Median FN-BMAD (g/cm³) changed from 0.14(0.12,0.18) at BL to 0.15(0.12,0.18) at 
6M (p=0.26), and 0.16(0.13,0.18) at 12M (p=0.47). Median FN-BMAD z-scores (SD) changed 
from -1.1(-1.8,0.3) at BL to -0.8(-1.8,0.3) at 6M (p=0.14), and -0.4(-1.6,- 0.2) at 12M (p=0.42) 
but stayed below zero through out the study interval. The median percentage change of FN-
BMAD (g/cm³) from BL to 6M was 4.0%(-10.1,19.5) (p=0.54) and BL to 12M was 6.7%(-
7.9,18.4) (p=0.75)(Table 5.4.23;Figure 5.4.18). 
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Table 5.4.20: Individual changes in densitometric evaluations of proximal femur bone mineral content (PF-BMC (g), proximal femur bone mineral 
density (PF-BMD (g/cm²) proximal femur bone area (PF-BA (cm²) at BL, 6M & 12M following treatment with biologic therapy in paediatric patients 
with CD 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
Bone area(cm²) 
BL 
6M 
12M 
 
24.4 
26.5 
27.6 
 
19.8 
20.4 
18.8 
 
33.5 
32.8 
33.6 
 
31.3 
32.3 
31.6 
 
17.0 
16.4 
17.0 
 
30.4 
29.9 
30.1 
 
24.0 
23.3 
26.0 
 
31.3 
32.8 
33.3 
 
20.2 
30.5 
30.6 
 
28.4 
28.9 
30.5 
 
34.3 
35.3 
35.5 
BMC(g) 
BL 
6M 
12M 
 
17.6 
20.9 
24.7 
 
12.9 
13.0 
12.5 
 
28.2 
28.0 
29.6 
 
29.2 
28.3 
29.4 
 
12.0 
11.9 
12.5 
 
21.7 
20.7 
20.4 
 
17.2 
17.2 
21.01 
 
33.2 
36.6 
35.7 
 
31.7 
29.3 
29.5 
 
23.0 
23.6 
26.6 
 
26.7 
29.5 
32.4 
BMD(g/cm²) 
BL 
6M 
12M 
 
0.72 
0.78 
0.89 
 
0.65 
0.63 
0.66 
 
0.84 
0.85 
0.88 
 
0.93 
0.87 
0.92 
 
0.70 
0.72 
0.73 
 
0.71 
0.69 
0.67 
 
0.71 
0.73 
0.80 
 
1.06 
1.11 
1.07 
 
1.05 
0.96 
0.96 
 
0.81 
0.81 
0.87 
 
0.77 
0.83 
0.91 
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Figure 5.4.14: Individual changes in densitometric evaluations of proximal femur bone mineral content (PF-BMC (g), proximal femur bone 
mineraldensity (PF-BMD (g/cm²) proximal femur bone area (PF-BA (cm²) at BL, 6M & 12M following treatment with biologic therapy in paediatric 
patients with CD 
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Table 5.4.21: Changes in densitometric evaluations of proximal femur bone mineral content (PF-BMC (g), proximal femur bone mineral density 
(PF-BMD (g/cm²) proximal femur bone area (PF-BA (cm²) at BL, 6M & 12M following treatment with biologic therapy in paediatric patients with CD 
(median-range) 
 
       Value 
 
 
BL 
N,11 
 
6M 
N,11 
 
12M 
N,11 
p-Value 
 
BL-6M               BL-12M 
%change 
 
BL-6M             BL-12M 
p-Value 
 
   BL-6M               BL-12M 
Bone area(cm²) 28 
(17,34) 
30 
(17,35) 
31 
(17,36) 
0.15 0.03 2.9 
(-3.5,50.8) 
3.5 
(-4.9,51.2) 
0.23 0.04 
BMC(g) 23 
(12,33) 
24 
(12,37) 
27 
(13,36) 
0.75 0.06 -0.3 
(-7.5,18.5) 
5.2 
(-7.1,40.1) 
0.75 0.08 
BMD(g/ cm²) 0.77 
(0.65,1.06) 
0.81 
(0.63,1.11) 
0.88 
(0.66,1.07) 
0.68 0.11 1.3 
(-8.3,8.9) 
4.4 
(-8.3,23.7) 
0.62 0.12 
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Figure 5.4.15: Percentage (%) change in proximal femur bone mineral content (PF-BMC (g), proximal femur bone mineral density (PF-BMD (g/cm²) 
proximal femur bone area (PF-BA (cm²) at BL, 6M & 12M following treatment with biologic therapy in paediatric CD 
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Table 5.4.22: Individual changes in femoral neck bone mineral content (FN-BMC (g), femoral neck bone mineral density (FN-BMD (g/cm²), femoral 
neck bone area (FN-BA (cm²), femoral neck volumetric bone mineral apparent density (BMAD (g/cm³), femoral neck volumetric bone mineral 
apparent density z-score (FN-BMAD z-score (SD) at BL, 6M & 12M following treatment with biologic therapy in paediatric patients with CD 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
Bone area(cm²) 
BL 
6M 
12M 
 
4.2 
4.3 
4.4 
 
3.5 
3.6 
3.2 
 
4.9 
5.0 
5.1 
 
4.5 
4.6 
4.5 
 
3.7 
3.4 
3.4 
 
4.5 
4.2 
4.4 
 
4.1 
4.0 
4.3 
 
4.8 
5.0 
5.0 
 
4.5 
4.5 
4.5 
 
5.0 
5.0 
4.7 
 
5.5 
5.4 
5.5 
BMC(g) 
BL 
6M 
12M 
 
2.9 
3.4 
3.8 
 
2.1 
2.2 
2.1 
 
4.2 
4.5 
4.6 
 
4.4 
4.1 
4.4 
 
2.6 
2.4 
2.4 
 
3.1 
3.3 
3.1 
 
3.1 
3.0 
3.6 
 
5.1 
5.4 
5.3 
 
4.5 
4.1 
4.1 
 
3.8 
3.8 
4.0 
 
4.4 
4.6 
5.0 
BMD(g/cm²) 
BL 
6M 
12M 
 
0.72 
0.78 
0.89 
 
0.65 
0.63 
0.66 
 
0.84 
0.85 
0.88 
 
0.93 
0.87 
0.92 
 
0.70 
0.72 
0.73 
 
0.71 
0.69 
0.67 
 
0.71 
0.73 
0.80 
 
1.06 
1.11 
1.07 
 
1.05 
0.96 
0.96 
 
0.81 
0.81 
0.87 
 
0.77 
0.83 
0.91 
BMAD(g/cm³ 
BL 
6M 
12M 
 
0.13 
0.14 
0.16 
 
0.14 
0.13 
0.16 
 
0.14 
0.15 
0.14 
 
0.17 
0.16 
0.18 
 
0.14 
0.17 
0.16 
 
0.12 
0.15 
0.12 
 
0.14 
0.15 
0.15 
 
0.17 
0.18 
0.17 
 
0.17 
0.16 
0.16 
 
0.12 
0.12 
0.14 
 
0.12 
0.13 
0.13 
BMAD SDS 
BL 
6M 
12M 
 
-1.36 
-0.86 
-0.43 
 
-1.14 
-1.36 
-0.36 
 
-1.07 
-0.79 
-1.07 
 
-0.25 
-0.39 
0.18 
 
-0.89 
0.07 
-0.07 
 
-1.57 
-0.75 
-1.61 
 
-0.79 
-0.57 
-0.43 
 
0.29 
0.32 
0.11 
 
0.21 
-0.07 
-0.29 
 
-1.71 
-1.82 
-0.93 
 
-1.82 
-1.46 
-1.21 
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Figure 5.4.16: Individual changes in femoral neck bone mineral content (FN-BMC (g), femoral neck bone mineral density (FN-BMD (g/cm²), femoral 
neck bone area (FN-BA (cm²), at BL, 6M & 12M following treatment with biologic therapy in paediatric patients with CD 
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Figure 5.4.17: Individual changes in femoral neck volumetric bone mineral apparent density (BMAD (g/cm³), femoral neck volumetric bone mineral 
apparent density z-score (FN-BMAD z-score (SD) at BL, 6M & 12M following treatment with biologic therapy in paediatric patients with CD 
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Table 5.4.23: changes in femoral neck bone mineral content (FN-BMC (g), femoral neck bone mineral density (FN-BMD (g/cm²), femoral neck bone 
area (FN-BA (cm²), femoral neck volumetric bone mineral apparent density (BMAD (g/cm³), femoral neck volumetric bone mineral apparent 
density z-score (FN-BMAD z-score (SD) at BL, 6M & 12M following treatment with biologic therapy in paediatric patients with CD (median-range) 
 
Value 
 
 
BL 
N,11 
 
6M 
N,11 
 
12M 
N,11 
p-Value 
 
BL-6M               BL-12M 
%change 
 
BL-6M             BL-12M 
p-Value 
 
     BL-6M                BL-12M 
Bone area(cm²) 4.5 
(3.6,5.5) 
4.5 
(3.4,5.4) 
4.6 
(3.3,5.5) 
0.68 0.42 0.4 
(-10.1,3.3) 
-0.2 
(-9.4,5.9) 
0.62 0.68 
BMC(g) 3.9 
(2.2,5.2) 
3.8 
(2.2,5.5) 
4.1 
(2.2,5.4) 
0.68 0.14 1.3 
(-7.6,16.3) 
4.4 
(-7.9,31.9) 
0.75 0.23 
BMD(g/cm²) 0.76 
(0.61,1.05) 
0.78 
(0.61,1.09) 
0.86 
(0.66,1.06) 
0.45 0.06 3.1 
(-8.5,12.6) 
4.3 
(-7.8,24.6) 
0.45 0.05 
BMAD (g/cm³) 0.14 
(0.12;0.18) 
0.15 
(0.12,0.18) 
0.16 
(0.13,0.18) 
0.26 0.47 4.0 
(-10.1,19.5) 
6.7 
(-7.9,18.4) 
0.54 0.75 
BMAD SDS -1.1 
(-1.8,0.3) 
-0.8 
(-1.8,0.3) 
-0.4 
(-1.6,0.2) 
0.14 0.05     
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Figure 5.4.18: Percentage (%) change femoral neck (bone mineral content (FN-BMC (g), bone mineral density (FN-BMD (g/cm²) and bone area (FN-
BA (cm²) and volumetric bone mineral apparent density (FN-BMAD (g/cm³) at BL, 6M & 12M following treatment with biologic therapy in paediatric 
CD 
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5.4.11 Musculoskeletal changes 
5.4.11.1 Tibia bone and muscle parameters 
As mentioned in methods bone and muscle measures in left tibia were measured by QCT. 
Individual changes in total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral 
density (TrbBMD (mg/cm³), at 4%, cortical bone mineral density (CrtBMD (mg/cm³), Stress-
strain index (SSI (mm³) at 38%, muscle cross-sectional area (Mus-CSA (mm²), fat cross-
sectional area (Fat-CSA (mm²) and cortical bone area (Crt-BA (mm²) at 66% of tibial length 
are presented in (Table 5.4.24; 
Figure 5.4.19-19). Median (range) tibia Tot BMD changed from 245(181,313) at BL to 
260(209,316) at 6M (p=0.03) and 260(208,317) at 12M(p=0.10). The median TrbBMD 
(mg/cm³) remain unchanged from 190(140,251) at BL, to 189(173,249) at 6M(p=0.30) and 
187(150,249) at 12M (p=0.75). Median SSI (mm³) changed from 1125(411,1711) at BL to 
1182(517,1809) at 6M (p=0.22) and 1189(581,1777) at 12M(p=0.04). Median CrtBMD 
(mg/cm³) was 1104(1088,1187) at BL, 1129(1036,1181) at 6M(p=0.47) and 1120(966,1183) 
at 12M(p=0.10). Median Mus-CSA mm²) increased from from 4665(3018,6184) at BL to 
5356(3210,6959) at 6M (p=0.02) and 5392(3373,7055) at 12M(p=0.04). Median Fat-CSA 
(mm²) changed from 1809(892,2763) at BL to 1971(986,3505) at 6M(p=0.04) and 
1899(1026,3475) at 12M(p=0.08). Median Crt-BA (mm²) was 283(138,374) at BL, 
298(134,380) at 6M(p=0.35) and 281(131,376) at 12M(p=0.96), respectively (Table 5.4.25). 
The median percentage change of TotBMD from BL to 6M was 5.8%(-4.1,15.1)(p=0.03) and 
from BL to 12M was 5.8%(-10.6,26.2)(p=0.06) (Table 5.4.25). Median percentage change of 
TrbBMD (mg/cm³) from BL to 6M was 0.9%(-7.4,24.1)(p=0.30) and from BL to 12M was -
0.8%(- 9.2,23.6)(p=0.75). Median percentage change of SSI from BL to 6M was 1.4%(- 
11.8,42.2)(p=0.22) and from BL to 12M was 6.5%(5.2,41.2)(p=0.01). Median percentage 
change of CrtBMD from BL to 6M was -0.3%(-6.0,2.2)(0.47) and from BL to 12M was - 0.5%(-
11.4,2.7)(p=0.47). Median percentage of Mus-CSA from BL to 6M was 7.4%(- 
3.1,23.3)(p=0.02) and from BL to 12M was 11.8%(-6.8,38.9)(p=0.04). Median percentage of 
Fat-CSA from BL to 6M was 10.6%(-16.8,42.4)(p=0.04) and from BL to12M was 7.5%(-
15.8,105.5)(p=0.10). Median percentage of Crt-BA from BL to 6M was 2.1%(- 
5.9,8.9)(p=0.96) and from BL-12M was -0.1%(-24.0,10.6)(p=0.47), respectively (Table 
5.4.25;Figure 5.4.21-21). 
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Table 5.4.24: Individual change tibia total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral density (TrbBMD (mg/cm³) at 4%, 
cortical bone mineral density (CrtBMD (mg/cm³), Stress-strain index (SSI (mm³) at 38%, muscle cross-sectional area (Mus-CSA (mm²), fat cross-
sectional area (Fat-CSA (mm²) and cortical bone area (Crt-BA (mm²) at 66% of tibial length at BL,6M &12M following biologic therapy in paediatric 
patients with CD 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
TotBMD(mg/cm³) 
BL 
6M 
12M 
 
1.81.3 
208.7 
207.9 
 
211.9 
227.9 
227.3 
 
277.5 
287.6 
281.1 
 
245.1 
245.1 
259.5 
 
208.2 
235.5 
257.7 
 
251.6 
262.2 
224.9 
 
201.9 
- 
212.7 
 
274.6 
302.9 
312.9 
 
312.9 
316.0 
317.2 
 
278.1 
265.3 
261.4 
 
226.1 
257.2 
285.5 
TrbBMD(mg/cm³) 
BL 
6M 
12M 
 
151.8 
182.6 
149.9 
 
189.9 
189.6 
172.4 
 
229.1 
233.4 
223.6 
 
174.4 
173.8 
182.8 
 
139.7 
173.3 
172.6 
 
190.2 
188.3 
187.0 
 
165.2 
* 
176.7 
 
210.1 
235.7 
212.4 
 
251.0 
249.2 
248.9 
 
217.2 
201.0 
204.2 
 
183.9 
189.7 
209.6 
SSI(mm³) 
BL 
6M 
12M 
 
566.5 
516.5 
684.1 
 
411.4 
554.7 
581.0 
 
843.8 
1200.2 
873.6 
 
1710.5 
1808.5 
1621.2 
 
566.3 
566.4 
612.3 
 
1170.9 
1163.4 
1189.3 
 
1125.4 
* 
1205.9 
 
1401.1 
1427.6 
1776.8 
 
1500.6 
1322.9 
1504.3 
 
1150.9 
1161.1 
1225.8 
 
1116.8 
1346.1 
1116.8 
CrtBMD(mg/cm³)  
BL 
6M 
12M 
 
1102.1 
1035.6 
1024.3 
 
1094.4 
1083.7 
1083.7 
 
1153.5 
1162.8 
1182.7 
 
1135.3 
1148.3 
1129.9 
 
1104.2 
1075.9 
1050.2 
 
1091.2 
1114.9 
1120.2 
 
1090.3 
* 
966.0 
 
1088.4 
1064.1 
1114.3 
 
1135.7 
1142.5 
1147.3 
 
1158.3 
1157.7 
1161.3 
 
1187.1 
1181.0 
1151.8 
Mus-CSA(mm²)  
BL 
6M 
12M 
 
4210.5 
5158.5 
5454.5 
 
3017.5 
3210.0 
3373.2 
 
4948.7 
5370.7 
5578.7 
 
5781.0 
6958.5 
7055.2 
 
3675.2 
3790.5 
4028.5 
 
4665.2 
4520.7 
4587.0 
 
3740.5 
* 
4238.2 
 
6183.5 
6303.2 
6492.7 
 
5360.1 
6007.2 
5392.0 
 
5483.5 
5340.5 
4228.5 
 
4430.2 
5460.5 
6152.5 
Fat-CSA(mm²)  
BL 
6M 
12M 
 
2204.2 
2061.8 
2074.5 
 
892.0 
985.5 
1026.0 
 
1818.7 
1992.8 
1898.7 
 
1931.0 
2138.0 
2075.0 
 
1365.5 
1621.7 
1540.2 
 
2152.2 
1790.0 
1812.5 
 
1497.5 
* 
1366.2 
 
1808.5 
1905.7 
1994.5 
 
2763.0 
3505.0 
3475.0 
 
1509.0 
2149.2 
3101.2 
 
1755.5 
1984.7 
1828.7 
Crt-BA(mm²)  
BL 
6M 
12M 
 
207.7 
215.0 
207.5 
 
137.7 
134.0 
131.0 
 
290.2 
316.3 
318.2 
 
373.7 
380.0 
376.2 
 
157.2 
161.5 
172.2 
 
283.0 
280.5 
275.5 
 
223.7 
* 
170.0 
 
339.2 
367.7 
375.2 
 
367.0 
355.0 
362.0 
 
268.5 
275.0 
281.2 
 
345.5 
325.0 
324.0 
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Figure 5.4.19: Individual changes in pQCT tibial total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral density (TrbBMD (mg/cm³) at 4%, cortical  
bone mineral density (CrtBMD (mg/cm³), Stress-strain index (SSI (mm³) at 38% at BL, 6M & 12M following treatment with biologic therapy in paediatric CD 
patients 
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Figure 5.4.20: Individual changes in pQCT tibial muscle cross-sectional area (Mus-CSA (mm²), fat cross-sectional area (Fat-CSA (mm²) and 
cortical bone area (Crt-BA (mm²) at BL, 6M & 12M following treatment with biologic therapy in paediatric CD patients 
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Table 5.4.25: Change tibia total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral density (TrbBMD (mg/cm³) at 4%, cortical bone 
mineral density (CrtBMD (mg/cm³), Stress-strain index (SSI (mm³) at 38%, muscle cross-sectional area (Mus-CSA (mm²), fat cross-sectional area 
(Fat-CSA (mm²) and cortical bone area (Crt-BA (mm²) at 66% of tibial length at BL,6M &12M following biologic therapy in paediatric patients with 
CD (median-range) 
 
Value 
 
 
BL 
N,11 
 
6M 
N,11 
 
12M 
N,11 
p-Value 
 
     BL-6M                   BL-12M     
%change 
 
BL-6M               BL-12M 
               p-Value 
 
   BL-6M                 BL-12M 
 Tibia 
   
  
    
TotBMD(mg/cm³) 245 
(181,313) 
260 
(209,316) 
260 
(208,317) 
0.03 0.10 5.8 
(-4.6,15.1) 
5.8 
(-10.6,26.2) 
0.03 0.06 
TrbBMD(mg/cm³) 190 
(140,251) 
189 
(173,249) 
187 
(150,249) 
0.30 0.75 0.9 
(-7.4,24.1) 
-0.8 
(-9.2,23.6) 
0.30 0.75 
SSI(mm³) 1125 
(411,1711) 
1182 
(517,1809) 
1189 
(581,1777) 
0.22 0.04 1.4 
(-11.8,42.2) 
6.5 
(5.2,41.2) 
0.22 0.01 
CrtBMD(mg/cm³) 1104 
(1088,1187) 
1129 
(1036,1181) 
1120 
(966,1183) 
0.47 0.10 -0.3 
(-6.0,2.2) 
-0.5 
(-11.4,2.7) 
0.47 0.39 
Mus-CSA(mm²) 4665 
(3018,6184) 
5356 
(3210,6959) 
5392 
(3373,7055) 
0.02 0.04 7.4 
(-3.1,23.3) 
11.8 
(-16.8,38.9) 
0.02 0.04 
Fat-CSA(mm²) 1809 
(892,2763) 
1971 
(986,3505) 
1899 
(1026,3475) 
0.04 0.08 10.6 
(-16.8,42.4) 
7.5 
(-15.8,105.5) 
0.04 0.10 
Crt-BA(mm²) 283 
(138,374) 
298 
(134,380) 
281 
(131,376) 
0.35 0.96 2.1 
(-5.9,8.9) 
-0.1 
(-24.0,10.6) 
0.96 0.47 
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Figure 5.4.21: Percentage (%) change in tibia tibial total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral density (TrbBMD 
(mg/cm³) at 4%, cortical bone mineral density (CrtBMD (mg/cm³), Stress-strain index (SSI (mm³) at 38% of tibial length at BL, 6M &12M following 
treatment with biologic therapy in paediatric patients with CD (median-range) 
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Figure 5.4.22:Percentage (%) change in tibia muscle cross-sectional area (Mus-CSA (mm²), fat cross-sectional area (Fat-CSA (mm²) and cortical 
bone area (Crt-BA (mm²)  at 66% of tibial length at BL, 6M &12M following treatment with biologic therapy in paediatric patients with CD (median-
range) 
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5.4.11.2 Radius bone and muscle parameters 
As mentioned in methods bone and muscle parameters of non-dominant radius were also 
measured by pQCT. Individual changes in total bone mineral density (TotBMD (mg/cm³), 
trabecular bone mineral density (TrbBMD (mg/cm³) at 4%, cortical bone mineral density 
(CrtBMD (mg/cm³), Stressstrain index (SSI (mm²) , muscle cross-sectional area (Mus-CSA 
mm²), fat cross-sectional area (Fat-CSA mm²) and cortical bone area (Crt-BA (mm²) at 66% 
of tibial length are presented in (Table 5.4.26; Figure 5.5.23-24). Median (range) radius 
TotBMD (mg/cm³) remained unchanged from 254(183,296) at BL to 253(195,353) at 6M 
(p=0.12) and 255(190,290) at 12M(p=0.16). The median TrbBMD (mg/cm³) also remain 
unchanged from 147(93,209) at BL, to 145(93,202) at 6M(p=0.68) and 143(113,184) at 
12M(p=0.89). Median SSI (mm²) was 156(89,330) at BL, 184(73,326) at 6M(p=0.68) and 
159(89,323) at 12M(p=0.75). Median CrtBMD (mg/cm³) was 1020(947,1155) at BL, 
1058(946,1171) at 6M(p=0.50) and 1023(852,1167) at 12M(p=0.82). Median Mus-CSA (mm²) 
changed from 1827(1216,2848) at BL to 2219(1369,3094) at 6M (p=0.01) and 
2539(1203,4238) at 12M(p=0.08). Median Fat-CSA (mm²) was 695(684,1231) at BL, 
871(600,1817) at 6M(p=0.26) and 758(366,2204) at 12M(p=0.68). Median Crt-BA (mm²) was 
106(68,164) at BL, 131(59,156) at 6M(p=0.62) and 133(26,170) at 12M (p=0.59), respectively 
(Table 5.4.27). The median percentage change of TotBMD (mg/cm³) from BL to 6M was 
5.5%(-15.7,37.9)(p=0.06) and from BL to 12M was 2.0%(-3.9,29.2)(p=0.16).  
Median percentage change of TrbBMD (mg/cm³), from BL to 6M was 0.1%(-
15.1,37.4)(p=0.56) and from BL to 12M was 2.5%(- 24.1,20.6)(p=0.89). Median percentage 
change of SSI (mm³) from BL to 6M was 0.7%(- 40.2,46.3)(p=0.68) and from BL to 12M was 
5.1%(-31.2,17.9)(p=0.68). Median percentage change of CrtBMD (mg/cm³) from BL to 6M 
was 1.4%(-7.2,11.2)(p=0.56) and from BL to 12M was 1.1%(-16.1,10.3)(p=0.89). Median 
percentage of Mus-CSA (mm²) from BL to 6M was 14.6%(-6.4,37.1)(p=0.01) and from BL to 
12M was 16.8%(-25.7,184)(p=0.08). Median percentage of Fat-CSA from BL to 6M was 
9.1%(-48.7,223)(p=0.14) and from BL to12M was 2.6%(-64.2,149)(p=0.35). Median 
percentage of Crt-BA (mm²) changed from BL to 6M was 1.4%(- 13.9,27.1)(p=0.50) and from 
BL-12M was 0.3%(-61.9,12)(p=0.50), respectively (Table 5.4.27;Figure 5.4.25-6). 
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Table 5.4.26: Individual change radius total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral density (TrbBMD (mg/cm³) at 4%, 
cortical bone mineral density (CrtBMD (mg/cm³), Stress-strain index (SSI (mm³), muscle cross-sectional area (Mus-CSA (mm²), fat cross-sectional 
area (Fat-CSA (mm²) and cortical bone area (Crt-BA (mm²) at 66% of radius length at BL,6M &12M following biologic therapy in paediatric 
patients with CD 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
TotBMD(mg/cm³) 
BL 
6M 
12M 
 
183.2 
194.6 
236.8 
 
262.3 
253.1 
282.2 
 
256.1 
253.2 
255.4 
 
231.0 
240.1 
235.7 
 
253.8 
267.7 
245.3 
 
191.1 
206.5 
189.9 
 
200.1 
216.5 
222.3 
 
245.0 
315.0 
289.5 
 
275.5 
261.7 
272.9 
 
296.0 
301.2 
284.4 
 
258.5 
243.6 
288.6 
TrbBMD(mg/cm³) 
BL 
6M 
12M 
 
108.7 
115.2 
116.5 
 
165.5 
176.9 
178.8 
 
141.9 
138.6 
130.5 
 
146.7 
131.7 
150.4 
 
147.2 
202.3 
143.2 
 
93.3 
93.4 
112.6 
 
143.7 
176.6 
151.9 
 
188.2 
164.3 
142.9 
 
146.9 
145.1 
146.9 
 
209.1 
177.3 
184.0 
 
118.2 
137.6 
131.9 
 
SSI(mm³) 
BL 
6M 
12M 
 
166.6 
167.9 
149.0 
 
121.9 
72.8 
89.3 
 
189.5 
218.1 
207.6 
 
329.6 
326.1 
323.4 
 
88.5 
87.9 
94.8 
 
160.2 
186.2 
128.8 
 
184.0 
177.0 
126.6 
 
191.4 
151.9 
200.9 
 
175.7 
183.7 
192.5 
 
202.1 
206.2 
214.4 
 
134.8 
197.3 
159.0 
CrtBMD(mg/cm³)  
BL 
6M 
12M 
 
1020.0 
945.8 
862.6 
 
947.1 
957.1 
851.5 
 
1073.9 
1103.4 
1130.5 
 
1129.4 
1081.9 
1071.5 
 
990.6 
975.6 
988.5 
 
973.8 
1082.4 
1074.8 
 
1052.1 
1030.5 
882.5 
 
954.0 
991.1 
1042.3 
 
1154.5 
1170.5 
1167.3 
 
1020.3 
1058.4 
1032.5 
 
1096.2 
1128.7 
1116.5 
Mus-CSA(mm²)  
BL 
6M 
12M 
 
1619.0 
2219.0 
1202.5 
 
1359.0 
1368.8 
1588.5 
 
2480.0 
2512.8 
2539.0 
 
2291.5 
3094.0 
3393.5 
 
1216.0 
1449.0 
1437.0 
 
1826.5 
1932.5 
2052.2 
 
1494.7 
1731.2 
4238.2 
 
2847.7 
2967.7 
2762.7 
 
1589.0 
1937.2 
2000.2 
 
2670.7 
2498.5 
2591.0 
 
2141.0 
2453.5 
2649.7 
Fat-CSA(mm²)  
BL 
6M 
12M 
 
1023.5 
966.3 
365.7 
 
661.0 
695.0 
552.5 
 
1230.7 
984.5 
766.7 
 
676.7 
871.0 
801.5 
 
744.0 
812.2 
757.7 
 
1170.5 
600.2 
649.2 
 
689.7 
879.2 
1334.5 
 
694.5 
740.5 
712.7 
 
1195.2 
1817.2 
2204.2 
 
284.0 
915.2 
706.0 
 
605.5 
793.5 
977.7 
Crt-BA(mm²)  
BL 
6M 
12M 
 
105.2 
99.0 
58.5 
 
68.2 
58.7 
26.0 
 
102.7 
130.5 
132.7 
 
164.0 
155.7 
164.5 
 
73.7 
73.5 
57.5 
 
129.2 
131.2 
129.0 
 
99.0 
105.0 
170.0 
 
125.7 
127.5 
139.5 
 
150.0 
146.0 
150.2 
 
105.5 
132.5 
120.7 
 
125.5 
134.2 
143.0 
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Figure 5.4.23: Individual change radius total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral density (TrbBMD (mg/cm³) at 4%, 
cortical bone mineral density (CrtBMD(mg/cm³), Stress-strain index (SSI (mm³) 66%, at BL, 6M & 12M following treatment with biologic therapy in paediatric CD 
patients 
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Figure 5.4.24: Individual changes in pQCT radius muscle cross-sectional area (Mus-CSA (mm²), fat cross-sectional area (Fat-CSA (mm²) and cortical bone area 
(Crt-BA (mm²) 66% site, at BL, 6M & 12M following treatment with biologic therapy in paediatric CD patients 
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Table 5.4.27: change radius total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral density (TrbBMD (mg/cm³) at 4%, cortical 
bone mineral density (CrtBMD (mg/cm³), Stress-strain index (SSI (mm³), muscle cross-sectional area (Mus-CSA (mm²), fat cross-sectional area 
(Fat-CSA (mm²) and cortical bone area (Crt-BA (mm²) at 66% of radius length at BL,6M &12M following biologic therapy in paediatric patients with 
CD (median-range) 
 
Value 
 
 
BL 
N,11 
 
6M 
N,11 
 
12M 
N,11 
p-Value 
 
     BL-6M                   BL-12M     
%change 
 
BL-6M               BL-12M 
               p-Value 
 
    BL-6M                BL-12M 
 Radius 
   
  
    
TotBMD(mg/cm³) 354 
(183,296) 
253 
(195,353) 
355 
(190,290) 
0.12 0.16 5.5 
(-15.7,37.9) 
2.0 
(-3.9,29.2) 
0.06 0.16 
TrbBMD(mg/cm³) 147 
(93,209) 
145 
(93,202) 
143 
(113,184) 
0.68 0.89 0.1 
(-15.1, 37.4) 
2.5 
(-24.1,20.6) 
0.56 0.89 
SSI(mm³) 156 
(89,330) 
184 
(73,326) 
159 
(89,323) 
0.68 0.75 0.7 
(-40.2,46.3) 
5.1 
(-31.2,17.9) 
0.68 0.68 
CrtBMD(mg/cm³) 1020 
(947,1155) 
1058 
(946,1171) 
1023 
(852,1167) 
0.50 0.82 1.4 
(-7.2,11.2) 
1.1 
(-16.1,10.3) 
0.56 0.89 
Mus-CSA(mm²) 1827 
(1216,2848) 
2219 
(1369,3094) 
2539 
(1203,4238) 
0.01 0.08 14.6 
(-6.4,37.1) 
16.8 
(-25.7,184) 
0.01 0.08 
Fat -CSA(mm²) 695 
(284,1231) 
871 
(600,1817) 
758 
(366,2204) 
0.26 0.68 9.1 
(-48.7,223) 
2.6 
(-64.2,149) 
0.14 0.35 
Crt-BA(mm²) 106 
(68,164) 
131 
(59,156) 
133 
(26,170) 
0.62 0.59 1.4 
(-13.9,27.1) 
0.3 
(-61.9,12) 
0.50 0.68 
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Figure 5.4.25: Percentage (%) change in radius total bone mineral density (TotBMD (mg/cm³), trabecular bone mineral density (TrbBMD (mg/cm³) at 4%, cortical 
bone mineral density (CrtBMD (mg/cm³), Stress-strain index (SSI (mm³) 66% site at BL, 6M &12M following treatment with biologic therapy in paediatric patients 
with CD (median-range) 
12M6M
30
20
10
0
-10
%
C
h
a
n
g
e
 
T
t
-
B
M
D
(
m
g
/
c
m
³
)
-
B
L
t
o
1
2
M
p=0.12
p=0.16
-------------------------------------------------------------------------------------------------
                   
12M6M
40
30
20
10
0
-10
-20
-30
%
C
h
a
n
g
e
 
T
r
b
-
B
M
D
(
m
g
/
c
m
³
)
-
B
L
t
o
1
2
M
p=0.56
p=0.89
------------------------------------------------------------------------------------------------
 
                                   
12M6M
20
10
0
-10
-20
-30%
C
h
a
n
g
e
 
S
S
I
(
m
m
³
)
-
 
B
L
 
t
o
 
1
2
M
p=0.68 p=0.68
------------------------------------------------------------------------------------------------
                 
12M6M
10
5
0
-5
-10
-15
-20
%
C
h
a
n
g
e
 
C
r
t
-
B
M
D
(
m
g
/
c
m
³
)
-
B
L
t
o
1
2
M p=0.56 p=0.89
------------------------------------------------------------------------------------------------
 
  
235 
Figure 5.4.26: Percentage (%) change in radius muscle cross-sectional area (Mus-CSA (mm²), fat cross-sectional area (Fat-CSA (mm²) and cortical bone area (Crt-
BA (mm²) at 66% of radius length at BL, 6M &12M following treatment with biologic therapy in paediatric patients with CD (median-range) 
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5.4.11.3 Height corrected radius pQCT parameters 
The radius pQCT outcome measure (bone and muscle) were adjusted for height. Individual 
changes in height-adjusted z-scores for radius total bone mineral density (TotBMD z-score 
(SD), trabecular bone mineral density (TrbBMD z-score (SD) at 4%, cortical bone mineral 
density (CrtBMD z-score (SD), Stress-strain index (SSI z-score (SD), muscle cross-sectional 
area (Mus-CSA z-score (SD), fat cross-sectional area (Fat-CSA z-score (SD) and cortical 
bone area (Crt-BA z-score (SD) and muscle bone cross-sectional area (Mus-bone CSA z-
score (SD) at 66% of radius length at BL,6M &12M are presented in (Table 5.4.28;Figure 
5.4.27-7).The height-adjusted z-scores for radius pQCT bone and muscle parameters did not 
change significantly and remained below zero throughout the study interval. The median 
(range) TotBMD z-score (SD) were -1.6(-2.8,-0.5) at BL, -2.0(-2.9,0.3) a6M (p=0.83) and -
1.5(-3.3,-0.3) at12M(p=0.75). Median TrbBMD z-score (SD) were -1.6(- 3.9,0.0) at BL,-1.6(-
3.5,0.1) at 6M (p=0.68) and -2.0(-2.8,-0.7) at 12M (p=0.89). Median CrtBMD z-score (SD) 
were -0.5(-2.3,2.0) at BL, 0.0(-2.2,2.5) at 6M(p=0.56) and -0.5(-4.8,2.0) at 12M(p=0.35). 
Median SSI z-score (SD) were -1.2(-2.6,1.2) at BL, -1.8(-3.0,0.2) at 6M(p=0.06) and -2.0(-
3.4,0.0) at 12M(p=0.18). Median Mus-CSA z-score (SD) were -2.4(- 4.3,-0.9) at BL, -2.2(-3.2,-
0.5) at 6M(p=0.45) and -1.9(-4.3,-0.8) at 12M(p=0.68). Median Fat-CSA z-score (SD) were -
0.5(-1.5,-0.8) at BL, -0.4(-2.4,-2.0) at 6M (p=0.82) and -0.2(- 1.0,1.08) at 12M(p=0.50). 
Median Crt-BA z-score (SD) were -2.2(-3.9,-0.4) at BL, -1.9(-4.1,-  0.7) at 6M(p=0.76) and -
2.8(-6.9,-0.8) at 12M(p=0.10). Median Mus-bone CSA z-score (SD) were -0.3(-1.9,3.9) at BL, 
-0.5(-2.4,1.7) at 6M(p=0.32) and -0.4(-6.2,1.7) at 12M(p=0.12) respectively (Table 5.4.29). 
 
5.4.11.4 Association between musculoskeletal parameters & disease activity 
5.4.11.4.1 Radius musculoskeletal parameters & disease activity 
A significant negative association was observed between greater PCDAI score and radius 
TotBMD (mg/cm³) and TrbBMD z-scores at BL only (r,0.54;p=0.01),(r,0.45;p=0.02) and with 
Crt-BA z-scores at 6M (r,0.48;p=0.01). No significant correlation was observed between 
CrtBMD, Mus-CSA, Fat-CSA, Mus-bone-CSA z-scores with PCDAI at BL, 6M and 12M. 
Association between radius musculoskeletal parameters and inflammatory markers were also 
observed. TotBMD Zscore and TrbBMD Zscore also had a significant negative association 
with CRP at BL (0.39;p=0.03), (r,0.36;p=0.048) and a significant positive association with ALB 
at BL (r,0.38;p=0.04),(0.36;p=0.048) and SSI z-scores with ALB at at BL(r,0.36;p=0.049). No 
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significant correlation was observed between CrtBMD, Mus-CSA, Fat-CSA and Mus bone-
CSA z-scores with ALB, ESR and CRP at BL, 6M and 12M. 
 
5.4.11.4.2 Tibia musculoskeletal parameters & disease activity 
No significant association was observed between tibia TotBMD (mg/cm³), TrbBMD (mg/cm³), 
CrtBMD (mg/cm³), SSI (mm³), Crt-BA (mm²), Mus-CSA (mm²) and Fat-CSA (mm²) with 
PCDAI at BL, 6M and 12M. No association was observed between TotBMD (mg/cm³), 
CrtBMD (mg/cm³), Crt-BA (mm²), SSI (mm³), Mus-CSA (mm²) with ALB, ESR and CRP at BL, 
6M and 12M. However, positive association was observed between TrbBMD (mg/cm³), and 
ALB at BL(r,0.40;p=0.03) and Fat-CSA (mm²)  with ALB at 6M(r,0.52;p=0.04). 
 
5.7.2.2.3 Radius musculoskeletal parameters & growth 
Association between radius musculoskeletal parameters and growth in terms of HV (cms/yr) 
and HtSDS and BMISDS were also observed at BL, 6M and 12M. No significant association 
was observed between radius TotBMD(mg/cm³),, TrbBMD(mg/cm³),, SSI (mm³), Crt-BA 
(mm²), and Mus-CSA z-scores with BMISDS, HtSDS and HV at BL, 6M and 12M. A negative 
significant association was observed between CrtBMD z-scores and HV(cms/yr)  at 6M 
(r,0.37;p=0.04), and 12M (r,0.45;p=0.02) and a positive association between HtSDS at BL 
(r,0.61;p=0.004)  and 6M (r,0.36;p=0.049). Fat-CSA-z-scores also had a positive significant 
association with HtSDS at 6M(r,0.39;p=0.03) but not with BMISDS and HV(cms/yr). A positive 
association was observed between Mus-bone CSA z-scores with BMISDS at 12m 
(r,0.31;p=0.049) and with HtSDS at BL (r,0.41;p=0.03) and 12M(r,0.42;p=0.03) respectively. 
 
5.7.2.2.4 Tibia musculoskeletal parameters & growth 
Association between tibia musculoskeletal parameters and growth in terms of HV (cms/yr) 
and HtSDS and BMISDS were also observed at BL, 6M and 12M.Tibia TotBMD (mg/cm³),  
was associated positively with HtSDS at only 12M (r,0.37;p=0.04). TrbBMD (mg/cm³) and 
Fat-CSA (mm²) did not show any association with HV (cms/yr), HtSDS and BMISDS. A 
positive significant association was observed between SSI (mm³) and HtSDS at 
BL(r,0.52;p=0.01) and 12M(r,0.42;p=0.03). A negative significant association was observed 
between CrtBMD (mg/cm³) and HV (cms/yr) at 6M (r,0.49;p=0.02) and 12M(r,0.39;p=0.03). A 
significant positive association was observed between CrtBMD (mg/cm³) and HtSDS at BL 
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(r,0.59;p=0.005), 6M(r,0.57;p=0.01) and 12M(r,0.39;p=0.03). A positive significant association 
was observed between Mus-CSA (mm²) and BMISDS at 12M (r,0.49;p=0.01) and HtSDS at 
6M (r,0.65;p=0.005)and 12M(r,0.46;p=0.02) respectively. 
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Table 5.4.28: Individual change radius height-adjusted z-scores (SD) for total bone mineral density (TotBMD), trabecular bone mineral density 
(TrbBMD) at 4%, cortical bone mineral density (CrtBMD), Stress-strain index (SSI), muscle cross-sectional area (Mus-CSA), fat cross-sectional 
area (Fat-CSA) and cortical bone area (Crt-BA) and muscle bone cross-sectional area (Mus-Bone CSA) at 66% of radius length at BL,6M &12M 
following biologic therapy in paediatric patients with CD 
 
Pt.No 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 Radius  
           
TotBMD SDS 
BL 
6M 
12M 
 
-2.8 
-2.6 
-1.6 
 
-0.8 
-1.1 
-0.3 
 
-2.2 
-2.3 
-2.5 
 
-2.0 
-2.0 
-2.2 
 
-1.1 
-0.6 
-1.2 
 
-2.8 
-2.9 
-3.3 
 
-2.4 
-2.0 
-1.9 
 
-1.4 
0.3 
-0.8 
 
-1.2 
-1.6 
-1.5 
 
-0.5 
-0.6 
-1.1 
 
-1.6 
-2.0 
-1.4 
TrbBMD SDS 
BL 
6M 
12M 
 
-2.0 
-2.6 
-2.5 
 
-1.0 
-0.7 
-0.7 
 
-2.0 
-2.0 
-2.0 
 
-2.1 
-2.8 
-2.1 
 
-1.5 
0.1 
-1.6 
 
-3.9 
-3.5 
-2.8 
 
-1.6 
-0.7 
-1.5 
 
-0.4 
-1.2 
-2.2 
 
-1.5 
-1.6 
-1.5 
 
0.0 
-1.1 
-1.0 
 
-3.2 
-2.5 
-2.5 
 SSI SDS 
BL 
6M 
12M 
 
-0.5 
-0.6 
-1.1 
 
-2.1 
-3.0 
-2.6 
 
-2.5 
-2.2 
-2.6 
 
0.5 
0.2 
0.0 
 
-2.6 
-2.8 
-2.7 
 
-1.4 
-2.3 
-3.4 
 
-0.7 
-1.0 
-2.0 
 
-1.1 
-1.8 
-1.4 
 
1.2 
-1.6 
-1.3 
 
-1.2 
-1.3 
-1.3 
 
-2.5 
-1.8 
-2.6 
CrtBMD SDS 
BL 
6M 
12M 
 
-0.3 
-2.2 
-4.8 
 
-1.7 
-1.5 
-3.6 
 
-0.5 
0.2 
0.9 
 
1.9 
0.3 
-0.2 
 
-0.8 
-1.0 
-0.7 
 
-2.3 
-0.1 
-0.5 
 
0.8 
0.2 
-3.1 
 
-1.6 
-1.1 
-0.4 
 
2.0 
2.5 
2.0 
 
-0.7 
0.0 
-1.0 
 
0.8 
1.7 
1.0 
Mus-CSA SDS 
BL 
6M 
12M 
 
-1.9 
-0.5 
-4.3 
 
-2.6 
-2.5 
-1.8 
 
-1.6 
-1.7 
-1.6 
 
-2.4 
-1.0 
-0.8 
 
-3.0 
-2.2 
-2.2 
 
-1.4 
-2.2 
-1.9 
 
-2.5 
-2.2 
-3.2 
 
-0.9 
-0.9 
-1.8 
 
-4.3 
-3.2 
-2.8 
 
-0.9 
-1.3 
-1.3 
 
-3.2 
-2.8 
-2.4 
Fat-CSA SDS 
BL 
6M 
12M 
 
-0.2 
-2.4 
-0.8 
 
-0.5 
-0.9 
-0.5 
 
0.8 
-0.2 
0.1 
 
-0.4 
-0.2 
0.0 
 
-0.4 
-0.6 
-0.2 
 
-0.5 
-0.9 
-1.0 
 
-1.0 
-0.2 
-0.5 
 
-0.5 
-0.4 
-0.3 
 
-0.5 
2.0 
1.0 
 
-1.5 
-0.5 
-0.1 
 
-0.6 
0.2 
-0.2 
Crt-BA SDS 
BL 
6M 
12M 
 
-0.4 
-1.5 
-3.9 
 
-3.4 
-4.1 
-6.9 
 
-3.9 
-2.8 
-2.7 
 
-1.5 
-1.9 
-1.8 
 
-3.0 
-3.0 
-4.6 
 
-0.7 
-0.7 
-0.8 
 
-2.2 
-1.9 
-3.7 
 
-2.3 
-2.9 
-2.8 
 
-0.8 
-1.1 
-0.8 
 
-2.1 
-1.3 
-2.4 
 
-3.7 
-3.4 
-3.0 
Mus-bone CSA SDS 
       BL 
6M 
       12M 
 
0.7 
-1.8 
-1.1 
 
-1.5 
-2.4 
-6.2 
 
-1.9 
-0.5 
-0.4 
 
1.4 
0.0 
-0.4 
 
-0.3 
-1.5 
-2.9 
 
-0.3 
1.2 
0.5 
 
0.6 
0.0 
-2.6 
 
-0.9 
-1.1 
0.1 
 
3.9 
1.7 
1.7 
 
-1.6 
-0.5 
-0.9 
 
-0.1 
-0.4 
0.3 
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Figure 5.4.27:Change in radius height-adjusted z-score(SD) for total bone mineral density (TotBMD), trabecular bone mineral density (TrbBMD) at 4%,cortical 
bone mineral density (CrtBMD), Stress-strain index (SSI) 66% at BL,6M &12M following biologic therapy in paediatric patients with CD 
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Figure 5.4.28:Change in radius height-adjusted z-scores (SD) for muscle cross-sectional area (Mus-CSA), fat cross-sectional area (Fat-CSA) and  cortical bone 
area (Crt-BA) and muscle bone area (Mus-BoneCSA) at 66% of tibial length at BL,6M &12M following biologic therapy in paediatric patients with CD (median-
range) 
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Table 5.4.29: Change in radius height-adjusted z-score(SD) total bone mineral density (TotBMD), trabecular bone mineral density (TrbBMD) at 
4%, cortical bone mineral density (CrtBMD), Stress-strain index (SSI), muscle cross-sectional area (Mus-CSA), fat cross-sectional area (Fat- 
CSA),cortical bone area (Crt-BA) and muscle bone cross-sectional area (Mus-Bone CSA)at 66% of tibial length at BL,6M &12M following biologic 
therapy in paediatric patients with CD (median-range) 
 
Value 
 
 
BL 
 
6M 
 
12M 
p-Value 
 
      BL-6M                          BL-12M 
Tot density z-score (SD) -1.6 
(-2.8,-0.5) 
-2.0 
(-2.9,0.3) 
-1.5 
(-3.3,-0.3) 
0.83 0.75 
Trb density z-score (SD) -1.6 
(-3.9,0.0) 
-1.6 
(-3.5,0.1) 
-2.0 
(-2.8,-0.7) 
0.68 0.89 
SSIPOL3 z-score (SD) -1.2 
(-2.6,1.2) 
-1.8 
(-3.0,0.2) 
-2.0 
(-3.4,0.0) 
0.06 0.18 
Crt density z-score (SD) -0.5 
(-2.3,2.0) 
0.0 
(-2.2,2.5) 
-0.5 
(-4.8,2.0) 
0.56 0.35 
Muscle Area z-score (SD) -2.4 
(-4.3,-0.9) 
-2.2 
(-3.2,-0.5) 
-1.9 
(-4.3,-0.8) 
0.45 0.68 
Fat Area z-score (SD) -0.5 
(-1.5,0.8) 
-0.4 
(-2.4,2.0) 
-0.2 
(-1.0,1.0) 
0.82 0.50 
Bone Area z-score (SD) -2.2 
(-3.9,-0.4) 
-1.9 
(-4.1,-0.7) 
-2.8 
(-6.9,-0.8) 
0.76 0.10 
MUS Bone Area z-score (SD) -0.3 
(-1.9,3.9) 
-0.5 
(-2.4,1.7) 
-0.4 
(-6.2,1.7) 
0.32 0.12 
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5.4.12 Changes in bone metabolism 
5.4.12.1 Changes in bone specific alkaline phosphatse 
Individual changes in serum bone specific alkaline phosphatase (BALP (µg/l) are presented in 
(Table 5.4.30;Figure 5.4.29). Median (range) BALP (µg/l) changed from 21.3(9.2,70.5) at BL 
to 16.9 (7.9,77.3) at 2wk (p=0.56), 26.7(7.6,88.7) at 6wk(p=0.045), 28.1(5.5,117.5) at 
6M(p=0.01) and 38.3(10.9,110.5) at 12M(p=0.03) (Table 5.8.2). The median percentage 
change of BALP(g/l)from BL to 2wk was -1.5%(-30.8,63.7) (p=0.62), from BL to 6wk was 
14.8%(-9.6,248.3)(p=0.02), from BL to 6M was 68.1%(-40.5,210.5) (p=0.01) and from BL to 
12M was 128.7%(-67.2,592.5)(p=0.01),respectively (Table 5.4.32;Figure 5.4.30). 
 
5.4.12.2 Changes in cross linked C-telopeptide of type I collagen 
Individual changes in serum cross linked C-telopeptide of type I collagen (CTX-1(ng/ml) are 
presented in (Table 5.4.30;Figure 5.4.29). Median (range) CTX-1(ng/ml) was 0.73(0.22,2.41) 
at BL, 0.87(0.22,2.29) at 2wk (p=0.82), 0.95(0.36,2.29) at 6wk(p=0.30), 1.21(0.73,2.35) at 
6M(p=0.04) and 1.08(0.29,2.01) at 12M(p=0.50) (Table 5.8.2). The median percentage 
change of CTX-1(ng/ml) from BL to 2wk was -7.9%(-65.4,271.3) (p=0.96), from BL to 6wk 
was 13.6%(-35.1,124.9)(p=0.14), from BL to 6M was 62.1%(-17.4,263.9) (p=0.03) and from 
BL to 12M was 19.9%(-50.9,823.7)(p=0.26) respectively, (Table 5.4.32;Figure 5.4.30). 
 
5.4.12.3 Association of bone markers and disease activity 
A significant negative association was observed between BALP(µg/l) and PCDAI at BL 
(r,0.46;p=0.02) only and there was no significant association between BALP(µg/l) and ESR, 
CRP and ALB at BL, 2wk, 6wk 6M and 12M. No significant association was observed 
between CTX-1(ng/ml) and PCDAI, ESR,CRP and ALB at BL, 2wk, 6wk 6M and 12M. 
5.4.12.4 Association of bone markers and growth 
A significant positive association was observed between BALP (µg/l) and HV (cms/yr) at 6M 
(r,0.55;p=0.01) and 12M (r,0.35;p=0.049). No significant association was observed between 
CTX-1(ng/ml) and HV (cms/yr) or HtSDS at BL, 6M and 12M. 
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Table 5.4.30: Individual changes in bone-specific alkaline phosphatase (BALP(µg/l) and cross linked C-telopeptide of type I collagen (CTX-
1(ng/ml) at BL, 2wk,6wk, 6M &12M during biologic therapy in paediatric patients with CD 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
BALP(µg/l) 
BL 
2wk 
6wk 
6M 
12M 
 
12.8 
14.7 
51.2 
- 
88.8 
 
24.5 
16.9 
16.8 
27.4 
56.1 
 
12.6 
16.9 
19.1 
21.4 
13.0 
 
9.24 
7.9 
7.6 
5.5 
43.2 
 
25.1 
24.7 
26.7 
28.7 
38.2 
 
9.76 
8.6 
22.8 
16.2 
25.2 
 
28.6 
46.8 
84.6 
88.7 
103.9 
 
70.4 
77.3 
88.7 
117.7 
23.1 
 
10.3 
9.4 
8.5 
24.1 
10.8 
 
21.2 
18.7 
29.9 
48.2 
110.5 
 
25.1 
30.6 
45.8 
42.6 
35.1 
CTX-1(ng/ml) 
BL 
2wk 
6wk 
6M 
12M 
 
1.27 
0.95 
1.82 
* 
1.52 
 
0.85 
0.29 
0.64 
0.73 
1.41 
 
0.47 
0.83 
0.94 
1.26 
1.29 
 
1.66 
0.86 
0.80 
1.37 
0.96 
 
0.73 
0.85 
0.72 
1.37 
0.68 
 
0.56 
0.88 
2.04 
1.16 
0.80 
 
2.40 
1.01 
2.29 
2.35 
1.69 
 
0.61 
2.29 
1.48 
1.03 
1.07 
 
0.59 
0.47 
0.98 
0.82 
0.29 
 
0.21 
0.22 
0.35 
0.79 
2.00 
 
0.98 
0.91 
0.78 
1.55 
0.90 
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Figure 5.4.29: Individual changes in bone-specific alkaline phosphatase (BALP(µg/l) and cross linked C-telopeptide of type I collagen (CTX-
1(ng/ml) at BL, 2wk,6wk, 6M &12M during biologic therapy in paediatric patients with CD 
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Table 5.4.31: Change in bone-specific alkaline phosphatase (BALP(µg/l) and cross linked C-telopeptide of type I collagen (CTX-1(ng/ml) at BL, 
2wk,6wk, 6M &12M during biologic therapy in paediatric patients with CD during biologic therapy in paediatric patients with CD (median-range) 
 
 
Value 
 
 
BL 
N,11 
 
 
2wk 
N,11 
 
 
6wk 
N,11 
 
 
6M 
N,11 
 
 
12M 
N,11 
p-Value 
 
    BL -2wk           BL- 6wk            BL -6M                BL-12M 
 
BALP(µg/L) 
 
21.3 
(9.2,70.5) 
 
16.9 
(7.9,77.3) 
 
26.7 
(7.6,88.7) 
 
28.1 
(5.5,117.7) 
 
38.3 
(10.9,110.5) 
 
0.56 
 
0.045 
 
0.01 
 
0.03 
 
CTX-1(ng/ml) 
 
 
0.73 
(0.22,2.41) 
 
0.87 
(0.22,2.29) 
 
0.95 
(0.36,2.29) 
 
1.21 
(0.73,2.35) 
 
1.08 
(0.29,2.01) 
 
0.82 
 
0.30 
 
0.04 
 
0.50 
 
 
 
Table 5.4.32: Percentage (%) change in bone-specific alkaline phosphatase (BALP(µg/l) and cross linked C-telopeptide of type I collagen (CTX-
1(ng/ml) at BL, 2wk, 6wk, 6M &12M during biologic therapy in paediatric patients with CD during biologic therapy in paediatric patients with CD 
(median-range) 
 
 
Value 
%Change 
 
          BL -2wk              BL- 6wk                  BL -6M                 BL-12M 
p-Value 
 
BL -2wk               BL- 6wk          BL -6M              BL-12M 
 
BALP(µg/L) 
 
 
-1.5 
(-30.8,63.7) 
 
14.8 
(-9.6,248.3) 
 
68.1 
(-40.5,210.5) 
 
128.7 
(-67.2,592.5) 
 
0.62 
 
0.02 
 
0.01 
 
0.01 
 
CTX-1(ng/ml) 
 
 
-7.9 
(-65.4,271.3) 
 
13.6 
(-35.1,124.9) 
 
62.1 
(-17.4,263.9) 
 
19.9 
(-50.9,823.7) 
 
0.96 
 
0.14 
 
0.03 
 
0.26 
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Figure 5.4.30: Percentage (%) changes in bone-specific alkaline phosphatase (BALP(µg/l) and cross linked C-telopeptide of type I collagen (CTX-
1(ng/ml) from BL to 2wk,6wk, 6M &12M during biologic therapy in paediatric patients with CD 
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5.4.13 Changes in markers of growth hormone secretion 
5.4.13.1 Changes in Insulin like growth factor-I (IGF-1) 
Individual changes in IGF-I ng/ml and IGF-1SDS height-age and chronological-age-matched 
are presented in (Table 5.4.33; Figure 5.5.31). Median (range) IGF-I ng/ml remained 
unchanged from 286(68,682) at BL to 300(82,649) at 2wk (p=0.56), 258(50,623) at 
6wk(p=0.35), 259(151,624) at 6M(p=0.68) and 303(141,524) at 12M (p=0.56). IGF-1 was 
converted to height-age and chronological-age-matched standard deviation scores (IGF-
1SDS). Median IGF-1SDS ht-age-matched was also unchanged at -0.3(-2.4,2.3) at BL , -0.4(-
2.8,1.9) at 2wk(p=0.91), -0.3(-3.2,1.2) at 6wk(p=0.48), -0.2(-2.6,1.8) at 6M(p=0.90) and -0.5(-
3.3,2.1) at 12M (p=0.68). Median IGF-1SDS chronological age-matched did not change from 
-0.2(-4.2,1.7) at BL to -1.0(-3.6,1.5) at 2wk(p=0.89), -0.8(-5.2,1.4) at 6wk(p=0.44), -0.7(-
2.3,1.2) at 6M(p=0.87) and -1.1(-3.6,1.0) at 12M (p=0.62)(Table 5.4.34).The median 
percentage change of IGF-I (ng/ml) from BL to 2wk was -4.8%(-32.7,122.6) (p=0.82), from BL 
to 6wk was -3.9%(-42.2,90.6)(p=0.82), from BL to 6M was -0.5%(-56.5,251.9)(p=0.83) and 
from BL to 12M was -13.7%(-61.8,413.1)(p=0.89)(Table 5.4.35; Figure 5.4.35). 
5.4.13.2 Association of IGF-1 and disease activity 
A significant negative association was observed between IGF-I(ng/ml) and PCDAI score at 
2wk(r,0.60;p=0.005) and a positive association was observed between IGF-I ng/ml and ALB 
at BL (r,0.59;p=0.005), at 2wk(r,0.36;p=0.49) and 12M(r,0.44;p=0.02). 
5.4.13.3 Association of IGF-1 and growth 
A significant negative association was observed between IGF-I(ng/ml) and HtSDS at 
BL(r,0.37;p=0.04). IGF-1 ng/ml levels were lower in patients who had low HtSDS (Figure 
5.4.33). 
5.4.13.4 Association of IGF-ISDS height-age-matched and disease activity 
A significant negative association was observed between IGF-ISDS ht-age-matched and 
PCDAI score BL(r,0.38;p=0.04), at 2wk(r,0.43;p=0.02) and at 6wk(r,0.41;p=0.03). A 
significant negative association was also observed between IGF-ISDS ht-age-matched and 
ESR at BL(r,0.57;p=0.01), at 2wk(r,0.51;p=0.01) and at 6wk(r,0.46;p=0.02), IGF-ISDS ht-age-
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matched and CRP at 2wk(r,0.47;p=0.01) and a significant positive association was observed 
between IGF-ISDS ht-age-matched and ALB at BL(r,0.44;p=0.02). 
5.4.13.5 Association of IGF-ISDS height-age-matched and growth 
A significant negative association was observed between IGF-ISDS ht-age-matched and 
change in HtSDS (∆HtSDS) at BL(r,0.66;p=0.004). However, no significant association was 
observed between IGF-ISDS ht-age-matched with HV(cms/yr) at BL, 6M or 12M. 
5.4.13.6 Association of IGF-ISDS age-matched and disease activity 
A significant negative association was observed between IGF-ISDS chronological-age-
matched and PCDAI score at 2wk(r,0.58;p=0.006) and at 6wk(r,0.51;p=0.01). A significant 
negative association was also observed between IGF-ISDS chronological-age-matched and 
ESR at BL(r,0.54;p=0.01) and at 2wk(r,0.48;p=0.01) and with CRP at BL(r,0.036;p=0.049)and 
a significant positive association was observed between IGF-ISDS chronological-age-
matched and ALB at BL(r,0.57;p=0.007), at 2wk(r,0.48;p=0.02) and at 6wk(r,0.36;p=0.048). 
 
5.9.1.4 Association of IGF-ISDS age-matched and growth 
A significant negative association was observed between IGF-ISDS chronological-age-
matched and change is HtSDS (∆HtSDS) at BL(r,0.43;p=0.03). However, no significant 
association was observed between IGF-ISDS chronological-age-matched with HV(cms/yr) at 
BL, 6M or 12M. 
5.4.13.7 Changes in Insulin like growth factor binding proteins 
Individual changes in insulin like growth factor binding protein 3 (IGFBP-3 (ng/ml), IGFBP-3 
SDS height-age and chronological-age-matched and insulin like growth factor binding protein 
2 (IGFBP-2 (ng/ml) are presented in (Table 5.4.33;Figure 5.4.33-34). Median (range) IGFBP-
3 (ng/ml) did not change with 3.8(1.7,5.9) at BL to 3.3(2.4,4.2) at 2wk(0.32), 3.3(2.1,4.5) at 
6wk(p=0.18), 3.4(2.1,4.5) at 6M(p=0.50) and 3.3(2.5,5.8) at 12M (0.79). Median IGFBP-3-
SDS ht-age-matched did not change from 0.1(-2.8,2.4) at BL to 0.0(-0.7,1.2) at 2wk(p=0.47), 
0.0(-0.9,1.5) at 6wk(p=0.23), 0.1(-2.1,2.6) at 6M (p=0.81), and 0.0(-1.3,2.0) at 12M(p=0.82). 
Median IGFBP-3-SDS chronological-age-matched remained unchanged from 0.5(-2.9,2.2) at 
BL to -0.2(-1.4,1.1) at 2wk(p=0.39),-0.2(-1.9,1.4) at 6wk(p=0.18), 0.0(-2.0,1.1) at 6M (p=0.68), 
and 0.0(-1.2,2.3) at 12M(p=0.82)(Table 5.4.34). The median percentage change of IGFBP-3 
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(ng/ml) from BL and 2wk was -5.7(-44.1,64.7) (p=0.50), from BL to 6wk was -8.7%(-
44.1,76.5)(p=0.56), from BL to 6M was -6.5%(-58.0,70.6) (p=0.83) and from BL to 12M was -
11.7%(-50.0,64.7)(p=0.89)(Table 5.9.3;Figure 5.9.4). Median (range) IGFBP-2 (ng/ml) did not 
change from 713.1(237.5, 1460) at BL to 764.1(153,1307) at 2wk(p=0.90), 
561.8(242.4,864.1) at 6wk(p=0.16), 606.5(106.3,877.3) at 6M(p=0.12) and 374.1(198.3,1089) 
at 12M (p=0.04) (Table 5.4.34; Figure 5.9.34). The median percentage change of IGFBP-2 
(ng/ml) from BL and 2wk was 0.7(-35.6,25.1) (p=0.75), from BL to 6wk was -7.2%(-
59.2,58.5)(p=0.39), from BL to 6M was -16.3%(-65.4,91.9) (p=0.15) and from BL to 12M was 
-46.3%(- 65.4,47.1)(p=0.045)(Table 5.4.35;Figure 5.4.35). 
5.4.13.8 Association of IGFBPs and disease activity 
A significant negative association was observed between IGFBP-3-SDS ht-age-matched and 
PCDAI score at BL(r,0.59;p=0.006) and CRP at BL(r,0.42;p=0.01) and significant positive 
association with ALB at BL(r,0.49;p=0.01). A significant positive association was observed 
between IGFBP-2 and PCDAI score at 2wk(r,0.61;p=0.004) and 12M(r,0.36;p=0.048) and a 
negative association between IGFBP-2 (ng/ml) and ALB at 12M(r,0.68;p=0.002). 
5.4.13.9 Association of IGFBPs and growth 
A significant positive association was observed between IGFBP-3-SDS ht-age-matched and 
HV(cms/yr) at 12M only (r,0.47; p=0.01). A significant negative association was observed 
between IGFBP-2 (ng/ml) and HV (cms/yr) at 6M only (r,0.52; p=0.01). 
5.4.13.10 Changes in acid labile subunits 
Individual changes in acid labile subunits (ALS (ng/ml) are presented in (Table 5.4.33; Figure 
5.4.34). The median (range) ALS (ng/ml) was 1607(612,4291) at BL, 1633(724,8516) at 
2wk(p=0.89), 1910(527,3366) at 6wk(p=0.75), 1732(736,2633) at 6M(p=0.26), 
1693(766,2530) at 12M(p=0.39)(Table 5.4.34). The median percentage change of ALS 
(ng/ml) from BL and 2wk was -0.8%(-83.1,123) (p=1.0), from BL to 6wk was -9.3%(-
235.9,365)(p=0.89), from BL to 6M was -8.4%(-47.3,105.4)(p=0.35) and from BL to 12M was 
-10.9%(-49.1,84.3)(p=0.045)( Table 5.4.35; Figure 5.4.35). 
 
 
  
251
 
5.9.3.1 Association of acid labile subunits and disease activity 
No significant association was observed between ALS (ng/ml) and PCDAI score at anytime 
point. However a significant positive association was observed with ALB at 
BL(r,0.67;p=0.002) and at 12M(r,0.41;p=0.03). 
 
 
5.9.3.2 Association of acid labile subunits and growth 
A significant positive association was observed between ALS (ng/ml) and HtSDS at 
BL(r,0.49; p=0.01), 6M(r,0.66;p=0.004) and 12M(r,0.61;p=0.004). No significantly association 
was observed between ALS (ng/ml) and HV(cms/yr at BL,6M and 12M. 
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Table 5.4.33: Individual change in Insulin like growth factor-I (IGF-1 (ng/ml), Insulin like growth factor-I height-age and chronological-age-matched 
standard deviation scores (IGF-ISDS ht-age-matched and IGF-1SDS age-matched), Insulin like growth factor binding protein-3 (IGFBP-3(ng/ml), 
Insulin like growth factor binding protein-3 ht-age-matched and chronological-age-matched standard deviation scores (IGFBP-3SDS ht-age-matched 
IGFBP-3SDS  age matched), Insulin like growth factor binding protein-2 (IGFBP-2 (ng/ml), and acid labile subunits (ALS (ng/ml) at BL, 2wk, 6wk, 6M 
& 12M following treatment with biologic therapy in paediatric patients with CD 
 
Pt.No 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
IGF-1(ng/ml) 
BL 
2wk 
6wk 
6M 
12M 
 
12.49 
171.6 
238.0 
* 
477.1 
 
67.6 
82.3 
49.6 
238 
347 
 
368.5 
286.8 
354.1 
260.4 
140.8 
 
285.5 
192.2 
347.0 
354.1 
248.7 
 
236.4 
300.2 
242.9 
151.0 
152.8 
 
144.8 
322.3 
257.8 
242.9 
242.3 
 
171.2 
157.8 
172.9 
257.8 
193.2 
 
397.9 
400.9 
366.7 
172.9 
343.3 
 
682 
649.1 
623.8 
366.7 
523.5 
 
652.5 
564.6 
448.4 
623.8 
331.7 
 
433.3 
363.7 
250.3 
448.4 
303.4 
IGF-1 Ht-age-matched SDS 
BL 
2wk 
6wk 
6M 
12M 
 
-1.6 
-0.7 
0.1 
* 
1.2 
 
-2.4 
-1.8 
-3.2 
1.0 
2.1 
 
-0.3 
-1.1 
-0.4 
-1.4 
-3.3 
 
-1.5 
-2.8 
-0.8 
-0.7 
-2.0 
 
1.0 
1.7 
1.1 
-0.4 
-0.5 
 
-2.0 
0.4 
-0.3 
-0.5 
-0.5 
 
-0.9 
-1.2 
-0.9 
0.1 
-1.2 
 
0.2 
0.2 
0.0 
-2.6 
-0.8 
 
0.0 
0.0 
0.0 
0.0 
0.0 
 
2.3 
1.9 
1.2 
1.8 
-0.3 
 
0.2 
-0.4 
-1.8 
0.6 
-0.8 
IGF-1 age-matched SDS 
BL 
2wk 
6wk 
6M 
12M 
 
-2.4 
-1.6 
-0.8 
* 
0.7 
 
-4.2 
-3.6 
-5.2 
-0.7 
0.0 
 
-0.2 
-1.1 
-0.3 
-1.4 
-3.6 
 
-1.4 
-2.8 
-0.8 
-0.7 
-1.9 
 
0.6 
1.3 
0.6 
-1.2 
-1.4 
 
-3.9 
-1.0 
-1.8 
-1.9 
-1.7 
 
-1.0 
-1.3 
-1.0 
0.0 
-1.3 
 
0.4 
0.4 
0.1 
-2.3 
-0.7 
 
1.7 
1.5 
1.4 
-0.6 
1.0 
 
1.4 
0.9 
0.2 
1.2 
-0.9 
 
0.0 
-0.6 
-1.9 
0.2 
-1.1 
IGFBP-3 (ng/ml) 
BL 
2wk 
6wk 
6M 
12M 
 
2.6 
3.6 
4.4 
* 
4.1 
 
2.6 
2.4 
2.1 
4.4 
2.8 
 
5.0 
3.9 
3.8 
2.1 
2.5 
 
4.1 
3.3 
2.8 
3.8 
3.4 
 
2.5 
2.7 
2.9 
2.9 
3.2 
 
1.7 
2.8 
3.0 
2.9 
2.8 
 
4.3 
4.2 
4.5 
3.0 
5.8 
 
4.3 
3.7 
3.5 
4.5 
3.5 
 
3.8 
3.7 
3.6 
3.5 
3.3 
 
5.9 
3.3 
3.3 
3.6 
3.4 
 
3.5 
3.3 
3.2 
3.3 
3.1 
IGFBP-3 Ht-age-matched SDS 
2wk 
6wk 
6M 
12M 
 
-0.8 
0.6 
1.5 
* 
0.8 
 
0.1 
-0.2 
-0.9 
2.6 
0.3 
 
1.5 
0.5 
0.4 
-2.1 
-1.3 
 
0.7 
-0.2 
-0.9 
0.4 
0.0 
 
-0.1 
0.3 
0.6 
0.3 
0.6 
 
-2.8 
-0.7 
-0.4 
-0.6 
-0.7 
 
1.3 
1.2 
1.5 
-0.4 
2.3 
 
0.9 
0.3 
0.1 
1.1 
0.1 
 
0.0 
0.0 
0.0 
0.0 
0.0 
 
2.4 
-0.1 
-0.1 
0.2 
-0.1 
 
0.1 
-0.1 
-0.3 
-0.1 
-0.3 
IGFBP-3 age-matched SDS 
BL 
 
-1.1 
 
-1.0 
 
1.6 
 
0.7 
 
-0.9 
 
-2.9 
 
1.3 
 
1.0 
 
0.5 
 
2.2 
 
0.1 
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2wk 
6wk 
6M 
12M 
0.3 
1.1 
* 
0.7 
-1.4 
-1.9 
1.1 
-0.8 
0.6 
0.5 
-2.0 
-1.2 
-0.2 
-0.9 
0.4 
0.0 
-0.6 
-0.3 
-0.4 
0.0 
-0.8 
-0.5 
-0.7 
-0.8 
1.1 
1.4 
-0.4 
2.3 
0.3 
0.1 
1.1 
0.1 
0.4 
0.2 
0.1 
0.0 
-0.2 
-0.2 
0.2 
-0.1 
-0.2 
-0.3 
-0.2 
-0.4 
IGFBP-2(ng/ml) 
         BL 
2wk 
6wk 
6M 
12M 
 
965.8 
117.2 
483.6 
* 
374.0 
 
1460.0 
1306.8 
533.3 
845.8 
504.6 
 
819.0 
825.3 
728.9 
877.3 
1089.5 
 
713.1 
832.0 
842.5 
735.8 
572.6 
 
528.9 
461.8 
428.4 
485.1 
777.3 
 
896.6 
696.5 
767.0 
748.5 
478.3 
 
628.0 
786.1 
674.8 
526.8 
337.0 
 
756.8 
509.4 
561.8 
385.1 
323.1 
 
357.6 
374.7 
299.3 
686.1 
198.3 
 
237.5 
152.9 
242.4 
106.3 
277.5 
 
679.5 
764.4 
864.1 
414.5 
352.1 
ALS(mU/ml) 
BL 
2wk 
6wk 
6M 
12M 
 
1308.4 
1633.2 
1915.7 
* 
2411.2 
 
829.3 
822.6 
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Figure 5.4.31: Individual change in Insulin like growth factor-I (IGF-1 (ng/ml), Insulin like growth factor-I height-age and chronological-age-matched standard 
deviation scores (IGF-ISDS ht-age-matched and IGF-1SDS age-matched) at BL, 2wk, 6wk, 6M & 12M following treatment with biologic therapy in paediatric patients 
with CD 
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Figure 5.4.32: Association between height standard deviation score (HtSDS) and (insulin like growth factor-1) IGF-1(ng/ml) 
 
 
7006005004003002001000
2
1
0
-1
-2
-3
IGF-I (ng/ml)-B L
H
t
S
D
-
B
L
r,0.37
p=0.04
 
256 
Figure 5.4.33: Individual change in Insulin like growth factor binding protein-3 (IGFBP-3(ng/ml),, Insulin like growth factor binding protein-3 ht-age-matched 
and chronological-age-matched standard deviation scores (IGFBP-3SDS ht-age-matched IGFBP-3SDS age-matched)  at BL, 2wk, 6wk, 6M & 12M following 
treatment with biologic therapy in paediatric patients with CD 
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Figure 5.4.34: Individual change in insulin like growth factor binding protein-2 (IGFBP-2 (ng/ml), and acid labile subunits (ALS (ng/ml) at BL, 
2wk, 6wk, 6M & 12M following treatment with biologic therapy in paediatric patients with CD 
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Table 5.4.34:Changes in Insulin like growth factor-I (IGF-1 (ng/ml), Insulin like growth factor-I height-age and chronological-age-matched standard 
deviation scores (IGF-ISDS ht-age-matched and IGF-1SDS age-matched), Insulin like growth factor binding protein-3 (IGFBP-3(ng/ml), Insulin like 
growth factor binding protein-3 ht-age-matched and chronological-age-matched standard deviation scores (IGFBP-3SDS ht-age-matched IGFBP-
3SDS  age matched), Insulin like growth factor binding protein-2 (IGFBP-2 (ng/ml), and acid labile subunits (ALS (ng/ml) at BL, 2wk, 6wk, 6M & 12M 
following treatment with biologic therapy in paediatric patients with CD (median-range) 
 
 
Value 
 
 
BL 
N,11 
 
 
2wk 
N,11 
 
 
6wk 
N,11 
 
 
6M 
N,11 
 
 
12M 
N,11 
p-Value 
 
BL -2wk      BL- 6wk       BL -6M     BL-12M 
 
IGF-1(ng/ml) 
 
 
286 
(68,682) 
 
300 
(82,649) 
 
258 
(49.6,623) 
 
259 
(151,624) 
 
303 
(141,524) 
 
0.56 
 
0.35 
 
0.68 
 
0.56 
 
IGF-1 Ht-age-matched SDS 
 
 
 
-0.3 
(-2.4,2.3) 
 
-0.4 
(-2.8,1.9) 
 
-0.3 
(-3.2,1.2) 
 
-0.2 
(-2.6,1.8) 
 
-0.5 
(-3.3,2.1) 
 
0.91 
 
0.48 
 
0.90 
 
0.68 
 
IGF-1S age-matched SDS 
 
 
 
-0.2 
(-4.2,1.7) 
 
-1.0 
(-3.6,1.5) 
 
-0.8 
(-5.2,1.4) 
 
-0.7 
(-2.3,1.2) 
 
-1.1 
(-3.6,1.0) 
 
0.89 
 
0.44 
 
0.87 
 
0.62 
 
IGFBP-3(ng/ml) 
 
3.8 
(1.7,5.9) 
 
3.3 
(2.4,4.2) 
 
3.3 
(2.1,4.5) 
 
3.4 
(2.1,4.5) 
 
3.3 
(2.5,5.8) 
 
0.32 
 
0.18 
 
0.50 
 
0.79 
 
IGFBP-3 Ht-age-matched SDS 
 
 
 
0.1 
(-2.8,2.4) 
 
0.0 
(-0.7,1.2) 
 
0.0 
(-0.9,1.5) 
 
0.1 
(-2.1,2.6) 
 
0.0 
(-1.3,2.0) 
 
0.47 
 
0.23 
 
0.81 
 
0.83 
 
IGFBP-3 age-matched SDS 
 
 
 
0.5 
(-2.9,2.2) 
 
-0.2 
(-1.4,1.1) 
 
-0.2 
(-1.9,1.4) 
 
0.0 
(-2.0,1.1) 
 
0.0 
(-1.2,2.3) 
 
0.39 
 
0.18 
 
0.68 
 
0.82 
 
IGFBP-2(ng/ml) 
 
713.1 
(237.5,1460) 
 
764.1 
(153,1307) 
 
561.8 
(242.4,864.1) 
 
606.5 
(106.3,877.3) 
 
374.1 
(198.3,1089) 
 
0.96 
 
0.16 
 
0.12 
 
0.04 
 
ALS(ng/ml) 
 
 
1607 
(612,4291) 
 
1633 
(724,8516) 
 
1910 
(527,3366) 
 
1732 
(736,2633) 
 
1693 
(766,2530) 
 
0.89 
 
0.75 
 
0.26 
 
0.39 
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Table 5.4.35:Percentage (%) change in insulin like growth factor-I (IGF-1 (ng/ml), Insulin like growth factor binding protein-3 (IGFBP-3 (ng/ml), 
Insulin like growth factor binding protein-2 (IGFBP-2 (ng/ml), and acid labile subunits (ALS (ng/ml) at BL, 2wk, 6wk, 6M & 12M following 
treatment with biologic therapy in paediatric patients with CD (median-range) 
 
 
Value 
%Change 
 
           BL-2wk                BL-6wk               BL-6M                  BL-12M 
                                     p-Value 
 
BL -2wk          BL- 6wk         BL -6M             BL-12M 
 
IGF-1(ng/ml) 
 
-7.8 
(-32.7,122.6) 
 
-3.9 
(-42.2,90.6) 
 
-0.5 
(-56.5,251.9) 
 
-13.7 
(-61.8,413.1) 
 
0.82 
 
0.82 
 
0.83 
 
0.89 
 
IGFBP-3(ng/ml) 
 
-5.7 
(-44.1,64.7) 
 
-8.6 
(-44.1,76.5) 
 
-6.5 
(-58.0,70.6) 
 
-11.7 
(-50.0,64.7) 
 
0.50 
 
0.56 
 
0.83 
 
0.89 
 
IGFBP-2(ng/ml) 
 
0.7 
(-35.6,25.1) 
 
-7.2 
(-59.2,58.5) 
 
-16.3 
(-55.2,91.9) 
 
-46.3 
(-65.4,47.1) 
 
0.75 
 
0.39 
 
0.15 
 
0.045 
 
ALS(ng/ml) 
 
-0.8 
(-83.1,123) 
 
-9.3 
(-235.9,365) 
 
-8.4 
(-47.3,105.4) 
 
-10.9 
(-49.1,84.3) 
 
1.00 
 
0.89 
 
0.35 
 
0.68 
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Figure 5.4.35: Percentage (%) change in Insulin like growth factor-I (IGF-1), Insulin like growth factor binding protein-3 (IGFBP-3(ng/ml), Insulin like growth 
factor binding protein-2 (IGFBP-2(ng/ml), and acid labile subunits (ALS (ng/ml) at BL, 2wk, 6wk, 6M & 12M following treatment with biologic therapy in 
paediatric patients with CD (median range) 
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5.4.14 : Infliximab pharmacokinetics 
Changes in Infliximab pharmacokinetics were observed at 2wk, 6wk, 6M and 12M and are 
shown in Table 5.4.36. The results show wide variation in pharmacokinetic levels. Some of 
them are high presuming that these are not trough but peak levels. As the trough levels were 
not reliable therefore it was difficult to observe association between Infliximab 
pharmacokinetic levels and disease activity. 
 
Table 5.4.36 : Pharmacokinetic levels of Infliximab in paediatric patients with CD 
 
Pt.No 
Infliximab (IFX) conc. (µg/mL) 
2wk               2wk                     6wk                       6M                                          12M 
1 37.2 28.2 * 10.6 
2 0.3 0.2 0.4 Stopped IFX/ started ADA 
3 ↑ 7.6 0.1 7.9 
4 ADA ADA ADA ADA 
5 20.5 4.8 0.6 0.4 
6 18.4 11.1 15.5 2.8 
7 ↑ ↑ ↑ ↑ 
8 ↑ ↑ 14.1 ↑ 
9 ↑ ↑ 10.2 ↑ 
10 ↑ 27.7 0.4 Stopped IFX/ started ADA 
11 ↑ 27.6 0.2 1.2 
Median(range) 19.5(0.3,37.2) 11.1(0.2,28.8) 0.5(0.1,15.5) 9.3(0.5,40.3) 
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5.5 Discussion 
In the present study, although with a small sample, treatment with biologic therapy over 
twelve months seems to induce beneficial effects on bone status, muscle function and body 
composition in the majority of children with CD who responded to and tolerated infliximab: it is 
possible that controlling disease activity with biologic therapy may positively outweigh the 
effects of CD on growth, body composition, muscle function and bone health. 
5.5.1 Effect on growth 
This study has shown improvement in both ∆HtSDS and HVcms/yr at 12M, but increase in 
median values did not reach significance as compared to BL. This observation is comparable 
to the results of the previously published studies by our own group (367)and others which 
reported improvement in growth following biologic therapy (156;207;247;279;310-312). 
5.5.2 Effects on bone 
The data demonstrated a significant change and in biomarker of bone formation (BALP) and 
a non-significant change in a biomarker of bone resorption (CTX-1) from BL to 12M. The 
median percentage(%) change of BALP was -1.5%(p=0.62),14.8%(p=0.02), 68.1%(p=0.01) 
and 128.7%(p=0.01) and CTX-1 was -7.9%(p=0.96), 13.6%(p=0.14),62.1%(p=0.03) and 
19.9%(p=0.26) from BL to 2wk 6wk, 6M and 12M, respectively. Moreover, data demonstrated 
that the bone formation marker was lower in patients with greater disease activity at baseline 
as depicted by a significant negative association of BALP and PCDAI score at BL and was 
found to be greater in patients who had a reduction in PCDAI score at 12M following biologic 
therapy. Furthermore, a significant positive association was observed between BALP and HV 
cm/yr at 6M and 12M. However, no association was observed for CTX-1 with PCDAI, 
inflammatory markers and HV. This finding is comparable to the results of previously 
published REACH study (207) which observed changes in the bone biomarkers at week 10 
after Infliximab induction therapy in paediatric patients with CD. In this study Thayu et al (207) 
reported improvement in markers of bone formation, BSAP and P1NP during the 10-week 
interval with the median increase of 87% and 103% respectively (both p<.001). Moreover, 
increase in BSAP at week-10 was significantly associated with the reductions in PCDAI at 
week 10 but no association was observed between changes in PINP and PCDAI. The bone 
resorption markers CTX-1 and DPD also increased significantly during the induction period 
(both p<.001); however, the magnitude of the changes (18% and 23%) were markedly less 
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pronounced than the changes in markers of bone formation. This study also reported 
association of changes in the bone biomarkers with subsequent changes in disease activity 
and linear growth during the 54-week interval after initiation of Infliximab therapy. 
Tumor necrosis factor- α (TNF-α) has direct effects on bone formation by inhibiting osteoblast 
differentiation and osteoblast collagen secretion, causing increased resorption by inducing 
osteoblasts secretion of IL-6, and inducing osteoblast apoptosis (203;204). In addition TNF-α 
promotes accelerated bone resorption by inducing osteoblast secretion of interleukin (IL)-6 
and the expression of the receptor activator of nuclear factor kappa B ligand (RANKL). 
RANKL stimulates osteoclast differentiation and activation and inhibit osteoclast apoptosis 
thereby dramatically increasing osteoclast survival and increasing bone resorption (198;199). 
Adult studies that examined bone formation biomarkers after a single dose of Infliximab 
reported a mean increase in BALP of 15%-18% (206;319;321). The study by Franchimont et 
al (319) demonstrated low formation markers and elevation resorption markers at baseline, 
with a significant further decrease in resorption marker after Infliximab therapy. One study 
reported an increase in resorption markers at baseline and with a significant increase during 
Infliximab induction therapy (322). For conclusive explanation of these changes, it would have 
been useful to have a control group in the study. The results presented here suggest the 
beneficial effect of Infliximab on bone formation might be due to the inhibition of TNF-α or 
through the indirect improvement in disease activity.  
5.5.3 Effect on muscle function 
This is the first study that charts the effect of biologic therapy on changes in lower limb 
muscle function using jumping mechanography in paediatric patients with CD. In our study we 
observed a non significant increase in jump height (m), V-max (m/s), EFI (%), efficiency % 
from BL to 12M following biologic therapy and a significant increase in both F-max (kN), and 
P-max (kW) at 12M. Despite the fact that the increase in efficiency % of the movement was 
not significant but however, the increase was likely to be through improvements in jump 
height and velocity thereby indicating higher muscular flexibility. These data are suggestive of 
an effect of biologic therapy on lower limb muscle function through improvements in the 
mechanical efficiency of the muscle. Thus, it is plausible that the better muscle function that 
we have observed is mediated through the effect of biologic therapy on muscle mass. 
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Moreover, we also observed a significant negative association of jump height (m), V-max 
(m/s, EFI (%), efficiency % with PCDAI at BL which shows the impact of disease activity on 
muscle function in patients with CD. We also observed significant improvement in dominant 
and non dominant MIGF and in age and height adjusted MIGFSDS.  
5.5.4 Effect on body composition 
This study is the first longitudinal study to show the effect of biologic therapy on changes in 
body composition in paediatric patients with CD. The study showed a significant increase in 
FM in paediatric patients with CD following biologic therapy an effect that has not been 
reported extensively in previously published studies. Thayu et al (365) did report a significant 
association between increased FM-ht z-score with cumulative glucocorticoid exposure, 
methotrexate and Infliximab at the end of any given interval but when all three medications 
were included in the same model the effect of Infliximab on FM-ht z-score was found to be 
attenuated. This observation is however, in concordance with the results of adult studies 
which reported a specific effect of anti-TNF treatment on body composition with an increase 
of FM after short term treatment in a group of patients with rheumatoid arthritis (407) and 
spondylarthropathy (408), a study in which  patients gained FM during 2 years of treatment 
with TNF antagonists. As no significant correlation was observed between FM and PCDAI 
score and markers of inflammation therefore increase in FM seems to be an anti-TNF-α 
therapy specific effect. We also observed significant improvement in both FFM and FFMI 
which shows that the treatment with anti-TNF-α therapy also had a significant impact on FFM. 
Our result is consistent with the previously published study in paediatric CD patients (365). 
Thayu et al (365) have shown that the concurrent Infliximab therapy was associated with 
improvement in LM ht-z-scores. 
5.5.5 Effect of GH/IGF-1 system 
In this study no significant change was observed in IGF-1, height-age and chronological-age-
matched IGF-1 SDS, IGFBP-3 and height-age and chronological-age-matched IGFBP-3 SDS 
following biologic therapy. Moreover height-age and chronological-age-matched IGF-1SDS 
and IGFBP-3 SDS remained below zero during the study interval. Our data demonstrated that 
IGF-1 and IGFBP-3 were lower in patients with greater disease activity at BL as depicted by a 
significant negative association of IGF-1 and IGFBP-3 with PCDAI score. Furthermore, a 
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significant positive association was observed between IGF-1 and HtSDS at BL and IGFBP-3 
and HVcm/yr at 12M. A significant negative association was also observed between age and 
height matched IGF-1SDS with PCDAI, ESR, CRP and ALB during induction therapy. Our 
finding is also similar to the previously published data by Vespasiani et al (328) who reported 
a negative association between IGF-1 and IGFBP-3 with CRP in adult CD patients.  
The effect of Infliximab on the GH/IGF-I axis has been assessed in a series of 14 adult IBD 
patients with low levels of IGF-I and IGFBP-3 treated with three induction doses (weeks 0, 2 
and 6) plus two additional infusions every eight weeks (328). Peripheral resistance to GH is 
apparently reversed after the second infusion of Infliximab, as judged by the significant 
increase in the serum levels of IGF-I and IGFBP-3 as compared to baseline. However, this 
effect is not sustained since they return to baseline values between the first and second 
maintenance dose(328). TNF blockade by Infliximab could account for the initial improvement 
of GH sensitivity as increased TNF activity suppresses the GH/IGF-I axis in the liver.  Another 
study conducted by Eivindson et al (329) assessed changes in the IGF system in patients 
with active CD before and during Infliximab treatment and studied 13 patients with therapy 
refractory CD, treated with Infliximab at baseline and after 2 weeks. The IGF system and 
markers of inflammation were examined at baseline, on days 2-5 and after 1, 4, and 8 weeks. 
Ten healthy age- and gender-matched persons served as controls. This study has shown 
treatment with Infliximab normalized circulating levels of total IGF-I and IGFBP-3, and 
partially normalized IGFBP-2, whereas free IGF-I remained suppressed and suggest that the 
changes in the IGF system may be part of the catabolic state in active CD and may have an 
association with metabolic bone disease and muscle wasting (329). 
Children with CD have normal stimulated and spontaneous GH secretion but have reduced 
plasma IGF-1 concentrations and IGFBP concentrations. The reduction in IGF-1 
concentration is mediated by multiple factors including increased cytokines expressed in 
active inflammation and malnutrition (409). The presence of lower levels of inflammatory 
cytokines in paediatric CD has been correlated with increased height velocity. A study by 
Thayu et al (365), which evaluated 78 paediatric patients with CD, showed significantly 
greater IL-6 and TNF-a levels in the CD patients as compared with normal population 
controls. Significantly lower IGF-1 levels and higher IGFBP-3 levels were also present in 
patients with CD compared with controls. The authors correlated increased height velocity in 
this cohort to increased serum IGF-1 and decreased serum levels of TNF-α and IL-6. 
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We observed significant reduction in IGFBP-2 at 12M as compared to BL. Moreover, a 
significant negative association was observed between IGFBP-2 and HVcms/yr at 6M. High 
IGFBP-2 levels have previously been described in IBD (410). IGFBP-2 is known as an 
inhibitor of IGF-1 activities. The elevated circulating IGFBP-2 levels may be caused by a 
certain degree of catabolism induced by inflammation itself. No significant change was 
observed in ALS following biologic therapy. However, we observed a significant positive 
association between ALS and HtSDS at BL, 6M and 12M and with ALB at BL and 12M. As 
the effect of biologic therapy on ALS have not been reported previously in patients with IBD 
therefore it is not possible to compare these results with those of other observations. 
5.5.6 Effect on bone mineral density 
In this study we did not observe any significant change in total body, LS (L2-L4) and proximal 
femur BMD following biologic therapy. Moreover, the bone area adjusted TB-BMCSDS and 
LS-BMCSDS remained below zero throughout the study interval. No significant change was 
observed in LS(L2-L4) and femoral neck BMAD. LS(L2-L4) and femoral neck BMADSDS also 
remained below zero during the study interval. The results of our study are not consistent with 
the previously published studies (324-327). Pazianas et al (325), conducted a retrospective 
study on 61 CD patients who had low BMD. In this study a number of confounding factors 
which could affect study outcome were analyzed including sex, number of postmenopausal 
women, number of women on hormone replacement therapy, glucocorticoid use and 
Infliximab infusions. In this study 23 patients were on Infliximab therapy and 36 patients were 
on bisphosphonates. After controlling for corticosteroid use, patients with concurrent 
Infliximab and bisphosphonate treatment had a greater increase in BMD as compared to 
those who had bisphosphonate alone; corticosteroids inhibited this effect. However, Infliximab 
alone had no effect on BMD(325). Mauro et al(326), conducted a retrospective study of 15 
CD patients who had Infliximab therapy for the first time and who underwent DXA before and 
during Infliximab therapy. These patients were then compared with 30 CD patients who were 
naïve to Infliximab therapy and who had DXA done at least one year apart. Age, gender, age 
at diagnosis, disease duration, final weight, change in weight, disease activity and the use of 
bisphosphonate and corticosteroids were used as confounding factors in this study. Patients 
in this study had Infliximab therapy at intervals of 4-8 weeks for a mean period of 18 months. 
Those patients who had Infliximab therapy had a significant increase in lumbar bone area, 
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BMC and BMD as compared to the control group but these data were not corrected for size. 
The increase in BMC in patients who had Infliximab therapy was significant when compared 
with those who had received glucocorticoid therapy or who had evidence of disease activity 
(326). Bernstein et al(327), also found that the maintenance treatment with Infliximab 
(5mg/kg) at 6-8 weeks interval for 1 year in 46 CD patients resulted in the improvement in 
BMD after 1 year in lumbar spin, at the femoral trochanter and at the femoral neck and this 
effect was independent of the glucocorticoids, calcium supplementation or changes in C-
reactive protein (CRP)(327). Paganelli et al (324) reported increase in bone mineral apparent 
density BMAD in Infliximab treated group than those never treated with Infliximab. This is the 
only study which reported the effect of Infliximab on BMD in children with IBD. It is speculated 
that significant differences in BMD may have been observed if the cohort was larger or had 
been followed up for longer than one year. 
5.5.7 Effect on bone and muscle parameters 
The current prospective study is the first longitudinal study which evaluated bone health using 
pQCT technique for radius and tibia both in children with CD following biologic therapy. We 
observed significant change in TotBMD and percentage change TotBMD of tibia at 6M. SSI 
and percentage change SSI for tibia was also changed significantly at 12M. Mus-CSA and 
percentage change Mus-CSA changed significantly at 6M and 12M. Fat-CSA and percentage 
change Fat-CSA significantly changed at 6M only. Only Mus-CSA and percentage change 
Mus-CSA of radius changed significantly and rest of the parameters did not show any 
significant change. Individual changes in height-adjusted z-scores for radius TotBMD, 
TrbBMD, CrtBMD-z-scores, SSI, Mus-CSA, fat Fat-CSA, Crt-BA and Mus-Bone CSA 
remained below zero throughout the study interval. Tibia bone and muscle parameters with 
did not show any association with PCDAI score. However a positive significant association 
was observed between Tibia TrbBMD and ALB at BL and tibia Fat-CSA with ALB at 6M. A 
significant association was observed between greater PCDAI score and radius TotBMD and 
TrbBMD at BL and with radius CrtBMD at 12M. The improvement in muscle and fat cross 
sectional area reflects the positive impact of biologic therapy on muscle and fat mass.  
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5.5.8 Infliximab pharmacokinetics 
This study could not provide much detail about Infliximab pharmacokinetic levels in children 
with CD due to unreliable “trough” levels therefore future studies are needed looking at 
Infliximab pharmacokinetic levels in children. 
 
5.6 Conclusion  
In conclusion, these prospective studies of growth, body composition and muscle function 
suggests that biologic therapy in children with CD has a beneficial effect on muscle mass and 
muscle function and which can be observed over the first year of therapy but for 
comprehensive conclusion this data needs to be adjusted for body size. These positive 
changes are also associated with an increase in bone turnover where the change in bone 
formation is much greater than bone resorption. These favourable effects on bone health 
were not accompanied by marked changes in BMD as assessed by DXA but did show some 
beneficial effects on pQCT assessed SSI, a surrogate marker of bone strength. The results of 
this preliminary study need to be confirmed in a larger group of children. 
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CHAPTER 6 
 
Conclusion and Future Directions 
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6.1 General discussion and conclusions 
Crohn's disease affects increasing numbers of children worldwide. Growth retardation 
associated with delayed puberty, is a frequent feature in paediatric patients with IBD 
especially CD. Control of disease activity and mucosal healing are paramount to promote 
growth and adequate pubertal onset. Current therapeutic strategies for maintenance in IBD 
include anti-inflammatory drugs, immunosuppressives and more recently, biologics. Although 
these treatments are efficient in minimising inflammation and inducing prolonged remission, 
their long-term effects on growth and final height remain controversial. Biologic drugs present 
remarkable advantages in terms of disease control for children, especially in those whose 
disease cannot be controlled with conventional therapies. Data regarding biologic use in 
children is limited but results have been promising, both in terms of controlling disease 
activity and improving growth parameters. 
Four different studies have been conducted in an attempt to explore the effects of the biologic 
therapy on changes in physical growth, puberty, GH/IGF-1 system, bone health, body 
composition and muscle function in paediatric patients with CD. 
 
In summary the hypothesis explored in the studies that comprised this PhD were: 
1. To summarize and evaluate effects of biologic therapy on growth and skeletal 
development in children with chronic inflammatory conditions 
2. To assess the frequency of short stature and poor growth and their relationship to 
disease course and therapy in children with CD 
3. To assess the effect of Infliximab therapy on growth, puberty and markers of disease 
in children with CD 
4. To assess the effect of Adalimumab therapy on growth in children with CD 
5. To investigate the effect of biologic therapy prospectively on 
a) Physical growth and puberty 
b) Bone mineral density, bone geometry and bone strength 
c) Bone metabolism 
d) GH/ IGF-1 system 
e) Body composition 
f) Muscle function in children with CD 
  
271
Effect of therapeutic interventions on growth in children with CD 
Three different retrospectives studies were conducted to explore the long-term and short-term 
impact of contemporary disease specific therapies, Infliximab therapy and Adalimumab 
therapy on growth and puberty in children with CD. 
The study about the impact of contemporary disease specific therapies in children with CD 
(Chapter 2) provides clear evidence that despite advances in therapy, short stature and slow 
growth continue to be encountered in a sub-group of children with CD. This study examined 
the relationship of a number of factors including therapeutic modalities to two commonly used 
anthropometric markers of growth - HVSDS and ∆HtSDS. The mean HtSDS of the study 
population as well as the percentage of children with HtSDS of less than -2 were similar to 
that reported in other contemporary studies (310;335). HtSDS did not show an improvement 
despite a significant improvement in HVSDS this observation suggest that the reduction in 
growth deceleration, as reflected by an improving HV is not sufficient to improve overall 
height but simply prevents any further deterioration in height. This study recommended that 
the change in HtSDS may be a more valid method of assessing and reporting longitudinal 
growth in children with chronic disease, particularly when there is a high prevalence of 
children of a peripubertal age.  
Several studies have reported the effect of Infliximab therapy on growth in children with CD 
(Section 1.9). The study about the effect of Infliximab therapy on growth in children with CD 
(Chapter 3) supports these findings (233;273;311). This study has shown an average 
improvement of approximately 50% in HV in the 6 months after the initiation of Infliximab 
therapy which was further sustained for a further 6 months. It was also observed that initiation 
of Infliximab was associated with an improvement in growth in those children who had not 
been exposed to exogenous GC at all, is noteworthy, and suggests that the growth-promoting 
effects of Infliximab are not solely due to its ‘GC-sparing effect’. The finding, that growth was 
more likely to improve in those children who were judged to be ‘responders’ also suggests 
that growth improves as a result of improved disease control. Improvement of the disease 
status would be expected to be associated to pubertal progression and improved growth as 
improvement in growth was also observed in children who remained pre-pubertal. Previous 
report of growth following Infliximab therapy have suggested that improvement is more likely 
in those, which are in early puberty (310), and this may be due to the possibility of pubertal 
progress following initiating Infliximab therapy.  
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At present there are no published paediatric studies that adequately assess the effect of 
Adalimumab on linear growth in children with CD. The study about the effect of Adalimumab 
therapy on growth in children with CD (Chapter 4) provides evidence that Adalimumab is 
associated with improvement in short term linear growth in children with CD who enter 
remission but not in those who do not. It is also more likely to happen in children who are on 
immunosuppression and those in early puberty but seems to be relatively independent of 
steroid use. These findings suggest that growth improves as a result of several interrelated 
factors, including improved disease control. Use of co-immunosuppression therapy with 
biologics remains controversial (369). It is also interesting to note that the growth response to 
Adalimumab varied dependent on the reason for discontinuing Infliximab; those who had an 
allergic reaction to Infliximab fared best paralleling preliminary Adalimumab clinical trial data 
suggesting clinical response and remission are higher in patient who are anti-TNF naïve 
rather than those who have had no/lost response to Infliximab previously (376).  
The above mentioned studies provided evidence that short term biologic therapy improves 
growth. Although these studies are reporting short term improvement in growth, future 
prospective studies need to look at final height as an outcome rather than the short term 
changes in height. 
 
The effects of biologic therapy on bone metabolism 
To date, few published studies have examined the effect of anti-TNF-α therapy on bone 
metabolism in patients with IBD and most of the data originate from studies performed in 
adult patients (Section 1.10). This longitudinal study demonstrated a significant increase in 
biomarker of bone formation (BALP) and a non-significant increase in a biomarker of bone 
resorption (CTX-1) from BL to 12M. Moreover, this study depicted that the bone formation 
marker was lower in patients with greater disease activity at baseline as depicted by a 
significant negative association of BALP and PCDAI score at BL and was found to be greater 
in patients who had a reduction in PCDAI score at 12M following biologic therapy. 
Furthermore, a significant positive association was observed between BALP and HV cm/yr at 
6M and 12M. However, no association was observed for CTX-1 with PCDAI, inflammatory 
markers and HV cms/yr. This finding is comparable to the results of previously published 
REACH study (207). Suggesting the beneficial impact of biologic therapy on bone formation 
may be due to the inhibition of proinflammatory cytokine TNF-α or through the indirect 
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improvement in disease activity. A limitation of this study is lack of controls therefore, in order 
to have conclusive explanation of these changes; it would have been useful to have a control 
group in the study. 
 
The effect of biologic therapy on bone geometry and bone mineral density 
This is the first longitudinal observational study which explores the impact of biologic therapy 
on bone geometry and muscle function in children with CD using a novel imaging device, 
pQCT. In this study, pQCT scans for distal radius and tibia did show increase in parameters 
of muscle function and bone strength following biologic therapy in paediatric patients with 
IBD.  It is difficult to compare the results of this study with previous reports and to assess 
sequential changes in bone and muscle parameters following biologic therapy due to the lack 
in currently available data in paediatric population with IBD. 
Moreover, no clear conclusions can be made due to the number of issues and limitations 
related to the use of pQCT in paediatric population. Firstly, the results are not comparable to 
any other study results due to the lack in currently available data regarding the impact of 
biologic therapy on bone geometry and muscle function. Secondly, pQCT reference data for 
children and adolescents are not yet available. Therefore, it is impossible to compare data 
obtained from clinical populations to normative datasets. Large population-based studies of 
healthy children across the growing years are essential to generate a reference data set and 
for determining the clinical application of pQCT technique, in children with chronic 
inflammatory conditions. 
This study did not show significant changes in BMD following biologic therapy in paediatric 
patients with CD. This result is not consistent with the previously published studies in adult 
and paediatric patients both (324-327). This may be due to small size of the cohort moreover; 
changes in BMD following biologic therapy were only assessed at three time points (BL, 6M 
and 12M). A more frequent, and possibly longer, follow-up of patients would provide a more 
comprehensive understanding of the long-term effects of biologic therapy on BMD of the total 
body, lumbar spine, proximal femur and femoral neck.  
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The effect of biologic therapy on body composition 
This study is the first longitudinal prospective study to show the effect of biologic therapy on 
changes in body composition in paediatric patients with CD. The study showed a significant 
increase in FM in paediatric patients with CD following biologic therapy an effect that has not 
been reported extensively in previously published studies. This observation is however, in 
concordance with the results of adult studies which reported a specific effect of anti-TNF 
treatment on body composition with an increase of FM after short term treatment in a group of 
patients with rheumatoid arthritis (407) and spondylarthropathy (408), a study in which  
patients gained FM during 2 years of treatment with TNF antagonists. As no significant 
correlation was observed between FM and PCDAI score and markers of inflammation 
therefore increase in FM seems to be an anti-TNF-α therapy specific effect. We also 
observed significant improvement in both FFM and FFMI which shows that the treatment with 
anti-TNF-α therapy also had a significant impact on FFM. This result is consistent with the 
previously published study in paediatric CD patients (365).  
Although this result is an interesting finding of this study and provide evidence for potential 
benefits of biologic therapy on FM and FFM in paediatric patients with CD. This result needs 
to be interpreted with care as the body composition measurements were not adjusted for 
body size. In growing subjects, body composition measurements must be adjusted to body 
size, specifically height, in addition to age and sex. Future studies should report the impact of 
biologic therapy on body size adjusted measurements of body composition for a better 
conclusion. 
 
The effect of biologic therapy on GH/IGF-1 system 
In this study no significant change was observed in height and age adjusted IGF-1SDS and 
IGFBP-3 SDS following biologic therapy and remained below zero during the study interval. 
IGF-1 and IGFBP-3 levels were lower in patients with greater disease activity at BL as 
depicted by a significant negative association of IGF-1 and IGFBP-3 with PCDAI score. 
Furthermore, a significant positive association was observed between IGF-1 and HtSDS at 
BL and IGFBP-3 and HV cm/yr at 12M. A significant negative association was also observed 
between age and height matched IGF-1SDS with PCDAI, ESR, CRP and ALB during 
induction therapy. Our finding is also similar to the previously published data by Vespasiani et 
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al (328) who reported a negative association between IGF-1 and IGFBP-3 with CRP in adult 
CD patients.  
The effect of Infliximab on the GH/IGF-I axis has been assessed in a series of 14 adult IBD 
patients with low levels of IGF-I and IGFBP-3 treated with three induction doses (weeks 0, 2 
and 6) plus two additional infusions every eight weeks (328). Peripheral resistance to GH is 
apparently reversed after the second infusion of Infliximab, as judged by the significant 
increase in the serum levels of IGF-I and IGFBP-3 as compared to baseline. However, this 
effect is not sustained since they return to baseline values between the first and second 
maintenance dose(328). TNF blockade by Infliximab could account for the initial improvement 
of GH sensitivity as increased TNF activity suppresses the GH/IGF-I axis in the liver.  Another 
study conducted by Eivindson et al (329) assessed changes in the IGF system in patients 
with active CD before and during Infliximab treatment and studied 13 patients with therapy 
refractory CD, treated with Infliximab at baseline and after 2 weeks. The IGF system and 
markers of inflammation were examined at baseline, on days 2-5 and after 1, 4, and 8 weeks. 
Ten healthy age- and gender-matched persons served as controls. This study has shown 
treatment with Infliximab normalized circulating levels of total IGF-I and IGFBP-3, and 
partially normalized IGFBP-2, whereas free IGF-I remained suppressed and suggest that the 
changes in the IGF system may be part of the catabolic state in active CD and may have an 
association with metabolic bone disease and muscle wasting (329). 
Children with CD have normal stimulated and spontaneous GH secretion but have reduced 
plasma IGF-1 concentrations and IGFBP concentrations. The reduction in IGF-1 
concentration is mediated by multiple factors including increased cytokines expressed in 
active inflammation and malnutrition (409). The presence of lower levels of inflammatory 
cytokines in paediatric CD has been correlated with increased height velocity. A study by 
Thayu et al (365), which evaluated 78 paediatric patients with CD, showed significantly 
greater IL-6 and TNF-a levels in the CD patients as compared with normal population 
controls. Significantly lower IGF-1 levels and higher IGFBP-3 levels were also present in 
patients with CD compared with controls. The authors correlated increased height velocity in 
this cohort to increased serum IGF-1 and decreased serum levels of TNF-α and IL-6. 
We observed significant reduction in IGFBP-2 at 12M as compared to BL. Moreover, a 
significant negative association was observed between IGFBP-2 and HVcms/yr at 6M. High 
IGFBP-2 levels have previously been described in IBD (410). IGFBP-2 is known as an 
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inhibitor of IGF-1 activities. The elevated circulating IGFBP-2 levels may be caused by a 
certain degree of catabolism induced by inflammation itself. No significant change was 
observed in ALS following biologic therapy. As the effect of biologic therapy on GH/IGF-1 
system have not been reported previously in paediatric patients with IBD therefore it is not 
possible to compare these results with other reports. The exact interaction between anti-
TNFα therapy and GH/IGF-1 system could be explored in group of paediatric patients with 
IBD in whom there is a continuous supporting evidence of impaired GH/IGF-1 system prior to 
starting biologic therapy.  
 
Infliximab pharmacokinetic levels 
This study could not provide much detail about Infliximab pharmacokinetic levels in paediatric 
patients with CD due to unreliable “trough” levels therefore future studies are needed looking 
at Infliximab pharmacokinetic levels in paediatric patients. 
 
Conclusion  
In conclusion, these prospective studies of growth, body composition and muscle function 
has clearly shown that biologic therapy in children with CD has a beneficial effect on muscle 
mass and muscle function and which can be observed over the first year of therapy but these 
observation needs to be interpreted with care as the measurements were not adjusted for 
body size. These positive changes are also associated with an increase in bone turnover 
where the change in bone formation is much greater than bone resorption. These favourable 
effects on bone health were not accompanied by marked changes in BMD as assessed by 
DXA but did show some beneficial effects on pQCT assessed SSI, a surrogate marker of 
bone strength. The results of this preliminary study need to be confirmed in a larger group of 
children. 
 
Clinical implications 
1. Markers of bone formation and bone resorption can be useful to determine the bone 
metabolism in children with IBD and may be used to explore the mechanism of bone 
loss in these children. It is easy to measure them, and the results are easy to 
construe. At present, these markers are only used in research. It is advisable to use 
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them in routine clinical practice in order to evaluate the impact of treatment particularly 
with glucocorticoids and anti-TNF-α on bone turnover.  
2. Body composition measurements and specifically FM and FFM measurements would 
be useful to provide appropriate treatment to paediatric patients with bone mass 
deficits. Moreover, body composition measurements should be adjusted for body size 
particularly in growing children these measurements should be adjusted for height 
along with sex and age. 
3. It is also recommended that clinical studies should report growth changes in terms of 
change in HtSDS. As change in HtSDS may be a more valid method of assessing and 
reporting longitudinal growth in children with chronic disease, particularly when there 
is a high prevalence of children of a peripubertal age. This will also allow comparison 
with studies that report results of endocrine growth promoting therapy. 
4. BMD should be monitored in all children with IBD. It is therefore important for 
paediatric gastroenterologist to focus on the prevention of generalized bone loss, 
particularly in those patients with long-term disease, recurrent flare-ups and 
glucocorticoid users. 
 
Future directions 
The studies in this thesis are cohort studies without appropriate control groups, which makes 
it tough to draw clear-cut conclusions from them. However they raise questions for further 
research to expand and explain the results. Multicentre prospective studies are essential to 
achieve better recruitment and acquire adequate sample sizes. Further, well-designed 
prospective studies on effect of biologics on growth and skeletal development are required. 
An improved understanding of the effect of biologic therapy may improve future therapy 
directed at promoting growth and skeletal development in a diverse group of children. Further 
studies are required to understand the duration of the window of opportunity during which 
linear growth, bone and muscle mass in children with CD can be optimised. It will also be 
useful to follow-up patient cohort for longer than one year in order to observe significant 
changes in BMD following biologic therapy. There is a need to explore biomarkers that 
identify children who are at risk for growth retardation, bone and muscle mass deficits.  
Future studies may also look at the impact of biologic therapy on changes in calprotectin 
levels as a marker for the presence and severity of gastrointestinal inflammation in IBD. 
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Moreover, future studies should be conducted to observe relationship between Infliximab 
pharmacokinetic levels and disease activity in patients with paediatric CD. Determination of 
antibodies against Infliximab would also be helpful to decide about continuation of biologic 
therapy and will further clarify the clinical use of these antibodies. It will also be worthy to 
determine the predictors of response for long-term anti-TNF-α therapy. 
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Appendix A 
Inclusion/exclusion criteria 
Biologics in Crohn’s Disease (BCD Study) 
Exclusion Inclusion criteria 
  
 
Screening date:-------------- 
Patient ID: ------------------ 
Patient Initials:  
      
 
DOB: 
     
 
Inclusion/exclusion 
 
Confirmed IBD diagnosis                                  □No   □ Yes    
   
Children on the same biologic over                □No   □ Yes    
Prior six months 
Age 6-18 years at start of biologic                   □No   □ Yes         
therapy                                                 
  
Adults more than 18 years at start of             □No   □ Yes    
Biologic therapy  
  
Comments: 
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Appendix B 
Study information sheet for the child under 8yrs 
    
STUDY INFORMATION SHEET FOR THE CHILD UNDER 8 YRS 
The effects of biologic therapy on linear growth, puberty and bone health in 
children with Crohn's disease (CD) 
 
We would like to ask you to take part in a study. This sheet will tell you more about the study. 
Do read this sheet or ask your Mum and Dad to read it to you. 
1. What happens to growth and bones in children with Crohn’s disease? 
       Crohn’s Disease can sometimes affect your growth or your bones.  
2. What is this study about? 
       Some medicines for Crohn’s Disease may help your growth and bones. We want to find 
out if this really happens. 
3. Why have you been chosen? 
       We know that your doctor has decided to start you on one of these medicines. 
4. What will happen to me if I take part? 
       We would like to measure your size. Also we would like to take a sample of your poo and 
wee. We will also take a sample from the blood that your doctors take when you come to 
the clinic. To check your bones, we will also take some special X-rays and scans of your 
body. There are no extra jags. 
5. What do I have to do? 
        If you want to take part, let your Mum or Dad know.  
6. Do I have to take part? 
       YOU DO NOT HAVE TO SAY ‘YES’. You can also change your mind later and decide to 
stop taking part. 
7. What happens if you are not happy with anything?  
 Ask your Mum or Dad to talk to us. 
8. Who is organizing the study? 
The study is being organized by Doctor Faisal Ahmed and the doctors you meet in your 
clinic. You can talk to them as well as your parents. 
 
You can keep this sheet with you.  
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Appendix C 
Study information sheet for the child under 8-14yrs 
 
 
STUDY INFORMATION SHEET FOR THE CHILD 8-14 YRS 
The effects of biologic therapy on linear growth, puberty and bone health in 
children with Crohn's disease (CD) 
 
We would like to ask you to take part in a study.  This study is done to see how a group of 
new medicines (biologics) affect growth and bones in children with Crohn’s disease. Before 
you decide you need to find out more about this study. Please read this sheet carefully and 
discuss it with your parents. Take your time and ask us if anything is not clear. 
 
1. What happens to growth and bones in children with Crohn’s disease? 
Children with Crohn’s disease often do not grow as well as healthy children and their 
bones might be weaker. This is due to the effects of some substances (called 
cytokines) that are increased in children with Crohn’s disease. Steroid medicines that 
are sometimes used can also slow growth and affect the bones.  
2. What is this study about? 
We want to find out how some medicines, called biologics, which are used to treat 
Crohn’s disease can help your growth and your bones. 
3. Why have you been chosen? 
We know that your doctor has decided to start you on a biologic medicine as part of 
your clinical care.  
4. What will happen to me if I take part? 
If you agree to take part, you will have measurements of your growth, height and 
weight, at 5 time points i.e. at the time of first infusion, after 2 weeks, 6 weeks, 6 
months and 12 months. On these occasions, we will also take some stool and urine 
samples and takes some blood (2 teaspoons) samples too. All the blood samples will 
be collected when you are having blood collected for other reasons. You will not 
notice anything different and will not need any extra jags. At the start and 6 months, 
and 12 months after your first biologic treatment, we will also check an x ray of your 
left hand to check the amount of growth there is. On these occasions, you will also 
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have a special scans, called a DXA and pQCT scan which will check the strength of 
your bones. 
5.  What do I have to do? 
If you would like to help us with the study we will ask your Mum or Dad to sign a piece 
of paper called a ‘consent form’. All you have to do is come for your biologic 
treatment. You can also sign an assent form. 
6. What are the possible problems of taking part? 
Taking the extra small amount of blood from you and having the special scans will not 
cause any problems. Sometimes getting the scans may prolong your visit. We will try 
our best to be as quick as we can. 
7. What are the possible benefits of taking part? 
We can tell you how your growth and bones are doing. By taking part in the study you 
will provide us with information that will help us help other children with Crohn’s 
disease with problems with their growth. 
8. Who can I contact for further information? 
If you want to discuss the study further, please contact: Dr Faisal Ahmed telephone 
number 0141 201 0767 or Dr R Russell telephone number at the Royal Hospital For 
Sick Children, Yorkhill, Glasgow G3 8SJ. 
9. Do I have to take part? 
YOU DO NOT HAVE TO SAY ‘YES’ to taking part in this study if you do not want to.  
10. What happens at the end of the study? 
When the results of the study are published, your name will not be shown, so there is 
no way of anyone knowing that you have taken part unless you tell them.  
11. What if something goes wrong? 
We are not expecting any problems. However, if you are not happy about anything 
about this study, talk to your parents or your family doctor and ask them to speak to 
us. You can also contact Kate Colquhoun, Patient Contact Office at Yorkhill on 0141 
201 9278. 
12. Who is organizing the study? 
The study is being organized by Dr Faisal Ahmed who looks after children with bone 
and growth problems at Yorkhill.  
13. Who is helping these doctors with the study? 
Most of the work in this study will be performed by a senior student, Ms Salma Malik, 
who is doing a PhD at the University of Glasgow. Other people who will be helping are 
members of the Bone & Endocrine Research Group and members of the GI team.  
 
14.     Who has looked at this study? 
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       The study has also been looked at by a group of people who belong to the Research 
Ethics Committee and the Research & Development Department. 
 
A copy of this information sheet and consent form will be given to you to keep. If you 
have any further questions about the study, please feel free to ask the doctors above. 
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Appendix D 
Study information sheet for the young person over 14yrs 
    
STUDY INFORMATION SHEET FOR THE YOUNG PERSON OVER 14 YEARS 
The effects of biologic therapy on linear growth, puberty and bone health in children 
with Crohn's disease (CD) 
 
You are being invited to take part in a research study. The study is being performed to see 
how biologic medicines may improve growth and bone health in Crohn’s disease. Before you 
decide, you need to find out more about this study. Please read this sheet carefully and 
discuss it with your parents. Take your time and ask us if anything is not clear. 
 
1. What happens to growth and bone health in children with Crohn’s disease? 
       Children and young people with Crohn’s disease may not grow as well as healthy people 
and their bones may also be affected This may be due to the effects of some substances 
called cytokines that are increased in Crohn’s disease. Cytokines cause the symptoms of 
Crohn’s disease but may also affect growth. Steroid medicines (e.g. Prednisolone) that 
are sometimes used to treat Crohn’s disease can also slow growth and affect the bones. 
2. What is this study about? 
        Biologics are special medicines that block the cytokines that may be increased in 
Crohn’s disease. We want to find out how these new medicines, affect growth and bones 
in Crohn’s disease. We are also interested in finding out how these new medicines can 
improve the hormones and substances that control growth and bone health. 
3. Why has your child been chosen?  
Your gastroenterologist has indicated that you will be started on biologic therapy to treat 
Crohn’s disease. We would like to add this study to your clinical treatment. The study will 
be fitted around your visits to receive the medicine or when you attend the clinic. 
4. What will happen to your child on participation? 
If you agree to take part, we will take some extra blood from your cannula (2 teaspoons) 
at the time of the biologic therapy. Routine blood tests are required before the infusion 
anyway and we will just take a little bit more. You will not notice anything different and 
there will not be any extra jags. We will also ask for a urine and stool sample each time 
you child attends for the study visits. We will also check your height and weight at each 
visit. If you do not continue on biologics after the first 3 doses, we will see you and 
organize for the tests at the clinic. At baseline and 6 months and 12 months after the first 
dose of biologic, we will ask for an x-ray of your left hand to check the amount of bone 
growth there is. In addition, at baseline and 6 months and 12 months, we will also ask for 
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special scans, called DXA and pQCT scans that check how strong your bones are. Some 
of these scans involve a very small amount of x-rays that are not harmful. The amount of 
radiation is about the same as you would get from playing outside in the sun on one 
average day. 
5. What do I have to do? 
If you would like to help us with the study we would like to ask you to sign a piece of 
paper called a ‘consent form’. All you have to do is to come for the biologic treatment or 
to the clinic visit as usual. 
6. What are the possible problems of taking part? 
Taking the extra small amount of blood from you and the special scans to measure how 
strong your bones will not cause any harm. Occasionally, your visit may be prolonged 
when waiting for the scans. We will try our best to shorten the visit as much as possible. 
7. What are the possible benefits of taking part? 
We are not introducing any treatment we would not have used to treat your condition or 
manage you any differently. The study may allow close monitoring of your growth and 
bone health. By taking part in the study you will provide us with information that will help 
us with addressing problems in other children with Crohn’s disease. 
8. Who can I contact for further information? 
If you want to discuss the study further, please contact: Dr Faisal Ahmed telephone 
number 0141 201 0571 or Dr R Russell telephone number at the Royal Hospital for Sick 
Children, Yorkhill, Glasgow G3 8SJ. 
9. Do I have to take part? 
YOU DO NOT HAVE TO SAY ‘YES’ to taking part in this study if you do not want to. You 
will still have your biologic treatment. 
10. What if something goes wrong? 
We are not expecting any problems. However, if you are not happy about anything about 
this study, talk to your relatives, other hospital staff or your family doctor and ask them to 
speak to us. You can also contact Kate Colquhoun, Patient Contact Office at Yorkhill on 
0141 201 9278. 
11. Who is organizing the study? 
The study is being organized by Dr Faisal Ahmed who looks after children and young 
people with bone and growth problems at Yorkhill.  
12. Who is helping these doctors with the study? 
Most of the work in this study will be performed by a senior student. Ms Salma Malik who 
is doing a PhD at the University of Glasgow. Other people who will be helping are 
members of the Bone & Endocrine Research Group and members of the GI team.  
13. Who has looked at this study? 
The study has also been looked at by a group of people who belong to the Research 
Ethics Committee and the Research & Development Department. 
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Appendix E 
Study information sheet for the parent 
 
      
STUDY INFORMATION SHEET FOR THE PARENT 
 
The effects of biologic therapy on linear growth, puberty and bone health in children 
with Crohn's disease (CD) 
 
You child is being invited to take part in a research study. The study is being performed to 
see how biological medicines may improve growth and bone health in your child with Crohn’s 
disease. Before you decide, you need to find out more about this study. Please read this 
sheet carefully and discuss it with your child. Take your time and ask us if anything is not 
clear. 
 
1. What happens to growth and bone health in children with Crohn’s disease? 
Children with Crohn’s disease often do not grow as well as healthy children and their 
bones may also be affected This may be due to the effects of some substances called 
cytokines that are increased in children with Crohn’s disease. Cytokines causes the 
symptoms of Crohn’s disease but may also slow down the growth of your child. Steroid 
medicines (e.g. Prednisolone) that are sometimes used to treat Crohn’s disease can also 
slow growth and affect the bones. 
2.    What is this study about? 
Biologics are special medicines that block the cytokines that may be increased in Crohn’s 
disease. We want to find out how these new medicines, affect growth and bones in 
children with Crohn’s disease. We are also interested in finding out how these new 
medicines can improve the hormones and substances that control growth and bone 
health. 
3.    Why has your child been chosen?  
We know that your child will be started on biologic therapy to treat their condition. We 
would like to add this study to your child’s clinical treatment. The study will be fitted 
around the visits your child has to receive the medicine or when your child attends the 
clinic. 
4.    What will happen to your child on participation? 
If you agree to take part, we will take some extra blood from your child’s cannula (2 
teaspoons) at the time of the biologic therapy. Routine blood tests are required before 
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the infusion anyway and we will just take a little bit more. Your child will not notice 
anything different and there will not be any extra jags. We will also ask for a urine and 
stool sample each time your child attends for the study visits. We will also check your 
child’s height and weight at each visit. If your child is not to continue on biologics after the 
first 3 doses, we will see your child and organize for the tests at the clinic. At baseline 
and 6 months and 12 months after the first dose of biologic, we will ask for an x-ray of 
your child’s left hand to check the amount of bone growth there is. In addition, at baseline 
and 6 months and 12 months, we will also ask for special scans, called DXA scans that 
check how strong your child’s bones are. Some of these scans involve a very small 
amount of x-rays that are not harmful. The amount of radiation is about the same as your 
child would get from playing outside in the sun on one average day. 
5.    What do I have to do? 
If you would like to help us with the study we would like to ask you to sign a piece of 
paper called a ‘consent form’. All you have to do is to bring your child for their biologic 
treatment or to the clinic visit as usual. 
6.    What are the possible problems of taking part? 
Taking the extra volume of blood from your child and the special scans to measure how 
strong your child’s bones are will not cause any harm. Occasionally your visit may be 
prolonged waiting for scans. 
7.    What are the possible benefits of taking part? 
We are not introducing any treatment we would not have used to treat your child’s 
condition or manage your child any differently. The study may allow close monitoring of 
your child’s growth and bone health. By taking part in the study you will provide us with 
information that will help us with addressing problems in other children with Crohn’s 
disease. 
8.    Who can I contact for further information? 
If you want to discuss the study further, please contact: Dr Faisal Ahmed telephone 
number 0141 201 0571 or Dr R Russell telephone number at the Royal Hospital for Sick 
Children, Yorkhill, Glasgow G3 8SJ. 
9.     Do I have to take part? 
YOU DO NOT HAVE TO SAY ‘YES’ to taking part in this study if you do not want to. 
Your child will still have his/her biological treatment. 
10.   What if something goes wrong? 
We are not expecting any problems. However, if you are not happy about anything about 
this study, talk to your relatives, other hospital staff or your family doctor and ask them to 
speak to us. You can also contact Kate Colquhoun, Patient Contact Office at Yorkhill on 
0141 201 9278 
11.   Who is organizing the study? 
The study is being organized by Dr Faisal Ahmed who looks after children with bone and 
growth problems at Yorkhill.  
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12.    Who is helping these doctors with the study? 
Most of the work in this study will be performed by a senior student. Ms Salma Malik 
who is doing a PhD at the University of Glasgow. Other people who will be helping are 
members of the Bone & Endocrine Research Group and members of the GI team.  
14. Who has looked at this study? 
The study has also been looked at by a group of people who belong to the Research 
Ethics Committee and the Research & Development Department. 
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Appendix F 
Assent form for the child 8-14 years 
 
ASSENT FORM FOR THE CHILD 8-14YEARS 
Patient Identification Number: 
 
The effects of biologic therapy on linear growth, puberty and bone health in children 
with Crohn's disease (CD) 
               
The study has been explained to me and I have read the information  
sheet and understand what I have to do.  
 
I know my child can come out of the study at any time.  
 
I understand that all medical information about my child is  
STRICTLY CONFIDENTIAL 
 
I would like my child to take part in this study. 
 
I am happy for my family doctor to know that my child is taking  
part in this study.  
 
Signatures: 
Parent(s) name (block letters)             -------------------------------------- 
Signature (s)                              -------------------------------------- 
Date                    -------------------------------------- 
 
Patient name (block letters)                        --------------------------------------- 
Patient signature (if applicable)           --------------------------------------- 
Date                          --------------------------------------- 
  
Name of person taking consent            -------------------------------------- 
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(If not the researcher) 
Signature               -------------------------------------- 
Date                -------------------------------------- 
 
Researcher’s name (block letters)                -------------------------------------- 
Signature               -------------------------------------- 
Date                -------------------------------------- 
 
THANK YOU FOR YOUR HELP 
1 for patient/ parent; 1 for researcher; 1 to be kept with hospital notes 
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Appendix G 
consent form for the young person over 14 years old 
    
CONSENT FORM FOR THE YOUNG PERSON OVER 14 YEARS OLD 
 
Patient Identification Number: 
The effects of biologic therapy on linear growth, puberty and bone health in children 
with Crohn's disease (CD) 
               
The study has been explained to me and I have read the information  
Sheet and understand what I have to do.  
 
I know I can come out of the study at any time.  
 
I understand that all medical information about myself is  
STRICTLY CONFIDENTIAL. 
 
I would like to take part in this study. 
 
I am happy for my family doctor to know that I am taking part in this study. 
Signatures: 
 
Parent(s) name (block letters)             -------------------------------------- 
Signature (s)                              -------------------------------------- 
Date                    -------------------------------------- 
 
Patient name (block letters)                         ------------------------------------- 
Patient signature (if applicable)            ------------------------------------- 
Date                           ------------------------------------- 
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Name of person taking consent            -------------------------------------- 
(If not the researcher) 
Signature               -------------------------------------- 
Date                -------------------------------------- 
 
Researcher’s name (block letters)                 ------------------------------------- 
Signature               -------------------------------------- 
Date                -------------------------------------- 
 
THANK YOU FOR YOUR HELP 
1 for patient/ parent; 1 for researcher; 1 to be kept with hospital notes 
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Appendix H 
Parent consent form 
    
PARENT CONSENT FORM 
 
Patient Identification Number: 
The effects of biologic therapy on linear growth, puberty and bone health in children 
with Crohn's disease (CD) 
               
The study has been explained to me and I have read the information  
Sheet and understand what I have to do.  
 
I know my child can come out of the study at any time.  
 
I understand that all medical information about my child is  
STRICTLY CONFIDENTIAL 
 
I would like my child to take part in this study. 
 
I am happy for my family doctor to know that my child is taking  
part in this study.  
 
Signatures: 
Parent(s) name (block letters)             -------------------------------------- 
Signature (s)                              ------------------------------------- 
Date                    -------------------------------------- 
 
Patient name (block letters)                        --------------------------------------- 
Patient signature (if applicable)            -------------------------------------- 
Date                          -------------------------------------- 
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Name of person taking consent            -------------------------------------- 
(If not the researcher) 
Signature               -------------------------------------- 
Date                -------------------------------------- 
 
Researcher’s name (block letters)                -------------------------------------- 
Signature               -------------------------------------- 
Date                -------------------------------------- 
 
THANK YOU FOR YOUR HELP 
1 for patient/ parent; 1 for researcher; 1 to be kept with hospital notes 
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Appendix I 
Data collection form baseline 
Biologics in Crohn’s Disease (BCD Study) 
VISIT: BASELINE                               Date: 
 
 
Patient ID: 
  
BCD…………….. 
  
Patient Initials: 
      
 
Sex:  
Male 
Female 
  
Date of Birth: 
      
  
  
Age in years: 
 
  
  
Parents height 
  
Mother: 
_________ 
  
father:   
_________ 
Baseline Height Weight Sitting height 
Date: 
      
 
  
cms:__________ 
  
Kgs: _______________ 
  
cms:___________ 
Diagnosis Height Weight Decimal age 
Date: 
      
  
  
cms:_________ 
  
Kgs: _______________ 
  
Years:_________ 
PARENT’S ETHINIC GROUP 
                                   Mother     Father 
 
White                         
 
Black –Caribbean    
 
Black –African           
 
Black –other               
 
 
Others                    
 
 
                            Mother       Father 
  
Jewish                  
  
Indian                   
 
Pakistani              
 
Bangladeshi          
 
Chinese                
 
Others                
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 MONTREAL DISEASE CLASSSIFICATION 
Age at diagnosis 
  
A1□ Below 16 years 
  
A2□ Between 17&14 years 
  
A3□ Above 40 years 
  
  
   
 Location 
  
L1□ Ileal 
  
L2□ Colonic 
  
L3□ Ileocolonic 
  
L4□ Isolated upper  disease 
Behaviour  
  
B1 □non stricturing, 
         non penetrating 
  
B2□ stricturing 
  
B3□ penetrating 
 
PCDAI                         □No   □ Yes        Date …………….      score: ------------------ 
GRIP STRENGTH 
Date:  _________ 
 
Dominant side: 
□   Left 
 
□  Right 
      Dominant Grip  
 
1  
2  
3  
    Non dominant Grip Strength 
  
 
  
   
1  
2  
3  
 
REASONS FOR BIOLOGIC THERAPY 
Date:____________ 
 
Sever disease despite of Immunomodulator therapy      
Sever disease awaiting response despite standard therapy 
Fistulating disease despite standard therapy 
Metastatic disease 
Non responder to Infliximab therapy 
Intolerant to Infliximab therapy 
 
Dose of INFLIXIMAB/ADALIMUMAB 
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CONCOMINTANT THERAPIES 
 
Date :  __________ 
Nutritional Support 
Elemental feeds    
Polymeric feeds    
 
 
 
□No   □ Yes    
□No   □ Yes    
 
  
  
5-ASA            
Osalazine                
Mesalazine             
 
□No   □ Yes    
□No   □ Yes   
 
Steroids 
Prednisolone         
 
 
□No   □ Yes    
 
 
Background 
immunosuppressants 
Methotrexate        
Azathioprine          
 
□No   □ Yes    
□No   □ Yes   
 
Antibiotics □No   □ Yes    
 
 
 
MECHANOGRAPH:SINGLE TWO LEG JUMP 
Date 
F.Max Yes No 
P.Max Yes No 
Efficiency Yes No 
RADIOGRAPHY 
Date 
DEXA Yes No 
pQCT Yes No 
Bone Age (X-ray of right hand ) Yes No 
PUBERTAL ASESSMENT 
Date : ____________ □No   □ Yes     
BIOLOGIC SAMPLES       DATE:                           
Blood Yes No 
Urine Yes No 
Stool Yes No 
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ADDITIONAL INFORMATION 
ANY REACTION TO INFLIXIMAB/ADALIMUMAB 
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Appendix J 
Data collection form 2 weeks 
Biologics in Crohn’s Disease (BCD Study) 
VISIT: 2weeks                               Date: 
  
Patient ID: 
  
BCD…………….. 
  
Patient Initials: 
      
 
Date of Birth: 
      
 Sex:  
Male 
Female 
  
2weeks Weight 
Date: 
      
 
  
Kgs: _______________ 
 
PCDAI                         □No   □ Yes        Date …………….      score: ------------------ 
 
GRIP STRENGT 
                                         
Date:  _________ 
Dominant side: 
□   Left 
 
□  Right 
      Dominant Grip  
 
1  
2  
3  
    Non dominant Grip Strength 
  
 
  
   
1  
2  
3  
CONCOMINTANT THERAPIES 
 
Date :  __________ 
 
Nutritional Support 
Elemental feeds    
Polymeric feeds    
 
 
 
□No   □ Yes    
□No   □ Yes    
 
  
  
5-ASA                  
Osalazine                
Mesalazine             
 
□No   □ Yes    
□No   □ Yes   
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Steroids 
Prednisolone         
 
□No   □ Yes    
 
 
Background 
immunosuppressants 
Methotrexate        
Azathioprine          
 
 
□No   □ Yes    
□No   □ Yes   
 
Antibiotics 
 
□No   □ Yes    
 
 
 
MECHANOGRAPH:SINGLE TWO LEG JUMP 
Date: Comments 
F.Max No Yes  
P.Max No Yes  
Efficiency No Yes  
BIOLOGIC SAMPLES 
Date:                                                                                                                    Comments 
Blood Yes No  
Urine Yes No  
Stool Yes No  
 
ADDITIONAL INFORMATION 
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Appendix K 
Data collection form 6weeks 
Biologics in Crohn’s Disease (BCD Study) 
VISIT: 6weeks                               Date: 
  
Patient ID: 
  
BCD…………….. 
  
Patient Initials: 
      
 
Date of Birth: 
      
 Sex:  
Male 
Female 
  
2weeks Weight 
Date: 
      
 
  
Kgs: _______________ 
 
PCDAI                         □No   □ Yes        Date …………….      score: ------------------ 
 
GRIP STRENGTH 
                                         
Date:  _________ 
Dominant side: 
□   Left 
 
□  Right 
      Dominant Grip  
 
1  
2  
3  
    Non dominant Grip Strength 
  
 
  
   
1  
2  
3  
CONCOMINTANT THERAPIES 
 
Date :  __________ 
 
Nutritional Support 
Elemental feeds    
Polymeric feeds    
 
 
 
□No   □ Yes    
□No   □ Yes    
 
  
  
5-ASA                  
Osalazine                
Mesalazine             
 
□No   □ Yes    
□No   □ Yes   
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Steroids 
 
Prednisolone         
 
 
 
□No   □ Yes    
 
 
Background 
immunosuppressants 
 
Methotrexate        
Azathioprine          
 
 
□No   □ Yes    
□No   □ Yes   
 
Antibiotics 
 
□No   □ Yes    
 
 
 
MECHANOGRAPH:SINGLE TWO LEG JUMP 
Date: Comments 
F.Max No Yes  
P.Max No Yes  
Efficiency No Yes  
BIOLOGIC SAMPLES 
Date:                                                                                                                    Comments 
Blood Yes No  
Urine Yes No  
Stool Yes No  
 
ADDITIONAL INFORMATION 
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Appendix L 
Data collection form 6 months 
Biologics in Crohn’s Disease (BCD Study) 
VISIT: 6 months                              Date: 
  
Patient ID: 
  
BCD…………….. 
  
Patient Initials: 
      
 
  
Sex:  
Male 
Female 
 Date of Birth: 
      
 
6 months Height Weight Sitting height 
Date: 
      
 
  
cms:______ 
  
Kgs: _______________ 
  
cms:___________ 
 
PCDAI                         □No   □ Yes        Date …………….      score: ------------------ 
 
PUBERTAL STATUS        □No   □ Yes        Date …………….      Tanner stage: ------------------ 
 
GRIP STRENGTH:   
                         
Date:  _________ 
 
Dominant side: 
□   Left 
 
□  Right 
      Dominant Grip  
 
1  
2  
3  
    Non dominant Grip Strength 
  
 
  
   
1  
2  
3  
CONCOMINTANT THERAPIES 
 
Date :  __________ 
 
Nutritional Support 
Elemental feeds    
Polymeric feeds    
 
 
 
□No   □ Yes    
□No   □ Yes    
 
  
  
5-ASA           
  
337
Osalazine                
Mesalazine             
□No   □ Yes    
□No   □ Yes   
Steroids 
Prednisolone         
 
 
□No   □ Yes    
 
 
Background 
immunosuppressants 
Methotrexate        
Azathioprine          
 
 
□No   □ Yes    
□No   □ Yes   
 
Antibiotics 
 
□No   □ Yes    
 
 
 
 
MECHANOGRAPH:SINGLE TWO LEG JUMP                                                        
Date 
F.Max  Yes No 
P.Max  Yes No 
Efficiency  Yes No 
RADIOGRAPHY 
Date 
DEXA  Yes No 
pQCT  Yes No 
BIOLOGIC SAMPLES 
 Date 
Blood  Yes No 
Urine  Yes No 
Stool  Yes No 
ADDITIONAL INFORMATION 
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Appendix M 
Data collection form 12 months 
Biologics in Crohn’s Disease (BCD Study) 
VISIT: 12 months                              Date: 
  
Patient ID: 
  
BCD…………….. 
  
Patient Initials: 
      
 
  
Sex:  
Male 
Female 
 Date of Birth: 
      
 
12 months Height Weight Sitting height 
Date: 
      
 
  
cms:______ 
  
Kgs: _______________ 
  
cms:___________ 
 
PCDAI                       □No   □ Yes        Date …………….      score: ------------------ 
PUBERTY                     □No   □ Yes        Date …………….      Tanner stage: ------------------ 
 
GRIP STRENGTH 
                                         
Date:  _________ 
Dominant side: 
□   Left 
 
□  Right 
      Dominant Grip  
 
1  
2  
3  
    Non dominant Grip Strength 
  
 
  
   
1  
2  
3  
CONCOMITANT THERAPIES 
 
Date :  __________ 
Nutritional Support 
Elemental feeds    
Polymeric feeds    
 
 
□No   □ Yes    
□No   □ Yes    
 
  
  
5-ASA         
Osalazine                
Mesalazine             
 
□No   □ Yes    
□No   □ Yes   
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Steroids 
Prednisolone         
 
 
□No   □ Yes    
 
 
Background immunosuppressants 
Methotrexate        
Azathioprine          
 
□No   □ Yes    
□No   □ Yes   
 
Antibiotics 
 
□No   □ Yes    
 
 
 
MECHANOGRAPH: SINGLE TWO LEG JUMP                                                       
Date 
F.Max  Yes No 
P.Max  Yes No 
Efficiency  Yes No 
RADIOGRAPHY 
Date 
DEXA  Yes No 
pQCT  Yes No 
Bone Age (X-ray of right hand )  Yes No 
 
BIOLOGICAL SAMPLES 
Blood  Yes No 
Urine  Yes No 
Stool  Yes No 
 
ADDITIONAL INFORMATION 
TOTAL NUMBER OF INJECTIONS/IFUSIONS IN 12 m 
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Appendix N 
Paediatric Crohn’s disease activity index score form 
Biologics in Crohn’s Disease (BCD-Study) 
                  Visit:                               Patient ID: BCD……..            DOB: 
 
         Visit date:                       Patient Initial: 
 
Paediatric Crohn’s Disease Activity Index 
 
1.Abdominal pain 
None 0 
Mild: Brief, does not interfere with activities 5 
Mod/severe - daily, longer lasting affects activities, nocturnal 10 
2.Stools 
Formed stools or up to 1 liquid stool, no blood 0 
Up to 2 semi-formed with small blood, or 2-5 liquid with or 
without small blood 
5 
Any gross bleeding, or ≥ 6 liquid, or nocturnal diarrhoea 10 
3.Functioning, well being 
No Limitation of activities, well 0 
Occasional difficulty in maintaining appropriate activities, 
below par 
5 
Frequent limitation of activity, very poor 10 
4.Weight 
Weight gain or voluntary weight stable/loss 0 
Involuntary weight stable, weight loss 1-9% 5 
Weight loss ≥ 10% 10 
5.Abdominal exam 
No tenderness, no mass 0 
Tenderness, or mass without tenderness 5 
Tenderness, involuntary guarding, definite mass 10 
6. Peri-rectal disease 
None, asymptomatic tags 0 
Inflamed tags or 1-2 indolent fistula(e) or fissure(s), scant 5 
  
341
drainage, no tenderness 
Active fistula, drainage, tenderness, or abscess 10 
7. Extra-intestinal Manifestations, (Fever≥38.5°C for 3 days over past week, oral ulcers, 
definte arthritis, uveitis, erythema nodosum, pyoderma gangrenosum) 
None 0 
One 5 
Two or more 10 
Height at diagnosis 
<1 channel decrease 0 
≥1<2 channel decrease 5 
≥ channel decrease 10 
Height velocity at follow-up 
Height velocity  -1SD 0 
Height velocity < -1SD, >- 2SD 5 
Height velocity ≤ - 2SD 10 
Hct(%)  
ESR  
Albumin  
  
 
 
  
 
  
 
 
 
 
